



Nigeria

Country Operational Plan

FY 2014

Note: Italicized sections of narrative text indicate that the content was not submitted in the Lite COP year, but was derived from the previous Full COP year. This includes data in Technical Area Narratives, and Mechanism Overview and Budget Code narratives from continued mechanisms.



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

| Agency | Funding Source | | | Total |
|------------|----------------|-------------|-----------|-------------|
| | GAP | GHP-State | GHP-USAID | |
| DOD | | 11,726,463 | | 11,726,463 |
| HHS/CDC | 1,962,500 | 148,313,620 | | 150,276,120 |
| State | | 311,250 | | 311,250 |
| State/OGAC | | 488,850 | | 488,850 |
| USAID | | 295,811,598 | | 295,811,598 |
| Total | 1,962,500 | 456,651,781 | 0 | 458,614,281 |

Summary of Planned Funding by Budget Code and Agency

| Budget Code | Agency | | | | | | | On Hold Amount | Total |
|-------------|---------|-----------|------------|----------|------------|------------|----------|----------------|-------------|
| | State | DOD | HHS/CDC | State/AF | State/OGAC | USAID | AllOther | | |
| HBHC | | 677,104 | 16,692,580 | | | 14,006,986 | | 0 | 31,376,670 |
| HKID | | | 7,826,187 | 0 | | 29,119,000 | | 0 | 36,945,187 |
| HLAB | | 1,415,036 | 17,366,544 | | 488,850 | 10,783,660 | | 0 | 30,054,090 |
| HMBL | | 7,879 | 2,067,582 | | | 1,243,849 | | 0 | 3,319,310 |
| HMIN | | 12,866 | 481,191 | | | 3,667,245 | | 0 | 4,161,302 |
| HTXD | | 0 | 0 | | | 99,781,401 | | 0 | 99,781,401 |
| HTXS | | 2,425,858 | 47,865,963 | | | 51,350,533 | | 0 | 101,642,354 |
| HVAB | | 118,405 | 47,752 | | | 546,098 | | 0 | 712,255 |
| HVCT | | 250,893 | 7,505,645 | | | 23,276,504 | | 0 | 31,033,042 |
| HVMS | 311,250 | 4,653,932 | 12,778,974 | | | 7,586,167 | | 0 | 25,330,323 |
| HVOP | | 199,125 | 7,090,775 | | | 12,946,191 | | 0 | 20,236,091 |
| HVSI | | 476,000 | 3,393,592 | | | 4,255,333 | | 0 | 8,124,925 |
| HVTB | | 140,734 | 5,253,696 | | | 5,367,771 | | 0 | 10,762,201 |
| MTCT | | 512,039 | 13,678,024 | | | 16,724,935 | | 0 | 30,914,998 |

Approved



| | | | | | | | | | |
|------|---------|------------|-------------|---|---------|-------------|---|---|-------------|
| OHSS | | 649,448 | 3,611,475 | | | 10,044,709 | | 0 | 14,305,632 |
| PDCS | | 54,541 | 1,196,851 | | | 2,230,797 | | 0 | 3,482,189 |
| PDTX | | 132,603 | 3,419,289 | | | 2,880,419 | | 0 | 6,432,311 |
| | 311,250 | 11,726,463 | 150,276,120 | 0 | 488,850 | 295,811,598 | 0 | 0 | 458,614,281 |



Budgetary Requirements Worksheet

Redacted

Technical Areas

Technical Area Summary

Technical Area: Care

| Budget Code | Budget Code Planned Amount | On Hold Amount |
|--|----------------------------|----------------|
| HBHC | 31,133,374 | 0 |
| HKID | 36,222,028 | 0 |
| HVTB | 10,411,037 | 0 |
| PDCS | 3,348,129 | 0 |
| Total Technical Area Planned Funding: | 81,114,568 | 0 |

Technical Area: Governance and Systems

| Budget Code | Budget Code Planned Amount | On Hold Amount |
|--|----------------------------|----------------|
| HLAB | 29,441,876 | 0 |
| HVSI | 6,943,226 | 0 |
| OHSS | 13,765,125 | 0 |
| Total Technical Area Planned Funding: | 50,150,227 | 0 |

Technical Area: Prevention

| Budget Code | Budget Code Planned Amount | On Hold Amount |
|-------------|----------------------------|----------------|
| HMBL | 3,198,938 | 0 |
| HMIN | 4,100,000 | 0 |
| HVAB | 550,911 | 0 |
| HVCT | 30,816,987 | 0 |

Approved



| | | |
|--|-------------------|----------|
| HVOP | 20,035,145 | 0 |
| MTCT | 30,450,856 | 0 |
| Total Technical Area Planned Funding: | 89,152,837 | 0 |

Technical Area: Treatment

| Budget Code | Budget Code Planned Amount | On Hold Amount |
|--|-----------------------------------|-----------------------|
| HTXD | 99,660,534 | 0 |
| HTXS | 101,428,594 | 0 |
| PDTX | 6,293,215 | 0 |
| Total Technical Area Planned Funding: | 207,382,343 | 0 |

Technical Area Summary Indicators and Targets

| Indicator Number | Label | 2014 | 2015 |
|------------------|---|-------|-------|
| SITE_SUPP | Number of unique sites supported by PEPFAR | | |
| | By program area/support type: HTC Direct Service Delivery (DSD) | 5,900 | 6,000 |
| | By program area/support type: HTC Technical Assistance-only (TA) | 373 | 373 |
| | By program area/support type: Treatment Direct Service Delivery (DSD) | 930 | 930 |
| | By program area/support type: Treatment Technical Assistance-only (TA) | 0 | 0 |
| | By program area/support type: Care and Support Direct Service Delivery (DSD) | 930 | 930 |
| | By program area/support type: Care and Support Technical Assistance-only (TA) | 0 | 0 |
| | By program area/support type: Food and Nutrition Direct Service Delivery (DSD) | 930 | 930 |
| | By program area/support type: Food and Nutrition Technical Assistance-only (TA) | 0 | 0 |



| | | | |
|--|--|-------|-------|
| | By program area/support type: PMTCT Direct Service Delivery (DSD) | 5,900 | 6,000 |
| | By program area/support type: PMTCT Technical Assistance-only (TA) | 0 | 0 |
| | By program area/support type: TB/HIV Direct Service Delivery (DSD) | 930 | 930 |
| | By program area/support type: TB/HIV Technical Assistance-only (TA) | 343 | 343 |
| | By program area/support type: VMMC Direct Service Delivery (DSD) | 0 | 0 |
| | By program area/support type: VMMC Technical Assistance-only (TA) | 0 | 0 |
| | By program area/support type: General Population Prevention Direct Service Delivery (DSD) | 0 | 0 |
| | By program area/support type: General Population Prevention Technical Assistance-only (TA) | 0 | 0 |
| | By program area/support type: Key Populations Prevention Direct Service Delivery (DSD) | 0 | 0 |
| | By program area/support type: Key Populations Prevention Technical Assistance-only (TA) | 0 | 0 |
| | By program area/support | 871 | 871 |

| | | | |
|------------|---|-----|-------|
| | type: OVC Direct Service Delivery (DSD) | | |
| | By program area/support type: OVC Technical Assistance-only (TA) | 0 | 0 |
| | By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD) | 0 | 0 |
| | By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA) | 0 | 0 |
| | By program area/support type: Lab Direct Service Delivery (DSD) | 565 | 508 |
| | By program area/support type: Lab Technical Assistance-only (TA) | 1 | 28 |
| PMTCT_SITE | PMTCT_SITE Percentage of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women | n/a | |
| | Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women | | 5,100 |
| | Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) | | 6,000 |
| | By site support type: Direct Service Delivery (DSD): | | 5,100 |



| | | | |
|----------------|---|-----------|-----------|
| | Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women | | |
| | By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women | | 0 |
| | Sum of Numerator Support Type disaggregates | | 5,100 |
| | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) | | 6,000 |
| | By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) | | 0 |
| | Sum of Denominator Support Type disaggregates | | 6,000 |
| PMTCT_STAT_DSD | PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD) | 91 % | |
| | Number of pregnant women | 2,140,343 | 2,344,810 |



| | | | |
|--|--|-----------|-----------|
| | with known HIV status (includes women who were tested for HIV and received their results) | | |
| | Number of new ANC and L&D clients | 2,354,377 | 2,579,291 |
| | By: Known positives at entry | 28,060 | 31,674 |
| | By: Number of new positives identified | 42,090 | 47,511 |
| | Sum of Positives Status disaggregates | 70,150 | 79,185 |
| | Required only for DREAMS Countries - By Number of new positives: <15 | | |
| | Required only for DREAMS Countries - By Number of new positives: 15-19 | | |
| | Required only for DREAMS Countries - By Number of new positives: 20-24 | | |
| | Required only for DREAMS Countries - By Number of new positives: 25+ | | |
| | Required only for DREAMS Countries - By Number of known positives: <15 | | |
| | Required only for DREAMS Countries - By Number of known positives: 15-19 | | |
| | Required only for DREAMS Countries - By Number of known positives: 20-24 | | |
| | Required only for DREAMS Countries - By Number of known positives: 25+ | | |

| | | | |
|----------------|---|------|---|
| | Required only for DREAMS Countries - Denominator: <15 | | |
| | Required only for DREAMS Countries - Denominator: <15-19 | | |
| | Required only for DREAMS Countries - Denominator: 20-24 | | |
| | Required only for DREAMS Countries - Denominator: 25+ | | |
| PMTCT_STAT_NA | PMTCT_STAT_NA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (Neither) | n/a | |
| | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 0 | 0 |
| | Number of new ANC and L&D clients | 0 | 0 |
| | By: Known positives at entry | 0 | 0 |
| | By: Number of new positives identified | 0 | 0 |
| | Sum of Positives Status disaggregates | 0 | 0 |
| PMTCT_STAT_NGI | PMTCT_STAT_NGI Number and percentage of pregnant women with known status (includes women who were tested for HIV and received | 91 % | |

| | | | |
|---------------|--|-----------|-----------|
| | their results) (NGI) | | |
| | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 2,140,343 | 2,344,810 |
| | Number of new ANC and L&D clients | 2,354,377 | 2,579,291 |
| | By: Known positives at entry | 28,060 | 31,674 |
| | By: Number of new positives identified | 42,090 | 47,511 |
| | Sum of Positives Status disaggregates | 70,150 | 79,185 |
| | | | |
| PMTCT_STAT_TA | PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA) | n/a | |
| | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 0 | 0 |
| | Number of new ANC and L&D clients | 0 | 0 |
| | By: Known positives at entry | 0 | 0 |
| | By: Number of new positives identified | 0 | 0 |
| | Sum of Positives Status disaggregates | 0 | 0 |
| | Required only for DREAMS countries - By known positives: <15 | | |
| | Required only for DREAMS | | |

| | | | |
|---------------|--|------|--|
| | countries - By known positives: 15-19 | | |
| | Required only for DREAMS countries - By known positives: 20-24 | | |
| | Required only for DREAMS countries - By known positives: 25+ | | |
| | Required only for DREAMS countries - By new positives: <15 | | |
| | Required only for DREAMS countries - By new positives: 15-19 | | |
| | Required only for DREAMS countries - By new positives: 20-24 | | |
| | Required only for DREAMS countries - By new positives: 25+ | | |
| | Required only for DREAMS countries - Denominator: <15 | | |
| | Required only for DREAMS countries - Denominator: 15-19 | | |
| | Required only for DREAMS countries - Denominator: 20-24 | | |
| | Required only for DREAMS countries - Denominator: 25+ | | |
| PMTCT_ARV_DSD | PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for | 88 % | |

| | | | |
|--|--|--------|--------|
| | mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD) | | |
| | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 61,732 | 69,683 |
| | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 70,150 | 76,770 |
| | Life-long ART (including Option B+) | 33,953 | 38,326 |
| | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 12,908 | 12,987 |
| | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 21,045 | 25,339 |
| | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 24,075 | 27,873 |
| | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 3,087 | 3,484 |
| | Single-dose nevirapine (with or without tail) | 617 | 0 |

| | | | |
|--------------|---|--------|--------|
| | Sum of Regimen Type disaggregates | 61,732 | 69,683 |
| | Sum of New and Current disaggregates | 33,953 | 38,326 |
| PMTCT_ARV_NA | PMTCT_ARV_NA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (Neither) | n/a | |
| | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 0 | 0 |
| | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 0 | 0 |
| | Life-long ART (including Option B+) | 0 | 0 |
| | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 0 | 0 |
| | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 0 | 0 |
| | Maternal triple ARV prophylaxis (provided with | 0 | 0 |
| | | | |

| | | | |
|---------------|--|--------|--------|
| | the intention to stop at the end of the breastfeeding period) | | |
| | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 0 | 0 |
| | Single-dose nevirapine (with or without tail) | 0 | 0 |
| | Sum of Regimen disaggregates | 0 | 0 |
| | Sum of New and Current disaggregates | 0 | 0 |
| PMTCT_ARV_NGI | PMTCT_ARV_NGI Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (NGI) | 88 % | |
| | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 61,732 | 69,683 |
| | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 70,150 | 76,770 |
| | Life-long ART (including Option B+) | 33,953 | 38,326 |

| | | | |
|--------------|--|--------|--------|
| | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 12,908 | 12,987 |
| | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 21,045 | 25,339 |
| | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 24,075 | 27,873 |
| | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 3,087 | 3,484 |
| | Single-dose nevirapine (with or without tail) | 617 | 0 |
| | Sum of Regimen disaggregates | 61,732 | 69,683 |
| | Sum of New and Current disaggregates | 33,953 | 38,326 |
| PMTCT_ARV_TA | PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA) | n/a | |
| | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission | 0 | 0 |



| | | | |
|---------|---|---------|---------|
| | (MTCT) during pregnancy and delivery | | |
| | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 0 | 0 |
| | Life-long ART (including Option B+) | 0 | 0 |
| | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 0 | 0 |
| | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 0 | 0 |
| | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 0 | 0 |
| | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 0 | 0 |
| | Single-dose nevirapine (with or without tail) | 0 | 0 |
| | Sum of Regimen Type disaggregates | 0 | 0 |
| | Sum of New and Current disaggregates | 0 | 0 |
| BS_COLL | Number of whole blood collections each year by the NBTs network | 350,000 | 385,000 |
| | By: Number of whole blood | 315,000 | 346,500 |

| | | | |
|-------------|---|---------|-----------|
| | donations screened for HIV in an NBTS network laboratory | | |
| | By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV | 7,000 | 7,700 |
| KP_MAT_DSD | KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months | n/a | |
| | Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months | 0 | 0 |
| | Sex: Male | 0 | 0 |
| | Sex: Female | 0 | 0 |
| | Sum of Sex disaggregates | 0 | 0 |
| | | | |
| PP_PREV_DSD | PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD) | 43 % | |
| | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 73,698 | 405,399 |
| | Total number of people in the target population | 171,044 | 1,472,849 |

| | | | |
|-------------|---|---------|---------|
| | Age/sex: 10-14 Male | 3,611 | 19,865 |
| | Age/sex: 15-19 Male | 4,333 | 23,837 |
| | Age/sex: 20-24 Male | 10,834 | 59,594 |
| | Age/sex: 25-49 Male | 16,250 | 89,391 |
| | Age/sex: 50+ Male | 1,083 | 5,959 |
| | Age/sex: 10-14 Female | 3,759 | 20,675 |
| | Age/sex: 15-19 Female | 4,510 | 24,810 |
| | Age/sex: 20-24 Female | 11,276 | 62,026 |
| | Age/sex: 25-49 Female | 16,914 | 93,039 |
| | Age/sex: 50+ Female | 1,128 | 6,203 |
| | Sum of Age/Sex disaggregates | 73,698 | 405,399 |
| KP_PREV_DSD | KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD) | n/a | |
| | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 221,133 | 131,538 |
| | Total estimated number of key population in the catchment area | | |
| | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group | 213,288 | 122,330 |

| | | | |
|--|---|--------|-------|
| | level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | | |
| | By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 3,669 | 2,105 |
| | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 917 | 526 |
| | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 11,467 | 6,577 |
| | By key population type: MSM/TG who are male sex | 1,147 | 658 |

| | | | |
|--|---|--|--|
| | workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | | |
| | By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) | | |
| | By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area) | | |
| | By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area) | | |
| | By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area) | | |
| | By key population type: MSM/TG who are male sex | | |

| | | | |
|------------|---|-----|---|
| | workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area) | | |
| KP_PREV_TA | KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only) | n/a | |
| | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 0 | 0 |
| | Total estimated number of key population in the catchment area | | |
| | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 0 | 0 |
| | By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations | 0 | 0 |

| | | | |
|--|--|---|---|
| | reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | | |
| | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 0 | 0 |
| | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 0 | 0 |
| | By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 0 | 0 |



| | | | |
|-------------|---|-----------|-----------|
| | By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) | | |
| | By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area) | | |
| | By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area) | | |
| | By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area) | | |
| | By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area) | | |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test | 6,737,522 | 7,856,834 |



| | | | |
|--|--|-----------|-----------|
| | results during the past 12 months | | |
| | By Test Result: Negative | 6,547,146 | 7,634,831 |
| | By Test Result: Positive | 190,376 | 222,003 |
| | Sum of Test Result disaggregates | 6,737,522 | 7,856,834 |
| | Test Result by Age and Sex: Positive: <1 Male | | |
| | Test Result by Age and Sex: Positive: 1-4 Male | | |
| | Test Result by Age and Sex: Positive: 5-9 Male | | |
| | Test Result by Age and Sex: Positive: 10-14 Male | | |
| | Test Result by Age and Sex: Positive: 15-19 Male | | |
| | Test Result by Age and Sex: Positive: 20-24 Male | | |
| | Test Result by Age and Sex: Positive: 25-49 Male | | |
| | Test Result by Age and Sex: Positive: 50+ Male | | |
| | Test Result by Age and Sex: Positive: <1 Female | | |
| | Test Result by Age and Sex: Positive: 1-4 Female | | |
| | Test Result by Age and Sex: Positive: 5-9 Female | | |
| | Test Result by Age and Sex: Positive: 10-14 Female | | |
| | Test Result by Age and Sex: Positive: 15-19 Female | | |
| | Test Result by Age and Sex: Positive: 20-24 Female | | |



| | | | |
|--|---|--|--|
| | Test Result by Age and Sex: Positive: 25-49 Female | | |
| | Test Result by Age and Sex: Positive: 50+ Female | | |
| | Test Result by Age and Sex: Negative: <1 Male | | |
| | Test Result by Age and Sex: Negative: 1-4 Male | | |
| | Test Result by Age and Sex: Negative: 5-9 Male | | |
| | Test Result by Age and Sex: Negative: 10-14 Male | | |
| | Test Result by Age and Sex: Negative: 15-19 Male | | |
| | Test Result by Age and Sex: Negative: 20-24 Male | | |
| | Test Result by Age and Sex: Negative: 25-49 Male | | |
| | Test Result by Age and Sex: Negative: 50+ Male | | |
| | Test Result by Age and Sex: Negative: <1 Female | | |
| | Test Result by Age and Sex: Negative: 1-4 Female | | |
| | Test Result by Age and Sex: Negative: 5-9 Female | | |
| | Test Result by Age and Sex: Negative: 10-14 Female | | |
| | Test Result by Age and Sex: Negative: 15-19 Female | | |
| | Test Result by Age and Sex: Negative: 20-24 Female | | |
| | Test Result by Age and Sex: Negative: 25-49 Female | | |



| | | | |
|--|--|-----------|-----------|
| | Test Result by Age and Sex: Negative: 50+ Female | | |
| | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 81,272 | 94,773 |
| | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 2,337,413 | 2,725,730 |
| | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 84,335 | 98,346 |
| | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 4,234,502 | 4,937,985 |
| | Sum of Aggregated Age/Sex <15 | 165,607 | 193,119 |
| | Sum of Aggregated Age/Sex 15+ | 6,571,915 | 7,663,715 |
| | Sum of Aggregated Age/Sex disaggregates | 6,737,522 | 7,856,834 |
| | Service Delivery Point by Result: Antenatal Clinic - All results | | |
| | Service Delivery Point by Result: Antenatal Clinic - Positive | | |
| | Service Delivery Point by Result: Antenatal Clinic - Negative | | |
| | Service Delivery Point by Result: Labor & delivery - All results | | |
| | Service Delivery Point by Result: Labor & delivery - Positive | | |



| | | | |
|--|--|--|--|
| | Service Delivery Point by Result: Labor & delivery - Negative | | |
| | Service Delivery Point by Result: Under 5 Clinic – All results | | |
| | Service Delivery Point by Result: Under 5 Clinic - Positive | | |
| | Service Delivery Point by Result: Under 5 Clinic - Negative | | |
| | Service Delivery Point by Result: Maternal and Child Health Clinic – All Results | | |
| | Service Delivery Point by Result: Maternal and Child Health Clinic - Positive | | |
| | Service Delivery Point by Result: Maternal and Child Health Clinic - Negative | | |
| | Service Delivery Point by Result: Tuberculosis – All results | | |
| | Service Delivery Point by Result: Tuberculosis - Positive | | |
| | Service Delivery Point by Result: Tuberculosis - Negative | | |
| | Service Delivery Point by Result: Sexually Transmitted Infections – All Results | | |
| | Service Delivery Point by Result: Sexually Transmitted | | |



| | | | |
|--|--|--|--|
| | Infections - Positive | | |
| | Service Delivery Point by Result: Sexually Transmitted Infections - Negative | | |
| | Service Delivery Point by Result: Outpatient Department – All Results | | |
| | Service Delivery Point by Result: Outpatient Department - Positive | | |
| | Service Delivery Point by Result: Outpatient Department - Negative | | |
| | Service Delivery Point by Result: Inpatient – All Results | | |
| | Service Delivery Point by Result: Inpatient - Positive | | |
| | Service Delivery Point by Result: Inpatient - Negative | | |
| | Service Delivery Point by Result: HIV care and treatment clinic – All Results | | |
| | Service Delivery Point by Result: HIV care and treatment clinic - Positive | | |
| | Service Delivery Point by Result: HIV care and treatment clinic - Negative | | |
| | Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results | | |
| | Service Delivery Point by Result: Voluntary Medical | | |



| | | | |
|--|---|--|--|
| | Male Circumcision - Positive | | |
| | Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative | | |
| | Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results | | |
| | Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive | | |
| | Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative | | |
| | Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results | | |
| | Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive | | |
| | Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative | | |
| | Service Delivery Point by Result: Mobile – All Results | | |
| | Service Delivery Point by Result: Mobile - Positive | | |
| | Service Delivery Point by Result: Mobile - Negative | | |
| | Service Delivery Point by | | |



| | | | |
|------------|---|---|---|
| | Result: Home-based – All Results | | |
| | Service Delivery Point by Result: Home-based - Positive | | |
| | Service Delivery Point by Result: Home-based - Negative | | |
| | Service Delivery Point by Result: Other – All Results | | |
| | Service Delivery Point by Result: Other - Positive | | |
| | Service Delivery Point by Result: Other - Negative | | |
| HTC_TST_NA | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 0 | 0 |
| | By Test Result: Negative | 0 | 0 |
| | By Test Result: Positive | 0 | 0 |
| | Sum of Test Result disaggregates | 0 | 0 |
| | Age/sex: <1 Male | 0 | 0 |
| | Age/sex: 1-4 Male | 0 | 0 |
| | Age/sex: 5-9 Male | 0 | 0 |
| | Age/sex: 10-14 Male | 0 | 0 |
| | Age/sex: 15-19 Male | 0 | 0 |
| | Age/sex: 20-24 Male | 0 | 0 |
| | Age/sex: 25-49 Male | 0 | 0 |
| | Age/sex: 50+ Male | 0 | 0 |
| | Age/sex: <1 Female | 0 | 0 |
| | Age/sex: 1-4 Female | 0 | 0 |
| | Age/sex: 5-9 Female | 0 | 0 |

| | | | |
|-------------|---|-----------|-----------|
| | Age/sex: 10-14 Female | 0 | 0 |
| | Age/sex: 15-19 Female | 0 | 0 |
| | Age/sex: 20-24 Female | 0 | 0 |
| | Age/sex: 25-49 Female | 0 | 0 |
| | Age/sex: 50+ Female | 0 | 0 |
| | Sum of Age/Sex disaggregates | 0 | 0 |
| | Aggregated Age/sex: <15 Male | 0 | 0 |
| | Aggregated Age/sex: 15+ Male | 0 | 0 |
| | Aggregated Age/sex: <15 Female | 0 | 0 |
| | Aggregated Age/sex: 15+ Female | 0 | 0 |
| | Sum of Aggregated Age/Sex <15 | 0 | 0 |
| | Sum of Aggregated Age/Sex 15+ | 0 | 0 |
| | Sum of Aggregated Age/Sex disaggregates | 0 | 0 |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 6,979,479 | 8,146,941 |
| | By Test Result: Negative | 6,782,266 | 7,916,740 |
| | By Test Result: Positive | 197,213 | 230,201 |
| | Sum of Test Result disaggregates | 6,979,479 | 8,146,941 |
| | Age/sex: <1 Male | 27,173 | 31,718 |
| | Age/sex: 1-4 Male | 24,691 | 28,821 |
| | Age/sex: 5-9 Male | 9,991 | 11,662 |
| | Age/sex: 10-14 Male | 22,336 | 26,072 |

| | | | |
|------------|---|-----------|-----------|
| | Age/sex: 15-19 Male | 247,766 | 289,210 |
| | Age/sex: 20-24 Male | 512,441 | 598,157 |
| | Age/sex: 25-49 Male | 1,611,193 | 1,880,698 |
| | Age/sex: 50+ Male | 49,955 | 58,311 |
| | Age/sex: <1 Female | 28,282 | 33,013 |
| | Age/sex: 1-4 Female | 25,862 | 30,188 |
| | Age/sex: 5-9 Female | 10,288 | 12,009 |
| | Age/sex: 10-14 Female | 22,932 | 26,768 |
| | Age/sex: 15-19 Female | 444,782 | 519,181 |
| | Age/sex: 20-24 Female | 1,186,861 | 1,385,387 |
| | Age/sex: 25-49 Female | 2,703,490 | 3,155,704 |
| | Age/sex: 50+ Female | 51,436 | 60,042 |
| | Sum of Age/Sex disaggregates | 6,979,479 | 8,146,941 |
| | Aggregated Age/sex: <15 Male | 84,190 | 98,273 |
| | Aggregated Age/sex: 15+ Male | 2,421,354 | 2,826,376 |
| | Aggregated Age/sex: <15 Female | 87,364 | 101,978 |
| | Aggregated Age/sex: 15+ Female | 4,386,571 | 5,120,314 |
| | Sum of Aggregated Age/Sex <15 | 171,554 | 200,251 |
| | Sum of Aggregated Age/Sex 15+ | 6,807,925 | 7,946,690 |
| | Sum of Aggregated Age/Sex disaggregates | 6,979,479 | 8,146,941 |
| HTC_TST_TA | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 241,957 | 290,107 |



| | | | |
|--|---|---------|---------|
| | By Test Result: Negative | 234,702 | 281,408 |
| | By Test Result: Positive | 7,255 | 8,699 |
| | Sum of Test Result disaggregates | 241,957 | 290,107 |
| | Test Result by Age and Sex: Positive: <1 Male | | |
| | Test Result by Age and Sex: Positive: 1-4 Male | | |
| | Test Result by Age and Sex: Positive: 5-9 Male | | |
| | Test Result by Age and Sex: Positive: 10-14 Male | | |
| | Test Result by Age and Sex: Positive: 15-19 Male | | |
| | Test Result by Age and Sex: Positive: 20-24 Male | | |
| | Test Result by Age and Sex: Positive: 25-49 Male | | |
| | Test Result by Age and Sex: Positive: 50+ Male | | |
| | Test Result by Age and Sex: Positive: <1 Female | | |
| | Test Result by Age and Sex: Positive: 1-4 Female | | |
| | Test Result by Age and Sex: Positive: 5-9 Female | | |
| | Test Result by Age and Sex: Positive: 10-14 Female | | |
| | Test Result by Age and Sex: Positive: 15-19 Female | | |
| | Test Result by Age and Sex: Positive: 20-24 Female | | |
| | Test Result by Age and Sex: Positive: 25-49 Female | | |



| | | | |
|--|---|--|--|
| | Test Result by Age and Sex: Positive: 50+ Female | | |
| | Test Result by Age and Sex: Negative: <1 Male | | |
| | Test Result by Age and Sex: Negative: 1-4 Male | | |
| | Test Result by Age and Sex: Negative: 5-9 Male | | |
| | Test Result by Age and Sex: Negative: 10-14 Male | | |
| | Test Result by Age and Sex: Negative: 15-19 Male | | |
| | Test Result by Age and Sex: Negative: 20-24 Male | | |
| | Test Result by Age and Sex: Negative: 25-49 Male | | |
| | Test Result by Age and Sex: Negative: 50+ Male | | |
| | Test Result by Age and Sex: Negative: <1 Female | | |
| | Test Result by Age and Sex: Negative: 1-4 Female | | |
| | Test Result by Age and Sex: Negative: 5-9 Female | | |
| | Test Result by Age and Sex: Negative: 10-14 Female | | |
| | Test Result by Age and Sex: Negative: 15-19 Female | | |
| | Test Result by Age and Sex: Negative: 20-24 Female | | |
| | Test Result by Age and Sex: Negative: 25-49 Female | | |
| | Test Result by Age and Sex: Negative: 50+ Female | | |

| | | | |
|--|--|---------|---------|
| | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 3,558 | 4,265 |
| | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 115,031 | 137,923 |
| | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 3,684 | 4,417 |
| | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 119,684 | 143,502 |
| | Sum of Aggregated Age/Sex <15 | 7,242 | 8,682 |
| | Sum of Aggregated Age/Sex 15+ | 234,715 | 281,425 |
| | Sum of Aggregated Age/Sex disaggregates | 241,957 | 290,107 |
| | Service Delivery Point by Result: Antenatal Clinic - All results | | |
| | Service Delivery Point by Result: Antenatal Clinic - Positive | | |
| | Service Delivery Point by Result: Antenatal Clinic - Negative | | |
| | Service Delivery Point by Result: Labor & delivery - All results | | |
| | Service Delivery Point by Result: Labor & delivery - Positive | | |
| | Service Delivery Point by Result: Labor & delivery - | | |



| | | | |
|--|--|--|--|
| | Negative | | |
| | Service Delivery Point by Result: Under 5 Clinic – All results | | |
| | Service Delivery Point by Result: Under 5 Clinic - Positive | | |
| | Service Delivery Point by Result: Under 5 Clinic - Negative | | |
| | Service Delivery Point by Result: Maternal and Child Health Clinic – All Results | | |
| | Service Delivery Point by Result: Maternal and Child Health Clinic - Positive | | |
| | Service Delivery Point by Result: Maternal and Child Health Clinic - Negative | | |
| | Service Delivery Point by Result: Tuberculosis – All results | | |
| | Service Delivery Point by Result: Tuberculosis - Positive | | |
| | Service Delivery Point by Result: Tuberculosis - Negative | | |
| | Service Delivery Point by Result: Sexually Transmitted Infections – All Results | | |
| | Service Delivery Point by Result: Sexually Transmitted Infections - Positive | | |
| | Service Delivery Point by | | |



| | | | |
|--|---|--|--|
| | Result: Sexually Transmitted Infections - Negative | | |
| | Service Delivery Point by Result: Outpatient Department – All Results | | |
| | Service Delivery Point by Result: Outpatient Department - Positive | | |
| | Service Delivery Point by Result: Outpatient Department - Negative | | |
| | Service Delivery Point by Result: Inpatient – All Results | | |
| | Service Delivery Point by Result: Inpatient - Positive | | |
| | Service Delivery Point by Result: Inpatient - Negative | | |
| | Service Delivery Point by Result: HIV care and treatment clinic – All Results | | |
| | Service Delivery Point by Result: HIV care and treatment clinic - Positive | | |
| | Service Delivery Point by Result: HIV care and treatment clinic - Negative | | |
| | Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results | | |
| | Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive | | |
| | Service Delivery Point by | | |



| | | | |
|--|---|--|--|
| | Result: Voluntary Medical Male Circumcision - Negative | | |
| | Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results | | |
| | Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive | | |
| | Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative | | |
| | Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All | | |
| | Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Positive | | |
| | Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Negative | | |
| | Service Delivery Point by Result: Mobile – All Results | | |
| | Service Delivery Point by Result: Mobile - Positive | | |
| | Service Delivery Point by Result: Mobile - Negative | | |
| | Service Delivery Point by Result: Home-based – All Results | | |
| | Service Delivery Point by | | |



| | | | |
|---------------|--|-------|---------|
| | Result: Home-based - Positive | | |
| | Service Delivery Point by Result: Home-based - Negative | | |
| | Service Delivery Point by Result: Other – All Results | | |
| | Service Delivery Point by Result: Other - Positive | | |
| | Service Delivery Point by Result: Other - Negative | | |
| GEND_GBV_DSD | Number of people receiving post-GBV care | 1,837 | 1,837 |
| | Age/Sex: <10 Male | | |
| | Age/Sex: 10-14 Male | | |
| | Age/Sex: 15-17 Male | | |
| | Age/Sex: 18-24 Male | | |
| | Age/Sex: 25+ Male | | |
| | Age/Sex: <10 Female | | |
| | Age/Sex: 10-14 Female | | |
| | Age/Sex: 15-17 Female | | |
| | Age/Sex: 18-24 Female | | |
| | Age/Sex: 25+ Female | | |
| | Sum of Age/Sex Disaggregates | | |
| | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) | 411 | 411 |
| | By type of service: Sexual Violence (Post-Rape Care) | 1,426 | 1,426 |
| | By PEP service provision (related to sexual violence services provided) | 1,425 | 1,425 |
| GEND_NORM_DSD | Number of people | | 571,748 |

| | | | |
|-------------|--|---------|---------|
| | completing an intervention pertaining to gender norms, that meets minimum criteria | | |
| | Age/Sex: <10 Male | | |
| | Age/Sex: 10-14 Male | | |
| | Age/Sex: 15-19 Male | | |
| | Age/Sex: 20-24 Male | | |
| | Age/Sex: 25+ Male | | |
| | Age/Sex: <10 Female | | |
| | Age/Sex: 10-14 Female | | |
| | Age/Sex: 15-19 Female | | |
| | Age/Sex: 20-24 Female | | |
| | Age/Sex: 25+ Female | | |
| | By Age: 0-9 | | 28,587 |
| | By Age: 10-14 | | 28,587 |
| | By Age: 15-19 | | 68,611 |
| | By Age: 20-24 | | 171,524 |
| | By Age: 25+ | | 274,439 |
| | Sum of Age disaggregates | | 571,748 |
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 262,813 | 392,845 |
| | Age/Sex: <1 Male | | |
| | Age/Sex: 1-4 Male | | |
| | Age/Sex: 5-9 Male | | |
| | Age/Sex: 10-14 Male | | |
| | Age/Sex: 15-17 Male | | |
| | Age/Sex: 18-24 Male | | |
| | Age/Sex: 25+ Male | | |
| | Age/Sex: <1 Female | | |
| | Age/Sex: 1-4 Female | | |



| | | | |
|--------------|---|---------|-----------|
| | Age/Sex: 5-9 Female | | |
| | Age/Sex: 10-14 Female | | |
| | Age/Sex: 15-17 Female | | |
| | Age/Sex: 18+ Female | | |
| | Age/Sex: 18-24 Female | | |
| | Age/Sex: 25+ Female | | |
| | Sum of Age/Sex disaggregates | | |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 876,044 | 1,309,488 |
| | Age/Sex: <1 Male | | |
| | Age/Sex: 1-4 Male | | |
| | Age/Sex: 5-9 Male | | |
| | Age/Sex: 10-14 Male | | |
| | Age/Sex: 15-17 Male | | |
| | By: Age/sex: Male 18-24 | | |
| | By: Age/sex: Male 25+ | | |
| | Age/Sex: <1 Female | | |
| | Age/Sex: 1-4 Female | | |
| | Age/Sex: 5-9 Female | | |
| | Age/Sex: 10-14 Female | | |
| | Age/Sex: 15-17 Female | | |
| | By: Age/sex: 18-24 Female | | |
| | By: Age/sex: 25+ Female | | |
| | Sum of Age/Sex disaggregates | | |
| | Required only for DREAMS countries - By service, age and sex: Education Support Female <1 | | |



| | | | |
|--|--|--|--|
| | Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4 | | |
| | Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9 | | |
| | Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14 | | |
| | Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17 | | |
| | Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24 | | |
| | Required only for DREAMS countries - By service, age and sex: Education Support Female 25+ | | |
| | Required only for DREAMS countries - By service, age and sex: Education Support Male <1 | | |
| | Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4 | | |
| | Required only for DREAMS countries - By service, age and sex: Education Support | | |



| | | | |
|--|---|--|--|
| | Male 5-9 | | |
| | Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14 | | |
| | Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17 | | |
| | Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24 | | |
| | Required only for DREAMS countries - By service, age and sex: Education Support Male 25+ | | |
| | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1 | | |
| | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4 | | |
| | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9 | | |
| | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14 | | |
| | Required only for DREAMS countries - By service, age | | |



| | | | |
|--|---|--|--|
| | and sex: Parenting/Caregiver Programs Female 15-17 | | |
| | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24 | | |
| | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+ | | |
| | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1 | | |
| | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4 | | |
| | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9 | | |
| | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14 | | |
| | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17 | | |
| | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24 | | |
| | Required only for DREAMS | | |



| | | | |
|--|--|--|--|
| | countries - By service, age and sex: Parenting/Caregiver Programs Male 25+ | | |
| | Required only for DREAMS countries - By service, age and sex: Social Protection Female <1 | | |
| | Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4 | | |
| | Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9 | | |
| | Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14 | | |
| | Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17 | | |
| | Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24 | | |
| | Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+ | | |
| | Required only for DREAMS countries - By service, age and sex: Social Protection Male <1 | | |



| | | | |
|--|---|--|--|
| | Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4 | | |
| | Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9 | | |
| | Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14 | | |
| | Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17 | | |
| | Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24 | | |
| | Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+ | | |
| | Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1 | | |
| | Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4 | | |
| | Required only for DREAMS countries - By service, age and sex: Economic | | |



| | | | |
|--|--|--|--|
| | Strengthening Female 5-9 | | |
| | Required only for DREAMS countries - By service, age and sex: Economic | | |
| | Strengthening Female 10-14 | | |
| | Required only for DREAMS countries - By service, age and sex: Economic | | |
| | Strengthening Female 15-17 | | |
| | Required only for DREAMS countries - By service, age and sex: Economic | | |
| | Strengthening Female 18-24 | | |
| | Required only for DREAMS countries - By service, age and sex: Economic | | |
| | Strengthening Female 25+ | | |
| | Required only for DREAMS countries - By service, age and sex: Economic | | |
| | Strengthening Male <1 | | |
| | Required only for DREAMS countries - By service, age and sex: Economic | | |
| | Strengthening Male 1-4 | | |
| | Required only for DREAMS countries - By service, age and sex: Economic | | |
| | Strengthening Male 5-9 | | |
| | Required only for DREAMS countries - By service, age and sex: Economic | | |
| | Strengthening Male 10-14 | | |
| | Required only for DREAMS countries - By service, age | | |

| | | | |
|------------|---|---------|---|
| | and sex: Economic Strengthening Male 15-17 | | |
| | Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24 | | |
| | Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+ | | |
| C2.1.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 920,103 | |
| | By Age/Sex: <15 Female | 32,204 | |
| | By Age/Sex: <15 Male | 13,802 | |
| | By Age/Sex: 15+ Female | 611,868 | |
| | By Age/Sex: 15+ Male | 262,229 | |
| | Sum of Age/Sex disaggregates | 920,103 | |
| | By Age: <15 | 46,005 | |
| | By Age: 15+ | 874,098 | |
| | Sum of Age disaggregates | 920,103 | |
| | By Sex: Female | 644,072 | |
| | By Sex: Male | 276,031 | |
| | Sum of Sex disaggregates | 920,103 | |
| C2.1.D_NA | Number of HIV-positive individuals receiving a minimum of one clinical service | 0 | 0 |
| | By Age/Sex: <15 Female | 0 | 0 |
| | By Age/Sex: <15 Male | 0 | 0 |
| | By Age/Sex: 15+ Female | 0 | 0 |
| | By Age/Sex: 15+ Male | 0 | 0 |

| | | | |
|------------|--|---------|---|
| | Sum of Age/Sex disaggregates | 0 | 0 |
| | By Age: <15 | 0 | 0 |
| | By Age: 15+ | 0 | 0 |
| | Sum of Age disaggregates | 0 | 0 |
| | By Sex: Female | 0 | 0 |
| | By Sex: Male | 0 | 0 |
| | Sum of Sex disaggregates | 0 | 0 |
| C2.1.D_NGI | Number of HIV-positive individuals receiving a minimum of one clinical service | 920,103 | |
| | By Age/Sex: <15 Female | 32,204 | |
| | By Age/Sex: <15 Male | 13,802 | |
| | By Age/Sex: 15+ Female | 611,868 | |
| | By Age/Sex: 15+ Male | 262,229 | |
| | Sum of Age/Sex disaggregates | 920,103 | |
| | By Age: <15 | 46,005 | |
| | By Age: 15+ | 874,098 | |
| | Sum of Age disaggregates | 920,103 | |
| | By Sex: Female | 644,072 | |
| | By Sex: Male | 276,031 | |
| | Sum of Sex disaggregates | 920,103 | |
| C2.1.D_TA | Number of HIV-positive individuals receiving a minimum of one clinical service | 0 | 0 |
| | By Age/Sex: <15 Female | 0 | 0 |
| | By Age/Sex: <15 Male | 0 | 0 |
| | By Age/Sex: 15+ Female | 0 | 0 |
| | By Age/Sex: 15+ Male | 0 | 0 |
| | Sum of Age/Sex | 0 | 0 |

| | | | |
|---------------|---|---------|-----------|
| | disaggregates | | |
| | By Age: <15 | 0 | 0 |
| | By Age: 15+ | 0 | 0 |
| | Sum of Age disaggregates | 0 | 0 |
| | By Sex: Female | 0 | 0 |
| | By Sex: Male | 0 | 0 |
| | Sum of Sex disaggregates | 0 | 0 |
| C2.4.D_DSD | C2.4.D_DSD TB/HIV: Percent of HIV-positive patients who were screened for TB in HIV care or treatment setting | 90 % | |
| | Number of HIV-positive patients who were screened for TB in HIV care or treatment setting | 828,096 | |
| | Number of HIV-positive individuals receiving a minimum of one clinical service | 920,103 | |
| CARE_CURR_DSD | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | | 1,039,375 |
| | Age/sex: <1 Male | | 7,265 |
| | Age/sex: 1-4 Male | | 5,301 |
| | Age/sex: 5-9 Male | | 2,495 |
| | Age/sex: 10-14 Male | | 1,559 |
| | Age/sex: 15-19 Male | | 31,181 |
| | Age/sex: 20-24 Male | | 46,772 |
| | Age/sex: 25-49 Male | | 202,678 |

| | | | |
|--------------|---|--|-----------|
| | Age/sex: 50+ Male | | 14,562 |
| | Age/sex: <1 Female | | 16,952 |
| | Age/sex: 1-4 Female | | 12,369 |
| | Age/sex: 5-9 Female | | 5,821 |
| | Age/sex: 10-14 Female | | 3,638 |
| | Age/sex: 15-19 Female | | 72,756 |
| | Age/sex: 20-24 Female | | 109,134 |
| | Age/sex: 25-49 Female | | 472,916 |
| | Age/sex: 50+ Female | | 33,976 |
| | Sun of Age/Sex disaggregates | | 1,039,375 |
| | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | | 16,620 |
| | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | | 295,193 |
| | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | | 38,779 |
| | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | | 688,783 |
| | Sum of Aggregated Age/Sex disaggregates | | 1,039,375 |
| CARE_NEW_DSD | Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load | | 130,858 |

| | | | |
|-----------|--|-----|---------|
| | Age/sex: <1 Male | | 915 |
| | Age/sex: 1-4 Male | | 667 |
| | Age/sex: 5-9 Male | | 314 |
| | Age/sex: 10-14 Male | | 196 |
| | Age/sex: 15-19 Male | | 3,926 |
| | Age/sex: 20-24 Male | | 5,889 |
| | Age/sex: 25-49 Male | | 25,517 |
| | Age/sex: 50+ Male | | 1,833 |
| | Age/sex: <1 Female | | 2,134 |
| | Age/sex: 1-4 Female | | 1,557 |
| | Age/sex: 5-9 Female | | 733 |
| | Age/sex: 10-14 Female | | 458 |
| | Age/sex: 15-19 Female | | 9,160 |
| | Age/sex: 20-24 Female | | 13,740 |
| | Age/sex: 25-49 Female | | 59,541 |
| | Age/sex: 50+ Female | | 4,278 |
| | Sum of Age/sex disaggregates | | 130,858 |
| | Aggregated Age/sex: <15 Male | | 2,092 |
| | Aggregated Age/sex: 15+ Male | | 37,165 |
| | Aggregated Age/sex: <15 Female | | 4,882 |
| | Aggregated Age/sex: 15+ Female | | 86,719 |
| | Sum of Aggregated Age/sex disaggregates | | 130,858 |
| CARE_SITE | CARE_SITE Percentage of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the | n/a | |

| | | | |
|--|--|--|-----|
| | reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole | | |
| | Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole | | 744 |
| | Total number of PEPFAR supported sites providing clinical care services | | 930 |
| | By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole | | 744 |
| | By site support type: Technical Assistance-only (TA): Number of | | 0 |

| | | | |
|---------|--|-----|-----|
| | PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole | | |
| | Sum of Numerator Site Support Type disaggregates | | 744 |
| | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services | | 930 |
| | By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services | | 0 |
| | Sum of Denominator Site Support Type disaggregates | | 930 |
| FN_SITE | FN_SITE Percentage of PEPFAR-supported sites achieving 90% of nutrition assessments that result in an accurate categorization of malnutrition | n/a | |
| | Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of | | 930 |

| | | | |
|--|---|--|-----|
| | malnutrition | | |
| | Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services | | 930 |
| | By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition | | 930 |
| | By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition | | 0 |
| | Sum of Numerator Support Type disaggregates | | 930 |
| | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services | | 930 |
| | By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition | | 0 |

| | | | |
|-------------|---|--------|-------|
| | assessment, counseling and support (NACS) services | | |
| | Sum of Denominator Support Type disaggregates | | 930 |
| FN_THER_DSD | FN_THER_DSD Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food | 100 % | |
| | Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period. | 36,804 | 3,668 |
| | Number of PLHIV who were nutritionally assessed and found to be clinically undernourished. | 36,804 | 3,668 |
| | Age: <1 | 1,067 | 550 |
| | Age: 1-4 | 2,355 | 1,834 |
| | Age: 5-14 | 3,754 | 917 |
| | Age: 15-17 | 3,680 | 367 |
| | Age: 18+ | 25,948 | 0 |
| | Sum of Age disaggregates | 36,804 | 3,668 |
| | Aggregated Age: <18 | 10,856 | 3,668 |
| | Aggregated Age: 18+ | 25,948 | 0 |
| | Sum of Aggregated Age disaggregates | 36,804 | 3,668 |
| | By Pregnancy/Postpartum Status: Pregnant | | |
| | By Pregnancy/Postpartum Status: Postpartum | | |
| TB_ART_DSD | TB_ART_DSD Percentage of HIV-positive new and | n/a | |

| | | | |
|--|--|--------|--------|
| | relapsed registered TB cases on ART during TB treatment | | |
| | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 27,833 | 30,393 |
| | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period | | |
| | Age: <1 | | |
| | Age: 1-4 | | |
| | Age: 5-9 | | |
| | Age: 10-14 | | |
| | Age: 15-19 | | |
| | Age: 20+ | | |
| | Sum of Age disaggregates | | |
| | Male | 13,638 | 14,893 |
| | Female | 14,195 | 15,500 |
| | Sum of Sex disaggregates | 27,833 | 30,393 |
| | Newly tested | 15,995 | 23,403 |
| | Known HIV-positive | 11,838 | 6,990 |
| | Sum of Test Status disaggregates | 27,833 | 30,393 |
| | Aggregated Age: <15 | 1,670 | 1,824 |
| | Aggregated Age: 15+ | 26,163 | 28,569 |
| | Sum of Aggregated Age disaggregates | 27,833 | 30,393 |
| | Timeliness: Art initiation <8 weeks of start of TB | | |

| | | | |
|------------|--|-----|-------|
| | treatment | | |
| | Timeliness: Art initiation >8 weeks of start of TB treatment | | |
| TB_ARTSITE | TB_ARTSITE Proportion of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART | n/a | |
| | The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period | | 1,082 |
| | The number of PEPFAR-supported TB basic management units | | 1,273 |
| | By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period | | 1,082 |
| | By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on | | 0 |



| | | | |
|---------------|---|---------|-----------|
| | ART, during the reporting period | | |
| | Sum of Numerator Site Support Type disaggregates | | 1,082 |
| | By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units | | 1,273 |
| | By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units | | 0 |
| | Sum of Denominator Site Support Type disaggregates | | 1,273 |
| TB_SCREEN_DSD | TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period. | n/a | |
| | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period | 828,096 | 935,450 |
| | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | | 1,039,375 |
| | Age: <1 | 19,295 | 21,796 |

| | | | |
|---------------|--|---------|---------|
| | Age: 1-4 | 14,078 | 15,903 |
| | Age: 5-9 | 6,625 | 7,484 |
| | Age: 10-14 | 4,140 | 4,677 |
| | Age: 15-19 | 82,810 | 93,545 |
| | Age: 20+ | | |
| | Sum of Age disaggregates | 126,948 | 143,405 |
| | Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 | 44,138 | 49,860 |
| | Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ | 783,958 | 885,590 |
| | Sum of Aggregated Age disaggregates | 828,096 | 935,450 |
| | Sex: Male | 248,429 | 280,635 |
| | Sex: Female | 579,667 | 654,815 |
| | Sum of Sex disaggregates | 828,096 | 935,450 |
| PMTCT_EID_DSD | PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD) | 88 % | |
| | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period | 61,732 | 69,683 |
| | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 70,075 | 76,769 |
| | By infants who received a virologic test within 2 months | 20,372 | 22,995 |

| | | | |
|-------------|---|---------|---------|
| | of birth | | |
| | By infants who received their first virologic HIV test between 2 and 12 months of age | 41,360 | 46,688 |
| | Sum of Infant Age disaggregates | 61,732 | 69,683 |
| | By infants with a positive virologic test result within 12 months of birth | | |
| | Number of infants with a positive virological test result within 2 months of birth | | |
| | Number of infants with a positive virological test result within 12 months of birth | | |
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 613,403 | 692,916 |
| | Age/Sex: <1 Male | 4,288 | 4,843 |
| | Age/Sex: 1-4 Male | 3,128 | 3,534 |
| | Age/Sex: 5-14 Male | 2,392 | 2,702 |
| | Age/Sex: 15-19 Male | | |
| | Age/Sex: 20+ Male | | |
| | Age/Sex: <1 Female | 10,005 | 11,301 |
| | Age/Sex: 1-4 Female | 7,299 | 8,246 |
| | Age/Sex: 5-14 Female | 5,582 | 6,306 |
| | Age/Sex: 15-19 Female | | |
| | Age/Sex: 20+ Female | | |
| | Aggregated Age/Sex: <1 Male | 4,288 | 4,843 |
| | Aggregated Age/Sex: <1 Female | 10,005 | 11,301 |
| | Aggregated Age/Sex: 1-14 | | |



| | | | |
|------------|--|---------|---------|
| | Male | | |
| | Aggregated Age/Sex: 15+ Male | 174,213 | 196,795 |
| | Aggregated Age/Sex: 1-14 Female | | |
| | Aggregated Age/Sex: 15+ Female | 406,496 | 459,189 |
| | Sum of Aggregated Age/Sex <15 | 32,694 | 36,932 |
| | Sum of Aggregated Age/Sex 15+ | 580,709 | 655,984 |
| | Sum of Aggregated Age/Sex disaggregates | 613,403 | 692,916 |
| TX_CURR_NA | Number of adults and children receiving antiretroviral therapy (ART) | 0 | 0 |
| | Age/Sex: <1 Male | 0 | 0 |
| | Age/Sex: 1-4 Male | 0 | 0 |
| | Age/Sex: 5-14 Male | 0 | 0 |
| | Age/Sex: 15+ Male | 0 | 0 |
| | Age/Sex: <1 Female | 0 | 0 |
| | Age/Sex: 1-4 Female | 0 | 0 |
| | Age/Sex: 5-14 Female | 0 | 0 |
| | Age/Sex: 15+ Female | 0 | 0 |
| | Sum of Age/Sex disaggregates | 0 | 0 |
| | Aggregated Age/Sex: <1 Male | 0 | 0 |
| | Aggregated Age/Sex: <1 Female | 0 | 0 |
| | Aggregated Age/Sex: <15 Male | 0 | 0 |
| | Aggregated Age/Sex: 15+ Male | 0 | 0 |



| | | | |
|-------------|--|---------|---------|
| | Aggregated Age/Sex: <15 Female | 0 | 0 |
| | Aggregated Age/Sex: 15+ Female | 0 | 0 |
| | Sum of Aggregated Age/Sex <15 | 0 | 0 |
| | Sum of Aggregated Age/Sex 15+ | 0 | 0 |
| | Sum of Aggregated Age/Sex disaggregations | 0 | 0 |
| TX_CURR_NGI | Number of adults and children receiving antiretroviral therapy (ART) | 613,403 | 692,916 |
| | Age/Sex: <1 Male | 4,288 | 4,843 |
| | Age/Sex: 1-4 Male | 3,128 | 3,534 |
| | Age/Sex: 5-14 Male | 2,392 | 2,702 |
| | Age/Sex: 15+ Male | 174,213 | 196,795 |
| | Age/Sex: <1 Female | 10,005 | 11,301 |
| | Age/Sex: 1-4 Female | 7,299 | 8,246 |
| | Age/Sex: 5-14 Female | 5,582 | 6,306 |
| | Age/Sex: 15+ Female | 406,496 | 459,189 |
| | Sum of Age/Sex disaggregates | 613,403 | 692,916 |
| | Aggregated Age/Sex: <1 Male | 4,288 | 4,843 |
| | Aggregated Age/Sex: <1 Female | 10,005 | 11,301 |
| | Aggregated Age/Sex: <15 Male | 9,808 | 11,079 |
| | Aggregated Age/Sex: 15+ Male | 174,213 | 196,795 |
| | Aggregated Age/Sex: <15 Female | 22,886 | 25,853 |
| | Aggregated Age/Sex: 15+ | 406,496 | 459,189 |

| | | | |
|------------|--|---------|---------|
| | Female | | |
| | Sum of Aggregated Age/Sex disaggregates | 613,403 | 692,916 |
| | Sum of Aggregated Age/Sex <15 | 32,694 | 36,932 |
| | Sum of Aggregated Age/Sex 15+ | 580,709 | 655,984 |
| TX_CURR_TA | Number of adults and children receiving antiretroviral therapy (ART) | 0 | 0 |
| | Age/Sex: <1 Male | 0 | 0 |
| | Age/Sex: 1-4 Male | 0 | 0 |
| | Age/Sex: 5-14 Male | 0 | 0 |
| | Age/Sex: 15-19 Male | | |
| | Age/Sex: 20+ Male | | |
| | Age/Sex: <1 Female | 0 | 0 |
| | Age/Sex: 1-4 Female | 0 | 0 |
| | Age/Sex: 5-14 Female | 0 | 0 |
| | Age/Sex: 15-19 Female | | |
| | Age/Sex: 20+ Female | | |
| | Sum of Age/Sex disaggregations | 0 | 0 |
| | Aggregated Age/Sex: <1 Male | 0 | 0 |
| | Aggregated Age/Sex: <1 Female | 0 | 0 |
| | Aggregated Age/Sex: 1-14 Male | | |
| | Aggregated Age/Sex: 15+ Male | 0 | 0 |
| | Aggregated Age/Sex: 1-14 Female | | |
| | Aggregated Age/Sex: 15+ | 0 | 0 |

| | | | |
|------------|---|---------|---------|
| | Female | | |
| | Sum of Aggregated Age/Sex <15 | 0 | 0 |
| | Sum of Aggregated Age/Sex 15+ | 0 | 0 |
| | Sum of Aggregated Age/Sex disaggregates | 0 | 0 |
| TX_DIST | TX_DIST Percentage of Districts that are PEPFAR supported with documented routine supportive supervision visits to 75% of ART sites in District | n/a | |
| | Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District | | 33 |
| | Total number of PEPFAR supported District Health Offices | | 37 |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 198,086 | 218,097 |
| | By Age/Sex: <1 Male | 1,385 | 1,524 |
| | By Age/Sex: 1-4 Male | 1,010 | 1,112 |
| | By Age/Sex: 5-9 Male | 475 | 523 |
| | By Age/Sex: 10-14 Male | 297 | 327 |
| | By Age/Sex: 15-19 Male | 5,943 | 6,543 |
| | By Age/Sex: 20-24 Male | 8,914 | 9,814 |
| | By Age/Sex: 25-49 Male | 38,628 | 42,530 |
| | By Age/Sex: 50+ Male | 2,775 | 3,056 |
| | By Age/Sex: <1 Female | 3,231 | 3,557 |

| | | | |
|------------|---|---------|---------|
| | By Age/Sex: 1-4 Female | 2,357 | 2,595 |
| | By Age/Sex: 5-9 Female | 1,109 | 1,221 |
| | By Age/Sex: 10-14 Female | 693 | 763 |
| | By Age/Sex: 15-19 Female | 13,866 | 15,267 |
| | By Age/Sex: 20-24 Female | 20,799 | 22,900 |
| | By Age/Sex: 25-49 Female | 90,129 | 99,235 |
| | By Age/Sex: 50+ Female | 6,475 | 7,130 |
| | Sum of Age/Sex disaggregates | 198,086 | 218,097 |
| | Aggregated Grouping by Age: <1 Male | 1,385 | 1,524 |
| | Aggregated Grouping by Age/Sex: 1-14 Male | | |
| | Aggregated Grouping by Age/Sex: 15+ Male | 56,260 | 61,943 |
| | Aggregated Grouping by Age/Sex: <1 Female | 3,231 | 3,557 |
| | Aggregated Grouping by Age/Sex: 1-14 Female | | |
| | Aggregated Grouping by Age/Sex: 15+ Female | 131,269 | 144,532 |
| | Sum of Aggregated Age/Sex disaggregates | 198,086 | 218,097 |
| | Pregnancy status | 13,127 | 14,453 |
| | Breastfeeding status | 6,563 | 7,227 |
| TX_RET_DSD | TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy | 85 % | |
| | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 108,254 | 168,373 |



| | | | |
|--|---|---------|---------|
| | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 127,358 | 198,086 |
| | Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | | |
| | Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | | |
| | Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | | |
| | Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | | |
| | Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at | | |



| | | | |
|--|--|--|--|
| | 12 months after initiating ART) | | |
| | Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | | |
| | Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | | |
| | Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | | |
| | Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | | |
| | Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | | |



| | | | |
|--|---|--|--|
| | including those who have died, those who have stopped ART, and those lost to follow-up) | | |
| | Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | | |
| | Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | | |
| | Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | | |
| | Age/Sex: 5-14 Female (Denominator: Total number | | |



| | | | |
|--|---|--|--|
| | of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | | |
| | Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | | |
| | Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | | |
| | Numerator by Status: Pregnant | | |
| | Numerator by Status: Breastfeeding | | |
| | Denominator by Status: Pregnant | | |
| | Denominator by Status: Breastfeeding | | |

| | | | |
|---------|--|-----|-----|
| TX_SITE | TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate | n/a | |
| | Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation | | 791 |
| | Total number of PEPFAR-supported ART sites | | 930 |
| | By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation | | 791 |
| | By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation | | 0 |
| | Sum of Numerator Site Support Type disaggregates | | 791 |
| | By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites | | 930 |

| | | | |
|-------------|---|-----|-----|
| | By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites | | 0 |
| | Sum of Denominator Site Support Type disaggregates | | 930 |
| LAB_ACC_DSD | Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation | 44 | 44 |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 565 | 536 |
| | By clinical laboratories | 565 | 536 |
| | By Point-of-care testing sites | 0 | 0 |
| LAB_PT_DSD | Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program | | |
| | HIV serologic/diagnostic testing: Number of laboratories that perform this testing | | |



| | | | |
|--|---|--|--|
| | HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program | | |
| | HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program | | |
| | CD4: Number of laboratories that perform this testing | | |
| | CD4: Number of laboratories that participate in this PT program | | |
| | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program | | |
| | Early infant diagnostics: Number of laboratories that perform this testing | | |
| | Early infant diagnostics: Number of laboratories that participate in this PT program | | |
| | Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program | | |
| | HIV viral load: Number of laboratories that perform this testing | | |
| | HIV viral load: Number of | | |



| | | | |
|--|--|--|--|
| | laboratories that participate in this PT program | | |
| | HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program | | |
| | TB diagnostics (AFB microscopy): Number of laboratories that perform this testing | | |
| | TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program | | |
| | TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program | | |
| | TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing | | |
| | TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program | | |
| | TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program | | |

| | | | |
|----------------|---|-------|--|
| | TB diagnostics (Culture/DST): Number of laboratories that perform this testing | | |
| | TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program | | |
| | TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program | | |
| HRH_PRE | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre | 1,282 | |
| | By Graduates: Doctors | 40 | |
| | By Graduates: Nurses | 430 | |
| | By Graduates: Midwives | 325 | |
| | By Graduates: Social service workers | 331 | |
| | By Graduates: Laboratory professionals | 146 | |
| | By Graduates: Other | 10 | |
| | Sum of Graduates disaggregates | 1,282 | |
| FPINT_SITE_DSD | FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of | n/a | |



| | | | |
|---------|--|-----|--|
| | HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services | | |
| | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | | |
| | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment | | |
| | Service delivery type: Care and Support | | |
| | Service delivery type: Treatment | | |
| | Service delivery type: PMTCT | | |
| | Sum of Service delivery type (Care, Tx and PMTCT) disaggregates | | |
| | Sum of Service delivery type (Care, Tx and PMTCT) disaggregates | | |
| QI_SITE | QI_SITE Percentage of PEPFAR-supported clinical service sites with quality improvement activities implemented that address clinical HIV program processes or outcomes and have documented process results in the last 6 months | n/a | |
| | Number of PEPFAR-supported clinical | | |



| | | | |
|--|--|--|--|
| | service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months | | |
| | Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC | | |
| | By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months | | |
| | By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months | | |
| | Sum of Numerator Site Support Type disaggregates | | |
| | By site support type: Direct Service Delivery (DSD): | | |



| | | | |
|--|---|--|--|
| | Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC | | |
| | By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC | | |
| | Sum of Denominator Site Support Type disaggregates | | |



Partners and Implementing Mechanisms

Partner List

| Mech ID | Partner Name | Organization Type | Agency | Funding Source | Planned Funding |
|---------|---|--------------------------------|---|----------------|-----------------|
| 10004 | Association of Public Health Laboratories | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 250,000 |
| 10015 | National Blood Transfusion Service of Nigeria | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 1,431,980 |
| 10019 | Safe Blood for Africa Foundation | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 443,281 |
| 10263 | American Society for Microbiology | Private Contractor | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 400,000 |



| | | | | | |
|-------|---|--------------------------------|---|-----------|-----------|
| 12831 | African Field Epidemiology Network | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 2,435,734 |
| 13190 | Institute of Human Virology, Nigeria | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0 |
| 13564 | Federal Ministry of Health, Nigeria | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0 |
| 13667 | Center for Integrated Health Programs | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0 |
| 13713 | Medical Laboratories Science Council of Nigeria | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 608,002 |
| 13753 | National Primary | Host Country | U.S. Department | GHP-State | 0 |



| | | | | | |
|-------|--------------------------------|--------------------|---|-----------|------------|
| | Health Care Development Agency | Government Agency | of Health and Human Services/Centers for Disease Control and Prevention | | |
| 14054 | University of North Carolina | University | U.S. Agency for International Development | GHP-State | 3,480,100 |
| 14055 | Management Sciences for Health | NGO | U.S. Agency for International Development | GHP-State | 1,213,000 |
| 14064 | IntraHealth International, Inc | NGO | U.S. Agency for International Development | GHP-State | 400,000 |
| 14162 | CDC Foundation | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0 |
| 14169 | Abt Associates | Private Contractor | U.S. Agency for International Development | GHP-State | 700,000 |
| 14298 | Deloitte Consulting Limited | Private Contractor | U.S. Agency for International Development | GHP-State | 948,237 |
| 14302 | TBD | TBD | Redacted | Redacted | Redacted |
| 14446 | The Mitchell Group | Private Contractor | U.S. Agency for International Development | GHP-State | 400,000 |
| 14505 | FHI 360 | NGO | U.S. Agency for International Development | GHP-State | 63,955,545 |



| | | | | | |
|-------|---|--------------------|---|-----------|-------------|
| 14664 | Heartland Alliance for Human Needs and Human Rights | NGO | U.S. Agency for International Development | GHP-State | 1,716,440 |
| 14666 | TBD | TBD | Redacted | Redacted | Redacted |
| 14768 | Partnership for Supply Chain Management | Private Contractor | U.S. Agency for International Development | GHP-State | 159,768,455 |
| 16797 | TBD | TBD | Redacted | Redacted | Redacted |
| 16827 | Center for Integrated Health Programs | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 763,046 |
| 16828 | AIDS Prevention Initiative in Nigeria, LTD | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 350,000 |
| 16838 | University of Maryland Baltimore | University | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 425,000 |
| 16839 | Institute of Human Virology, Nigeria | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and | GHP-State | 350,000 |



| | | | | | |
|-------|--|---------------------|---|-----------|------------|
| | | | Prevention | | |
| 16846 | Institute of Human Virology, Nigeria | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0 |
| 16848 | Catholic Caritas Foundation of Nigeria (CCFN) | Implementing Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 14,907,191 |
| 16849 | Center for Clinical Care and Clinical Research Ltd | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0 |
| 16850 | AIDS Prevention Initiative in Nigeria, LTD | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 20,431,131 |
| 16852 | African Society for Laboratory Medicine | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 350,000 |



| | | | | | |
|-------|---|-----|---|-----------|------------|
| 16853 | Center for Clinical Care and Clinical Research Ltd | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 400,000 |
| 16854 | Center for Clinical Care and Clinical Research Ltd | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 9,203,866 |
| 16855 | Center for Integrated Health Programs | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 32,843,400 |
| 16871 | Institute of Human Virology, Nigeria | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 35,743,182 |
| 17195 | Health Initiatives for Safety and Stability in Africa | NGO | U.S. Department of Defense | GHP-State | 1,228,432 |
| 17727 | Management Sciences for Health | NGO | U.S. Agency for International Development | GHP-State | 12,491,207 |
| 17728 | Catholic Relief Services | FBO | U.S. Agency for International | GHP-State | 6,447,269 |



| | | | | | |
|-------|--|----------------------|---|-----------|------------|
| | | | Development | | |
| 17729 | Save the Children UK | NGO | U.S. Agency for International Development | GHP-State | 6,447,269 |
| 17730 | Johns Hopkins University Center for Communication Programs | University | U.S. Agency for International Development | GHP-State | 400,000 |
| 17733 | John Snow Inc (JSI) | Implementing Agency | U.S. Agency for International Development | GHP-State | 1,000,000 |
| 17734 | TBHIV FOLLOW ON | Implementing Agency | U.S. Agency for International Development | GHP-State | 856,678 |
| 17735 | Society for Family Health-Nigeria | Private Contractor | U.S. Agency for International Development | GHP-State | 11,462,273 |
| 17736 | World Health Organization | Multi-lateral Agency | U.S. Agency for International Development | GHP-State | 700,000 |
| 17737 | TBD | TBD | Redacted | Redacted | Redacted |
| 17739 | United Nations Children's Fund | Multi-lateral Agency | U.S. Agency for International Development | GHP-State | 800,000 |
| 17742 | Gembu Center for AIDS Advocacy, Nigeria | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 5,616,145 |
| 17743 | Pro-Health International | Implementing Agency | U.S. Department of Health and Human | GHP-State | 3,716,158 |



| | | | | | |
|-------|---|--------------------|---|-----------|-----------|
| | | | Services/Centers for Disease Control and Prevention | | |
| 17744 | Excellence Community Education Welfare Scheme (ECEWS) | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 3,352,523 |
| 17745 | Achieving Health Nigeria Initiative | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 1,255,480 |
| 17747 | Henry Jackson Foundation | Private Contractor | U.S. Department of Defense | GHP-State | 5,498,031 |
| 17749 | TBD | TBD | Redacted | Redacted | Redacted |
| 17751 | TBD | TBD | Redacted | Redacted | Redacted |
| 17758 | TBD | TBD | Redacted | Redacted | Redacted |



Implementing Mechanism(s)

Implementing Mechanism Details

| | |
|----------------------------|-----------------|
| Mechanism ID: 17758 | TBD: Yes |
| REDACTED | |

Implementing Mechanism Details

| | |
|----------------------------|-----------------|
| Mechanism ID: 17751 | TBD: Yes |
| REDACTED | |

Implementing Mechanism Details

| | |
|----------------------------|-----------------|
| Mechanism ID: 17749 | TBD: Yes |
| REDACTED | |

Implementing Mechanism Details

| | |
|--|---|
| Mechanism ID: 17747 | Mechanism Name: Henry Jackson Foundation |
| Funding Agency: DOD | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Henry Jackson Foundation | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 5,498,031 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 5,033,285 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 5,498,031 |

**Sub Partner Name(s)**

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|----------------------------|--|
| Human Resources for Health | 2,500,000 |
| Gender: GBV | 150,000 |
| Focus Area: | GBV Prevention |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Gender: Gender Equality | 300,000 |
| Focus Area: | Changing harmful gender norms and promoting positive gender norms |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Focus Area: | Increase gender-equitable access to income and productive resources, including education |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Focus Area: | Equity in HIV prevention, care, treatment and support |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |



| | |
|-----------------------------|---|
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Key Populations: MSM and TG | 500,000 |
| Focus Area: | Training of health workers and community outreach workers |
| Focus Area: | Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance |
| Focus Area: | Collection and use of strategic information |
| Focus Area: | Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners |
| Focus Area: | Monitoring and evaluation of MSM/TG programs |
| Focus Area: | Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG |

Key Issues

Malaria (PMI)
 Military Population
 TB
 Family Planning

Budget Code Information

| Mechanism ID: 17747 Mechanism Name: Henry Jackson Foundation Prime Partner Name: Henry Jackson Foundation | | | |
|--|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 613,582 | 0 |



| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|------------------------|-------------|----------------|----------------|
| Care | HVTB | 140,734 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 42,399 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 1,105,717 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 375,291 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 297,461 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMBL | 7,879 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMIN | 12,866 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVAB | 118,405 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 158,625 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 199,125 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |



| | | | |
|-----------------------|--------------------|-----------------------|-----------------------|
| Prevention | MTCT | 390,612 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXD | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 1,914,874 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 120,461 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 |
|------------------|--|------|------|
| SITE_SUPP | Number of unique sites supported by PEPFAR | 46 | 49 |
| SITE_SUPP | By program area/support type: HTC Direct Service Delivery (DSD) | 46 | 49 |
| SITE_SUPP | By program area/support type: HTC Technical Assistance-only (TA) | 0 | 0 |
| SITE_SUPP | By program area/support type: Treatment Direct Service Delivery (DSD) | 24 | 27 |
| SITE_SUPP | By program area/support type: Treatment Technical Assistance-only (TA) | 0 | 0 |
| SITE_SUPP | By program area/support type: Care and Support Direct Service Delivery (DSD) | 24 | 27 |
| SITE_SUPP | By program area/support type: PMTCT Direct Service Delivery (DSD) | 44 | 49 |
| SITE_SUPP | By program area/support type: PMTCT Technical Assistance-only (TA) | 0 | 0 |
| SITE_SUPP | By program area/support type: TB/HIV Direct Service Delivery (DSD) | 42 | 45 |
| SITE_SUPP | By program area/support type: TB/HIV | 0 | 0 |



| | | | |
|---------------|--|-------|-------|
| | Technical Assistance-only (TA) | | |
| SITE_SUPP | By program area/support type: General Population Prevention Direct Service Delivery (DSD) | 46 | 49 |
| SITE_SUPP | By program area/support type: Key Populations Prevention Direct Service Delivery (DSD) | 46 | 49 |
| SITE_SUPP | By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD) | 14 | 14 |
| SITE_SUPP | By program area/support type: Lab Direct Service Delivery (DSD) | 23 | 26 |
| SITE_SUPP | By program area/support type: Lab Technical Assistance-only (TA) | 0 | 0 |
| PMTCT_ARV_DSD | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 1,381 | 1,179 |
| PMTCT_ARV_DSD | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 1,569 | 1,296 |
| PMTCT_ARV_DSD | Life-long ART (including Option B+) | 759 | 648 |
| PMTCT_ARV_DSD | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 289 | 220 |
| PMTCT_ARV_DSD | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 470 | 428 |
| PMTCT_ARV_DSD | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 539 | 472 |
| PMTCT_ARV_DSD | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 69 | 59 |
| PMTCT_ARV_DSD | Single-dose nevirapine (with or without tail) | 14 | 0 |



| | | | |
|---------------|--|-------|-------|
| PMTCT_ARV_DSD | Sum of Regimen Type disaggregates | 1,381 | 1,179 |
| PMTCT_ARV_DSD | Sum of New and Current disaggregates | 759 | 648 |
| PMTCT_ARV_NGI | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 1,381 | 1,179 |
| PMTCT_ARV_NGI | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 1,569 | 1,296 |
| PMTCT_ARV_NGI | Life-long ART (including Option B+) | 759 | 648 |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 289 | 220 |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 470 | 428 |
| PMTCT_ARV_NGI | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 539 | 472 |
| PMTCT_ARV_NGI | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 69 | 59 |
| PMTCT_ARV_NGI | Single-dose nevirapine (with or without tail) | 14 | 0 |
| PMTCT_ARV_NGI | Sum of Regimen disaggregates | 1,381 | 1,179 |
| PMTCT_ARV_NGI | Sum of New and Current disaggregates | 759 | 648 |
| PMTCT_SITE | Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women | 35 | 41 |
| PMTCT_SITE | Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) | 44 | 49 |
| PMTCT_SITE | By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women | 35 | 41 |



| | | | |
|----------------|---|--------|--------|
| PMTCT_SITE | By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women | 0 | 0 |
| PMTCT_SITE | Sum of Numerator Support Type disaggregates | 35 | 41 |
| PMTCT_SITE | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) | 44 | 49 |
| PMTCT_SITE | By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) | 0 | 0 |
| PMTCT_SITE | Sum of Denominator Support Type disaggregates | 44 | 49 |
| PMTCT_STAT_DSD | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 14,963 | 15,711 |
| PMTCT_STAT_DSD | Number of new ANC and L&D clients | 16,443 | 17,265 |
| PMTCT_STAT_DSD | By: Known positives at entry | 628 | 518 |
| PMTCT_STAT_DSD | By: Number of new positives identified | 941 | 778 |
| PMTCT_STAT_DSD | Sum of Positives Status disaggregates | 1,569 | 1,296 |
| PMTCT_STAT_NGI | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 14,963 | 15,711 |
| PMTCT_STAT_NGI | Number of new ANC and L&D clients | 16,443 | 17,265 |
| PMTCT_STAT_NGI | By: Known positives at entry | 628 | 628 |
| PMTCT_STAT_NGI | By: Number of new positives identified | 941 | 941 |
| PMTCT_STAT_NGI | Sum of Positives Status disaggregates | 1,569 | 1,569 |
| BS_COLL | Number of whole blood collections each year by the NBTS network | 130 | 163 |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network | 130 | 163 |



| | | | |
|-------------|---|--------|--------|
| | laboratory | | |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV | 26 | 33 |
| PP_PREV_DSD | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 31,667 | 31,667 |
| PP_PREV_DSD | Age/sex: 10-14 Male | 1,552 | 1,552 |
| PP_PREV_DSD | Age/sex: 15-19 Male | 1,862 | 1,862 |
| PP_PREV_DSD | Age/sex: 20-24 Male | 4,655 | 4,655 |
| PP_PREV_DSD | Age/sex: 25-49 Male | 6,982 | 6,982 |
| PP_PREV_DSD | Age/sex: 50+ Male | 465 | 465 |
| PP_PREV_DSD | Age/sex: 10-14 Female | 1,615 | 1,615 |
| PP_PREV_DSD | Age/sex: 15-19 Female | 1,938 | 1,938 |
| PP_PREV_DSD | Age/sex: 20-24 Female | 4,845 | 4,845 |
| PP_PREV_DSD | Age/sex: 25-49 Female | 7,268 | 7,268 |
| PP_PREV_DSD | Age/sex: 50+ Female | 485 | 485 |
| PP_PREV_DSD | Sum of Age/Sex disaggregates | 31,667 | 31,667 |
| KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 2,655 | 2,655 |
| KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 2,469 | 2,469 |
| KP_PREV_DSD | By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or | 42 | 42 |

| | | | |
|-------------|--|---------|---------|
| | small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | | |
| KP_PREV_DSD | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 11 | 11 |
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 133 | 133 |
| KP_PREV_DSD | By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 13 | 13 |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 190,506 | 178,954 |
| HTC_TST_DSD | By Test Result: Negative | 184,791 | 173,585 |
| HTC_TST_DSD | By Test Result: Positive | 5,715 | 5,369 |
| HTC_TST_DSD | Sum of Test Result disaggregates | 190,506 | 178,954 |
| HTC_TST_DSD | Age/sex: <1 Male | 653 | 614 |
| HTC_TST_DSD | Age/sex: 1-4 Male | 933 | 877 |
| HTC_TST_DSD | Age/sex: 5-9 Male | 373 | 351 |
| HTC_TST_DSD | Age/sex: 10-14 Male | 840 | 789 |
| HTC_TST_DSD | Age/sex: 15-19 Male | 9,335 | 8,769 |
| HTC_TST_DSD | Age/sex: 20-24 Male | 18,670 | 17,537 |

| | | | |
|-------------|---|---------|---------|
| HTC_TST_DSD | Age/sex: 25-49 Male | 60,676 | 56,997 |
| HTC_TST_DSD | Age/sex: 50+ Male | 1,867 | 1,754 |
| HTC_TST_DSD | Age/sex: <1 Female | 680 | 639 |
| HTC_TST_DSD | Age/sex: 1-4 Female | 972 | 913 |
| HTC_TST_DSD | Age/sex: 5-9 Female | 389 | 365 |
| HTC_TST_DSD | Age/sex: 10-14 Female | 874 | 821 |
| HTC_TST_DSD | Age/sex: 15-19 Female | 9,716 | 9,127 |
| HTC_TST_DSD | Age/sex: 20-24 Female | 19,432 | 18,253 |
| HTC_TST_DSD | Age/sex: 25-49 Female | 63,153 | 59,323 |
| HTC_TST_DSD | Age/sex: 50+ Female | 1,943 | 1,825 |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 190,506 | 178,954 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 2,800 | 2,631 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 90,548 | 85,057 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 2,915 | 2,738 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 94,243 | 88,528 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 5,715 | 5,369 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 184,791 | 173,585 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 190,506 | 178,954 |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 190,506 | 178,954 |
| HTC_TST_NGI | By Test Result: Negative | 5,715 | 5,369 |
| HTC_TST_NGI | By Test Result: Positive | 184,791 | 173,585 |
| HTC_TST_NGI | Sum of Test Result disaggregates | 190,506 | 178,954 |
| HTC_TST_NGI | Age/sex: <1 Male | 653 | 614 |
| HTC_TST_NGI | Age/sex: 1-4 Male | 933 | 877 |
| HTC_TST_NGI | Age/sex: 5-9 Male | 373 | 351 |
| HTC_TST_NGI | Age/sex: 10-14 Male | 840 | 789 |
| HTC_TST_NGI | Age/sex: 15-19 Male | 9,335 | 8,769 |



| | | | |
|--------------|--|---------|---------|
| HTC_TST_NGI | Age/sex: 20-24 Male | 18,670 | 17,537 |
| HTC_TST_NGI | Age/sex: 25-49 Male | 60,676 | 56,997 |
| HTC_TST_NGI | Age/sex: 50+ Male | 1,867 | 1,754 |
| HTC_TST_NGI | Age/sex: <1 Female | 680 | 639 |
| HTC_TST_NGI | Age/sex: 1-4 Female | 972 | 913 |
| HTC_TST_NGI | Age/sex: 5-9 Female | 389 | 365 |
| HTC_TST_NGI | Age/sex: 10-14 Female | 874 | 821 |
| HTC_TST_NGI | Age/sex: 15-19 Female | 9,716 | 9,127 |
| HTC_TST_NGI | Age/sex: 20-24 Female | 19,432 | 18,253 |
| HTC_TST_NGI | Age/sex: 25-49 Female | 63,153 | 59,323 |
| HTC_TST_NGI | Age/sex: 50+ Female | 1,943 | 1,825 |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 190,506 | 178,954 |
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 2,800 | 2,631 |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 90,548 | 85,057 |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 2,915 | 2,738 |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 94,243 | 88,528 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 5,715 | 5,369 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 184,791 | 173,585 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 190,506 | 178,954 |
| GEND_GBV_DSD | Number of people receiving post-GBV care | 17 | 17 |
| GEND_GBV_DSD | Age: 0-9 | 2 | 2 |
| GEND_GBV_DSD | Age: 10-14 | 4 | 4 |
| GEND_GBV_DSD | Age: 15-17 | 6 | 6 |
| GEND_GBV_DSD | Age: 18-24 | 3 | 3 |
| GEND_GBV_DSD | Age: 25+ | 2 | 2 |
| GEND_GBV_DSD | Sum of Age disaggregates | 17 | 17 |
| GEND_GBV_DSD | Sex: Male | 6 | 6 |
| GEND_GBV_DSD | Sex: Female | 11 | 11 |
| GEND_GBV_DSD | Sum of Sex disaggregates | 17 | 17 |
| GEND_GBV_DSD | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) | 4 | 4 |
| GEND_GBV_DSD | By type of service: Sexual Violence | 13 | 13 |

| | | | |
|-------------|---|--------|----|
| | (Post-Rape Care) | | |
| GEND_GBVDSD | By PEP service provision (related to sexual violence services provided) | 13 | 13 |
| C2.1.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 37,680 | |
| C2.1.D_DSD | By Age/Sex: <15 Female | 890 | |
| C2.1.D_DSD | By Age/Sex: <15 Male | 381 | |
| C2.1.D_DSD | By Age/Sex: 15+ Female | 25,486 | |
| C2.1.D_DSD | By Age/Sex: 15+ Male | 10,923 | |
| C2.1.D_DSD | Sum of Age/Sex disaggregates | 37,680 | |
| C2.1.D_DSD | By Age: <15 | 1,271 | |
| C2.1.D_DSD | By Age: 15+ | 36,409 | |
| C2.1.D_DSD | Sum of Age disaggregates | 37,680 | |
| C2.1.D_DSD | By Sex: Female | 26,376 | |
| C2.1.D_DSD | By Sex: Male | 11,304 | |
| C2.1.D_DSD | Sum of Sex disaggregates | 37,680 | |
| C2.1.D_NGI | Number of HIV-positive individuals receiving a minimum of one clinical service | 37,680 | |
| C2.1.D_NGI | By Age/Sex: <15 Female | 890 | |
| C2.1.D_NGI | By Age/Sex: <15 Male | 381 | |
| C2.1.D_NGI | By Age/Sex: 15+ Female | 25,486 | |
| C2.1.D_NGI | By Age/Sex: 15+ Male | 10,923 | |
| C2.1.D_NGI | Sum of Age/Sex disaggregates | 37,680 | |
| C2.1.D_NGI | By Age: <15 | 1,271 | |
| C2.1.D_NGI | By Age: 15+ | 36,409 | |
| C2.1.D_NGI | Sum of Age disaggregates | 37,680 | |
| C2.1.D_NGI | By Sex: Female | 26,376 | |
| C2.1.D_NGI | By Sex: Male | 11,304 | |
| C2.1.D_NGI | Sum of Sex disaggregates | 37,680 | |
| C2.4.D_DSD | Number of HIV-positive patients who were screened for TB in HIV care or treatment setting | 33,912 | |



| | | | |
|---------------|--|--------|--------|
| C2.4.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 37,680 | |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period | 1,381 | 1,179 |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 1,569 | 1,340 |
| PMTCT_EID_DSD | By infants who received a virologic test within 2 months of birth | 456 | 389 |
| PMTCT_EID_DSD | By infants who received their first virologic HIV test between 2 and 12 months of age | 925 | 790 |
| PMTCT_EID_DSD | Sum of Infant Age disaggregates | 1,381 | 1,179 |
| PMTCT_EID_DSD | By infants with a positive virologic test result within 12 months of birth | 69 | 59 |
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 25,120 | 26,376 |
| TX_CURR_DSD | Age/Sex: <1 Male | 31 | 33 |
| TX_CURR_DSD | Age/Sex: 1-4 Male | 148 | 155 |
| TX_CURR_DSD | Age/Sex: 5-14 Male | 270 | 283 |
| TX_CURR_DSD | Age/Sex: 15+ Male | 8,010 | 8,411 |
| TX_CURR_DSD | Age/Sex: <1 Female | 28 | 29 |
| TX_CURR_DSD | Age/Sex: 1-4 Female | 131 | 138 |
| TX_CURR_DSD | Age/Sex: 5-14 Female | 239 | 251 |
| TX_CURR_DSD | Age/Sex: 15+ Female | 16,263 | 17,076 |
| TX_CURR_DSD | Sum of age/sex disaggregates | 847 | 889 |
| TX_CURR_DSD | Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 0 | 0 |
| TX_CURR_DSD | Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 1 | 1 |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Male | 31 | 33 |



| | | | |
|-------------|--|--------|--------|
| TX_CURR_DSD | Aggregated Age/Sex: <1 Female | 28 | 29 |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male | 449 | 471 |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 8,010 | 8,411 |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female | 398 | 418 |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Female | 16,263 | 17,076 |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 847 | 889 |
| TX_CURR_DSD | Sum of Aggregated Age/Sex 15+ | 24,273 | 25,487 |
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates | 25,120 | 26,376 |
| TX_CURR_NGI | Number of adults and children receiving antiretroviral therapy (ART) | 25,120 | 26,376 |
| TX_CURR_NGI | Age/Sex: <1 Male | 31 | 33 |
| TX_CURR_NGI | Age/Sex: 1-4 Male | 148 | 155 |
| TX_CURR_NGI | Age/Sex: 5-14 Male | 270 | 283 |
| TX_CURR_NGI | Age/Sex: 15+ Male | 8,010 | 8,411 |
| TX_CURR_NGI | Age/Sex: <1 Female | 28 | 29 |
| TX_CURR_NGI | Age/Sex: 1-4 Female | 131 | 138 |
| TX_CURR_NGI | Age/Sex: 5-14 Female | 239 | 251 |
| TX_CURR_NGI | Age/Sex: 15+ Female | 16,263 | 17,076 |
| TX_CURR_NGI | Sum of Age/Sex disaggregates | 25,120 | 26,376 |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Male | 31 | 33 |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Female | 28 | 29 |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Male | 449 | 471 |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Male | 8,010 | 8,411 |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Female | 398 | 418 |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Female | 16,263 | 17,076 |
| TX_CURR_NGI | Sum of Aggregated Age/Sex disaggregates | 25,120 | 26,376 |
| TX_CURR_NGI | Sum of Aggregated Age/Sex <15 | 847 | 889 |
| TX_CURR_NGI | Sum of Aggregated Age/Sex 15+ | 24,273 | 25,487 |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 8,108 | 6,531 |
| TX_NEW_DSD | By Age/Sex: <1 Male | 20 | 16 |
| TX_NEW_DSD | By Age/Sex: 1-4 Male | 29 | 23 |



| | | | |
|------------|--|-------|-------|
| TX_NEW_DSD | By Age/Sex: 5-9 Male | 36 | 29 |
| TX_NEW_DSD | By Age/Sex: 10-14 Male | 60 | 48 |
| TX_NEW_DSD | By Age/Sex: 15-19 Male | 364 | 293 |
| TX_NEW_DSD | By Age/Sex: 20-24 Male | 607 | 489 |
| TX_NEW_DSD | By Age/Sex: 25-49 Male | 972 | 783 |
| TX_NEW_DSD | By Age/Sex: 50+ Male | 486 | 391 |
| TX_NEW_DSD | By Age/Sex: <1 Female | 19 | 16 |
| TX_NEW_DSD | By Age/Sex: 1-4 Female | 26 | 21 |
| TX_NEW_DSD | By Age/Sex: 5-9 Female | 32 | 26 |
| TX_NEW_DSD | By Age/Sex: 10-14 Female | 51 | 41 |
| TX_NEW_DSD | By Age/Sex: 15-19 Female | 811 | 653 |
| TX_NEW_DSD | By Age/Sex: 20-24 Female | 1,352 | 1,089 |
| TX_NEW_DSD | By Age/Sex: 25-49 Female | 2,162 | 1,742 |
| TX_NEW_DSD | By Age/Sex: 50+ Female | 1,081 | 871 |
| TX_NEW_DSD | Sum of Age/Sex disaggregates | 8,108 | 6,531 |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male | 20 | 16 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male | 145 | 117 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 2,429 | 1,956 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female | 19 | 16 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female | 128 | 103 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 5,406 | 4,355 |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 8,108 | 6,531 |
| TX_NEW_DSD | Pregnancy status | 432 | 348 |
| TX_NEW_DSD | Breastfeeding status | 269 | 216 |
| TX_RET_DSD | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 3,103 | 6,892 |
| TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped | 3,650 | 8,108 |



| | | | |
|------------|--|-------|-------|
| | ART, and those lost to follow-up | | |
| TX_RET_DSD | Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 62 | 138 |
| TX_RET_DSD | Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 93 | 207 |
| TX_RET_DSD | Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 2,947 | 6,547 |
| TX_RET_DSD | Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 73 | 162 |
| TX_RET_DSD | Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 110 | 243 |
| TX_RET_DSD | Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 3,467 | 7,703 |
| TX_RET_DSD | Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 155 | 345 |
| TX_RET_DSD | Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 2,947 | 6,547 |
| TX_RET_DSD | Aggregated Age: <15 (Denominator: Total | 183 | 405 |



| | | | |
|-------------|---|-------|-------|
| | number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | | |
| TX_RET_DSD | Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 3,467 | 7,703 |
| TX_RET_DSD | Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 1,458 | 3,239 |
| TX_RET_DSD | Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 172 | 381 |
| LAB_ACC_DSD | Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation | 3 | 5 |
| LAB_ACC_DSD | By site support type: Direct Service Delivery (DSD) | 3 | 5 |
| LAB_ACC_DSD | By site support type: Technical Assistance-only (TA) | 0 | 0 |
| LAB_ACC_DSD | Sum of Support Type disaggregates | 3 | 5 |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical | 23 | 26 |

| | | | |
|-------------|---|----|----|
| | laboratory tests | | |
| LAB_CAP_DSD | By clinical laboratories | 23 | 26 |
| LAB_CAP_DSD | By Point-of-care testing sites | 0 | 0 |
| LAB_CAP_DSD | By site support type: Direct Service Delivery (DSD) | 23 | 26 |
| LAB_CAP_DSD | By site support type: Technical Assistance-only (TA) | 0 | 0 |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates | 23 | 26 |
| LAB_PT_DSD | Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program | 23 | 26 |
| LAB_PT_DSD | HIV serologic/diagnostic testing: Number of laboratories that perform this testing | 23 | 26 |
| LAB_PT_DSD | HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program | 23 | 26 |
| LAB_PT_DSD | HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 18 | 21 |
| LAB_PT_DSD | CD4: Number of laboratories that perform this testing | 23 | 26 |
| LAB_PT_DSD | CD4: Number of laboratories that participate in this PT program | 23 | 26 |
| LAB_PT_DSD | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 18 | 21 |
| LAB_PT_DSD | Early infant diagnostics: Number of laboratories that perform this testing | 1 | 2 |
| LAB_PT_DSD | Early infant diagnostics: Number of laboratories that participate in this PT program | 1 | 2 |
| LAB_PT_DSD | Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 | 2 |



| | | | |
|----------------|--|----|----|
| LAB_PT_DSD | HIV viral load: Number of laboratories that perform this testing | 2 | 3 |
| LAB_PT_DSD | HIV viral load: Number of laboratories that participate in this PT program | 2 | 3 |
| LAB_PT_DSD | HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 2 | 3 |
| LAB_PT_DSD | TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing | 42 | 45 |
| LAB_PT_DSD | TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program | 42 | 45 |
| LAB_PT_DSD | TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 34 | 36 |
| FPINT_SITE_DSD | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 14 | 14 |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment | 14 | 14 |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 14 | 14 |
| FPINT_SITE_DSD | By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 0 | 0 |
| FPINT_SITE_DSD | Sum of Numerator Site Support Type | 14 | 14 |



| | | | |
|----------------|--|----|----|
| | disaggregates | | |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points | 14 | 14 |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates | 14 | 14 |
| FPINT_SITE_DSD | Service delivery type: Clinical | 14 | 14 |
| FPINT_SITE_DSD | Sum of Service Delivery Type disaggregates | 14 | 14 |
| QI_SITE | Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months | 12 | 23 |
| QI_SITE | Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC | 24 | 27 |
| QI_SITE | By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months | 12 | 23 |
| QI_SITE | By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months | 0 | 0 |
| QI_SITE | Sum of Numerator Site Support Type disaggregates | 12 | 23 |
| QI_SITE | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, | 24 | 27 |



| | | | |
|---------|--|----|----|
| | VMMC, HTC | | |
| QI_SITE | By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC | 0 | 0 |
| QI_SITE | Sum of Denominator Site Support Type disaggregates | 24 | 27 |

Implementing Mechanism Details

| | |
|---|---|
| Mechanism ID: 17745 | Mechanism Name: SUSTAINING COMPREHENSIVE HI/AIDS RESPONSE THROUGH PARTNERSHIPS |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Achieving Health Nigeria Initiative | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 1,255,480 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 1,255,480 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|-------------|----------------|
| Renovation | 10,000 |
| Gender: GBV | 1,000 |
| Focus Area: | GBV Prevention |



| | |
|-----------|-------------------|
| Sub Area: | Capacity building |
|-----------|-------------------|

Key Issues

Child Survival Activities

Mobile Population

Safe Motherhood

TB

Workplace Programs

End-of-Program Evaluation

Family Planning

Budget Code Information

| Mechanism ID: | 17745 | | |
|----------------------------|---|----------------|----------------|
| Mechanism Name: | SUSTAINING COMPREHENSIVE HI/AIDS RESPONSE THROUGH | | |
| Prime Partner Name: | PARTNERSHIPS | | |
| | Achieving Health Nigeria Initiative | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 101,405 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 27,183 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 44,106 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 6,203 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and | HLAB | 439,154 | 0 |



| Systems | | | |
|----------------|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMIN | 30,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 74,029 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 227,172 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 288,605 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 17,623 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|------------------|--|------|------|-------------------------|
| SITE_SUPP | By program area/support type: Lab Direct Service Delivery (DSD) | 3 | 3 | Redacted |
| PMTCT_ARV_DS D | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 681 | 681 | Redacted |
| PMTCT_ARV_DS D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 774 | 744 | Redacted |
| PMTCT_ARV_DS | Life-long ART (including Option B+) | 375 | 375 | Redacted |

| | | | | |
|-------------------|--|-----|-----|----------|
| D | | | | |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 141 | 127 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 232 | 248 | Redacted |
| PMTCT_ARV_DS D | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 265 | 265 | Redacted |
| PMTCT_ARV_DS D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 34 | 34 | Redacted |
| PMTCT_ARV_DS D | Single-dose nevirapine (with or without tail) | 7 | 7 | Redacted |
| PMTCT_ARV_DS D | Sum of Regimen Type disaggregates | 681 | 681 | Redacted |
| PMTCT_ARV_DS D | Sum of New and Current disaggregates | 373 | 375 | Redacted |
| PMTCT_ARV_NGI | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 681 | 681 | Redacted |
| PMTCT_ARV_NGI | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 774 | 748 | Redacted |
| PMTCT_ARV_NGI | Life-long ART (including Option B+) | 375 | 375 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 141 | 127 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 232 | 248 | Redacted |
| PMTCT_ARV_NGI | Maternal triple ARV prophylaxis | 265 | 272 | Redacted |

| | | | | |
|--------------------|--|--------|--------|----------|
| | (provided with the intention to stop at the end of the breastfeeding period) | | | |
| PMTCT_ARV_NGI | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 34 | 34 | Redacted |
| PMTCT_ARV_NGI | Single-dose nevirapine (with or without tail) | 7 | | Redacted |
| PMTCT_ARV_NGI | Sum of Regimen disaggregates | 681 | 681 | Redacted |
| PMTCT_ARV_NGI | Sum of New and Current disaggregates | 373 | 375 | Redacted |
| PMTCT_STAT_DS D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 24,860 | 24,860 | Redacted |
| PMTCT_STAT_DS D | Number of new ANC and L&D clients | 27,319 | 27,319 | Redacted |
| PMTCT_STAT_DS D | By: Known positives at entry | 310 | 299 | Redacted |
| PMTCT_STAT_DS D | By: Number of new positives identified | 464 | 449 | Redacted |
| PMTCT_STAT_DS D | Sum of Positives Status disaggregates | 774 | 748 | Redacted |
| PMTCT_STAT_NG I | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 24,860 | 24,860 | Redacted |
| PMTCT_STAT_NG I | Number of new ANC and L&D clients | 27,319 | 27,319 | Redacted |
| PMTCT_STAT_NG I | By: Known positives at entry | 310 | 299 | Redacted |
| PMTCT_STAT_NG I | By: Number of new positives identified | 464 | 449 | Redacted |
| PMTCT_STAT_NG I | Sum of Positives Status disaggregates | 774 | 748 | Redacted |
| HTC_TST_DSD | Number of individuals who received | 26,362 | 54,192 | Redacted |

| | | | | |
|-------------|--|--------|--------|----------|
| | T&C services for HIV and received their test results during the past 12 months | | | |
| HTC_TST_DSD | By Test Result: Negative | 25,789 | 52,874 | Redacted |
| HTC_TST_DSD | By Test Result: Positive | 573 | 1,318 | Redacted |
| HTC_TST_DSD | Sum of Test Result disaggregates | 26,362 | 54,192 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Male | 338 | 334 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Male | 6 | 141 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Male | 2 | 57 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Male | 5 | 128 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Male | 55 | 1,418 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Male | 111 | 2,936 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Male | 360 | 9,223 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Male | 11 | 286 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Female | 351 | 347 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Female | 6 | 148 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Female | 2 | 59 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Female | 5 | 131 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Female | 2,513 | 3,933 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Female | 8,708 | 11,651 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Female | 13,877 | 23,106 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Female | 12 | 294 | Redacted |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 26,362 | 54,192 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 350 | 660 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 538 | 13,863 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 364 | 685 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 25,110 | 38,984 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 714 | 1,345 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 25,648 | 52,847 | Redacted |



| | | | | |
|-------------|---|--------|--------|----------|
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 26,362 | 54,192 | Redacted |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 26,362 | 54,192 | Redacted |
| HTC_TST_NGI | By Test Result: Negative | 25,789 | 52,874 | Redacted |
| HTC_TST_NGI | By Test Result: Positive | 573 | 1,318 | Redacted |
| HTC_TST_NGI | Sum of Test Result disaggregates | 26,362 | 54,192 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Male | 338 | 334 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Male | 6 | 141 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Male | 2 | 57 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Male | 5 | 128 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Male | 55 | 1,418 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Male | 111 | 2,936 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Male | 360 | 9,223 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Male | 11 | 286 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Female | 351 | 347 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Female | 6 | 148 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Female | 2 | 59 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Female | 5 | 131 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Female | 2,513 | 3,933 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Female | 8,708 | 11,651 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Female | 13,877 | 23,106 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Female | 12 | 294 | Redacted |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 26,362 | 54,192 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 350 | 660 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 538 | 13,863 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 364 | 685 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 25,110 | 38,984 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 714 | 1,345 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 25,648 | 52,847 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex | 26,362 | 54,192 | Redacted |

| | | | | |
|--------------|--|-----|-----|----------|
| | disaggregates | | | |
| GEND_GBV_DSD | Number of people receiving post-GBV care | 31 | 31 | Redacted |
| GEND_GBV_DSD | Age: 0-9 | 4 | 4 | Redacted |
| GEND_GBV_DSD | Age: 10-14 | 7 | 7 | Redacted |
| GEND_GBV_DSD | Age: 15-17 | 11 | 11 | Redacted |
| GEND_GBV_DSD | Age: 18-24 | 6 | 6 | Redacted |
| GEND_GBV_DSD | Age: 25+ | 3 | 3 | Redacted |
| GEND_GBV_DSD | Sum of Age disaggregates | 31 | 31 | Redacted |
| GEND_GBV_DSD | Sex: Male | 10 | 10 | Redacted |
| GEND_GBV_DSD | Sex: Female | 21 | 21 | Redacted |
| GEND_GBV_DSD | Sum of Sex disaggregates | 31 | 31 | Redacted |
| GEND_GBV_DSD | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) | 7 | 7 | Redacted |
| GEND_GBV_DSD | By type of service: Sexual Violence (Post-Rape Care) | 24 | 24 | Redacted |
| GEND_GBV_DSD | By PEP service provision (related to sexual violence services provided) | 24 | 24 | Redacted |
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 281 | 281 | Redacted |
| OVC_ACC_DSD | Sex: Male | 138 | 138 | Redacted |
| OVC_ACC_DSD | Sex: Female | 143 | 143 | Redacted |
| OVC_ACC_DSD | Sum of Sex disaggregates | 281 | 281 | Redacted |
| OVC_ACC_DSD | Age: <1 | 17 | 17 | Redacted |
| OVC_ACC_DSD | Age: 1-4 | 70 | 70 | Redacted |
| OVC_ACC_DSD | Age: 5-9 | 79 | 79 | Redacted |
| OVC_ACC_DSD | Age: 10-14 | 67 | 67 | Redacted |
| OVC_ACC_DSD | Age: 15-17 | 40 | 40 | Redacted |
| OVC_ACC_DSD | Age: 18+ | 8 | 8 | Redacted |
| OVC_ACC_DSD | Sum of Age disaggregates | 281 | 281 | Redacted |
| OVC_SERV_DSD | Number of active beneficiaries served | 937 | 937 | Redacted |

| | | | | |
|--------------|--|-------|-----|----------|
| | by PEPFAR OVC programs for children and families affected by HIV/AIDS | | | |
| OVC_SERV_DSD | Sex: Male | 459 | 459 | Redacted |
| OVC_SERV_DSD | Sex: Female | 478 | 478 | Redacted |
| OVC_SERV_DSD | Sum of Sex disaggregates | 937 | 937 | Redacted |
| OVC_SERV_DSD | Age: <1 | 56 | 56 | Redacted |
| OVC_SERV_DSD | Age: 1-4 | 234 | 234 | Redacted |
| OVC_SERV_DSD | Age: 5-9 | 262 | 262 | Redacted |
| OVC_SERV_DSD | Age: 10-14 | 216 | 216 | Redacted |
| OVC_SERV_DSD | Age: 15-17 | 132 | 132 | Redacted |
| OVC_SERV_DSD | Age: 18+ | 37 | 37 | Redacted |
| OVC_SERV_DSD | Sum of Age disaggregates | 937 | 937 | Redacted |
| C2.1.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 5,139 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Female | 180 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Male | 77 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Female | 3,417 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Male | 1,465 | | Redacted |
| C2.1.D_DSD | Sum of Age/Sex disaggregates | 5,139 | | Redacted |
| C2.1.D_DSD | By Age: <15 | 257 | | Redacted |
| C2.1.D_DSD | By Age: 15+ | 4,882 | | Redacted |
| C2.1.D_DSD | Sum of Age disaggregates | 5,139 | | Redacted |
| C2.1.D_DSD | By Sex: Female | 3,597 | | Redacted |
| C2.1.D_DSD | By Sex: Male | 1,542 | | Redacted |
| C2.1.D_DSD | Sum of Sex disaggregates | 5,139 | | Redacted |
| C2.1.D_NGI | Number of HIV-positive individuals receiving a minimum of one clinical service | 5,139 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Female | 180 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Male | 77 | | Redacted |
| C2.1.D_NGI | By Age/Sex: 15+ Female | 3,417 | | Redacted |

| | | | | |
|------------|--|-------|-----|----------|
| C2.1.D_NGI | By Age/Sex: 15+ Male | 1,465 | | Redacted |
| C2.1.D_NGI | Sum of Age/Sex disaggregates | 5,139 | | Redacted |
| C2.1.D_NGI | By Age: <15 | 257 | | Redacted |
| C2.1.D_NGI | By Age: 15+ | 4,882 | | Redacted |
| C2.1.D_NGI | Sum of Age disaggregates | 5,139 | | Redacted |
| C2.1.D_NGI | By Sex: Female | 3,597 | | Redacted |
| C2.1.D_NGI | By Sex: Male | 1,542 | | Redacted |
| C2.1.D_NGI | Sum of Sex disaggregates | 5,139 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive patients who were screened for TB in HIV care or treatment setting | 4,625 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 5,139 | | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 276 | 300 | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period | 325 | 353 | Redacted |
| TB_ART_DSD | Age: 0-4 | 3 | 3 | Redacted |
| TB_ART_DSD | Age: 5-14 | 14 | 15 | Redacted |
| TB_ART_DSD | Age: 15+ | 259 | 282 | Redacted |
| TB_ART_DSD | Male | 135 | 147 | Redacted |
| TB_ART_DSD | Female | 141 | 153 | Redacted |
| TB_ART_DSD | Sum of Sex disaggregates | 276 | 300 | Redacted |
| TB_ART_DSD | Newly tested | 157 | 171 | Redacted |
| TB_ART_DSD | Known HIV-positive | 119 | 129 | Redacted |
| TB_ART_DSD | Sum of Test Status disaggregates | 276 | 300 | Redacted |
| TB_ART_DSD | Aggregated Age: <15 | 17 | 18 | Redacted |

| | | | | |
|---------------|--|-------|-------|----------|
| TB_ART_DSD | Aggregated Age: 15+ | 259 | 282 | Redacted |
| TB_ART_DSD | Sum of Aggregated Age disaggregates | 276 | 300 | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period | 681 | 681 | Redacted |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 774 | 748 | Redacted |
| PMTCT_EID_DSD | By infants who received a virologic test within 2 months of birth | 225 | 225 | Redacted |
| PMTCT_EID_DSD | By infants who received their first virologic HIV test between 2 and 12 months of age | 456 | 456 | Redacted |
| PMTCT_EID_DSD | Sum of Infant Age disaggregates | 681 | 681 | Redacted |
| PMTCT_EID_DSD | By infants with a positive virologic test result within 12 months of birth | 34 | 34 | Redacted |
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 3,426 | 2,487 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Male | 7 | 5 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Male | 32 | 23 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Male | 58 | 42 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Male | 1,070 | 777 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Female | 6 | 4 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Female | 28 | 21 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Female | 52 | 38 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Female | 2,173 | 1,577 | Redacted |
| TX_CURR_DSD | Sum of age/sex disaggregates | 183 | 133 | Redacted |
| TX_CURR_DSD | Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 5 | 5 | Redacted |
| TX_CURR_DSD | Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) | 66 | 66 | Redacted |

| | [CURRENT] | | | |
|-------------|--|-------|-------|----------|
| TX_CURR_DSD | Aggregated Age/Sex: <1 Male | 7 | 5 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Female | 6 | 4 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male | 97 | 70 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 1,070 | 777 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female | 86 | 63 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Female | 2,173 | 1,577 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 183 | 133 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex 15+ | 3,243 | 2,354 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates | 3,426 | 2,487 | Redacted |
| TX_CURR_NGI | Number of adults and children receiving antiretroviral therapy (ART) | 3,426 | 2,487 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Male | 7 | 5 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Male | 32 | 23 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Male | 58 | 42 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Male | 1,070 | 777 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Female | 6 | 4 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Female | 28 | 21 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Female | 52 | 38 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Female | 2,173 | 1,577 | Redacted |
| TX_CURR_NGI | Sum of Age/Sex disaggregates | 3,426 | 2,487 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Male | 7 | 5 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Female | 6 | 4 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Male | 97 | 70 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Male | 1,070 | 777 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Female | 86 | 63 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Female | 2,173 | 1,577 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex disaggregates | 3,426 | 2,487 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex <15 | 183 | 133 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex 15+ | 3,243 | 2,354 | Redacted |

| | | | | |
|------------|--|-------|-----|----------|
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 1,106 | 616 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Male | 4 | 2 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Male | 6 | 3 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Male | 8 | 4 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Male | 13 | 7 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Male | 49 | 27 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Male | 81 | 45 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Male | 130 | 72 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Male | 65 | 36 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Female | 4 | 2 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Female | 6 | 3 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Female | 7 | 4 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Female | 11 | 6 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Female | 108 | 60 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Female | 181 | 101 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Female | 289 | 161 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Female | 144 | 83 | Redacted |
| TX_NEW_DSD | Sum of Age/Sex disaggregates | 1,106 | 616 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male | 4 | 2 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male | 31 | 17 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 325 | 181 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female | 4 | 2 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female | 28 | 16 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 722 | 402 | Redacted |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 1,106 | 616 | Redacted |
| TX_NEW_DSD | Pregnancy status | 58 | 32 | Redacted |

| | | | | |
|------------|--|-------|-------|----------|
| TX_NEW_DSD | Breastfeeding status | 37 | 20 | Redacted |
| TX_RET_DSD | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 2,361 | 940 | Redacted |
| TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 2,778 | 1,106 | Redacted |
| TX_RET_DSD | Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 47 | 19 | Redacted |
| TX_RET_DSD | Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 71 | 28 | Redacted |
| TX_RET_DSD | Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 2,243 | 893 | Redacted |
| TX_RET_DSD | Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 56 | 22 | Redacted |
| TX_RET_DSD | Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 83 | 33 | Redacted |

| | | | | |
|------------|--|-------|-------|----------|
| TX_RET_DSD | Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 2,639 | 1,051 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 118 | 47 | Redacted |
| TX_RET_DSD | Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 2,243 | 893 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 139 | 55 | Redacted |
| TX_RET_DSD | Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 2,639 | 1,051 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 1,110 | 442 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status (Denominator: Total number of adults | 131 | 52 | Redacted |

| | | | | |
|----------------|---|----|----|----------|
| | and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | | | |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 15 | 15 | Redacted |
| LAB_CAP_DSD | By clinical laboratories | 15 | 15 | Redacted |
| LAB_CAP_DSD | By Point-of-care testing sites | 0 | | Redacted |
| LAB_CAP_DSD | By site support type: Direct Service Delivery (DSD) | 15 | 15 | Redacted |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates | 15 | 15 | Redacted |
| FPINT_SITE_DSD | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 5 | 9 | Redacted |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment | 9 | 11 | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 5 | 9 | Redacted |
| FPINT_SITE_DSD | Sum of Numerator Site Support Type disaggregates | 5 | 9 | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points | 9 | 11 | Redacted |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates | 9 | 11 | Redacted |



| | | | | |
|---------------|--|-------|-------|----------|
| TB_SCREEN_DSD | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period | 4,625 | 4,856 | Redacted |
| TB_SCREEN_DSD | Age: <1 | 93 | 97 | Redacted |
| TB_SCREEN_DSD | Age: 1-4 | 46 | 49 | Redacted |
| TB_SCREEN_DSD | Age: 5-9 | 93 | 97 | Redacted |
| TB_SCREEN_DSD | Age: 10-14 | 46 | 49 | Redacted |
| TB_SCREEN_DSD | Age: 15-19 | 463 | 486 | Redacted |
| TB_SCREEN_DSD | Age: 20-24 | 1,155 | 1,214 | Redacted |
| TB_SCREEN_DSD | Age: 25-49 | 2,544 | 2,670 | Redacted |
| TB_SCREEN_DSD | Age: 50+ | 185 | 194 | Redacted |
| TB_SCREEN_DSD | Sum of Age disaggregates | 741 | 778 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 | 278 | 291 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ | 4,347 | 4,565 | Redacted |
| TB_SCREEN_DSD | Sum of Aggregated Age disaggregates | 4,625 | 4,856 | Redacted |
| TB_SCREEN_DSD | Sex: Male | 1,388 | 1,457 | Redacted |
| TB_SCREEN_DSD | Sex: Female | 3,237 | 3,399 | Redacted |
| TB_SCREEN_DSD | Sum of Sex disaggregates | 4,625 | 4,856 | Redacted |

Implementing Mechanism Details

| | |
|---|---|
| Mechanism ID: 17744 | Mechanism Name: ECEWS-LOCATE PROJECT |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Excellence Community Education Welfare Scheme (ECEWS) | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 3,352,523 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |



| FY 2013 Burn Rate: Redacted | |
|-----------------------------|----------------|
| Funding Source | Funding Amount |
| GHP-State | 3,352,523 |

Sub Partner Name(s)

| | | |
|--------------------------------|-----------------------------|-------------------------|
| Achi Joint Hospital, Oji River | District Hospital Udi | General Hospital Onueke |
| General Hospital Okigwe | General Hospital, Oji River | |

Cross-Cutting Budget Attribution(s)

| | |
|---------------------------------|--|
| Human Resources for Health | 384,542 |
| Motor Vehicles: Purchased | 208,763 |
| Key Populations: FSW | 31,000 |
| Focus Area: | Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention |
| Focus Area: | Training of health workers and community outreach workers |
| Focus Area: | Collection and use of strategic information on SWs and clients |
| Focus Area: | Monitoring and evaluation of SW programs |
| Focus Area: | Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs |
| Food and Nutrition: Commodities | 20,000 |
| Economic Strengthening | 15,000 |
| Gender: GBV | 2,718 |
| Focus Area: | GBV Prevention |
| Sub Area: | Implementation |
| Focus Area: | Post GBV Care |
| Sub Area: | Monitoring and Evaluation |
| Condom programming | 47,000 |
| Condom procurement | 10,000 |



Key Issues

Child Survival Activities

Military Population

Mobile Population

Safe Motherhood

TB

Family Planning

Budget Code Information

| Mechanism ID: | 17744 | | |
|----------------------------|---|----------------|----------------|
| Mechanism Name: | ECEWS-LOCATE PROJECT | | |
| Prime Partner Name: | Excellence Community Education Welfare Scheme (ECEWS) | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 439,195 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 27,184 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 132,676 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 29,290 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 271,458 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |



| | | | |
|-----------------------|--------------------|-----------------------|-----------------------|
| Prevention | HMIN | 25,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVAB | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 356,998 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 441,028 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 296,497 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 1,249,977 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 83,220 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|-------------------|--|------|------|-------------------------|
| PMTCT_ARV_DS D | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 750 | 750 | Redacted |
| PMTCT_ARV_DS D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 852 | 824 | Redacted |

| | | | | |
|-------------------|--|-----|-----|----------|
| PMTCT_ARV_DS D | Life-long ART (including Option B+) | 368 | 413 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 220 | 157 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 147 | 256 | Redacted |
| PMTCT_ARV_DS D | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 315 | 291 | Redacted |
| PMTCT_ARV_DS D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 60 | 38 | Redacted |
| PMTCT_ARV_DS D | Single-dose nevirapine (with or without tail) | 7 | 8 | Redacted |
| PMTCT_ARV_DS D | Sum of Regimen Type disaggregates | 750 | 750 | Redacted |
| PMTCT_ARV_DS D | Sum of New and Current disaggregates | 367 | 413 | Redacted |
| PMTCT_ARV_NGI | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 750 | 750 | Redacted |
| PMTCT_ARV_NGI | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 852 | 824 | Redacted |
| PMTCT_ARV_NGI | Life-long ART (including Option B+) | 368 | 413 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 220 | 157 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 147 | 256 | Redacted |

| | | | | |
|--------------------|--|--------|--------|----------|
| PMTCT_ARV_NGI | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 315 | 291 | Redacted |
| PMTCT_ARV_NGI | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 60 | 38 | Redacted |
| PMTCT_ARV_NGI | Single-dose nevirapine (with or without tail) | 7 | 8 | Redacted |
| PMTCT_ARV_NGI | Sum of Regimen disaggregates | 750 | 750 | Redacted |
| PMTCT_ARV_NGI | Sum of New and Current disaggregates | 367 | 413 | Redacted |
| PMTCT_STAT_DS D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 45,892 | 45,892 | Redacted |
| PMTCT_STAT_DS D | Number of new ANC and L&D clients | 50,431 | 50,431 | Redacted |
| PMTCT_STAT_DS D | By: Known positives at entry | 341 | 330 | Redacted |
| PMTCT_STAT_DS D | By: Number of new positives identified | 511 | 495 | Redacted |
| PMTCT_STAT_DS D | Sum of Positives Status disaggregates | 852 | 825 | Redacted |
| PMTCT_STAT_NG I | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 45,892 | 45,892 | Redacted |
| PMTCT_STAT_NG I | Number of new ANC and L&D clients | 50,431 | 50,431 | Redacted |
| PMTCT_STAT_NG I | By: Known positives at entry | 341 | 0 | Redacted |
| PMTCT_STAT_NG I | By: Number of new positives identified | 511 | 0 | Redacted |
| PMTCT_STAT_NG I | Sum of Positives Status disaggregates | 852 | 0 | Redacted |

| | | | | |
|-------------|---|-------|--|----------|
| KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 5,712 | | Redacted |
| KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 5,312 | | Redacted |
| KP_PREV_DSD | By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 114 | | Redacted |
| KP_PREV_DSD | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 91 | | Redacted |
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 286 | | Redacted |
| KP_PREV_DSD | By key population type: MSM/TG who | 29 | | Redacted |

| | | | | |
|-------------|---|---------|---------|----------|
| | are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | | | |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 181,164 | 184,068 | Redacted |
| HTC_TST_DSD | By Test Result: Negative | 176,470 | 179,418 | Redacted |
| HTC_TST_DSD | By Test Result: Positive | 4,694 | 4,650 | Redacted |
| HTC_TST_DSD | Sum of Test Result disaggregates | 181,164 | 184,068 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Male | 6 | 0 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Male | 662 | 676 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Male | 268 | 274 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Male | 599 | 612 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Male | 6,644 | 6,785 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Male | 13,746 | 14,045 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Male | 43,202 | 44,124 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Male | 1,340 | 1,368 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Female | 6 | 0 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Female | 693 | 708 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Female | 276 | 282 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Female | 615 | 628 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Female | 11,474 | 11,623 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Female | 30,249 | 30,564 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Female | 70,005 | 70,970 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Female | 1,379 | 1,409 | Redacted |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 181,164 | 184,068 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 1,535 | 1,561 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ | 64,932 | 66,323 | Redacted |



| | | | | |
|-------------|---|---------|---------|----------|
| | PERMISSION ONLY: 15+ Male | | | |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 1,590 | 1,618 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 113,107 | 114,566 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 3,125 | 3,179 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 178,039 | 180,889 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 181,164 | 184,068 | Redacted |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 181,164 | 184,068 | Redacted |
| HTC_TST_NGI | By Test Result: Negative | 176,470 | 179,418 | Redacted |
| HTC_TST_NGI | By Test Result: Positive | 4,694 | 4,650 | Redacted |
| HTC_TST_NGI | Sum of Test Result disaggregates | 181,164 | 184,068 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Male | 6 | | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Male | 662 | 676 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Male | 268 | 274 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Male | 599 | 612 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Male | 6,644 | 6,785 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Male | 13,746 | 14,045 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Male | 43,202 | 44,124 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Male | 1,340 | 1,368 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Female | 6 | 0 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Female | 693 | 708 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Female | 276 | 282 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Female | 615 | 628 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Female | 11,475 | 11,623 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Female | 30,248 | 30,564 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Female | 70,005 | 70,970 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Female | 1,379 | 1,409 | Redacted |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 181,164 | 184,068 | Redacted |

| | | | | |
|----------------|---|---------|---------|----------|
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 1,535 | 1,561 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 64,932 | 66,323 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 1,590 | 1,618 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 113,107 | 114,566 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 3,125 | 3,179 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 178,039 | 180,889 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 181,164 | 184,068 | Redacted |
| GEND_GBV_DSD | Number of people receiving post-GBV care | 29 | 29 | Redacted |
| GEND_GBV_DSD | Age: 0-9 | 3 | 3 | Redacted |
| GEND_GBV_DSD | Age: 10-14 | 7 | 7 | Redacted |
| GEND_GBV_DSD | Age: 15-17 | 10 | 10 | Redacted |
| GEND_GBV_DSD | Age: 18-24 | 6 | 6 | Redacted |
| GEND_GBV_DSD | Age: 25+ | 3 | 3 | Redacted |
| GEND_GBV_DSD | Sum of Age disaggregates | 29 | 29 | Redacted |
| GEND_GBV_DSD | Sex: Male | 10 | 10 | Redacted |
| GEND_GBV_DSD | Sex: Female | 19 | 19 | Redacted |
| GEND_GBV_DSD | Sum of Sex disaggregates | 29 | 29 | Redacted |
| GEND_GBV_DSD | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) | 6 | 6 | Redacted |
| GEND_GBV_DSD | By type of service: Sexual Violence (Post-Rape Care) | 23 | 23 | Redacted |
| GEND_GBV_DSD | By PEP service provision (related to sexual violence services provided) | 23 | 23 | Redacted |
| GEND_NORM_DS D | Number of people completing an intervention pertaining to gender norms, that meets minimum criteria | 3,234 | 3,234 | Redacted |
| GEND_NORM_DS D | By Age: 0-9 | 162 | 162 | Redacted |
| GEND_NORM_DS D | By Age: 10-14 | 162 | 162 | Redacted |

| | | | | |
|-------------------|--|-------|-------|----------|
| GEND_NORM_DS D | By Age: 15-19 | 388 | 388 | Redacted |
| GEND_NORM_DS D | By Age: 20-24 | 970 | 970 | Redacted |
| GEND_NORM_DS D | By Age: 25+ | 1,552 | 1,552 | Redacted |
| GEND_NORM_DS D | Sum of Age disaggregates | 3,234 | 3,234 | Redacted |
| GEND_NORM_DS D | By Sex: Male | 1,585 | 1,585 | Redacted |
| GEND_NORM_DS D | By Sex: Female | 1,649 | 1,649 | Redacted |
| GEND_NORM_DS D | Sum of Sex disaggregates | 3,234 | 3,234 | Redacted |
| GEND_NORM_DS D | By type of activity: Individual | 323 | 323 | Redacted |
| GEND_NORM_DS D | By type of activity: Small Group | 647 | 647 | Redacted |
| GEND_NORM_DS D | By type of activity: Community-level | 2,264 | 2,264 | Redacted |
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 281 | 281 | Redacted |
| OVC_ACC_DSD | Sex: Male | 138 | 138 | Redacted |
| OVC_ACC_DSD | Sex: Female | 143 | 143 | Redacted |
| OVC_ACC_DSD | Sum of Sex disaggregates | 281 | 281 | Redacted |
| OVC_ACC_DSD | Age: <1 | 17 | 17 | Redacted |
| OVC_ACC_DSD | Age: 1-4 | 70 | 70 | Redacted |
| OVC_ACC_DSD | Age: 5-9 | 79 | 79 | Redacted |
| OVC_ACC_DSD | Age: 10-14 | 68 | 68 | Redacted |
| OVC_ACC_DSD | Age: 15-17 | 39 | 39 | Redacted |
| OVC_ACC_DSD | Age: 18+ | 8 | 8 | Redacted |
| OVC_ACC_DSD | Sum of Age disaggregates | 281 | 281 | Redacted |



| | | | | |
|--------------|---|--------|-----|----------|
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 937 | 937 | Redacted |
| OVC_SERV_DSD | Sex: Male | 459 | 459 | Redacted |
| OVC_SERV_DSD | Sex: Female | 478 | 478 | Redacted |
| OVC_SERV_DSD | Sum of Sex disaggregates | 937 | 937 | Redacted |
| OVC_SERV_DSD | Age: <1 | 56 | 56 | Redacted |
| OVC_SERV_DSD | Age: 1-4 | 234 | 234 | Redacted |
| OVC_SERV_DSD | Age: 5-9 | 262 | 262 | Redacted |
| OVC_SERV_DSD | Age: 10-14 | 216 | 216 | Redacted |
| OVC_SERV_DSD | Age: 15-17 | 131 | 131 | Redacted |
| OVC_SERV_DSD | Age: 18+ | 38 | 38 | Redacted |
| OVC_SERV_DSD | Sum of Age disaggregates | 937 | 937 | Redacted |
| C2.1.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 15,458 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Female | 773 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Male | 232 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Female | 14,685 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Male | 14,685 | | Redacted |
| C2.1.D_DSD | Sum of Age/Sex disaggregates | 30,375 | | Redacted |
| C2.1.D_DSD | By Age: <15 | 1,005 | | Redacted |
| C2.1.D_DSD | By Age: 15+ | 29,370 | | Redacted |
| C2.1.D_DSD | Sum of Age disaggregates | 30,375 | | Redacted |
| C2.1.D_DSD | By Sex: Female | 10,821 | | Redacted |
| C2.1.D_DSD | By Sex: Male | 4,637 | | Redacted |
| C2.1.D_DSD | Sum of Sex disaggregates | 15,458 | | Redacted |
| C2.1.D_NGI | Number of HIV-positive individuals receiving a minimum of one clinical service | 15,458 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Female | 773 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Male | 232 | | Redacted |
| C2.1.D_NGI | By Age/Sex: 15+ Female | 14,685 | | Redacted |

| | | | | |
|-------------------|---|--------|--------|----------|
| C2.1.D_NGI | By Age/Sex: 15+ Male | 14,685 | | Redacted |
| C2.1.D_NGI | Sum of Age/Sex disaggregates | 30,375 | | Redacted |
| C2.1.D_NGI | By Age: <15 | 1,005 | | Redacted |
| C2.1.D_NGI | By Age: 15+ | 29,370 | | Redacted |
| C2.1.D_NGI | Sum of Age disaggregates | 30,375 | | Redacted |
| C2.1.D_NGI | By Sex: Female | 10,821 | | Redacted |
| C2.1.D_NGI | By Sex: Male | 4,637 | | Redacted |
| C2.1.D_NGI | Sum of Sex disaggregates | 15,458 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive patients who were screened for TB in HIV care or treatment setting | 13,913 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 15,458 | | Redacted |
| CARE_CURR_DS D | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 16,231 | 16,231 | Redacted |
| CARE_CURR_DS D | Age/sex: <1 Male | 113 | 113 | Redacted |
| CARE_CURR_DS D | Age/sex: 1-4 Male | 83 | 83 | Redacted |
| CARE_CURR_DS D | Age/sex: 5-9 Male | 39 | 39 | Redacted |
| CARE_CURR_DS D | Age/sex: 10-14 Male | 24 | 24 | Redacted |
| CARE_CURR_DS D | Age/sex: 15-19 Male | 487 | 487 | Redacted |
| CARE_CURR_DS D | Age/sex: 20-24 Male | 730 | 730 | Redacted |
| CARE_CURR_DS D | Age/sex: 25-49 Male | 3,165 | 3,165 | Redacted |
| CARE_CURR_DS | Age/sex: 50+ Male | 227 | 227 | Redacted |

| | | | | |
|-------------------|---|--------|--------|----------|
| D | | | | |
| CARE_CURR_DS D | Age/sex: <1 Female | 265 | 265 | Redacted |
| CARE_CURR_DS D | Age/sex: 1-4 Female | 193 | 193 | Redacted |
| CARE_CURR_DS D | Age/sex: 5-9 Female | 91 | 91 | Redacted |
| CARE_CURR_DS D | Age/sex: 10-14 Female | 57 | 57 | Redacted |
| CARE_CURR_DS D | Age/sex: 15-19 Female | 1,136 | 1,136 | Redacted |
| CARE_CURR_DS D | Age/sex: 20-24 Female | 1,705 | 1,705 | Redacted |
| CARE_CURR_DS D | Age/sex: 25-49 Female | 7,385 | 7,385 | Redacted |
| CARE_CURR_DS D | Age/sex: 50+ Female | 531 | 531 | Redacted |
| CARE_CURR_DS D | Sum of Age/Sex disaggregates | 16,231 | 16,231 | Redacted |
| CARE_CURR_DS D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 260 | 260 | Redacted |
| CARE_CURR_DS D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 4,609 | 4,609 | Redacted |
| CARE_CURR_DS D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 606 | 606 | Redacted |
| CARE_CURR_DS D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 10,756 | 10,756 | Redacted |
| CARE_CURR_DS D | Sum of Aggregated Age/Sex disaggregates | 16,231 | 16,231 | Redacted |
| CARE_NEW_DSD | Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO | 1,610 | 1,610 | Redacted |

| | | | | |
|---------------|---|-------|-------|----------|
| | staging) OR CD4 count OR viral load | | | |
| CARE_NEW_DSD | Age/sex: <1 Male | 3 | 3 | Redacted |
| CARE_NEW_DSD | Age/sex: 1-4 Male | 5 | 5 | Redacted |
| CARE_NEW_DSD | Age/sex: 5-9 Male | 8 | 8 | Redacted |
| CARE_NEW_DSD | Age/sex: 10-14 Male | 10 | 10 | Redacted |
| CARE_NEW_DSD | Age/sex: 15-19 Male | 46 | 46 | Redacted |
| CARE_NEW_DSD | Age/sex: 20-24 Male | 160 | 160 | Redacted |
| CARE_NEW_DSD | Age/sex: 25-49 Male | 183 | 183 | Redacted |
| CARE_NEW_DSD | Age/sex: 50+ Male | 69 | 69 | Redacted |
| CARE_NEW_DSD | Age/sex: <1 Female | 6 | 6 | Redacted |
| CARE_NEW_DSD | Age/sex: 1-4 Female | 12 | 12 | Redacted |
| CARE_NEW_DSD | Age/sex: 5-9 Female | 18 | 18 | Redacted |
| CARE_NEW_DSD | Age/sex: 10-14 Female | 24 | 24 | Redacted |
| CARE_NEW_DSD | Age/sex: 15-19 Female | 107 | 107 | Redacted |
| CARE_NEW_DSD | Age/sex: 20-24 Female | 373 | 373 | Redacted |
| CARE_NEW_DSD | Age/sex: 25-49 Female | 426 | 426 | Redacted |
| CARE_NEW_DSD | Age/sex: 50+ Female | 160 | 160 | Redacted |
| CARE_NEW_DSD | Sum of Age/sex disaggregates | 1,610 | 1,610 | Redacted |
| CARE_NEW_DSD | Aggregated Age/sex: <15 Male | 26 | 26 | Redacted |
| CARE_NEW_DSD | Aggregated Age/sex: 15+ Male | 457 | 457 | Redacted |
| CARE_NEW_DSD | Aggregated Age/sex: <15 Female | 60 | 60 | Redacted |
| CARE_NEW_DSD | Aggregated Age/sex: 15+ Female | 1,067 | 1,067 | Redacted |
| CARE_NEW_DSD | Sum of Aggregated Age/sex disaggregates | 1,610 | 1,610 | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period | 457 | 457 | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period | 750 | 750 | Redacted |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting | 852 | 0 | Redacted |

| | | | | |
|---------------|--|--------|--------|----------|
| | period (include known HIV-positive women at entry into PMTCT) | | | |
| PMTCT_EID_DSD | By infants who received a virologic test within 2 months of birth | 247 | 247 | Redacted |
| PMTCT_EID_DSD | By infants who received their first virologic HIV test between 2 and 12 months of age | 503 | 503 | Redacted |
| PMTCT_EID_DSD | Sum of Infant Age disaggregates | 750 | 750 | Redacted |
| PMTCT_EID_DSD | By infants with a positive virologic test result within 12 months of birth | 38 | 38 | Redacted |
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 10,305 | 11,073 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Male | 72 | 31 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Male | 53 | 145 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Male | 40 | 264 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Male | 2,926 | 3,381 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Female | 168 | 27 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Female | 123 | 129 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Female | 94 | 234 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Female | 6,829 | 6,863 | Redacted |
| TX_CURR_DSD | Sum of age/sex disaggregates | 550 | 830 | Redacted |
| TX_CURR_DSD | Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 0 | 0 | Redacted |
| TX_CURR_DSD | Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 1 | 1 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Male | 72 | 31 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Female | 168 | 27 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male | 165 | 439 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 2,927 | 3,381 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female | 384 | 390 | Redacted |

| | | | | |
|-------------|--|--------|--------|----------|
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Female | 6,829 | 6,863 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 549 | 829 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex 15+ | 9,756 | 10,244 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates | 10,305 | 11,073 | Redacted |
| TX_CURR_NGI | Number of adults and children receiving antiretroviral therapy (ART) | 10,305 | 11,073 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Male | 72 | 31 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Male | 53 | 145 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Male | 40 | 264 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Male | 2,926 | 3,381 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Female | 168 | 27 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Female | 123 | 129 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Female | 94 | 234 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Female | 6,829 | 6,862 | Redacted |
| TX_CURR_NGI | Sum of Age/Sex disaggregates | 10,305 | 11,073 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Male | 72 | 31 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Female | 168 | 27 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Male | 165 | 439 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Male | 2,927 | 3,381 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Female | 384 | 390 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Female | 6,829 | 6,863 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex disaggregates | 10,305 | 11,073 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex <15 | 549 | 829 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex 15+ | 9,756 | 10,244 | Redacted |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 2,743 | 2,743 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Male | 15 | 15 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Male | 22 | 22 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Male | 27 | 27 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Male | 45 | 45 | Redacted |

| | | | | |
|------------|--|-------|-------|----------|
| TX_NEW_DSD | By Age/Sex: 15-19 Male | 118 | 118 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Male | 197 | 197 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Male | 315 | 315 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Male | 157 | 157 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Female | 14 | 14 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Female | 19 | 19 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Female | 24 | 24 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Female | 39 | 39 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Female | 263 | 263 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Female | 438 | 438 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Female | 700 | 700 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Female | 350 | 350 | Redacted |
| TX_NEW_DSD | Sum of Age/Sex disaggregates | 2,743 | 2,743 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male | 15 | 15 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male | 109 | 109 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 786 | 786 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female | 14 | 14 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female | 96 | 96 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 1,751 | 1,751 | Redacted |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 2,742 | 2,742 | Redacted |
| TX_NEW_DSD | Pregnancy status | 140 | 140 | Redacted |
| TX_NEW_DSD | Breastfeeding status | 89 | 89 | Redacted |
| TX_RET_DSD | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 2,828 | 2,828 | Redacted |
| TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months | 3,327 | 3,327 | Redacted |

| | | | | |
|------------|--|-------|-------|----------|
| | prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | | | |
| TX_RET_DSD | Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 57 | 57 | Redacted |
| TX_RET_DSD | Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 113 | 113 | Redacted |
| TX_RET_DSD | Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 2,658 | 2,658 | Redacted |
| TX_RET_DSD | Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 67 | 67 | Redacted |
| TX_RET_DSD | Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 133 | 133 | Redacted |
| TX_RET_DSD | Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to | 3,127 | 3,127 | Redacted |

| | | | | |
|-------------|---|-------|-------|----------|
| | follow-up) | | | |
| TX_RET_DSD | Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 170 | 170 | Redacted |
| TX_RET_DSD | Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 2,658 | 2,658 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 200 | 200 | Redacted |
| TX_RET_DSD | Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 3,127 | 3,127 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 133 | 133 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 0 | 0 | Redacted |
| LAB_CAP_DSD | Number of PEPFAR-supported testing | 9 | 9 | Redacted |

| | | | | |
|---------------|--|--------|--------|----------|
| | facilities with capacity to perform clinical laboratory tests | | | |
| LAB_CAP_DSD | By clinical laboratories | 9 | 9 | Redacted |
| LAB_CAP_DSD | By Point-of-care testing sites | 0 | | Redacted |
| LAB_CAP_DSD | By site support type: Direct Service Delivery (DSD) | 9 | 9 | Redacted |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates | 9 | 9 | Redacted |
| QI_SITE | Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months | 9 | 9 | Redacted |
| QI_SITE | Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC | 13 | 13 | Redacted |
| TB_SCREEN_DSD | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period | 14,611 | 14,611 | Redacted |
| TB_SCREEN_DSD | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 16,231 | 16,231 | Redacted |
| TB_SCREEN_DSD | Age: <1 | 340 | 340 | Redacted |
| TB_SCREEN_DSD | Age: 1-4 | 248 | 248 | Redacted |
| TB_SCREEN_DSD | Age: 5-9 | 117 | 117 | Redacted |
| TB_SCREEN_DSD | Age: 10-14 | 73 | 73 | Redacted |
| TB_SCREEN_DSD | Age: 15-19 | 1,461 | 1,461 | Redacted |
| TB_SCREEN_DSD | Age: 20-24 | 2,192 | 2,192 | Redacted |
| TB_SCREEN_DSD | Age: 25-49 | 9,498 | 9,498 | Redacted |



| | | | | |
|---------------|--|--------|--------|----------|
| TB_SCREEN_DSD | Age: 50+ | 682 | 682 | Redacted |
| TB_SCREEN_DSD | Sum of Age disaggregates | 2,239 | 2,239 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 | 779 | 779 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ | 13,832 | 13,832 | Redacted |
| TB_SCREEN_DSD | Sum of Aggregated Age disaggregates | 14,611 | 14,611 | Redacted |
| TB_SCREEN_DSD | Sex: Male | 4,383 | 4,383 | Redacted |
| TB_SCREEN_DSD | Sex: Female | 10,228 | 10,228 | Redacted |
| TB_SCREEN_DSD | Sum of Sex disaggregates | 14,611 | 14,611 | Redacted |

Implementing Mechanism Details

| | |
|--|---|
| Mechanism ID: 17743 | Mechanism Name: PHI_INTEGRATED PROGRAMS FOR SUSTAINABLE ACTION AGAINST HIV/AIDS IN NIGERIA |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Pro-Health International | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 3,716,158 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 3,716,158 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|-------------------------|-------|
| Gender: Gender Equality | 8,500 |
|-------------------------|-------|



| | |
|-------------|---|
| Focus Area: | Promoting gender-related policies and laws that increase legal protection |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Capacity building |
| Focus Area: | Equity in HIV prevention, care, treatment and support |

Key Issues

(No data provided.)

Budget Code Information

| Mechanism ID: | 17743 | | |
|----------------------------|--|----------------|----------------|
| Mechanism Name: | PHI_INTEGRATED PROGRAMS FOR SUSTAINABLE ACTION AGAINST | | |
| Prime Partner Name: | HIV/AIDS IN NIGERIA | | |
| | Pro-Health International | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 525,367 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 158,456 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 246,911 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 35,692 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 241,296 | 0 |



| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|----------------|-------------|----------------|----------------|
| Prevention | HMIN | 20,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 357,333 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 499,971 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 1,525,227 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 105,905 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|-------------------|--|-------|-------|-------------------------|
| PMTCT_ARV_DS D | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 1,534 | 1,596 | Redacted |
| PMTCT_ARV_DS D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 1,743 | 1,754 | Redacted |
| PMTCT_ARV_DS D | Life-long ART (including Option B+) | 844 | 878 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 321 | 334 | Redacted |

| | | | | |
|-------------------|--|-------|-------|----------|
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 523 | 544 | Redacted |
| PMTCT_ARV_DS D | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 598 | 622 | Redacted |
| PMTCT_ARV_DS D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 77 | 80 | Redacted |
| PMTCT_ARV_DS D | Single-dose nevirapine (with or without tail) | 15 | 16 | Redacted |
| PMTCT_ARV_DS D | Sum of Regimen Type disaggregates | 1,534 | 1,596 | Redacted |
| PMTCT_ARV_DS D | Sum of New and Current disaggregates | 844 | 878 | Redacted |
| PMTCT_ARV_NGI | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 1,534 | 1,596 | Redacted |
| PMTCT_ARV_NGI | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 1,743 | 1,754 | Redacted |
| PMTCT_ARV_NGI | Life-long ART (including Option B+) | 844 | 878 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 321 | 334 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 523 | 544 | Redacted |
| PMTCT_ARV_NGI | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 598 | 622 | Redacted |
| PMTCT_ARV_NGI | Maternal AZT (prophylaxis component of WHO Option A during pregnancy | 77 | 80 | Redacted |

| | | | | |
|--------------------|--|--------|---------|----------|
| | and delivery) | | | |
| PMTCT_ARV_NGI | Single-dose nevirapine (with or without tail) | 15 | 16 | Redacted |
| PMTCT_ARV_NGI | Sum of Regimen disaggregates | 1,534 | 1,596 | Redacted |
| PMTCT_ARV_NGI | Sum of New and Current disaggregates | 844 | 878 | Redacted |
| PMTCT_STAT_DS D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 35,223 | 36,229 | Redacted |
| PMTCT_STAT_DS D | Number of new ANC and L&D clients | 38,707 | 39,812 | Redacted |
| PMTCT_STAT_DS D | By: Known positives at entry | 679 | 725 | Redacted |
| PMTCT_STAT_DS D | By: Number of new positives identified | 1,046 | 1,088 | Redacted |
| PMTCT_STAT_DS D | Sum of Positives Status disaggregates | 1,725 | 1,813 | Redacted |
| PMTCT_STAT_NG I | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 35,223 | 36,229 | Redacted |
| PMTCT_STAT_NG I | Number of new ANC and L&D clients | 38,707 | 39,812 | Redacted |
| PMTCT_STAT_NG I | By: Known positives at entry | 679 | 725 | Redacted |
| PMTCT_STAT_NG I | By: Number of new positives identified | 1,046 | 1,088 | Redacted |
| PMTCT_STAT_NG I | Sum of Positives Status disaggregates | 1,725 | 1,813 | Redacted |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 36,977 | 167,941 | Redacted |
| HTC_TST_DSD | By Test Result: Negative | 35,843 | 162,964 | Redacted |
| HTC_TST_DSD | By Test Result: Positive | 1,134 | 4,977 | Redacted |

| | | | | |
|-------------|---|--------|---------|----------|
| HTC_TST_DSD | Sum of Test Result disaggregates | 36,977 | 167,941 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Male | 755 | 782 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Male | 4 | 639 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Male | 2 | 258 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Male | 4 | 578 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Male | 45 | 6,409 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Male | 90 | 13,266 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Male | 292 | 41,675 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Male | 9 | 1,292 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Female | 786 | 814 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Female | 5 | 669 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Female | 2 | 266 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Female | 4 | 593 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Female | 3,499 | 10,227 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Female | 12,178 | 26,240 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Female | 19,293 | 62,903 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Female | 9 | 1,330 | Redacted |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 36,977 | 167,941 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 765 | 2,256 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 436 | 62,642 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 797 | 2,342 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 34,979 | 100,701 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 1,562 | 4,598 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 35,415 | 163,343 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 36,977 | 167,941 | Redacted |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 36,977 | 167,941 | Redacted |

| | | | | |
|--------------|--|--------|---------|----------|
| HTC_TST_NGI | By Test Result: Negative | 35,843 | 162,965 | Redacted |
| HTC_TST_NGI | By Test Result: Positive | 1,134 | 4,976 | Redacted |
| HTC_TST_NGI | Sum of Test Result disaggregates | 36,977 | 167,941 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Male | 755 | 782 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Male | 4 | 639 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Male | 2 | 258 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Male | 4 | 578 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Male | 45 | 6,409 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Male | 90 | 13,266 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Male | 292 | 41,675 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Male | 9 | 1,292 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Female | 786 | 814 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Female | 5 | 669 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Female | 2 | 266 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Female | 4 | 593 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Female | 3,499 | 10,227 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Female | 12,178 | 26,240 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Female | 19,293 | 62,903 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Female | 9 | 1,330 | Redacted |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 36,977 | 167,941 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 765 | 2,257 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 436 | 62,641 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 797 | 2,342 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 34,979 | 100,701 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 1,562 | 4,599 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 35,415 | 163,342 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 36,977 | 167,941 | Redacted |
| GEND_GBV_DSD | Number of people receiving post-GBV care | 37 | 37 | Redacted |
| GEND_GBV_DSD | Age: 0-9 | 4 | 4 | Redacted |
| GEND_GBV_DSD | Age: 10-14 | 9 | 9 | Redacted |



| | | | | |
|--------------|---|-----|-------|----------|
| GEND_GBVDSD | Age: 15-17 | 13 | 13 | Redacted |
| GEND_GBVDSD | Age: 18-24 | 7 | 7 | Redacted |
| GEND_GBVDSD | Age: 25+ | 4 | 4 | Redacted |
| GEND_GBVDSD | Sum of Age disaggregates | 37 | 37 | Redacted |
| GEND_GBVDSD | Sex: Male | 12 | 12 | Redacted |
| GEND_GBVDSD | Sex: Female | 25 | 25 | Redacted |
| GEND_GBVDSD | Sum of Sex disaggregates | 37 | 37 | Redacted |
| GEND_GBVDSD | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) | 8 | 8 | Redacted |
| GEND_GBVDSD | By type of service: Sexual Violence (Post-Rape Care) | 29 | 29 | Redacted |
| GEND_GBVDSD | By PEP service provision (related to sexual violence services provided) | 29 | 29 | Redacted |
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 625 | 1,639 | Redacted |
| OVC_ACC_DSD | Sex: Male | 306 | 803 | Redacted |
| OVC_ACC_DSD | Sex: Female | 319 | 836 | Redacted |
| OVC_ACC_DSD | Sum of Sex disaggregates | 625 | 1,639 | Redacted |
| OVC_ACC_DSD | Age: <1 | 38 | 98 | Redacted |
| OVC_ACC_DSD | Age: 1-4 | 156 | 410 | Redacted |
| OVC_ACC_DSD | Age: 5-9 | 175 | 459 | Redacted |
| OVC_ACC_DSD | Age: 10-14 | 150 | 394 | Redacted |
| OVC_ACC_DSD | Age: 15-17 | 87 | 229 | Redacted |
| OVC_ACC_DSD | Age: 18+ | 19 | 49 | Redacted |
| OVC_ACC_DSD | Sum of Age disaggregates | 625 | 1,639 | Redacted |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 937 | 5,464 | Redacted |
| OVC_SERV_DSD | Sex: Male | 459 | 2,677 | Redacted |
| OVC_SERV_DSD | Sex: Female | 478 | 2,787 | Redacted |
| OVC_SERV_DSD | Sum of Sex disaggregates | 937 | 5,464 | Redacted |

| | | | | |
|--------------|--|--------|-------|----------|
| OVC_SERV_DSD | Age: <1 | 56 | 328 | Redacted |
| OVC_SERV_DSD | Age: 1-4 | 234 | 1,366 | Redacted |
| OVC_SERV_DSD | Age: 5-9 | 262 | 1,530 | Redacted |
| OVC_SERV_DSD | Age: 10-14 | 226 | 1,311 | Redacted |
| OVC_SERV_DSD | Age: 15-17 | 131 | 765 | Redacted |
| OVC_SERV_DSD | Age: 18+ | 28 | 164 | Redacted |
| OVC_SERV_DSD | Sum of Age disaggregates | 937 | 5,464 | Redacted |
| C2.1.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 28,264 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Female | 989 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Male | 424 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Female | 18,796 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Male | 8,055 | | Redacted |
| C2.1.D_DSD | Sum of Age/Sex disaggregates | 28,264 | | Redacted |
| C2.1.D_DSD | By Age: <15 | 1,413 | | Redacted |
| C2.1.D_DSD | By Age: 15+ | 26,851 | | Redacted |
| C2.1.D_DSD | Sum of Age disaggregates | 28,264 | | Redacted |
| C2.1.D_DSD | By Sex: Female | 19,785 | | Redacted |
| C2.1.D_DSD | By Sex: Male | 8,479 | | Redacted |
| C2.1.D_DSD | Sum of Sex disaggregates | 28,264 | | Redacted |
| C2.1.D_NGI | Number of HIV-positive individuals receiving a minimum of one clinical service | 28,264 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Female | 989 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Male | 424 | | Redacted |
| C2.1.D_NGI | By Age/Sex: 15+ Female | 18,796 | | Redacted |
| C2.1.D_NGI | By Age/Sex: 15+ Male | 8,055 | | Redacted |
| C2.1.D_NGI | Sum of Age/Sex disaggregates | 28,264 | | Redacted |
| C2.1.D_NGI | By Age: <15 | 1,413 | | Redacted |
| C2.1.D_NGI | By Age: 15+ | 26,851 | | Redacted |
| C2.1.D_NGI | Sum of Age disaggregates | 28,264 | | Redacted |

| | | | | |
|---------------|--|--------|-------|----------|
| C2.1.D_NGI | By Sex: Female | 19,785 | | Redacted |
| C2.1.D_NGI | By Sex: Male | 8,479 | | Redacted |
| C2.1.D_NGI | Sum of Sex disaggregates | 28,264 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive patients who were screened for TB in HIV care or treatment setting | 25,437 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 28,264 | | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 224 | 234 | Redacted |
| TB_ART_DSD | Age: 0-4 | 2 | 2 | Redacted |
| TB_ART_DSD | Age: 5-14 | 11 | 12 | Redacted |
| TB_ART_DSD | Age: 15+ | 211 | 220 | Redacted |
| TB_ART_DSD | Male | 110 | 115 | Redacted |
| TB_ART_DSD | Female | 114 | 119 | Redacted |
| TB_ART_DSD | Sum of Sex disaggregates | 224 | 234 | Redacted |
| TB_ART_DSD | Newly tested | 128 | 133 | Redacted |
| TB_ART_DSD | Known HIV-positive | 96 | 101 | Redacted |
| TB_ART_DSD | Sum of Test Status disaggregates | 224 | 234 | Redacted |
| TB_ART_DSD | Aggregated Age: <15 | 13 | 14 | Redacted |
| TB_ART_DSD | Aggregated Age: 15+ | 211 | 220 | Redacted |
| TB_ART_DSD | Sum of Aggregated Age disaggregates | 224 | 234 | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period | 1,534 | 1,596 | Redacted |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 1,743 | 1,814 | Redacted |
| PMTCT_EID_DSD | By infants who received a virologic test | 506 | 527 | Redacted |

| | | | | |
|---------------|--|--------|--------|----------|
| | within 2 months of birth | | | |
| PMTCT_EID_DSD | By infants who received their first virologic HIV test between 2 and 12 months of age | 1,028 | 1,069 | Redacted |
| PMTCT_EID_DSD | Sum of Infant Age disaggregates | 1,534 | 1,596 | Redacted |
| PMTCT_EID_DSD | By infants with a positive virologic test result within 12 months of birth | 77 | 80 | Redacted |
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 12,627 | 12,957 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Male | 25 | 26 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Male | 118 | 121 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Male | 214 | 219 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Male | 3,945 | 4,048 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Female | 22 | 23 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Female | 104 | 107 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Female | 190 | 194 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Female | 8,009 | 8,219 | Redacted |
| TX_CURR_DSD | Sum of age/sex disaggregates | 673 | 690 | Redacted |
| TX_CURR_DSD | Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 5 | 5 | Redacted |
| TX_CURR_DSD | Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 66 | 66 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Male | 25 | 26 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Female | 22 | 23 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male | 357 | 366 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 3,945 | 4,048 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female | 316 | 324 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Female | 8,009 | 8,219 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 673 | 690 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex 15+ | 11,954 | 12,267 | Redacted |

| | | | | |
|-------------|--|--------|--------|----------|
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates | 12,627 | 12,957 | Redacted |
| TX_CURR_NGI | Number of adults and children receiving antiretroviral therapy (ART) | 12,627 | 12,957 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Male | 25 | 26 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Male | 118 | 121 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Male | 214 | 219 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Male | 3,945 | 4,048 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Female | 22 | 23 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Female | 104 | 107 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Female | 190 | 194 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Female | 8,009 | 8,219 | Redacted |
| TX_CURR_NGI | Sum of Age/Sex disaggregates | 12,627 | 12,957 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Male | 25 | 26 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Female | 22 | 23 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Male | 357 | 366 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Male | 3,945 | 4,048 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Female | 316 | 324 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Female | 8,009 | 8,219 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex disaggregates | 12,627 | 12,957 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex <15 | 673 | 690 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex 15+ | 11,954 | 12,267 | Redacted |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 4,076 | 4,008 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Male | 16 | 16 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Male | 23 | 23 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Male | 29 | 28 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Male | 47 | 47 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Male | 179 | 176 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Male | 299 | 294 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Male | 479 | 470 | Redacted |

| | | | | |
|------------|---|--------|-------|----------|
| TX_NEW_DSD | By Age/Sex: 50+ Male | 239 | 235 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Female | 15 | 15 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Female | 20 | 20 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Female | 25 | 25 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Female | 41 | 40 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Female | 399 | 393 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Female | 666 | 654 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Female | 1,065 | 1,047 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Female | 533 | 524 | Redacted |
| TX_NEW_DSD | Sum of Age/Sex disaggregates | 4,075 | 4,007 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male | 16 | 16 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male | 115 | 113 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 1,196 | 1,176 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female | 15 | 15 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female | 102 | 101 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 2,663 | 2,618 | Redacted |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 4,076 | 4,008 | Redacted |
| TX_NEW_DSD | Pregnancy status | 213 | 209 | Redacted |
| TX_NEW_DSD | Breastfeeding status | 0 | 0 | Redacted |
| TX_RET_DSD | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 13,003 | 3,465 | Redacted |
| TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 15,298 | 4,076 | Redacted |

| | | | | |
|------------|--|--------|-------|----------|
| TX_RET_DSD | Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 260 | 69 | Redacted |
| TX_RET_DSD | Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 390 | 139 | Redacted |
| TX_RET_DSD | Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 12,353 | 3,257 | Redacted |
| TX_RET_DSD | Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 306 | 82 | Redacted |
| TX_RET_DSD | Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 459 | 163 | Redacted |
| TX_RET_DSD | Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 14,533 | 3,831 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 | 650 | 208 | Redacted |

| | | | | |
|-------------|---|--------|-------|----------|
| | months after initiating ART) | | | |
| TX_RET_DSD | Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 12,353 | 3,257 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 765 | 245 | Redacted |
| TX_RET_DSD | Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 14,533 | 3,831 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 6,112 | 163 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 719 | 0 | Redacted |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 8 | | Redacted |
| LAB_CAP_DSD | By clinical laboratories | 8 | | Redacted |



| | | | | |
|---------------|--|--------|--------|----------|
| LAB_CAP_DSD | By Point-of-care testing sites | 0 | | Redacted |
| LAB_CAP_DSD | By site support type: Direct Service Delivery (DSD) | 8 | | Redacted |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates | 8 | | Redacted |
| TB_SCREEN_DSD | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period | 25,437 | 28,289 | Redacted |
| TB_SCREEN_DSD | Age: <1 | 509 | 566 | Redacted |
| TB_SCREEN_DSD | Age: 1-4 | 254 | 283 | Redacted |
| TB_SCREEN_DSD | Age: 5-9 | 509 | 566 | Redacted |
| TB_SCREEN_DSD | Age: 10-14 | 254 | 283 | Redacted |
| TB_SCREEN_DSD | Age: 15-19 | 2,544 | 2,829 | Redacted |
| TB_SCREEN_DSD | Age: 20-24 | 6,359 | 7,072 | Redacted |
| TB_SCREEN_DSD | Age: 25-49 | 13,991 | 15,558 | Redacted |
| TB_SCREEN_DSD | Age: 50+ | 1,017 | 1,132 | Redacted |
| TB_SCREEN_DSD | Sum of Age disaggregates | 4,070 | 4,527 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 | 1,526 | 1,697 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ | 23,911 | 26,592 | Redacted |
| TB_SCREEN_DSD | Sum of Aggregated Age disaggregates | 25,437 | 28,289 | Redacted |
| TB_SCREEN_DSD | Sex: Male | 7,631 | 8,487 | Redacted |
| TB_SCREEN_DSD | Sex: Female | 17,806 | 19,802 | Redacted |
| TB_SCREEN_DSD | Sum of Sex disaggregates | 25,437 | 28,289 | Redacted |

Implementing Mechanism Details

| | |
|---|--|
| Mechanism ID: 17742 | Mechanism Name: Friends for Global Health Initiative in Nigeria(FGHIN) |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Gembu Center for AIDS Advocacy, Nigeria | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |

Approved



| | |
|---|--------------------|
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 5,616,145 | |
| Total Mechanism Pipeline: Redacted | |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 5,616,145 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|---------------------------|---|
| Renovation | 99,747 |
| Gender: Gender Equality | 23,513 |
| Focus Area: | Promoting gender-related policies and laws that increase legal protection |
| Sub Area: | Implementation |
| Motor Vehicles: Purchased | 127,500 |

Key Issues

Malaria (PMI)
Child Survival Activities
Mobile Population
Safe Motherhood
TB
Family Planning



Budget Code Information

| Mechanism ID: 17742 | | | |
|--|-------------|----------------|----------------|
| Mechanism Name: Friends for Global Health Initiative in Nigeria(FGHIN) | | | |
| Prime Partner Name: Gembu Center for AIDS Advocacy, Nigeria | | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 750,100 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 235,132 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 270,381 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 50,804 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 601,638 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMIN | 25,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVAB | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 474,452 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 341,250 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 544,341 | 0 |



| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|----------------|-------------|----------------|----------------|
| Treatment | HTXS | 2,172,332 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 150,715 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|------------------|---|------|------|-------------------------|
| SITE_SUPP | By program area/support type: HTC Direct Service Delivery (DSD) | 87 | 155 | Redacted |
| SITE_SUPP | By program area/support type: Treatment Direct Service Delivery (DSD) | 7 | 15 | Redacted |
| SITE_SUPP | By program area/support type: Care and Support Direct Service Delivery (DSD) | 7 | 15 | Redacted |
| SITE_SUPP | By program area/support type: Food and Nutrition Direct Service Delivery (DSD) | 7 | 15 | Redacted |
| SITE_SUPP | By program area/support type: PMTCT Direct Service Delivery (DSD) | 87 | 155 | Redacted |
| SITE_SUPP | By program area/support type: TB/HIV Direct Service Delivery (DSD) | 7 | 15 | Redacted |
| SITE_SUPP | By program area/support type: VMMC Direct Service Delivery (DSD) | 7 | 15 | Redacted |
| SITE_SUPP | By program area/support type: General Population Prevention Direct Service Delivery (DSD) | 87 | 155 | Redacted |
| SITE_SUPP | By program area/support type: Key | 7 | 15 | Redacted |

| | | | | |
|-------------------|--|-------|-------|----------|
| | Populations Prevention Direct Service Delivery (DSD) | | | |
| SITE_SUPP | By program area/support type: OVC Direct Service Delivery (DSD) | 7 | 15 | Redacted |
| SITE_SUPP | By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD) | 87 | 155 | Redacted |
| SITE_SUPP | By program area/support type: Lab Direct Service Delivery (DSD) | 4 | 15 | Redacted |
| PMTCT_ARV_DS D | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 1,428 | 1,595 | Redacted |
| PMTCT_ARV_DS D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 1,623 | 1,753 | Redacted |
| PMTCT_ARV_DS D | Life-long ART (including Option B+) | 785 | 877 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 299 | 297 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 487 | 580 | Redacted |
| PMTCT_ARV_DS D | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 558 | 638 | Redacted |
| PMTCT_ARV_DS D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 71 | 80 | Redacted |
| PMTCT_ARV_DS D | Single-dose nevirapine (with or without tail) | 14 | 0 | Redacted |
| PMTCT_ARV_DS D | Sum of Regimen Type disaggregates | 1,428 | 1,595 | Redacted |

| | | | | |
|--------------------|--|--------|--------|----------|
| PMTCT_ARV_DS D | Sum of New and Current disaggregates | 786 | 877 | Redacted |
| PMTCT_ARV_NGI | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 1,428 | 1,595 | Redacted |
| PMTCT_ARV_NGI | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 1,623 | 1,753 | Redacted |
| PMTCT_ARV_NGI | Life-long ART (including Option B+) | 785 | 877 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 299 | 297 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 487 | 580 | Redacted |
| PMTCT_ARV_NGI | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 558 | 638 | Redacted |
| PMTCT_ARV_NGI | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 71 | 80 | Redacted |
| PMTCT_ARV_NGI | Single-dose nevirapine (with or without tail) | 14 | 0 | Redacted |
| PMTCT_ARV_NGI | Sum of Regimen disaggregates | 1,428 | 1,595 | Redacted |
| PMTCT_ARV_NGI | Sum of New and Current disaggregates | 786 | 877 | Redacted |
| PMTCT_STAT_DS D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 37,971 | 40,367 | Redacted |
| PMTCT_STAT_DS D | Number of new ANC and L&D clients | 41,726 | 44,359 | Redacted |
| PMTCT_STAT_DS D | By: Known positives at entry | 649 | 701 | Redacted |

| | | | | |
|--------------------|--|--------|--------|----------|
| PMTCT_STAT_DS D | By: Number of new positives identified | 974 | 1,052 | Redacted |
| PMTCT_STAT_DS D | Sum of Positives Status disaggregates | 1,623 | 1,753 | Redacted |
| PMTCT_STAT_NG I | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 37,971 | 40,367 | Redacted |
| PMTCT_STAT_NG I | Number of new ANC and L&D clients | 41,726 | 44,359 | Redacted |
| PMTCT_STAT_NG I | By: Known positives at entry | 649 | 701 | Redacted |
| PMTCT_STAT_NG I | By: Number of new positives identified | 974 | 1,052 | Redacted |
| PMTCT_STAT_NG I | Sum of Positives Status disaggregates | 1,623 | 1,753 | Redacted |
| PP_PREV_DSD | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 731 | 24,548 | Redacted |
| PP_PREV_DSD | Total number of people in the target population | 1,697 | 89,185 | Redacted |
| PP_PREV_DSD | Age/sex: 10-14 Male | 36 | 1,203 | Redacted |
| PP_PREV_DSD | Age/sex: 15-19 Male | 43 | 1,443 | Redacted |
| PP_PREV_DSD | Age/sex: 20-24 Male | 107 | 3,609 | Redacted |
| PP_PREV_DSD | Age/sex: 25-49 Male | 161 | 5,413 | Redacted |
| PP_PREV_DSD | Age/sex: 50+ Male | 11 | 361 | Redacted |
| PP_PREV_DSD | Age/sex: 10-14 Female | 37 | 1,252 | Redacted |
| PP_PREV_DSD | Age/sex: 15-19 Female | 45 | 1,502 | Redacted |
| PP_PREV_DSD | Age/sex: 20-24 Female | 112 | 3,755 | Redacted |
| PP_PREV_DSD | Age/sex: 25-49 Female | 168 | 5,634 | Redacted |
| PP_PREV_DSD | Age/sex: 50+ Female | 11 | 376 | Redacted |
| PP_PREV_DSD | Sum of Age/Sex disaggregates | 731 | 24,548 | Redacted |

| | | | | |
|-------------|---|-------|--|----------|
| KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 3,694 | | Redacted |
| KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 3,435 | | Redacted |
| KP_PREV_DSD | By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 59 | | Redacted |
| KP_PREV_DSD | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 15 | | Redacted |
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 185 | | Redacted |
| KP_PREV_DSD | By key population type: MSM/TG who | 18 | | Redacted |

| | | | | |
|-------------|---|--------|---------|----------|
| | are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | | | |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 41,497 | 219,016 | Redacted |
| HTC_TST_DSD | By Test Result: Negative | 40,259 | 212,632 | Redacted |
| HTC_TST_DSD | By Test Result: Positive | 1,238 | 6,384 | Redacted |
| HTC_TST_DSD | Sum of Test Result disaggregates | 41,497 | 219,016 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Male | 709 | 782 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Male | 13 | 868 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Male | 5 | 351 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Male | 12 | 785 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Male | 135 | 8,708 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Male | 269 | 18,025 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Male | 875 | 56,628 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Male | 27 | 1,756 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Female | 738 | 813 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Female | 14 | 909 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Female | 6 | 362 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Female | 13 | 806 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Female | 3,872 | 13,036 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Female | 13,343 | 32,642 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Female | 21,438 | 80,737 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Female | 28 | 1,808 | Redacted |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 41,497 | 219,016 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 740 | 2,786 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ | 1,306 | 85,117 | Redacted |

| | | | | |
|-------------|---|--------|---------|----------|
| | PERMISSION ONLY: 15+ Male | | | |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 770 | 2,890 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 38,681 | 128,223 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 1,510 | 5,676 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 39,987 | 213,340 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 41,497 | 219,016 | Redacted |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 41,497 | 219,016 | Redacted |
| HTC_TST_NGI | By Test Result: Negative | 40,259 | 212,632 | Redacted |
| HTC_TST_NGI | By Test Result: Positive | 1,238 | 6,384 | Redacted |
| HTC_TST_NGI | Sum of Test Result disaggregates | 41,497 | 219,016 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Male | 709 | 782 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Male | 13 | 868 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Male | 5 | 351 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Male | 12 | 785 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Male | 135 | 8,708 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Male | 269 | 18,025 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Male | 875 | 56,628 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Male | 27 | 1,756 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Female | 738 | 813 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Female | 14 | 909 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Female | 6 | 362 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Female | 13 | 806 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Female | 3,872 | 13,036 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Female | 13,343 | 32,642 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Female | 21,438 | 80,737 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Female | 28 | 1,808 | Redacted |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 41,497 | 219,016 | Redacted |

| | | | | |
|-------------------|---|--------|---------|----------|
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 740 | 2,786 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 1,306 | 85,117 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 770 | 2,890 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 38,681 | 128,223 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 1,510 | 5,676 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 39,987 | 213,340 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 41,497 | 219,016 | Redacted |
| GEND_GBV_DSD | Number of people receiving post-GBV care | 37 | 37 | Redacted |
| GEND_GBV_DSD | Age: 0-9 | 4 | 4 | Redacted |
| GEND_GBV_DSD | Age: 10-14 | 9 | 9 | Redacted |
| GEND_GBV_DSD | Age: 15-17 | 12 | 12 | Redacted |
| GEND_GBV_DSD | Age: 18-24 | 8 | 8 | Redacted |
| GEND_GBV_DSD | Age: 25+ | 4 | 4 | Redacted |
| GEND_GBV_DSD | Sum of Age disaggregates | 37 | 37 | Redacted |
| GEND_GBV_DSD | Sex: Male | 12 | 12 | Redacted |
| GEND_GBV_DSD | Sex: Female | 25 | 25 | Redacted |
| GEND_GBV_DSD | Sum of Sex disaggregates | 37 | 37 | Redacted |
| GEND_GBV_DSD | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) | 8 | 8 | Redacted |
| GEND_GBV_DSD | By type of service: Sexual Violence (Post-Rape Care) | 29 | 29 | Redacted |
| GEND_GBV_DSD | By PEP service provision (related to sexual violence services provided) | 29 | 29 | Redacted |
| GEND_NORM_DS D | Number of people completing an intervention pertaining to gender norms, that meets minimum criteria | 4,141 | 4,141 | Redacted |
| GEND_NORM_DS D | By Age: 0-9 | 207 | 207 | Redacted |
| GEND_NORM_DS D | By Age: 10-14 | 207 | 207 | Redacted |

| | | | | |
|-------------------|--|-------|-------|----------|
| GEND_NORM_DS D | By Age: 15-19 | 497 | 497 | Redacted |
| GEND_NORM_DS D | By Age: 20-24 | 1,242 | 1,242 | Redacted |
| GEND_NORM_DS D | By Age: 25+ | 1,988 | 1,988 | Redacted |
| GEND_NORM_DS D | Sum of Age disaggregates | 4,141 | 4,141 | Redacted |
| GEND_NORM_DS D | By Sex: Male | 2,029 | 2,029 | Redacted |
| GEND_NORM_DS D | By Sex: Female | 2,112 | 2,112 | Redacted |
| GEND_NORM_DS D | Sum of Sex disaggregates | 4,141 | 4,141 | Redacted |
| GEND_NORM_DS D | By type of activity: Individual | 414 | 414 | Redacted |
| GEND_NORM_DS D | By type of activity: Small Group | 828 | 828 | Redacted |
| GEND_NORM_DS D | By type of activity: Community-level | 2,899 | 2,899 | Redacted |
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 891 | 2,432 | Redacted |
| OVC_ACC_DSD | Sex: Male | 437 | 1,192 | Redacted |
| OVC_ACC_DSD | Sex: Female | 454 | 1,240 | Redacted |
| OVC_ACC_DSD | Sum of Sex disaggregates | 891 | 2,432 | Redacted |
| OVC_ACC_DSD | Age: <1 | 53 | 146 | Redacted |
| OVC_ACC_DSD | Age: 1-4 | 223 | 608 | Redacted |
| OVC_ACC_DSD | Age: 5-9 | 249 | 681 | Redacted |
| OVC_ACC_DSD | Age: 10-14 | 214 | 584 | Redacted |
| OVC_ACC_DSD | Age: 15-17 | 125 | 340 | Redacted |
| OVC_ACC_DSD | Age: 18+ | 27 | 73 | Redacted |
| OVC_ACC_DSD | Sum of Age disaggregates | 891 | 2,432 | Redacted |



| | | | | |
|--------------|---|--------|-------|----------|
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 2,969 | 8,108 | Redacted |
| OVC_SERV_DSD | Sex: Male | 1,455 | 3,973 | Redacted |
| OVC_SERV_DSD | Sex: Female | 1,514 | 4,135 | Redacted |
| OVC_SERV_DSD | Sum of Sex disaggregates | 2,969 | 8,108 | Redacted |
| OVC_SERV_DSD | Age: <1 | 178 | 486 | Redacted |
| OVC_SERV_DSD | Age: 1-4 | 742 | 2,027 | Redacted |
| OVC_SERV_DSD | Age: 5-9 | 831 | 2,270 | Redacted |
| OVC_SERV_DSD | Age: 10-14 | 713 | 1,947 | Redacted |
| OVC_SERV_DSD | Age: 15-17 | 416 | 1,135 | Redacted |
| OVC_SERV_DSD | Age: 18+ | 89 | 243 | Redacted |
| OVC_SERV_DSD | Sum of Age disaggregates | 2,969 | 8,108 | Redacted |
| C2.1.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 27,843 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Female | 975 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Male | 418 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Female | 18,515 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Male | 7,935 | | Redacted |
| C2.1.D_DSD | Sum of Age/Sex disaggregates | 27,843 | | Redacted |
| C2.1.D_DSD | By Age: <15 | 1,392 | | Redacted |
| C2.1.D_DSD | By Age: 15+ | 26,451 | | Redacted |
| C2.1.D_DSD | Sum of Age disaggregates | 27,843 | | Redacted |
| C2.1.D_DSD | By Sex: Female | 19,490 | | Redacted |
| C2.1.D_DSD | By Sex: Male | 8,353 | | Redacted |
| C2.1.D_DSD | Sum of Sex disaggregates | 27,843 | | Redacted |
| C2.1.D_NGI | Number of HIV-positive individuals receiving a minimum of one clinical service | 27,843 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Female | 975 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Male | 418 | | Redacted |
| C2.1.D_NGI | By Age/Sex: 15+ Female | 18,515 | | Redacted |

| | | | | |
|---------------|--|--------|-------|----------|
| C2.1.D_NGI | By Age/Sex: 15+ Male | 7,935 | | Redacted |
| C2.1.D_NGI | Sum of Age/Sex disaggregates | 27,843 | | Redacted |
| C2.1.D_NGI | By Age: <15 | 1,392 | | Redacted |
| C2.1.D_NGI | By Age: 15+ | 26,451 | | Redacted |
| C2.1.D_NGI | Sum of Age disaggregates | 27,843 | | Redacted |
| C2.1.D_NGI | By Sex: Female | 19,490 | | Redacted |
| C2.1.D_NGI | By Sex: Male | 8,353 | | Redacted |
| C2.1.D_NGI | Sum of Sex disaggregates | 27,843 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive patients who were screened for TB in HIV care or treatment setting | 25,059 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 27,843 | | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 1,220 | 752 | Redacted |
| TB_ART_DSD | Age: 0-4 | 12 | 8 | Redacted |
| TB_ART_DSD | Age: 5-14 | 61 | 38 | Redacted |
| TB_ART_DSD | Age: 15+ | 1,147 | 706 | Redacted |
| TB_ART_DSD | Male | 598 | 368 | Redacted |
| TB_ART_DSD | Female | 622 | 384 | Redacted |
| TB_ART_DSD | Sum of Sex disaggregates | 1,220 | 752 | Redacted |
| TB_ART_DSD | Newly tested | 695 | 429 | Redacted |
| TB_ART_DSD | Known HIV-positive | 525 | 323 | Redacted |
| TB_ART_DSD | Sum of Test Status disaggregates | 1,220 | 752 | Redacted |
| TB_ART_DSD | Aggregated Age: <15 | 73 | 45 | Redacted |
| TB_ART_DSD | Aggregated Age: 15+ | 1,147 | 707 | Redacted |
| TB_ART_DSD | Sum of Aggregated Age disaggregates | 1,220 | 752 | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth | 1,428 | 1,595 | Redacted |

| | | | | |
|---------------|--|--------|--------|----------|
| | during the reporting period | | | |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 1,623 | 0 | Redacted |
| PMTCT_EID_DSD | By infants who received a virologic test within 2 months of birth | 471 | 526 | Redacted |
| PMTCT_EID_DSD | By infants who received their first virologic HIV test between 2 and 12 months of age | 957 | 1,069 | Redacted |
| PMTCT_EID_DSD | Sum of Infant Age disaggregates | 1,428 | 1,595 | Redacted |
| PMTCT_EID_DSD | By infants with a positive virologic test result within 12 months of birth | 71 | 80 | Redacted |
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 18,562 | 18,497 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Male | 37 | 37 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Male | 173 | 173 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Male | 315 | 314 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Male | 5,799 | 5,779 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Female | 33 | 32 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Female | 153 | 153 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Female | 279 | 278 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Female | 11,773 | 11,731 | Redacted |
| TX_CURR_DSD | Sum of age/sex disaggregates | 990 | 987 | Redacted |
| TX_CURR_DSD | Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 5 | 5 | Redacted |
| TX_CURR_DSD | Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 66 | 66 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Male | 37 | 37 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Female | 33 | 32 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male | 524 | 523 | Redacted |

| | | | | |
|-------------|--|--------|--------|----------|
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 5,799 | 5,779 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female | 465 | 463 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Female | 11,774 | 11,732 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 989 | 986 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex 15+ | 17,573 | 17,511 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates | 18,562 | 18,497 | Redacted |
| TX_CURR_NGI | Number of adults and children receiving antiretroviral therapy (ART) | 18,562 | 18,497 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Male | 37 | 37 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Male | 173 | 173 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Male | 315 | 314 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Male | 5,799 | 5,779 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Female | 33 | 32 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Female | 153 | 153 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Female | 278 | 277 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Female | 11,774 | 11,732 | Redacted |
| TX_CURR_NGI | Sum of Age/Sex disaggregates | 18,562 | 18,497 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Male | 37 | 37 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Female | 33 | 32 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Male | 524 | 523 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Male | 5,799 | 5,779 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Female | 465 | 463 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Female | 11,774 | 11,732 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex disaggregates | 18,562 | 18,497 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex <15 | 989 | 986 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex 15+ | 17,573 | 17,511 | Redacted |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 6,007 | 7,325 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Male | 24 | 51 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Male | 34 | 37 | Redacted |

| | | | | |
|-------------|--|-------|-------|----------|
| TX_NEW_DSD | By Age/Sex: 5-9 Male | 42 | 18 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Male | 70 | 11 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Male | 264 | 220 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Male | 441 | 330 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Male | 705 | 1,428 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Male | 353 | 103 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Female | 23 | 119 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Female | 30 | 87 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Female | 38 | 41 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Female | 60 | 26 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Female | 589 | 513 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Female | 981 | 769 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Female | 1,569 | 3,333 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Female | 784 | 239 | Redacted |
| TX_NEW_DSD | Sum of Age/Sex disaggregates | 6,007 | 7,325 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male | 24 | 51 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male | 170 | 117 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 1,763 | 2,080 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female | 23 | 119 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female | 150 | 273 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 3,924 | 4,854 | Redacted |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 6,007 | 7,324 | Redacted |
| TX_NEW_DSD | Pregnancy status | 398 | 485 | Redacted |
| TX_NEW_DSD | Breastfeeding status | 199 | 243 | Redacted |
| LAB_ACC_DSD | Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or | 1 | 1 | Redacted |

| | | | | |
|---------------|--|--------|--------|----------|
| | international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation | | | |
| LAB_ACC_DSD | By site support type: Direct Service Delivery (DSD) | 1 | 1 | Redacted |
| LAB_ACC_DSD | Sum of Support Type disaggregates | 1 | 1 | Redacted |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 15 | 15 | Redacted |
| LAB_CAP_DSD | By clinical laboratories | 15 | 15 | Redacted |
| LAB_CAP_DSD | By Point-of-care testing sites | 0 | | Redacted |
| LAB_CAP_DSD | By site support type: Direct Service Delivery (DSD) | 15 | 15 | Redacted |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates | 15 | 15 | Redacted |
| TB_SCREEN_DSD | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period | 25,059 | 31,499 | Redacted |
| TB_SCREEN_DSD | Age: <1 | 501 | 630 | Redacted |
| TB_SCREEN_DSD | Age: 1-4 | 251 | 315 | Redacted |
| TB_SCREEN_DSD | Age: 5-9 | 501 | 630 | Redacted |
| TB_SCREEN_DSD | Age: 10-14 | 251 | 315 | Redacted |
| TB_SCREEN_DSD | Age: 15-19 | 2,506 | 3,150 | Redacted |
| TB_SCREEN_DSD | Age: 20-24 | 6,265 | 7,875 | Redacted |
| TB_SCREEN_DSD | Age: 25-49 | 13,782 | 17,324 | Redacted |
| TB_SCREEN_DSD | Age: 50+ | 1,002 | 1,260 | Redacted |
| TB_SCREEN_DSD | Sum of Age disaggregates | 4,010 | 5,040 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 | 1,503 | 1,890 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ | 23,556 | 29,609 | Redacted |
| TB_SCREEN_DSD | Sum of Aggregated Age disaggregates | 25,059 | 31,499 | Redacted |



| | | | | |
|---------------|--------------------------|--------|--------|----------|
| TB_SCREEN_DSD | Sex: Male | 7,518 | 9,450 | Redacted |
| TB_SCREEN_DSD | Sex: Female | 17,541 | 22,049 | Redacted |
| TB_SCREEN_DSD | Sum of Sex disaggregates | 25,059 | 31,499 | Redacted |

Implementing Mechanism Details

| | |
|--|-------------------------------|
| Mechanism ID: 17739 | Mechanism Name: UNICEF |
| Funding Agency: USAID | Procurement Type: Grant |
| Prime Partner Name: United Nations Children's Fund | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 800,000 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 800,000 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|-------------|-------------------|
| Gender: GBV | 540,000 |
| Focus Area: | Post GBV Care |
| Sub Area: | Capacity building |

Key Issues

Mobile Population



Budget Code Information

| Mechanism ID: | 17739 | | |
|----------------------------|--------------------------------|----------------|----------------|
| Mechanism Name: | UNICEF | | |
| Prime Partner Name: | United Nations Children's Fund | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 800,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|----------------------------|-----------------|
| Mechanism ID: 17737 | TBD: Yes |
| REDACTED | |

Implementing Mechanism Details

| | |
|---|--|
| Mechanism ID: 17736 | Mechanism Name: World Health Organization |
| Funding Agency: USAID | Procurement Type: Umbrella Agreement |
| Prime Partner Name: World Health Organization | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| Total All Funding Sources: 700,000 | Total Mechanism Pipeline: Redacted |
|---|---|
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 700,000 |



Sub Partner Name(s)

| | | |
|-------------------|---|-----------------------------|
| Damien Foundation | German Leprosy and TB Relief Association (GLRA) | The Leprosy Mission Nigeria |
|-------------------|---|-----------------------------|

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

TB

Budget Code Information

| Mechanism ID: | 17736 | | |
|----------------------------|---------------------------|----------------|----------------|
| Mechanism Name: | World Health Organization | | |
| Prime Partner Name: | World Health Organization | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 700,000 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 |
|------------------|---|------|--------|
| HTC_TST_TA | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 0 | 80,000 |
| HTC_TST_TA | By Test Result: Negative | 0 | 77,600 |
| HTC_TST_TA | By Test Result: Positive | 0 | 2,400 |
| HTC_TST_TA | Sum of Test Result disaggregates | 0 | 80,000 |
| HTC_TST_TA | Age/sex: <1 Male | 0 | 274 |



| | | | |
|------------|--|---|--------|
| HTC_TST_TA | Age/sex: 1-4 Male | 0 | 392 |
| HTC_TST_TA | Age/sex: 5-9 Male | 0 | 157 |
| HTC_TST_TA | Age/sex: 10-14 Male | 0 | 353 |
| HTC_TST_TA | Age/sex: 15-19 Male | 0 | 3,920 |
| HTC_TST_TA | Age/sex: 20-24 Male | 0 | 7,840 |
| HTC_TST_TA | Age/sex: 25-49 Male | 0 | 25,480 |
| HTC_TST_TA | Age/sex: 50+ Male | 0 | 784 |
| HTC_TST_TA | Age/sex: <1 Female | 0 | 286 |
| HTC_TST_TA | Age/sex: 1-4 Female | 0 | 408 |
| HTC_TST_TA | Age/sex: 5-9 Female | 0 | 163 |
| HTC_TST_TA | Age/sex: 10-14 Female | 0 | 367 |
| HTC_TST_TA | Age/sex: 15-19 Female | 0 | 4,080 |
| HTC_TST_TA | Age/sex: 20-24 Female | 0 | 8,160 |
| HTC_TST_TA | Age/sex: 25-49 Female | 0 | 26,520 |
| HTC_TST_TA | Age/sex: 50+ Female | 0 | 816 |
| HTC_TST_TA | Sum of Age/Sex disaggregates | 0 | 80,000 |
| HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 0 | 1,176 |
| HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 0 | 38,024 |
| HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 0 | 1,224 |
| HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 0 | 39,576 |
| HTC_TST_TA | Sum of Aggregated Age/Sex <15 | 0 | 2,400 |
| HTC_TST_TA | Sum of Aggregated Age/Sex 15+ | 0 | 77,600 |
| HTC_TST_TA | Sum of Aggregated Age/Sex disaggregates | 0 | 80,000 |

Implementing Mechanism Details

| | |
|---|---|
| Mechanism ID: 17735 | Mechanism Name: SHiPS for MARPs |
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Society for Family Health-Nigeria | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |

Approved



| | |
|--|---|
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 11,462,273 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 11,462,273 |

Sub Partner Name(s)

| | | |
|----------------------------|--------------------|---|
| Center for Right to Health | Population Council | Population Services International (PSI) |
|----------------------------|--------------------|---|

Cross-Cutting Budget Attribution(s)

| | |
|--------------------|---------|
| Condom programming | 950,118 |
|--------------------|---------|

Key Issues

Mobile Population

Family Planning

Budget Code Information

| | | | |
|----------------------------|-----------------------------------|-----------------------|-----------------------|
| Mechanism ID: | 17735 | | |
| Mechanism Name: | SHiPS for MARPs | | |
| Prime Partner Name: | Society for Family Health-Nigeria | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and | OHSS | 400,000 | 0 |



| Systems | | | |
|----------------|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 252,053 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 10,810,220 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 |
|------------------|---|---------|--------|
| KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 104,136 | 91,550 |
| KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 96,847 | 85,141 |
| KP_PREV_DSD | By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 1,666 | 1,465 |
| KP_PREV_DSD | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 416 | 366 |

| | | | |
|-------------|--|---------|--------|
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 5,207 | 4,578 |
| KP_PREV_DSD | By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 521 | 458 |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 131,774 | 63,013 |
| HTC_TST_DSD | By Test Result: Negative | 128,051 | 61,233 |
| HTC_TST_DSD | By Test Result: Positive | 3,723 | 1,780 |
| HTC_TST_DSD | Sum of Test Result disaggregates | 131,774 | 63,013 |
| HTC_TST_DSD | Age/sex: <1 Male | 513 | 245 |
| HTC_TST_DSD | Age/sex: 1-4 Male | 466 | 223 |
| HTC_TST_DSD | Age/sex: 5-9 Male | 189 | 90 |
| HTC_TST_DSD | Age/sex: 10-14 Male | 422 | 202 |
| HTC_TST_DSD | Age/sex: 15-19 Male | 4,678 | 2,237 |
| HTC_TST_DSD | Age/sex: 20-24 Male | 9,675 | 4,627 |
| HTC_TST_DSD | Age/sex: 25-49 Male | 30,420 | 14,546 |
| HTC_TST_DSD | Age/sex: 50+ Male | 943 | 451 |
| HTC_TST_DSD | Age/sex: <1 Female | 534 | 255 |
| HTC_TST_DSD | Age/sex: 1-4 Female | 488 | 233 |
| HTC_TST_DSD | Age/sex: 5-9 Female | 194 | 93 |
| HTC_TST_DSD | Age/sex: 10-14 Female | 433 | 207 |
| HTC_TST_DSD | Age/sex: 15-19 Female | 8,398 | 4,016 |
| HTC_TST_DSD | Age/sex: 20-24 Female | 22,408 | 10,715 |



| | | | |
|-------------|---|---------|--------|
| HTC_TST_DSD | Age/sex: 25-49 Female | 51,043 | 24,408 |
| HTC_TST_DSD | Age/sex: 50+ Female | 970 | 465 |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 131,774 | 63,013 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 1,590 | 760 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 45,715 | 21,860 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 1,649 | 789 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 82,820 | 39,604 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 3,239 | 1,549 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 128,535 | 61,464 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 131,774 | 63,013 |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 131,774 | 63,013 |
| HTC_TST_NGI | By Test Result: Negative | 128,051 | 61,233 |
| HTC_TST_NGI | By Test Result: Positive | 3,723 | 1,780 |
| HTC_TST_NGI | Sum of Test Result disaggregates | 131,774 | 63,013 |
| HTC_TST_NGI | Age/sex: <1 Male | 513 | 245 |
| HTC_TST_NGI | Age/sex: 1-4 Male | 466 | 223 |
| HTC_TST_NGI | Age/sex: 5-9 Male | 189 | 90 |
| HTC_TST_NGI | Age/sex: 10-14 Male | 422 | 202 |
| HTC_TST_NGI | Age/sex: 15-19 Male | 4,678 | 2,237 |
| HTC_TST_NGI | Age/sex: 20-24 Male | 9,675 | 4,627 |
| HTC_TST_NGI | Age/sex: 25-49 Male | 30,420 | 14,546 |
| HTC_TST_NGI | Age/sex: 50+ Male | 943 | 451 |
| HTC_TST_NGI | Age/sex: <1 Female | 534 | 255 |
| HTC_TST_NGI | Age/sex: 1-4 Female | 488 | 233 |
| HTC_TST_NGI | Age/sex: 5-9 Female | 194 | 93 |
| HTC_TST_NGI | Age/sex: 10-14 Female | 433 | 207 |
| HTC_TST_NGI | Age/sex: 15-19 Female | 8,398 | 4,016 |



| | | | |
|-------------|---|---------|--------|
| HTC_TST_NGI | Age/sex: 20-24 Female | 22,408 | 10,715 |
| HTC_TST_NGI | Age/sex: 25-49 Female | 51,043 | 24,408 |
| HTC_TST_NGI | Age/sex: 50+ Female | 970 | 465 |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 131,774 | 63,013 |
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 1,590 | 760 |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 45,715 | 21,860 |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 1,649 | 789 |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 82,820 | 39,604 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 3,239 | 1,549 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 128,535 | 61,464 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 131,774 | 63,013 |

Implementing Mechanism Details

| | |
|---|---|
| Mechanism ID: 17734 | Mechanism Name: TB Care II - Challenge |
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: TBHIV FOLLOW ON | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 856,678 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 856,678 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

TB

Budget Code Information

| Mechanism ID: | 17734 | | |
|----------------------------|------------------------|----------------|----------------|
| Mechanism Name: | TB Care II - Challenge | | |
| Prime Partner Name: | TBHIV FOLLOW ON | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 856,678 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|---|---|
| Mechanism ID: 17733 | Mechanism Name: Strengthening Partnerships, Results and Innovations in Nutrition Globally (SPRING) |
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: John Snow Inc (JSI) | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| Total All Funding Sources: 1,000,000 | Total Mechanism Pipeline: Redacted |
|---|---|
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |

Approved



| | |
|-----------|-----------|
| GHP-State | 1,000,000 |
|-----------|-----------|

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|---|---------|
| Food and Nutrition: Policy, Tools, and Service Delivery | 250,000 |
| Human Resources for Health | 250,000 |

Key Issues

Child Survival Activities

End-of-Program Evaluation

Budget Code Information

| Mechanism ID: | 17733 | | |
|----------------------------|--|----------------|----------------|
| Mechanism Name: | Strengthening Partnerships, Results and Innovations in Nutrition | | |
| Prime Partner Name: | Globally (SPRING) | | |
| | John Snow Inc (JSI) | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 1,000,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|----------------------------|---|
| Mechanism ID: 17730 | Mechanism Name: K4Health/Nigeria Web-based |
|----------------------------|---|



| | |
|--|---|
| | CMLE Program - AID-620-LA-11-00002 |
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Johns Hopkins University Center for Communication Programs | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 400,000 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 400,000 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

| | | | |
|----------------------------|---|-----------------------|-----------------------|
| Mechanism ID: | 17730 | | |
| Mechanism Name: | K4Health/Nigeria Web-based CMLE Program - AID-620-LA-11-00002 | | |
| Prime Partner Name: | Johns Hopkins University Center for Communication Programs | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and | HLAB | 400,000 | 0 |



| | | | |
|---------|--|--|--|
| Systems | | | |
|---------|--|--|--|

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|---|---|
| Mechanism ID: 17729 | Mechanism Name: Systems Transformed for Empowered Action and Enabling Responses for Vulnerable Children and Families (STEER) |
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Save the Children UK | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 6,447,269 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 6,447,269 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|---|---|
| Food and Nutrition: Policy, Tools, and Service Delivery | 682,850 |
| Economic Strengthening | 1,600,000 |
| Gender: Gender Equality | 65,000 |
| Focus Area: | Changing harmful gender norms and promoting |



| | |
|-------------|--|
| | positive gender norms |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Focus Area: | Promoting gender-related policies and laws that increase legal protection |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Focus Area: | Increase gender-equitable access to income and productive resources, including education |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Education | 70,000 |

Key Issues

Child Survival Activities

Family Planning

Budget Code Information

| | |
|----------------------------|--|
| Mechanism ID: | 17729 |
| Mechanism Name: | Systems Transformed for Empowered Action and Enabling Responses |
| Prime Partner Name: | for Vulnerable Children and Families (STEER) |



| Save the Children UK | | | |
|----------------------|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 6,447,269 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 |
|------------------|---|---------|---------|
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 30,000 | 60,000 |
| OVC_ACC_DSD | Sex: Male | 14,700 | 29,400 |
| OVC_ACC_DSD | Sex: Female | 15,300 | 30,600 |
| OVC_ACC_DSD | Sum of Sex disaggregates | 30,000 | 60,000 |
| OVC_ACC_DSD | Age: <1 | 1,800 | 3,600 |
| OVC_ACC_DSD | Age: 1-4 | 7,500 | 15,000 |
| OVC_ACC_DSD | Age: 5-9 | 8,400 | 16,800 |
| OVC_ACC_DSD | Age: 10-14 | 6,900 | 13,800 |
| OVC_ACC_DSD | Age: 15-17 | 4,200 | 8,400 |
| OVC_ACC_DSD | Age: 18+ | 1,200 | 2,400 |
| OVC_ACC_DSD | Sum of Age disaggregates | 30,000 | 60,000 |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 171,027 | 278,129 |
| OVC_SERV_DSD | Sex: Male | 83,803 | 136,284 |
| OVC_SERV_DSD | Sex: Female | 87,224 | 141,845 |
| OVC_SERV_DSD | Sum of Sex disaggregates | 171,027 | 278,129 |
| OVC_SERV_DSD | Age: <1 | 10,262 | 16,687 |
| OVC_SERV_DSD | Age: 1-4 | 42,757 | 69,533 |
| OVC_SERV_DSD | Age: 5-9 | 47,887 | 77,877 |
| OVC_SERV_DSD | Age: 10-14 | 39,336 | 63,969 |
| OVC_SERV_DSD | Age: 15-17 | 23,944 | 38,938 |



| | | | |
|--------------|--------------------------|---------|---------|
| OVC_SERV_DSD | Age: 18+ | 6,841 | 11,125 |
| OVC_SERV_DSD | Sum of Age disaggregates | 171,027 | 278,129 |

Implementing Mechanism Details

| | |
|--|---|
| Mechanism ID: 17728 | Mechanism Name: Sustainable Mechanism for Improving Livelihood & Household Empowerment (SMILE) |
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Catholic Relief Services | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 6,447,269 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 6,447,269 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|---|---|
| Food and Nutrition: Policy, Tools, and Service Delivery | 1,200,000 |
| Economic Strengthening | 2,000,000 |
| Gender: Gender Equality | 82,500 |
| Focus Area: | Changing harmful gender norms and promoting positive gender norms |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |



| | |
|-------------|--|
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Focus Area: | Promoting gender-related policies and laws that increase legal protection |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Focus Area: | Increase gender-equitable access to income and productive resources, including education |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |

Key Issues

Child Survival Activities

Budget Code Information

| Mechanism ID: | 17728 | | |
|----------------------------|--|----------------|----------------|
| Mechanism Name: | Sustainable Mechanism for Improving Livelihood & Household | | |
| Prime Partner Name: | Empowerment (SMILE) | | |
| | Catholic Relief Services | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 6,447,269 | 0 |

Implementing Mechanism Indicator Information



| Indicator Number | Label | 2014 | 2015 |
|------------------|---|---------|---------|
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 30,000 | 60,000 |
| OVC_ACC_DSD | Sex: Male | 14,700 | 29,400 |
| OVC_ACC_DSD | Sex: Female | 15,300 | 30,600 |
| OVC_ACC_DSD | Sum of Sex disaggregates | 30,000 | 60,000 |
| OVC_ACC_DSD | Age: <1 | 1,800 | 3,600 |
| OVC_ACC_DSD | Age: 1-4 | 7,500 | 15,000 |
| OVC_ACC_DSD | Age: 5-9 | 8,400 | 16,800 |
| OVC_ACC_DSD | Age: 10-14 | 6,900 | 13,800 |
| OVC_ACC_DSD | Age: 15-17 | 4,200 | 8,400 |
| OVC_ACC_DSD | Age: 18+ | 1,200 | 2,400 |
| OVC_ACC_DSD | Sum of Age disaggregates | 30,000 | 60,000 |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 100,000 | 200,000 |
| OVC_SERV_DSD | Sex: Male | 49,000 | 98,000 |
| OVC_SERV_DSD | Sex: Female | 51,000 | 102,000 |
| OVC_SERV_DSD | Sum of Sex disaggregates | 100,000 | 200,000 |
| OVC_SERV_DSD | Age: <1 | 6,000 | 12,000 |
| OVC_SERV_DSD | Age: 1-4 | 25,000 | 50,000 |
| OVC_SERV_DSD | Age: 5-9 | 28,000 | 56,000 |
| OVC_SERV_DSD | Age: 10-14 | 23,000 | 46,000 |
| OVC_SERV_DSD | Age: 15-17 | 14,000 | 28,000 |
| OVC_SERV_DSD | Age: 18+ | 4,000 | 8,000 |
| OVC_SERV_DSD | Sum of Age disaggregates | 100,000 | 200,000 |

Implementing Mechanism Details

| | |
|----------------------------|--|
| Mechanism ID: 17727 | Mechanism Name: MSH - Prevention Organisation Systems AIDS Care and |
|----------------------------|--|



| | |
|--|---|
| | Treatment(MSH -ProACT) |
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Management Sciences for Health | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: Yes |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|--|---|
| Total All Funding Sources: 12,491,207 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 12,491,207 |

Sub Partner Name(s)

| | | |
|-----------------------|--|--|
| Axios Foundation Inc. | | |
|-----------------------|--|--|

Cross-Cutting Budget Attribution(s)

| | |
|-----------------------------|--|
| Gender: Gender Equality | 352,381 |
| Focus Area: | Increase gender-equitable access to income and productive resources, including education |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Capacity building |
| Focus Area: | Equity in HIV prevention, care, treatment and support |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Capacity building |
| Human Resources for Health | 1,134,524 |
| Key Populations: MSM and TG | 100,000 |



| | |
|----------------------|---|
| Focus Area: | Training of health workers and community outreach workers |
| Focus Area: | Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance |
| Focus Area: | Collection and use of strategic information |
| Focus Area: | Monitoring and evaluation of MSM/TG programs |
| Focus Area: | Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG |
| Key Populations: FSW | 100,000 |
| Focus Area: | Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention |
| Focus Area: | Training of health workers and community outreach workers |
| Focus Area: | Collection and use of strategic information on SWs and clients |
| Focus Area: | Monitoring and evaluation of SW programs |
| Focus Area: | Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs |
| Renovation | 190,948 |
| Condom programming | 100,000 |

Key Issues

Malaria (PMI)

TB

End-of-Program Evaluation

Family Planning



Budget Code Information

| Mechanism ID: | 17727 | | |
|----------------------------|---|----------------|----------------|
| Mechanism Name: | MSH - Prevention Organisation Systems AIDS Care and Treatment(MSH | | |
| Prime Partner Name: | -ProACT) | | |
| | Management Sciences for Health | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 1,534,861 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 1,160,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 460,170 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 88,792 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 1,576,033 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 225,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMBL | 22,568 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMIN | 114,248 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVAB | 60,194 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |



| | | | |
|-----------------------|--------------------|-----------------------|-----------------------|
| Prevention | HVCT | 1,409,359 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 100,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 1,119,401 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 4,368,309 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 252,272 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 |
|------------------|--|-------|-------|
| PMTCT_ARV_DSD | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 2,970 | 2,970 |
| PMTCT_ARV_DSD | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 5,236 | 5,236 |
| PMTCT_ARV_DSD | Life-long ART (including Option B+) | 1,455 | 1,455 |
| PMTCT_ARV_DSD | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 764 | 764 |
| PMTCT_ARV_DSD | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 691 | 691 |
| PMTCT_ARV_DSD | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the | 1,247 | 1,247 |

| | | | |
|---------------|--|-------|-------|
| | breastfeeding period) | | |
| PMTCT_ARV_DSD | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 238 | 238 |
| PMTCT_ARV_DSD | Single-dose nevirapine (with or without tail) | 30 | 30 |
| PMTCT_ARV_DSD | Sum of Regimen Type disaggregates | 2,970 | 2,970 |
| PMTCT_ARV_DSD | Sum of New and Current disaggregates | 1,455 | 1,455 |
| PMTCT_ARV_NA | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 2,970 | 2,970 |
| PMTCT_ARV_NA | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 3,375 | 3,375 |
| PMTCT_ARV_NA | Life-long ART (including Option B+) | 1,634 | 1,634 |
| PMTCT_ARV_NA | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 621 | 554 |
| PMTCT_ARV_NA | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 1,013 | 1,080 |
| PMTCT_ARV_NA | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 1,158 | 1,188 |
| PMTCT_ARV_NA | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 149 | 148 |
| PMTCT_ARV_NA | Single-dose nevirapine (with or without tail) | 29 | 0 |
| PMTCT_ARV_NA | Sum of Regimen disaggregates | 2,970 | 2,970 |
| PMTCT_ARV_NA | Sum of New and Current disaggregates | 1,634 | 1,634 |
| PMTCT_ARV_NGI | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 2,970 | 2,970 |
| PMTCT_ARV_NGI | Number of HIV- positive pregnant women | 3,375 | 3,375 |



| | | | |
|----------------|--|---------|---------|
| | identified in the reporting period (including known HIV-positive at entry) | | |
| PMTCT_ARV_NGI | Life-long ART (including Option B+) | 1,634 | 1,634 |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 621 | 554 |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 1,013 | 1,080 |
| PMTCT_ARV_NGI | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 1,158 | 1,188 |
| PMTCT_ARV_NGI | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 149 | 148 |
| PMTCT_ARV_NGI | Single-dose nevirapine (with or without tail) | 29 | 0 |
| PMTCT_ARV_NGI | Sum of Regimen disaggregates | 2,970 | 2,970 |
| PMTCT_ARV_NGI | Sum of New and Current disaggregates | 1,634 | 1,634 |
| PMTCT_STAT_DSD | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 159,941 | 159,941 |
| PMTCT_STAT_DSD | Number of new ANC and L&D clients | 159,941 | 159,941 |
| PMTCT_STAT_DSD | By: Known positives at entry | 2,079 | 2,079 |
| PMTCT_STAT_DSD | By: Number of new positives identified | 3,157 | 3,157 |
| PMTCT_STAT_DSD | Sum of Positives Status disaggregates | 5,236 | 5,236 |
| PMTCT_STAT_NGI | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 159,941 | 159,941 |
| PMTCT_STAT_NGI | Number of new ANC and L&D clients | 159,941 | 159,941 |
| PMTCT_STAT_NGI | By: Known positives at entry | 2,079 | 2,079 |
| PMTCT_STAT_NGI | By: Number of new positives identified | 3,157 | 3,157 |
| PMTCT_STAT_NGI | Sum of Positives Status disaggregates | 5,236 | 5,236 |
| PP_PREV_DSD | Number of the target population who completed a standardized HIV prevention intervention including the minimum | 2,866 | 9,448 |



| | | | |
|-------------|--|-------|--------|
| | components during the reporting period. | | |
| PP_PREV_DSD | Total number of people in the target population | 6,653 | 34,325 |
| PP_PREV_DSD | Age/sex: 10-14 Male | 140 | 463 |
| PP_PREV_DSD | Age/sex: 15-19 Male | 169 | 556 |
| PP_PREV_DSD | Age/sex: 20-24 Male | 421 | 1,389 |
| PP_PREV_DSD | Age/sex: 25-49 Male | 632 | 2,083 |
| PP_PREV_DSD | Age/sex: 50+ Male | 42 | 139 |
| PP_PREV_DSD | Age/sex: 10-14 Female | 146 | 482 |
| PP_PREV_DSD | Age/sex: 15-19 Female | 175 | 578 |
| PP_PREV_DSD | Age/sex: 20-24 Female | 439 | 1,446 |
| PP_PREV_DSD | Age/sex: 25-49 Female | 658 | 2,168 |
| PP_PREV_DSD | Age/sex: 50+ Female | 44 | 144 |
| PP_PREV_DSD | Sum of Age/Sex disaggregates | 2,866 | 9,448 |
| KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 1,333 | |
| KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 1,240 | |
| KP_PREV_DSD | By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 21 | |
| KP_PREV_DSD | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or | 5 | |

| | | | |
|-------------|--|---------|---------|
| | small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | | |
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 67 | |
| KP_PREV_DSD | By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 7 | |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 522,661 | 563,744 |
| HTC_TST_DSD | By Test Result: Negative | 507,893 | 547,815 |
| HTC_TST_DSD | By Test Result: Positive | 14,768 | 15,929 |
| HTC_TST_DSD | Sum of Test Result disaggregates | 522,661 | 563,744 |
| HTC_TST_DSD | Age/sex: <1 Male | 2,035 | 2,195 |
| HTC_TST_DSD | Age/sex: 1-4 Male | 1,849 | 1,994 |
| HTC_TST_DSD | Age/sex: 5-9 Male | 748 | 807 |
| HTC_TST_DSD | Age/sex: 10-14 Male | 1,673 | 1,804 |
| HTC_TST_DSD | Age/sex: 15-19 Male | 18,554 | 20,012 |
| HTC_TST_DSD | Age/sex: 20-24 Male | 38,374 | 41,391 |
| HTC_TST_DSD | Age/sex: 25-49 Male | 120,655 | 130,139 |
| HTC_TST_DSD | Age/sex: 50+ Male | 3,741 | 4,035 |
| HTC_TST_DSD | Age/sex: <1 Female | 2,118 | 2,284 |
| HTC_TST_DSD | Age/sex: 1-4 Female | 1,937 | 2,089 |
| HTC_TST_DSD | Age/sex: 5-9 Female | 770 | 831 |



| | | | |
|-------------|---|---------|---------|
| HTC_TST_DSD | Age/sex: 10-14 Female | 1,717 | 1,852 |
| HTC_TST_DSD | Age/sex: 15-19 Female | 33,308 | 35,926 |
| HTC_TST_DSD | Age/sex: 20-24 Female | 88,879 | 95,865 |
| HTC_TST_DSD | Age/sex: 25-49 Female | 202,452 | 218,365 |
| HTC_TST_DSD | Age/sex: 50+ Female | 3,851 | 4,155 |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 522,661 | 563,744 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 6,305 | 6,800 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 181,324 | 195,577 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 6,542 | 7,057 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 328,490 | 354,310 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 12,847 | 13,857 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 509,814 | 549,887 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 522,661 | 563,744 |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 522,661 | 563,744 |
| HTC_TST_NGI | By Test Result: Negative | 507,893 | 547,815 |
| HTC_TST_NGI | By Test Result: Positive | 14,768 | 15,929 |
| HTC_TST_NGI | Sum of Test Result disaggregates | 522,661 | 563,744 |
| HTC_TST_NGI | Age/sex: <1 Male | 2,035 | 2,195 |
| HTC_TST_NGI | Age/sex: 1-4 Male | 1,849 | 1,994 |
| HTC_TST_NGI | Age/sex: 5-9 Male | 748 | 807 |
| HTC_TST_NGI | Age/sex: 10-14 Male | 1,673 | 1,804 |
| HTC_TST_NGI | Age/sex: 15-19 Male | 18,554 | 20,012 |
| HTC_TST_NGI | Age/sex: 20-24 Male | 38,374 | 41,391 |
| HTC_TST_NGI | Age/sex: 25-49 Male | 120,655 | 130,139 |
| HTC_TST_NGI | Age/sex: 50+ Male | 3,741 | 4,035 |
| HTC_TST_NGI | Age/sex: <1 Female | 2,118 | 2,284 |
| HTC_TST_NGI | Age/sex: 1-4 Female | 1,937 | 2,089 |

| | | | |
|--------------|--|---------|---------|
| HTC_TST_NGI | Age/sex: 5-9 Female | 770 | 831 |
| HTC_TST_NGI | Age/sex: 10-14 Female | 1,717 | 1,852 |
| HTC_TST_NGI | Age/sex: 15-19 Female | 33,308 | 35,926 |
| HTC_TST_NGI | Age/sex: 20-24 Female | 88,879 | 95,865 |
| HTC_TST_NGI | Age/sex: 25-49 Female | 202,452 | 218,365 |
| HTC_TST_NGI | Age/sex: 50+ Female | 3,851 | 4,155 |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 522,661 | 563,744 |
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 6,305 | 6,800 |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 181,324 | 195,577 |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 6,542 | 7,057 |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 328,490 | 354,310 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 12,847 | 13,857 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 509,814 | 549,887 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 522,661 | 563,744 |
| GEND_GBV_DSD | Number of people receiving post-GBV care | 90 | 90 |
| GEND_GBV_DSD | Age: 0-9 | 10 | 10 |
| GEND_GBV_DSD | Age: 10-14 | 21 | 21 |
| GEND_GBV_DSD | Age: 15-17 | 31 | 31 |
| GEND_GBV_DSD | Age: 18-24 | 18 | 18 |
| GEND_GBV_DSD | Age: 25+ | 10 | 10 |
| GEND_GBV_DSD | Sum of Age disaggregates | 90 | 90 |
| GEND_GBV_DSD | Sex: Male | 30 | 30 |
| GEND_GBV_DSD | Sex: Female | 60 | 60 |
| GEND_GBV_DSD | Sum of Sex disaggregates | 90 | 90 |
| GEND_GBV_DSD | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) | 20 | 20 |
| GEND_GBV_DSD | By type of service: Sexual Violence (Post-Rape Care) | 70 | 70 |
| GEND_GBV_DSD | By PEP service provision (related to sexual violence services provided) | 70 | 70 |
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to | 12,000 | 13,200 |



| | | | |
|--------------|---|--------|--------|
| | access HIV services | | |
| OVC_ACC_DSD | Sex: Male | 5,880 | 6,468 |
| OVC_ACC_DSD | Sex: Female | 6,120 | 6,732 |
| OVC_ACC_DSD | Sum of Sex disaggregates | 12,000 | 13,200 |
| OVC_ACC_DSD | Age: <1 | 720 | 792 |
| OVC_ACC_DSD | Age: 1-4 | 3,000 | 3,300 |
| OVC_ACC_DSD | Age: 5-9 | 3,360 | 3,696 |
| OVC_ACC_DSD | Age: 10-14 | 2,760 | 3,036 |
| OVC_ACC_DSD | Age: 15-17 | 1,680 | 1,848 |
| OVC_ACC_DSD | Age: 18+ | 480 | 528 |
| OVC_ACC_DSD | Sum of Age disaggregates | 12,000 | 13,200 |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 40,000 | 44,000 |
| OVC_SERV_DSD | Sex: Male | 19,600 | 21,560 |
| OVC_SERV_DSD | Sex: Female | 20,400 | 22,440 |
| OVC_SERV_DSD | Sum of Sex disaggregates | 40,000 | 44,000 |
| OVC_SERV_DSD | Age: <1 | 2,400 | 2,640 |
| OVC_SERV_DSD | Age: 1-4 | 10,000 | 11,000 |
| OVC_SERV_DSD | Age: 5-9 | 11,200 | 12,320 |
| OVC_SERV_DSD | Age: 10-14 | 9,200 | 10,120 |
| OVC_SERV_DSD | Age: 15-17 | 5,600 | 6,160 |
| OVC_SERV_DSD | Age: 18+ | 1,600 | 1,760 |
| OVC_SERV_DSD | Sum of Age disaggregates | 40,000 | 44,000 |
| C2.1.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 53,615 | |
| C2.1.D_DSD | By Age/Sex: <15 Female | 1,877 | |
| C2.1.D_DSD | By Age/Sex: <15 Male | 804 | |
| C2.1.D_DSD | By Age/Sex: 15+ Female | 35,654 | |
| C2.1.D_DSD | By Age/Sex: 15+ Male | 15,280 | |
| C2.1.D_DSD | Sum of Age/Sex disaggregates | 53,615 | |
| C2.1.D_DSD | By Age: <15 | 2,681 | |

| | | | |
|-------------|---|--------|--|
| C2.1.D_DSD | By Age: 15+ | 50,934 | |
| C2.1.D_DSD | Sum of Age disaggregates | 53,615 | |
| C2.1.D_DSD | By Sex: Female | 37,531 | |
| C2.1.D_DSD | By Sex: Male | 16,084 | |
| C2.1.D_DSD | Sum of Sex disaggregates | 53,615 | |
| C2.1.D_NGI | Number of HIV-positive individuals receiving a minimum of one clinical service | 53,615 | |
| C2.1.D_NGI | By Age/Sex: <15 Female | 1,877 | |
| C2.1.D_NGI | By Age/Sex: <15 Male | 804 | |
| C2.1.D_NGI | By Age/Sex: 15+ Female | 35,654 | |
| C2.1.D_NGI | By Age/Sex: 15+ Male | 15,280 | |
| C2.1.D_NGI | Sum of Age/Sex disaggregates | 53,615 | |
| C2.1.D_NGI | By Age: <15 | 2,681 | |
| C2.1.D_NGI | By Age: 15+ | 50,934 | |
| C2.1.D_NGI | Sum of Age disaggregates | 53,615 | |
| C2.1.D_NGI | By Sex: Female | 37,531 | |
| C2.1.D_NGI | By Sex: Male | 16,084 | |
| C2.1.D_NGI | Sum of Sex disaggregates | 53,615 | |
| C2.4.D_DSD | Number of HIV-positive patients who were screened for TB in HIV care or treatment setting | 48,254 | |
| C2.4.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 53,615 | |
| FN_THER_DSD | Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period. | 2,145 | |
| FN_THER_DSD | Number of PLHIV who were nutritionally assessed and found to be clinically undernourished. | 2,145 | |
| FN_THER_DSD | Age: <1 | 107 | |
| FN_THER_DSD | Age: 1-4 | 258 | |
| FN_THER_DSD | Age: 5-14 | 279 | |
| FN_THER_DSD | Age: 15-17 | 214 | |

| | | | |
|---------------|--|-------|-------|
| FN_THER_DSD | Age: 18+ | 1,287 | |
| FN_THER_DSD | Sum of Age disaggregates | 2,145 | |
| FN_THER_DSD | Aggregated Age: <18 | 858 | |
| FN_THER_DSD | Aggregated Age: 18+ | 1,287 | |
| FN_THER_DSD | Sum of Aggregated Age disaggregates | 2,145 | |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 2,515 | 2,730 |
| TB_ART_DSD | Age: 0-4 | 0 | 0 |
| TB_ART_DSD | Age: 5-14 | 151 | 164 |
| TB_ART_DSD | Age: 15+ | 2,364 | 2,566 |
| TB_ART_DSD | Male | 1,232 | 1,338 |
| TB_ART_DSD | Female | 1,283 | 1,392 |
| TB_ART_DSD | Sum of Sex disaggregates | 2,515 | 2,730 |
| TB_ART_DSD | Newly tested | 1,936 | 2,102 |
| TB_ART_DSD | Known HIV-positive | 579 | 628 |
| TB_ART_DSD | Sum of Test Status disaggregates | 2,515 | 2,730 |
| TB_ART_DSD | Aggregated Age: <15 | 151 | 164 |
| TB_ART_DSD | Aggregated Age: 15+ | 2,364 | 2,566 |
| TB_ART_DSD | Sum of Aggregated Age disaggregates | 2,515 | 2,730 |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period | 2,970 | 2,970 |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 5,236 | 5,236 |
| PMTCT_EID_DSD | By infants who received a virologic test within 2 months of birth | 980 | 980 |
| PMTCT_EID_DSD | By infants who received their first virologic HIV test between 2 and 12 months of age | 1,990 | 1,990 |
| PMTCT_EID_DSD | Sum of Infant Age disaggregates | 2,970 | 2,970 |



| | | | |
|-------------|---|--------|--------|
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 35,744 | 37,530 |
| TX_CURR_DSD | Age/Sex: <1 Male | 250 | 262 |
| TX_CURR_DSD | Age/Sex: 1-4 Male | 182 | 191 |
| TX_CURR_DSD | Age/Sex: 5-14 Male | 140 | 146 |
| TX_CURR_DSD | Age/Sex: 15+ Male | 10,152 | 10,659 |
| TX_CURR_DSD | Age/Sex: <1 Female | 583 | 612 |
| TX_CURR_DSD | Age/Sex: 1-4 Female | 425 | 447 |
| TX_CURR_DSD | Age/Sex: 5-14 Female | 325 | 342 |
| TX_CURR_DSD | Age/Sex: 15+ Female | 23,687 | 24,871 |
| TX_CURR_DSD | Sum of age/sex disaggregates | 1,905 | 2,000 |
| TX_CURR_DSD | Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 0 | 0 |
| TX_CURR_DSD | Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 1 | 1 |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Male | 250 | 262 |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Female | 583 | 612 |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male | 572 | 600 |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 10,152 | 10,659 |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female | 1,333 | 1,400 |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Female | 23,687 | 24,871 |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 1,905 | 2,000 |
| TX_CURR_DSD | Sum of Aggregated Age/Sex 15+ | 33,839 | 35,530 |
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates | 35,744 | 37,530 |
| TX_CURR_NGI | Number of adults and children receiving antiretroviral therapy (ART) | 35,744 | 37,530 |
| TX_CURR_NGI | Age/Sex: <1 Male | 250 | 262 |
| TX_CURR_NGI | Age/Sex: 1-4 Male | 182 | 191 |
| TX_CURR_NGI | Age/Sex: 5-14 Male | 140 | 146 |
| TX_CURR_NGI | Age/Sex: 15+ Male | 10,152 | 10,659 |
| TX_CURR_NGI | Age/Sex: <1 Female | 583 | 612 |

| | | | |
|-------------|--|--------|--------|
| TX_CURR_NGI | Age/Sex: 1-4 Female | 425 | 447 |
| TX_CURR_NGI | Age/Sex: 5-14 Female | 325 | 342 |
| TX_CURR_NGI | Age/Sex: 15+ Female | 23,687 | 24,871 |
| TX_CURR_NGI | Sum of Age/Sex disaggregates | 35,744 | 37,530 |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Male | 250 | 262 |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Female | 583 | 612 |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Male | 572 | 600 |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Male | 10,152 | 10,659 |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Female | 1,333 | 1,400 |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Female | 23,687 | 24,871 |
| TX_CURR_NGI | Sum of Aggregated Age/Sex disaggregates | 35,744 | 37,530 |
| TX_CURR_NGI | Sum of Aggregated Age/Sex <15 | 1,905 | 2,000 |
| TX_CURR_NGI | Sum of Aggregated Age/Sex 15+ | 33,839 | 35,530 |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 11,538 | 9,294 |
| TX_NEW_DSD | By Age/Sex: <1 Male | 81 | 65 |
| TX_NEW_DSD | By Age/Sex: 1-4 Male | 59 | 47 |
| TX_NEW_DSD | By Age/Sex: 5-9 Male | 28 | 22 |
| TX_NEW_DSD | By Age/Sex: 10-14 Male | 17 | 14 |
| TX_NEW_DSD | By Age/Sex: 15-19 Male | 346 | 279 |
| TX_NEW_DSD | By Age/Sex: 20-24 Male | 519 | 418 |
| TX_NEW_DSD | By Age/Sex: 25-49 Male | 2,250 | 1,812 |
| TX_NEW_DSD | By Age/Sex: 50+ Male | 162 | 130 |
| TX_NEW_DSD | By Age/Sex: <1 Female | 188 | 152 |
| TX_NEW_DSD | By Age/Sex: 1-4 Female | 137 | 111 |
| TX_NEW_DSD | By Age/Sex: 5-9 Female | 65 | 52 |
| TX_NEW_DSD | By Age/Sex: 10-14 Female | 40 | 33 |
| TX_NEW_DSD | By Age/Sex: 15-19 Female | 808 | 651 |
| TX_NEW_DSD | By Age/Sex: 20-24 Female | 1,211 | 976 |
| TX_NEW_DSD | By Age/Sex: 25-49 Female | 5,250 | 4,228 |
| TX_NEW_DSD | By Age/Sex: 50+ Female | 377 | 304 |
| TX_NEW_DSD | Sum of Age/Sex disaggregates | 11,538 | 9,294 |



| | | | |
|------------|---|--------|--------|
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male | 81 | 65 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male | 185 | 149 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 3,277 | 2,639 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female | 188 | 152 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female | 430 | 347 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 7,646 | 6,159 |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 11,538 | 9,294 |
| TX_NEW_DSD | Pregnancy status | 765 | 616 |
| TX_NEW_DSD | Breastfeeding status | 382 | 308 |
| TX_RET_DSD | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 8,331 | 9,807 |
| TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 9,801 | 11,538 |
| TX_RET_DSD | Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 167 | 196 |
| TX_RET_DSD | Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 333 | 392 |
| TX_RET_DSD | Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 7,831 | 9,219 |
| TX_RET_DSD | Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 196 | 231 |



| | | | |
|-------------|--|-------|--------|
| TX_RET_DSD | Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 392 | 462 |
| TX_RET_DSD | Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 9,213 | 10,846 |
| TX_RET_DSD | Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 500 | 588 |
| TX_RET_DSD | Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 7,831 | 9,219 |
| TX_RET_DSD | Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 588 | 692 |
| TX_RET_DSD | Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 9,213 | 10,846 |
| LAB_ACC_DSD | Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation | 2 | 2 |

| | | | |
|-------------|---|----|----|
| LAB_ACC_DSD | By site support type: Direct Service Delivery (DSD) | 2 | 2 |
| LAB_ACC_DSD | Sum of Support Type disaggregates | 2 | 2 |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 44 | 44 |
| LAB_CAP_DSD | By clinical laboratories | 44 | 44 |
| LAB_CAP_DSD | By site support type: Direct Service Delivery (DSD) | 44 | 44 |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates | 44 | 44 |
| LAB_PT_DSD | Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program | 1 | 1 |
| LAB_PT_DSD | HIV serologic/diagnostic testing: Number of laboratories that perform this testing | 44 | 44 |
| LAB_PT_DSD | HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program | 37 | 37 |
| LAB_PT_DSD | HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 29 | 29 |
| LAB_PT_DSD | CD4: Number of laboratories that perform this testing | 44 | 44 |
| LAB_PT_DSD | CD4: Number of laboratories that participate in this PT program | 36 | 36 |
| LAB_PT_DSD | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 29 | 29 |
| LAB_PT_DSD | Early infant diagnostics: Number of laboratories that perform this testing | 1 | 1 |
| LAB_PT_DSD | Early infant diagnostics: Number of laboratories that participate in this PT program | 1 | 1 |
| LAB_PT_DSD | Early infant diagnostics: Number of | 1 | 1 |



| | | | |
|---------------|--|--------|--------|
| | laboratories that achieve acceptable successful passing criteria in this PT program | | |
| TB_SCREEN_DSD | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period | 48,254 | 50,666 |
| TB_SCREEN_DSD | Age: <1 | 1,124 | 1,181 |
| TB_SCREEN_DSD | Age: 1-4 | 820 | 861 |
| TB_SCREEN_DSD | Age: 5-9 | 386 | 405 |
| TB_SCREEN_DSD | Age: 10-14 | 241 | 253 |
| TB_SCREEN_DSD | Age: 15-19 | 4,825 | 5,067 |
| TB_SCREEN_DSD | Age: 20-24 | 7,239 | 7,600 |
| TB_SCREEN_DSD | Age: 25-49 | 31,366 | 32,933 |
| TB_SCREEN_DSD | Age: 50+ | 2,253 | 2,366 |
| TB_SCREEN_DSD | Sum of Age disaggregates | 7,396 | 7,767 |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 | 2,572 | 2,700 |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ | 45,682 | 47,966 |
| TB_SCREEN_DSD | Sum of Aggregated Age disaggregates | 48,254 | 50,666 |
| TB_SCREEN_DSD | Sex: Male | 14,476 | 15,200 |
| TB_SCREEN_DSD | Sex: Female | 33,778 | 35,466 |
| TB_SCREEN_DSD | Sum of Sex disaggregates | 48,254 | 50,666 |

Implementing Mechanism Details

| | |
|---|---|
| Mechanism ID: 17195 | Mechanism Name: DOD CA |
| Funding Agency: DOD | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Health Initiatives for Safety and Stability in Africa | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 1,228,432 | Total Mechanism Pipeline: Redacted |



| Applied Pipeline Amount: 1,930,537 | |
|---|-----------------------|
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 1,228,432 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|----------------------------|-----------|
| Human Resources for Health | 1,228,432 |
|----------------------------|-----------|

Key Issues

Military Population

Budget Code Information

| Mechanism ID: 17195 | | | |
|--|--------------------|-----------------------|-----------------------|
| Mechanism Name: DOD CA | | | |
| Prime Partner Name: Health Initiatives for Safety and Stability in Africa | | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 21,022 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 309,319 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 100,709 | 0 |



| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|------------------------|-------------|----------------|----------------|
| Governance and Systems | OHSS | 236,630 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 92,268 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 468,484 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|--|---|
| Mechanism ID: 16871 | Mechanism Name: ENGAGING INDIGINOUS ORGANIZATIONS TO SUSTAIN AND ENHANCE COMPREHENSIVE CLINICAL SERVICES |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Institute of Human Virology, Nigeria | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: PR/SR | |
| G2G: No | Managing Agency: |

| Total All Funding Sources: 35,743,182 | Total Mechanism Pipeline: Redacted |
|--|---|
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 35,743,182 |

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

| | |
|-------------------------|---|
| Renovation | 305,000 |
| Gender: Gender Equality | 234,865 |
| Focus Area: | Promoting gender-related policies and laws that increase legal protection |
| Sub Area: | Capacity building |
| Focus Area: | Equity in HIV prevention, care, treatment and support |
| Sub Area: | Monitoring and Evaluation |
| Gender: GBV | 117,432 |
| Focus Area: | GBV Prevention |
| Sub Area: | Capacity building |
| Focus Area: | Post GBV Care |
| Sub Area: | Monitoring and Evaluation |
| Condom programming | 1,527,157 |

Key Issues

Malaria (PMI)

Child Survival Activities

Mobile Population

Safe Motherhood

TB

End-of-Program Evaluation

Family Planning

Budget Code Information

| | |
|------------------------|---|
| Mechanism ID: | 16871 |
| Mechanism Name: | ENGAGING INDIGINOUS ORGANIZATIONS TO SUSTAIN AND ENHANCE |



| | | | |
|--|--------------------|-----------------------|-----------------------|
| Prime Partner Name: COMPREHENSIVE CLINICAL SERVICES | | | |
| Institute of Human Virology, Nigeria | | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 4,147,244 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 2,352,166 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 1,368,322 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 314,580 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 4,379,417 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 405,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMBL | 41,483 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMIN | 117,652 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVAB | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 1,865,634 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |



| | | | |
|-----------------------|--------------------|-----------------------|-----------------------|
| Prevention | HVOP | 3,947,208 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 3,910,745 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 11,974,319 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 919,412 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|-------------------|--|--------|--------|-------------------------|
| PMTCT_ARV_DS D | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 11,191 | 11,474 | Redacted |
| PMTCT_ARV_DS D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 12,717 | 12,609 | Redacted |
| PMTCT_ARV_DS D | Life-long ART (including Option B+) | 6,155 | 6,311 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 2,340 | 2,138 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 3,815 | 4,172 | Redacted |
| PMTCT_ARV_DS | Maternal triple ARV prophylaxis | 4,364 | 4,590 | Redacted |

| | | | | |
|-------------------|--|--------|--------|----------|
| D | (provided with the intention to stop at the end of the breastfeeding period) | | | |
| PMTCT_ARV_DS D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 560 | 573 | Redacted |
| PMTCT_ARV_DS D | Single-dose nevirapine (with or without tail) | 112 | 0 | Redacted |
| PMTCT_ARV_DS D | Sum of Regimen Type disaggregates | 11,191 | 11,474 | Redacted |
| PMTCT_ARV_DS D | Sum of New and Current disaggregates | 6,155 | 6,310 | Redacted |
| PMTCT_ARV_NGI | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 11,191 | 11,474 | Redacted |
| PMTCT_ARV_NGI | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 12,717 | 12,609 | Redacted |
| PMTCT_ARV_NGI | Life-long ART (including Option B+) | 6,155 | 6,311 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 2,340 | 2,138 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 3,815 | 4,172 | Redacted |
| PMTCT_ARV_NGI | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 4,364 | 4,590 | Redacted |
| PMTCT_ARV_NGI | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 560 | 573 | Redacted |
| PMTCT_ARV_NGI | Single-dose nevirapine (with or without tail) | 112 | 0 | Redacted |
| PMTCT_ARV_NGI | Sum of Regimen disaggregates | 11,191 | 11,474 | Redacted |



| | | | | |
|--------------------|--|---------|---------|----------|
| PMTCT_ARV_NGI | Sum of New and Current disaggregates | 6,155 | 6,310 | Redacted |
| PMTCT_STAT_DS D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 401,176 | 405,727 | Redacted |
| PMTCT_STAT_DS D | Number of new ANC and L&D clients | 440,853 | 445,854 | Redacted |
| PMTCT_STAT_DS D | By: Known positives at entry | 5,087 | 5,044 | Redacted |
| PMTCT_STAT_DS D | By: Number of new positives identified | 7,630 | 7,565 | Redacted |
| PMTCT_STAT_DS D | Sum of Positives Status disaggregates | 12,717 | 12,609 | Redacted |
| PMTCT_STAT_NG I | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 401,176 | 405,727 | Redacted |
| PMTCT_STAT_NG I | Number of new ANC and L&D clients | 440,853 | 445,854 | Redacted |
| PMTCT_STAT_NG I | By: Known positives at entry | 5,087 | 5,044 | Redacted |
| PMTCT_STAT_NG I | By: Number of new positives identified | 7,630 | 7,565 | Redacted |
| PMTCT_STAT_NG I | Sum of Positives Status disaggregates | 12,717 | 12,609 | Redacted |
| BS_COLL | Number of whole blood collections each year by the NBTS network | 213,000 | 213,000 | Redacted |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network laboratory | 191,700 | 191,700 | Redacted |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV | 4,260 | 4,260 | Redacted |

| | | | | |
|-------------|---|--------|---------|----------|
| PP_PREV_DSD | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 1,724 | 57,390 | Redacted |
| PP_PREV_DSD | Total number of people in the target population | 4,001 | 208,503 | Redacted |
| PP_PREV_DSD | Age/sex: 10-14 Male | 84 | 2,812 | Redacted |
| PP_PREV_DSD | Age/sex: 15-19 Male | 101 | 3,374 | Redacted |
| PP_PREV_DSD | Age/sex: 20-24 Male | 253 | 8,436 | Redacted |
| PP_PREV_DSD | Age/sex: 25-49 Male | 379 | 12,655 | Redacted |
| PP_PREV_DSD | Age/sex: 50+ Male | 25 | 844 | Redacted |
| PP_PREV_DSD | Age/sex: 10-14 Female | 88 | 2,927 | Redacted |
| PP_PREV_DSD | Age/sex: 15-19 Female | 107 | 3,512 | Redacted |
| PP_PREV_DSD | Age/sex: 20-24 Female | 264 | 8,781 | Redacted |
| PP_PREV_DSD | Age/sex: 25-49 Female | 397 | 13,171 | Redacted |
| PP_PREV_DSD | Age/sex: 50+ Female | 26 | 878 | Redacted |
| PP_PREV_DSD | Sum of Age/Sex disaggregates | 1,724 | 57,390 | Redacted |
| KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 50,905 | | Redacted |
| KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 47,342 | | Redacted |
| KP_PREV_DSD | By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level | 814 | | Redacted |

| | | | | |
|-------------|--|-----------|-----------|----------|
| | HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | | | |
| KP_PREV_DSD | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 204 | | Redacted |
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 2,545 | | Redacted |
| KP_PREV_DSD | By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 255 | | Redacted |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 1,031,230 | 1,110,286 | Redacted |
| HTC_TST_DSD | By Test Result: Negative | 1,003,683 | 1,081,777 | Redacted |
| HTC_TST_DSD | By Test Result: Positive | 27,547 | 28,509 | Redacted |
| HTC_TST_DSD | Sum of Test Result disaggregates | 1,031,230 | 1,110,286 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Male | 5,546 | 5,622 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Male | 3,046 | 3,407 | Redacted |



| | | | | |
|-------------|---|-----------|-----------|----------|
| HTC_TST_DSD | Age/sex: 5-9 Male | 1,232 | 1,379 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Male | 2,756 | 3,083 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Male | 30,567 | 34,201 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Male | 63,211 | 70,795 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Male | 198,772 | 222,405 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Male | 6,163 | 6,897 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Female | 5,772 | 5,852 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Female | 3,191 | 3,570 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Female | 1,269 | 1,420 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Female | 2,829 | 3,165 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Female | 71,444 | 75,689 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Female | 204,414 | 213,914 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Female | 424,672 | 451,787 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Female | 6,346 | 7,100 | Redacted |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 1,031,230 | 1,110,286 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 12,580 | 13,493 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 298,713 | 334,297 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 13,061 | 14,006 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 706,876 | 748,490 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 25,641 | 27,499 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 1,005,589 | 1,082,787 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 1,031,230 | 1,110,286 | Redacted |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 1,031,230 | 1,110,286 | Redacted |
| HTC_TST_NGI | By Test Result: Negative | 1,003,683 | 1,081,777 | Redacted |
| HTC_TST_NGI | By Test Result: Positive | 27,547 | 28,509 | Redacted |
| HTC_TST_NGI | Sum of Test Result disaggregates | 1,031,230 | 1,110,286 | Redacted |

| | | | | |
|--------------|--|-----------|-----------|----------|
| HTC_TST_NGI | Age/sex: <1 Male | 5,546 | 5,622 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Male | 3,046 | 3,408 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Male | 1,232 | 1,379 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Male | 2,756 | 3,083 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Male | 30,567 | 34,201 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Male | 63,211 | 70,795 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Male | 198,772 | 222,405 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Male | 6,163 | 6,897 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Female | 5,772 | 5,852 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Female | 3,191 | 3,570 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Female | 1,269 | 1,420 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Female | 2,829 | 3,165 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Female | 71,444 | 75,689 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Female | 204,414 | 213,914 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Female | 424,672 | 451,786 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Female | 6,346 | 7,100 | Redacted |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 1,031,230 | 1,110,286 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 12,580 | 13,493 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 298,713 | 334,297 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 13,061 | 14,006 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 706,877 | 748,490 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 25,641 | 27,499 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 1,005,590 | 1,082,787 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 1,031,231 | 1,110,286 | Redacted |
| GEND_GBV_DSD | Number of people receiving post-GBV care | 367 | 367 | Redacted |
| GEND_GBV_DSD | Age: 0-9 | 42 | 42 | Redacted |
| GEND_GBV_DSD | Age: 10-14 | 86 | 86 | Redacted |
| GEND_GBV_DSD | Age: 15-17 | 127 | 127 | Redacted |
| GEND_GBV_DSD | Age: 18-24 | 75 | 75 | Redacted |
| GEND_GBV_DSD | Age: 25+ | 37 | 37 | Redacted |



| | | | | |
|--------------|---|--------|--------|----------|
| GEND_GBV_DSD | Sum of Age disaggregates | 367 | 367 | Redacted |
| GEND_GBV_DSD | Sex: Male | 122 | 122 | Redacted |
| GEND_GBV_DSD | Sex: Female | 245 | 245 | Redacted |
| GEND_GBV_DSD | Sum of Sex disaggregates | 367 | 367 | Redacted |
| GEND_GBV_DSD | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) | 82 | 82 | Redacted |
| GEND_GBV_DSD | By type of service: Sexual Violence (Post-Rape Care) | 285 | 285 | Redacted |
| GEND_GBV_DSD | By PEP service provision (related to sexual violence services provided) | 285 | 285 | Redacted |
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 19,678 | 24,333 | Redacted |
| OVC_ACC_DSD | Sex: Male | 9,642 | 11,923 | Redacted |
| OVC_ACC_DSD | Sex: Female | 10,036 | 12,410 | Redacted |
| OVC_ACC_DSD | Sum of Sex disaggregates | 19,678 | 24,333 | Redacted |
| OVC_ACC_DSD | Age: <1 | 1,181 | 1,460 | Redacted |
| OVC_ACC_DSD | Age: 1-4 | 4,919 | 6,083 | Redacted |
| OVC_ACC_DSD | Age: 5-9 | 5,510 | 6,813 | Redacted |
| OVC_ACC_DSD | Age: 10-14 | 4,723 | 5,840 | Redacted |
| OVC_ACC_DSD | Age: 15-17 | 2,755 | 3,407 | Redacted |
| OVC_ACC_DSD | Age: 18+ | 590 | 730 | Redacted |
| OVC_ACC_DSD | Sum of Age disaggregates | 19,678 | 24,333 | Redacted |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 65,594 | 81,109 | Redacted |
| OVC_SERV_DSD | Sex: Male | 32,141 | 39,743 | Redacted |
| OVC_SERV_DSD | Sex: Female | 33,453 | 41,366 | Redacted |
| OVC_SERV_DSD | Sum of Sex disaggregates | 65,594 | 81,109 | Redacted |
| OVC_SERV_DSD | Age: <1 | 3,936 | 4,867 | Redacted |
| OVC_SERV_DSD | Age: 1-4 | 16,398 | 20,277 | Redacted |
| OVC_SERV_DSD | Age: 5-9 | 18,366 | 22,711 | Redacted |

| | | | | |
|--------------|--|---------|--------|----------|
| OVC_SERV_DSD | Age: 10-14 | 15,087 | 19,466 | Redacted |
| OVC_SERV_DSD | Age: 15-17 | 9,183 | 11,355 | Redacted |
| OVC_SERV_DSD | Age: 18+ | 2,624 | 2,433 | Redacted |
| OVC_SERV_DSD | Sum of Age disaggregates | 65,594 | 81,109 | Redacted |
| C2.1.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 149,970 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Female | 5,249 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Male | 2,250 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Female | 42,741 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Male | 99,730 | | Redacted |
| C2.1.D_DSD | Sum of Age/Sex disaggregates | 149,970 | | Redacted |
| C2.1.D_DSD | By Age: <15 | 7,498 | | Redacted |
| C2.1.D_DSD | By Age: 15+ | 142,472 | | Redacted |
| C2.1.D_DSD | Sum of Age disaggregates | 149,970 | | Redacted |
| C2.1.D_DSD | By Sex: Female | 104,979 | | Redacted |
| C2.1.D_DSD | By Sex: Male | 44,991 | | Redacted |
| C2.1.D_DSD | Sum of Sex disaggregates | 149,970 | | Redacted |
| C2.1.D_NGI | Number of HIV-positive individuals receiving a minimum of one clinical service | 149,970 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Female | 5,249 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Male | 2,250 | | Redacted |
| C2.1.D_NGI | By Age/Sex: 15+ Female | 42,741 | | Redacted |
| C2.1.D_NGI | By Age/Sex: 15+ Male | 99,730 | | Redacted |
| C2.1.D_NGI | Sum of Age/Sex disaggregates | 149,970 | | Redacted |
| C2.1.D_NGI | By Age: <15 | 7,498 | | Redacted |
| C2.1.D_NGI | By Age: 15+ | 142,472 | | Redacted |
| C2.1.D_NGI | Sum of Age disaggregates | 149,970 | | Redacted |
| C2.1.D_NGI | By Sex: Female | 104,979 | | Redacted |
| C2.1.D_NGI | By Sex: Male | 44,991 | | Redacted |
| C2.1.D_NGI | Sum of Sex disaggregates | 149,970 | | Redacted |

| | | | | |
|---------------|--|---------|--------|----------|
| C2.4.D_DSD | Number of HIV-positive patients who were screened for TB in HIV care or treatment setting | 126,582 | 0 | Redacted |
| C2.4.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 149,970 | | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 4,416 | 4,794 | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period | 0 | 4,794 | Redacted |
| TB_ART_DSD | Age: 0-4 | 44 | 48 | Redacted |
| TB_ART_DSD | Age: 5-14 | 221 | 240 | Redacted |
| TB_ART_DSD | Age: 15+ | 4,151 | 4,506 | Redacted |
| TB_ART_DSD | Male | 2,164 | 2,349 | Redacted |
| TB_ART_DSD | Female | 2,252 | 2,445 | Redacted |
| TB_ART_DSD | Sum of Sex disaggregates | 4,416 | 4,794 | Redacted |
| TB_ART_DSD | Newly tested | 2,517 | 2,733 | Redacted |
| TB_ART_DSD | Known HIV-positive | 1,899 | 2,061 | Redacted |
| TB_ART_DSD | Sum of Test Status disaggregates | 4,416 | 4,794 | Redacted |
| TB_ART_DSD | Aggregated Age: <15 | 265 | 288 | Redacted |
| TB_ART_DSD | Aggregated Age: 15+ | 4,151 | 4,506 | Redacted |
| TB_ART_DSD | Sum of Aggregated Age disaggregates | 4,416 | 4,794 | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period | 11,191 | 11,474 | Redacted |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 12,717 | 13,284 | Redacted |

| | | | | |
|---------------|--|--------|---------|----------|
| PMTCT_EID_DSD | By infants who received a virologic test within 2 months of birth | 3,693 | 3,786 | Redacted |
| PMTCT_EID_DSD | By infants who received their first virologic HIV test between 2 and 12 months of age | 7,498 | 7,688 | Redacted |
| PMTCT_EID_DSD | Sum of Infant Age disaggregates | 11,191 | 11,474 | Redacted |
| PMTCT_EID_DSD | By infants with a positive virologic test result within 12 months of birth | 560 | 574 | Redacted |
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 99,980 | 102,976 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Male | 198 | 204 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Male | 932 | 960 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Male | 1,695 | 1,746 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Male | 31,234 | 32,171 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Female | 175 | 181 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Female | 827 | 851 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Female | 1,503 | 1,548 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Female | 63,416 | 65,315 | Redacted |
| TX_CURR_DSD | Sum of age/sex disaggregates | 5,330 | 5,490 | Redacted |
| TX_CURR_DSD | Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 5 | 5 | Redacted |
| TX_CURR_DSD | Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 66 | 66 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Male | 198 | 204 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Female | 175 | 181 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male | 2,824 | 2,909 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 31,235 | 32,171 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female | 2,505 | 2,580 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Female | 63,416 | 65,316 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 5,329 | 5,489 | Redacted |

| | | | | |
|-------------|--|--------|---------|----------|
| TX_CURR_DSD | Sum of Aggregated Age/Sex 15+ | 94,651 | 97,487 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates | 99,980 | 102,976 | Redacted |
| TX_CURR_NGI | Number of adults and children receiving antiretroviral therapy (ART) | 99,980 | 102,975 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Male | 198 | 204 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Male | 932 | 960 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Male | 1,695 | 1,746 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Male | 31,235 | 32,171 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Female | 175 | 181 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Female | 827 | 851 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Female | 1,502 | 1,546 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Female | 63,416 | 65,316 | Redacted |
| TX_CURR_NGI | Sum of Age/Sex disaggregates | 99,980 | 102,975 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Male | 198 | 204 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Female | 175 | 181 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Male | 2,824 | 2,909 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Male | 31,235 | 32,170 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Female | 2,505 | 2,580 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Female | 63,416 | 65,316 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex disaggregates | 99,980 | 102,975 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex <15 | 5,329 | 5,489 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex 15+ | 94,651 | 97,486 | Redacted |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 32,274 | 31,765 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Male | 128 | 222 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Male | 182 | 162 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Male | 228 | 76 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Male | 374 | 48 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Male | 1,421 | 953 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Male | 2,368 | 1,429 | Redacted |

| | | | | |
|------------|---|--------|--------|----------|
| TX_NEW_DSD | By Age/Sex: 25-49 Male | 3,789 | 6,194 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Male | 1,894 | 445 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Female | 121 | 518 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Female | 162 | 378 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Female | 202 | 178 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Female | 323 | 111 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Female | 3,162 | 2,224 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Female | 5,271 | 3,335 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Female | 8,433 | 14,454 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Female | 4,216 | 1,038 | Redacted |
| TX_NEW_DSD | Sum of Age/Sex disaggregates | 32,274 | 31,765 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male | 128 | 222 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male | 912 | 508 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 9,472 | 9,022 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female | 121 | 518 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female | 808 | 1,185 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 21,082 | 21,050 | Redacted |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 32,274 | 31,765 | Redacted |
| TX_NEW_DSD | Pregnancy status | 1,687 | 2,105 | Redacted |
| TX_NEW_DSD | Breastfeeding status | 1,069 | 1,053 | Redacted |
| TX_RET_DSD | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 18,003 | 27,433 | Redacted |
| TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, | 21,180 | 32,274 | Redacted |

| | | | | |
|------------|--|--------|--------|----------|
| | those who have stopped ART, and those lost to follow-up | | | |
| TX_RET_DSD | Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 360 | 549 | Redacted |
| TX_RET_DSD | Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 540 | 823 | Redacted |
| TX_RET_DSD | Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 17,103 | 26,061 | Redacted |
| TX_RET_DSD | Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 424 | 645 | Redacted |
| TX_RET_DSD | Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 635 | 968 | Redacted |
| TX_RET_DSD | Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 20,121 | 30,660 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Numerator: | 900 | 1,372 | Redacted |

| | | | | |
|-------------|---|--------|--------|----------|
| | Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | | | |
| TX_RET_DSD | Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 17,101 | 26,061 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 1,059 | 1,614 | Redacted |
| TX_RET_DSD | Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 20,121 | 30,660 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 8,461 | 12,893 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 995 | 1,517 | Redacted |
| LAB_ACC_DSD | Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or | 10 | 10 | Redacted |

| | | | | |
|-------------|---|-----|-----|----------|
| | international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation | | | |
| LAB_ACC_DSD | By site support type: Direct Service Delivery (DSD) | 10 | 10 | Redacted |
| LAB_ACC_DSD | Sum of Support Type disaggregates | 10 | 10 | Redacted |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 94 | 94 | Redacted |
| LAB_CAP_DSD | By clinical laboratories | 94 | 94 | Redacted |
| LAB_CAP_DSD | By Point-of-care testing sites | 0 | 0 | Redacted |
| LAB_CAP_DSD | By site support type: Direct Service Delivery (DSD) | 94 | 94 | Redacted |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates | 94 | 94 | Redacted |
| QI_SITE | Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months | 120 | 156 | Redacted |
| QI_SITE | Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC | 146 | 204 | Redacted |
| QI_SITE | By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months | 120 | 156 | Redacted |
| QI_SITE | Sum of Numerator Site Support Type disaggregates | 120 | 156 | Redacted |



| | | | | |
|---------------|---|---------|---------|----------|
| QI_SITE | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC | 146 | 204 | Redacted |
| QI_SITE | Sum of Denominator Site Support Type disaggregates | 146 | 204 | Redacted |
| TB_SCREEN_DSD | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period | 126,582 | 142,036 | Redacted |
| TB_SCREEN_DSD | Age: <1 | 2,532 | 2,841 | Redacted |
| TB_SCREEN_DSD | Age: 1-4 | 1,266 | 1,420 | Redacted |
| TB_SCREEN_DSD | Age: 5-9 | 2,532 | 2,841 | Redacted |
| TB_SCREEN_DSD | Age: 10-14 | 1,266 | 1,420 | Redacted |
| TB_SCREEN_DSD | Age: 15-19 | 12,658 | 14,204 | Redacted |
| TB_SCREEN_DSD | Age: 20-24 | 31,646 | 35,509 | Redacted |
| TB_SCREEN_DSD | Age: 25-49 | 69,620 | 78,120 | Redacted |
| TB_SCREEN_DSD | Age: 50+ | 5,063 | 5,681 | Redacted |
| TB_SCREEN_DSD | Sum of Age disaggregates | 20,254 | 22,726 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 | 7,595 | 8,522 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ | 118,987 | 133,514 | Redacted |
| TB_SCREEN_DSD | Sum of Aggregated Age disaggregates | 126,582 | 142,036 | Redacted |
| TB_SCREEN_DSD | Sex: Male | 37,975 | 42,611 | Redacted |
| TB_SCREEN_DSD | Sex: Female | 88,607 | 99,425 | Redacted |
| TB_SCREEN_DSD | Sum of Sex disaggregates | 126,582 | 142,036 | Redacted |

Implementing Mechanism Details

| | |
|----------------------------|--|
| Mechanism ID: 16855 | Mechanism Name: Engaging Indigenous Organization to Sustain and Enhance Comprehensive Clinical Services |
|----------------------------|--|



| | |
|---|---|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Center for Integrated Health Programs | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: PR/SR | |
| G2G: No | Managing Agency: |

| Total All Funding Sources: 32,843,400 | Total Mechanism Pipeline: Redacted |
|--|---|
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 32,843,400 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|---------------------------|---|
| Renovation | 998,625 |
| Gender: Gender Equality | 254,373 |
| Focus Area: | Promoting gender-related policies and laws that increase legal protection |
| Sub Area: | Monitoring and Evaluation |
| Focus Area: | Equity in HIV prevention, care, treatment and support |
| Sub Area: | Implementation |
| Motor Vehicles: Purchased | 325,476 |
| Condom programming | 205,642 |

Key Issues

Malaria (PMI)

Approved



TB

Family Planning

Budget Code Information

| | | | |
|----------------------------|--|-----------------------|-----------------------|
| Mechanism ID: | 16855 | | |
| Mechanism Name: | Engaging Indigenous Organization to Sustain and Enhance | | |
| Prime Partner Name: | Comprehensive Clinical Services | | |
| | Center for Integrated Health Programs | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 4,241,911 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 2,543,735 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 1,187,125 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 298,300 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 4,387,569 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 951,113 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |



| | | | |
|-----------------------|--------------------|-----------------------|-----------------------|
| Prevention | HMBL | 21,077 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMIN | 61,711 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVAB | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 1,388,377 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 607,348 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 3,977,554 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXD | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 12,293,247 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 884,333 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|-------------------|---|--------|--------|-------------------------|
| PMTCT_ARV_DS D | Number of HIV-positive pregnant women who received antiretrovirals to | 12,057 | 12,848 | Redacted |

| | | | | |
|-------------------|--|--------|--------|----------|
| | reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | | | |
| PMTCT_ARV_DS D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 13,701 | 14,119 | Redacted |
| PMTCT_ARV_DS D | Life-long ART (including Option B+) | 6,631 | 6,296 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 2,521 | 2,815 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 4,110 | 3,481 | Redacted |
| PMTCT_ARV_DS D | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 4,702 | 5,396 | Redacted |
| PMTCT_ARV_DS D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 603 | 1,028 | Redacted |
| PMTCT_ARV_DS D | Single-dose nevirapine (with or without tail) | 121 | 128 | Redacted |
| PMTCT_ARV_DS D | Sum of Regimen Type disaggregates | 12,057 | 12,848 | Redacted |
| PMTCT_ARV_DS D | Sum of New and Current disaggregates | 6,631 | 6,296 | Redacted |
| PMTCT_ARV_NGI | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 12,057 | 12,848 | Redacted |
| PMTCT_ARV_NGI | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 13,701 | 14,119 | Redacted |
| PMTCT_ARV_NGI | Life-long ART (including Option B+) | 6,631 | 6,296 | Redacted |

| | | | | |
|--------------------|--|---------|---------|----------|
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 2,521 | 2,815 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 4,110 | 3,481 | Redacted |
| PMTCT_ARV_NGI | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 4,702 | 5,396 | Redacted |
| PMTCT_ARV_NGI | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 603 | 1,028 | Redacted |
| PMTCT_ARV_NGI | Single-dose nevirapine (with or without tail) | 121 | 128 | Redacted |
| PMTCT_ARV_NGI | Sum of Regimen disaggregates | 12,057 | 12,848 | Redacted |
| PMTCT_ARV_NGI | Sum of New and Current disaggregates | 6,631 | 6,296 | Redacted |
| PMTCT_STAT_DS D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 212,816 | 224,123 | Redacted |
| PMTCT_STAT_DS D | Number of new ANC and L&D clients | 233,864 | 246,289 | Redacted |
| PMTCT_STAT_DS D | By: Known positives at entry | 5,480 | 5,647 | Redacted |
| PMTCT_STAT_DS D | By: Number of new positives identified | 8,221 | 8,471 | Redacted |
| PMTCT_STAT_DS D | Sum of Positives Status disaggregates | 13,701 | 14,118 | Redacted |
| PMTCT_STAT_NG I | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 212,816 | 224,123 | Redacted |
| PMTCT_STAT_NG I | Number of new ANC and L&D clients | 233,864 | 246,289 | Redacted |

| | | | | |
|--------------------|--|--------|---------|----------|
| PMTCT_STAT_NG I | By: Known positives at entry | 5,480 | 5,647 | Redacted |
| PMTCT_STAT_NG I | By: Number of new positives identified | 8,221 | 8,471 | Redacted |
| PMTCT_STAT_NG I | Sum of Positives Status disaggregates | 13,701 | 14,118 | Redacted |
| BS_COLL | Number of whole blood collections each year by the NBTS network | 17,000 | 17,000 | Redacted |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network laboratory | 15,300 | 15,300 | Redacted |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV | 340 | 340 | Redacted |
| PP_PREV_DSD | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 4,440 | 41,479 | Redacted |
| PP_PREV_DSD | Total number of people in the target population | 10,305 | 150,697 | Redacted |
| PP_PREV_DSD | Age/sex: 10-14 Male | 218 | 2,033 | Redacted |
| PP_PREV_DSD | Age/sex: 15-19 Male | 261 | 2,439 | Redacted |
| PP_PREV_DSD | Age/sex: 20-24 Male | 653 | 6,097 | Redacted |
| PP_PREV_DSD | Age/sex: 25-49 Male | 979 | 9,146 | Redacted |
| PP_PREV_DSD | Age/sex: 50+ Male | 65 | 610 | Redacted |
| PP_PREV_DSD | Age/sex: 10-14 Female | 226 | 2,115 | Redacted |
| PP_PREV_DSD | Age/sex: 15-19 Female | 272 | 2,538 | Redacted |
| PP_PREV_DSD | Age/sex: 20-24 Female | 679 | 6,347 | Redacted |
| PP_PREV_DSD | Age/sex: 25-49 Female | 1,019 | 9,519 | Redacted |
| PP_PREV_DSD | Age/sex: 50+ Female | 68 | 635 | Redacted |
| PP_PREV_DSD | Sum of Age/Sex disaggregates | 4,440 | 41,479 | Redacted |
| KP_PREV_DSD | Number of key populations reached | 6,855 | | Redacted |

| | | | | |
|-------------|---|-------|--|----------|
| | with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | | | |
| KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 6,375 | | Redacted |
| KP_PREV_DSD | By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 110 | | Redacted |
| KP_PREV_DSD | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 27 | | Redacted |
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 343 | | Redacted |
| KP_PREV_DSD | By key population type: MSM/TG who are male sex workers (subset | 34 | | Redacted |

| | | | | |
|-------------|--|---------|---------|----------|
| | MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | | | |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 647,094 | 757,446 | Redacted |
| HTC_TST_DSD | By Test Result: Negative | 625,449 | 733,191 | Redacted |
| HTC_TST_DSD | By Test Result: Positive | 21,645 | 24,255 | Redacted |
| HTC_TST_DSD | Sum of Test Result disaggregates | 647,094 | 757,446 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Male | 5,939 | 6,296 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Male | 2,088 | 2,568 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Male | 845 | 1,040 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Male | 1,889 | 2,324 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Male | 20,953 | 25,774 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Male | 43,341 | 53,352 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Male | 136,253 | 167,608 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Male | 4,225 | 5,198 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Female | 6,181 | 6,552 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Female | 2,187 | 2,691 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Female | 870 | 1,070 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Female | 1,939 | 2,385 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Female | 42,556 | 48,692 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Female | 117,672 | 131,989 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Female | 255,806 | 294,556 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Female | 4,350 | 5,351 | Redacted |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 647,094 | 757,446 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 10,760 | 12,227 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 204,772 | 251,932 | Redacted |

| | | | | |
|-------------|---|---------|---------|----------|
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 11,177 | 12,698 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 420,385 | 480,589 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 21,937 | 24,925 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 625,157 | 732,521 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 647,094 | 757,446 | Redacted |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 647,094 | 757,446 | Redacted |
| HTC_TST_NGI | By Test Result: Negative | 625,449 | 733,191 | Redacted |
| HTC_TST_NGI | By Test Result: Positive | 21,645 | 24,255 | Redacted |
| HTC_TST_NGI | Sum of Test Result disaggregates | 647,094 | 757,446 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Male | 5,939 | 6,296 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Male | 2,088 | 2,568 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Male | 845 | 1,040 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Male | 1,889 | 2,324 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Male | 20,953 | 25,774 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Male | 43,341 | 53,352 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Male | 136,253 | 167,608 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Male | 4,225 | 5,198 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Female | 6,181 | 6,552 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Female | 2,187 | 2,691 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Female | 870 | 1,070 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Female | 1,939 | 2,385 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Female | 42,556 | 48,692 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Female | 117,672 | 131,989 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Female | 255,806 | 294,556 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Female | 4,350 | 5,351 | Redacted |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 647,094 | 757,446 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 10,760 | 12,227 | Redacted |



| | | | | |
|--------------|--|---------|---------|----------|
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 204,772 | 251,932 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 11,178 | 12,698 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 420,384 | 480,589 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 21,938 | 24,925 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 625,156 | 732,521 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 647,094 | 757,446 | Redacted |
| GEND_GBV_DSD | Number of people receiving post-GBV care | 338 | 338 | Redacted |
| GEND_GBV_DSD | Age: 0-9 | 39 | 39 | Redacted |
| GEND_GBV_DSD | Age: 10-14 | 79 | 79 | Redacted |
| GEND_GBV_DSD | Age: 15-17 | 117 | 117 | Redacted |
| GEND_GBV_DSD | Age: 18-24 | 69 | 69 | Redacted |
| GEND_GBV_DSD | Age: 25+ | 34 | 34 | Redacted |
| GEND_GBV_DSD | Sum of Age disaggregates | 338 | 338 | Redacted |
| GEND_GBV_DSD | Sex: Male | 113 | 113 | Redacted |
| GEND_GBV_DSD | Sex: Female | 225 | 225 | Redacted |
| GEND_GBV_DSD | Sum of Sex disaggregates | 338 | 338 | Redacted |
| GEND_GBV_DSD | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) | 76 | 76 | Redacted |
| GEND_GBV_DSD | By type of service: Sexual Violence (Post-Rape Care) | 262 | 262 | Redacted |
| GEND_GBV_DSD | By PEP service provision (related to sexual violence services provided) | 262 | 262 | Redacted |
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 19,304 | 26,315 | Redacted |
| OVC_ACC_DSD | Sex: Male | 9,459 | 12,894 | Redacted |
| OVC_ACC_DSD | Sex: Female | 9,845 | 13,421 | Redacted |
| OVC_ACC_DSD | Sum of Sex disaggregates | 19,304 | 26,315 | Redacted |
| OVC_ACC_DSD | Age: <1 | 1,158 | 1,579 | Redacted |
| OVC_ACC_DSD | Age: 1-4 | 4,826 | 6,579 | Redacted |



| | | | | |
|--------------|---|---------|--------|----------|
| OVC_ACC_DSD | Age: 5-9 | 5,405 | 7,368 | Redacted |
| OVC_ACC_DSD | Age: 10-14 | 4,633 | 6,316 | Redacted |
| OVC_ACC_DSD | Age: 15-17 | 2,703 | 3,684 | Redacted |
| OVC_ACC_DSD | Age: 18+ | 579 | 789 | Redacted |
| OVC_ACC_DSD | Sum of Age disaggregates | 19,304 | 26,315 | Redacted |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 64,345 | 87,715 | Redacted |
| OVC_SERV_DSD | Sex: Male | 31,529 | 42,980 | Redacted |
| OVC_SERV_DSD | Sex: Female | 32,816 | 44,735 | Redacted |
| OVC_SERV_DSD | Sum of Sex disaggregates | 64,345 | 87,715 | Redacted |
| OVC_SERV_DSD | Age: <1 | 3,861 | 5,263 | Redacted |
| OVC_SERV_DSD | Age: 1-4 | 16,086 | 21,929 | Redacted |
| OVC_SERV_DSD | Age: 5-9 | 18,017 | 24,560 | Redacted |
| OVC_SERV_DSD | Age: 10-14 | 15,443 | 21,052 | Redacted |
| OVC_SERV_DSD | Age: 15-17 | 9,008 | 12,280 | Redacted |
| OVC_SERV_DSD | Age: 18+ | 1,930 | 2,631 | Redacted |
| OVC_SERV_DSD | Sum of Age disaggregates | 64,345 | 87,715 | Redacted |
| C2.1.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 155,799 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Female | 5,453 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Male | 2,337 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Female | 103,606 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Male | 44,403 | | Redacted |
| C2.1.D_DSD | Sum of Age/Sex disaggregates | 155,799 | | Redacted |
| C2.1.D_DSD | By Age: <15 | 7,790 | | Redacted |
| C2.1.D_DSD | By Age: 15+ | 148,009 | | Redacted |
| C2.1.D_DSD | Sum of Age disaggregates | 155,799 | | Redacted |
| C2.1.D_DSD | By Sex: Female | 109,059 | | Redacted |
| C2.1.D_DSD | By Sex: Male | 46,740 | | Redacted |
| C2.1.D_DSD | Sum of Sex disaggregates | 155,799 | | Redacted |

| | | | | |
|------------|--|---------|-------|----------|
| C2.1.D_NGI | Number of HIV-positive individuals receiving a minimum of one clinical service | 155,799 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Female | 5,453 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Male | 2,337 | | Redacted |
| C2.1.D_NGI | By Age/Sex: 15+ Female | 103,606 | | Redacted |
| C2.1.D_NGI | By Age/Sex: 15+ Male | 44,403 | | Redacted |
| C2.1.D_NGI | Sum of Age/Sex disaggregates | 155,799 | | Redacted |
| C2.1.D_NGI | By Age: <15 | 7,790 | | Redacted |
| C2.1.D_NGI | By Age: 15+ | 148,009 | | Redacted |
| C2.1.D_NGI | Sum of Age disaggregates | 155,799 | | Redacted |
| C2.1.D_NGI | By Sex: Female | 109,059 | | Redacted |
| C2.1.D_NGI | By Sex: Male | 46,740 | | Redacted |
| C2.1.D_NGI | Sum of Sex disaggregates | 155,799 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive patients who were screened for TB in HIV care or treatment setting | 140,219 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 155,799 | | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 2,185 | 2,455 | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period | 0 | 0 | Redacted |
| TB_ART_DSD | Age: 0-4 | 22 | 25 | Redacted |
| TB_ART_DSD | Age: 5-14 | 109 | 123 | Redacted |
| TB_ART_DSD | Age: 15+ | 2,054 | 2,307 | Redacted |
| TB_ART_DSD | Male | 1,071 | 1,203 | Redacted |
| TB_ART_DSD | Female | 1,114 | 1,252 | Redacted |

| | | | | |
|---------------|--|---------|---------|----------|
| TB_ART_DSD | Sum of Sex disaggregates | 2,185 | 2,455 | Redacted |
| TB_ART_DSD | Newly tested | 1,245 | 1,399 | Redacted |
| TB_ART_DSD | Known HIV-positive | 940 | 1,056 | Redacted |
| TB_ART_DSD | Sum of Test Status disaggregates | 2,185 | 2,455 | Redacted |
| TB_ART_DSD | Aggregated Age: <15 | 131 | 147 | Redacted |
| TB_ART_DSD | Aggregated Age: 15+ | 2,054 | 2,308 | Redacted |
| TB_ART_DSD | Sum of Aggregated Age disaggregates | 2,185 | 2,455 | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period | 12,057 | 12,848 | Redacted |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 13,701 | 14,119 | Redacted |
| PMTCT_EID_DSD | By infants who received a virologic test within 2 months of birth | 3,979 | 4,240 | Redacted |
| PMTCT_EID_DSD | By infants who received their first virologic HIV test between 2 and 12 months of age | 8,078 | 8,608 | Redacted |
| PMTCT_EID_DSD | Sum of Infant Age disaggregates | 12,057 | 12,848 | Redacted |
| PMTCT_EID_DSD | By infants with a positive virologic test result within 12 months of birth | 603 | 642 | Redacted |
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 103,866 | 104,833 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Male | 205 | 207 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Male | 968 | 977 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Male | 1,760 | 1,777 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Male | 32,449 | 32,751 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Female | 182 | 184 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Female | 859 | 867 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Female | 1,562 | 1,576 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Female | 65,881 | 66,494 | Redacted |
| TX_CURR_DSD | Sum of age/sex disaggregates | 5,536 | 5,588 | Redacted |

| | | | | |
|-------------|--|---------|---------|----------|
| TX_CURR_DSD | Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 5 | 5 | Redacted |
| TX_CURR_DSD | Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 66 | 66 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Male | 205 | 207 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Female | 182 | 184 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male | 2,934 | 2,961 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 32,449 | 32,751 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female | 2,602 | 2,626 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Female | 65,881 | 66,495 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 5,536 | 5,587 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex 15+ | 98,330 | 99,246 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates | 103,866 | 104,833 | Redacted |
| TX_CURR_NGI | Number of adults and children receiving antiretroviral therapy (ART) | 103,866 | 104,833 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Male | 205 | 207 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Male | 968 | 977 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Male | 1,760 | 1,777 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Male | 32,449 | 32,751 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Female | 182 | 184 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Female | 859 | 867 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Female | 1,561 | 1,576 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Female | 65,882 | 66,494 | Redacted |
| TX_CURR_NGI | Sum of Age/Sex disaggregates | 103,866 | 104,833 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Male | 205 | 207 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Female | 182 | 184 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Male | 2,934 | 2,961 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Male | 32,449 | 32,751 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Female | 2,602 | 2,626 | Redacted |

| | | | | |
|-------------|--|---------|---------|----------|
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Female | 65,881 | 66,495 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex disaggregates | 103,866 | 104,833 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex <15 | 5,536 | 5,587 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex 15+ | 98,330 | 99,246 | Redacted |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 33,581 | 42,472 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Male | 133 | 168 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Male | 190 | 240 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Male | 237 | 300 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Male | 389 | 492 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Male | 1,478 | 1,870 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Male | 2,464 | 3,116 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Male | 3,942 | 4,986 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Male | 1,971 | 2,493 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Female | 126 | 160 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Female | 168 | 213 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Female | 210 | 266 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Female | 337 | 426 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Female | 3,290 | 4,162 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Female | 5,484 | 6,936 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Female | 8,775 | 11,095 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Female | 4,387 | 5,549 | Redacted |
| TX_NEW_DSD | Sum of Age/Sex disaggregates | 33,581 | 42,472 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male | 133 | 168 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male | 949 | 1,200 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 9,855 | 12,464 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female | 126 | 160 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female | 841 | 1,064 | Redacted |

| | | | | |
|------------|---|--------|--------|----------|
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 21,936 | 27,744 | Redacted |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 33,581 | 42,472 | Redacted |
| TX_NEW_DSD | Pregnancy status | 1,755 | 2,219 | Redacted |
| TX_NEW_DSD | Breastfeeding status | 0 | 0 | Redacted |
| TX_RET_DSD | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 15,686 | 28,544 | Redacted |
| TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 18,454 | 33,581 | Redacted |
| TX_RET_DSD | Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 314 | 571 | Redacted |
| TX_RET_DSD | Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 627 | 1,142 | Redacted |
| TX_RET_DSD | Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 14,745 | 26,831 | Redacted |
| TX_RET_DSD | Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 369 | 672 | Redacted |
| TX_RET_DSD | Age: 5-14 (Denominator: Total number | 738 | 1,343 | Redacted |

| | | | | |
|------------|--|--------|--------|----------|
| | of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | | | |
| TX_RET_DSD | Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 17,347 | 31,566 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 941 | 1,713 | Redacted |
| TX_RET_DSD | Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 14,745 | 26,831 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 1,107 | 2,015 | Redacted |
| TX_RET_DSD | Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 17,347 | 31,566 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status | 737 | 1,342 | Redacted |

| | | | | |
|-------------|---|-----|-----|----------|
| | (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | | | |
| TX_RET_DSD | Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 0 | 0 | Redacted |
| LAB_ACC_DSD | Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation | 2 | 2 | Redacted |
| LAB_ACC_DSD | By site support type: Direct Service Delivery (DSD) | 2 | 2 | Redacted |
| LAB_ACC_DSD | Sum of Support Type disaggregates | 2 | 2 | Redacted |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 111 | 111 | Redacted |
| LAB_CAP_DSD | By clinical laboratories | 111 | 111 | Redacted |
| LAB_CAP_DSD | By Point-of-care testing sites | 0 | | Redacted |
| LAB_CAP_DSD | By site support type: Direct Service Delivery (DSD) | 111 | 111 | Redacted |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates | 111 | 111 | Redacted |

Implementing Mechanism Details

| | |
|----------------------------|--|
| Mechanism ID: 16854 | Mechanism Name: Engaging Indigenous Organisation to Sustain and Enhance Comprehensive Clinical Services |
|----------------------------|--|



| | |
|--|---|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Center for Clinical Care and Clinical Research Ltd | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| Total All Funding Sources: 9,203,866 | Total Mechanism Pipeline: Redacted |
|---|---|
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 9,203,866 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|-------------------------|---|
| Gender: Gender Equality | 77,265 |
| Focus Area: | Promoting gender-related policies and laws that increase legal protection |
| Sub Area: | Capacity building |
| Focus Area: | Equity in HIV prevention, care, treatment and support |
| Sub Area: | Monitoring and Evaluation |
| Gender: GBV | 38,632 |
| Focus Area: | GBV Prevention |
| Sub Area: | Capacity building |
| Focus Area: | Post GBV Care |
| Sub Area: | Monitoring and Evaluation |



Key Issues

Malaria (PMI)

TB

Family Planning

Budget Code Information

| Mechanism ID: | 16854 | | |
|----------------------------|---|----------------|----------------|
| Mechanism Name: | Engaging Indigenous Organisation to Sustain and Enhance | | |
| Prime Partner Name: | Comprehensive Clinical Services | | |
| | Center for Clinical Care and Clinical Research Ltd | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 1,024,789 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 772,650 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 484,066 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 68,346 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 1,354,999 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 135,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMBL | 30,284 | 0 |



| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|----------------|-------------|----------------|----------------|
| Prevention | HMIN | 49,602 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVAB | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 766,207 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 221,139 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 1,185,989 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 2,916,614 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 194,181 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|-------------------|--|-------|-------|-------------------------|
| PMTCT_ARV_DS D | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 3,001 | 3,031 | Redacted |
| PMTCT_ARV_DS D | Number of HIV- positive pregnant women identified in the reporting period | 3,410 | 3,298 | Redacted |

| | | | | |
|-------------------|--|-------|-------|----------|
| | (including known HIV-positive at entry) | | | |
| PMTCT_ARV_DS D | Life-long ART (including Option B+) | 1,651 | 1,651 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 627 | 559 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 1,023 | 1,091 | Redacted |
| PMTCT_ARV_DS D | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 1,170 | 1,200 | Redacted |
| PMTCT_ARV_DS D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 150 | 150 | Redacted |
| PMTCT_ARV_DS D | Single-dose nevirapine (with or without tail) | 30 | 30 | Redacted |
| PMTCT_ARV_DS D | Sum of Regimen Type disaggregates | 3,001 | 3,031 | Redacted |
| PMTCT_ARV_DS D | Sum of New and Current disaggregates | 1,650 | 1,650 | Redacted |
| PMTCT_ARV_NGI | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 3,001 | 3,001 | Redacted |
| PMTCT_ARV_NGI | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 3,410 | 3,410 | Redacted |
| PMTCT_ARV_NGI | Life-long ART (including Option B+) | 1,651 | 1,651 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 628 | 628 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Already on treatment at the beginning of the | 1,023 | 1,023 | Redacted |

| | | | | |
|--------------------|--|---------|---------|----------|
| | current pregnancy | | | |
| PMTCT_ARV_NGI | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 1,170 | 1,170 | Redacted |
| PMTCT_ARV_NGI | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 150 | 150 | Redacted |
| PMTCT_ARV_NGI | Single-dose nevirapine (with or without tail) | 30 | 30 | Redacted |
| PMTCT_ARV_NGI | Sum of Regimen disaggregates | 3,001 | 3,001 | Redacted |
| PMTCT_ARV_NGI | Sum of New and Current disaggregates | 1,651 | 1,651 | Redacted |
| PMTCT_STAT_DS D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 183,567 | 183,567 | Redacted |
| PMTCT_STAT_DS D | Number of new ANC and L&D clients | 201,722 | 201,722 | Redacted |
| PMTCT_STAT_DS D | By: Known positives at entry | 1,364 | 1,364 | Redacted |
| PMTCT_STAT_DS D | By: Number of new positives identified | 2,046 | 2,046 | Redacted |
| PMTCT_STAT_DS D | Sum of Positives Status disaggregates | 3,410 | 3,410 | Redacted |
| PMTCT_STAT_NG I | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 183,567 | 183,567 | Redacted |
| PMTCT_STAT_NG I | Number of new ANC and L&D clients | 201,722 | 201,722 | Redacted |
| PMTCT_STAT_NG I | By: Known positives at entry | 1,364 | 1,364 | Redacted |
| PMTCT_STAT_NG I | By: Number of new positives identified | 2,046 | 2,046 | Redacted |
| PMTCT_STAT_NG | Sum of Positives Status disaggregates | 3,410 | 3,410 | Redacted |

| | | | | |
|-------------|---|-------|--------|----------|
| I | | | | |
| BS_COLL | Number of whole blood collections each year by the NBTS network | 7,000 | 7,000 | Redacted |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network laboratory | 6,300 | 6,300 | Redacted |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV | 140 | 140 | Redacted |
| PP_PREV_DSD | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 2,370 | 22,304 | Redacted |
| PP_PREV_DSD | Total number of people in the target population | 5,500 | 81,032 | Redacted |
| PP_PREV_DSD | Age/sex: 10-14 Male | 116 | 1,093 | Redacted |
| PP_PREV_DSD | Age/sex: 15-19 Male | 139 | 1,311 | Redacted |
| PP_PREV_DSD | Age/sex: 20-24 Male | 348 | 3,279 | Redacted |
| PP_PREV_DSD | Age/sex: 25-49 Male | 523 | 4,918 | Redacted |
| PP_PREV_DSD | Age/sex: 50+ Male | 35 | 328 | Redacted |
| PP_PREV_DSD | Age/sex: 10-14 Female | 121 | 1,137 | Redacted |
| PP_PREV_DSD | Age/sex: 15-19 Female | 145 | 1,365 | Redacted |
| PP_PREV_DSD | Age/sex: 20-24 Female | 363 | 3,413 | Redacted |
| PP_PREV_DSD | Age/sex: 25-49 Female | 544 | 5,119 | Redacted |
| PP_PREV_DSD | Age/sex: 50+ Female | 36 | 341 | Redacted |
| PP_PREV_DSD | Sum of Age/Sex disaggregates | 2,370 | 22,304 | Redacted |
| KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 2,285 | | Redacted |
| KP_PREV_DSD | By key population type: Female sex | 2,125 | | Redacted |

| | | | | |
|-------------|---|-----|--|----------|
| | workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | | | |
| KP_PREV_DSD | By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 46 | | Redacted |
| KP_PREV_DSD | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 37 | | Redacted |
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 114 | | Redacted |
| KP_PREV_DSD | By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum | 11 | | Redacted |

| | | | | |
|-------------|---|---------|---------|----------|
| | standards required) | | | |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 490,306 | 491,732 | Redacted |
| HTC_TST_DSD | By Test Result: Negative | 478,861 | 480,559 | Redacted |
| HTC_TST_DSD | By Test Result: Positive | 11,445 | 11,173 | Redacted |
| HTC_TST_DSD | Sum of Test Result disaggregates | 490,306 | 491,732 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Male | 8 | 1,470 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Male | 1,504 | 1,496 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Male | 609 | 606 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Male | 1,361 | 1,354 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Male | 15,094 | 15,014 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Male | 31,236 | 31,079 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Male | 98,153 | 97,637 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Male | 3,044 | 3,028 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Female | 8 | 1,531 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Female | 1,576 | 1,567 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Female | 627 | 623 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Female | 1,396 | 1,389 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Female | 33,940 | 33,863 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Female | 96,277 | 96,131 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Female | 202,340 | 201,827 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Female | 3,133 | 3,117 | Redacted |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 490,306 | 491,732 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 3,482 | 4,926 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 147,526 | 146,758 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 3,607 | 5,110 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 335,691 | 334,938 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 7,089 | 10,036 | Redacted |

| | | | | |
|-------------|---|---------|---------|----------|
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 483,217 | 481,696 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 490,306 | 491,732 | Redacted |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 490,306 | 491,732 | Redacted |
| HTC_TST_NGI | By Test Result: Negative | 478,861 | 480,559 | Redacted |
| HTC_TST_NGI | By Test Result: Positive | 11,445 | 11,173 | Redacted |
| HTC_TST_NGI | Sum of Test Result disaggregates | 490,306 | 491,732 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Male | 8 | 1,470 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Male | 1,504 | 1,496 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Male | 609 | 606 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Male | 1,361 | 1,354 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Male | 15,094 | 15,014 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Male | 31,236 | 31,079 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Male | 98,153 | 97,637 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Male | 3,044 | 3,028 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Female | 8 | 1,531 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Female | 1,576 | 1,567 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Female | 627 | 623 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Female | 1,396 | 1,389 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Female | 33,940 | 33,863 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Female | 96,277 | 96,131 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Female | 202,340 | 201,827 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Female | 3,133 | 3,117 | Redacted |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 490,306 | 491,732 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 3,482 | 4,926 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 147,526 | 146,758 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 3,607 | 5,110 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 335,691 | 334,938 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 7,089 | 10,036 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 483,217 | 481,696 | Redacted |

| | | | | |
|-------------------|---|---------|---------|----------|
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 490,306 | 491,732 | Redacted |
| GEND_GBV_DSD | Number of people receiving post-GBV care | 74 | 74 | Redacted |
| GEND_GBV_DSD | Age: 0-9 | 9 | 9 | Redacted |
| GEND_GBV_DSD | Age: 10-14 | 17 | 17 | Redacted |
| GEND_GBV_DSD | Age: 15-17 | 26 | 26 | Redacted |
| GEND_GBV_DSD | Age: 18-24 | 15 | 15 | Redacted |
| GEND_GBV_DSD | Age: 25+ | 7 | 7 | Redacted |
| GEND_GBV_DSD | Sum of Age disaggregates | 74 | 74 | Redacted |
| GEND_GBV_DSD | Sex: Male | 25 | 25 | Redacted |
| GEND_GBV_DSD | Sex: Female | 49 | 49 | Redacted |
| GEND_GBV_DSD | Sum of Sex disaggregates | 74 | 74 | Redacted |
| GEND_GBV_DSD | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) | 17 | 17 | Redacted |
| GEND_GBV_DSD | By type of service: Sexual Violence (Post-Rape Care) | 57 | 57 | Redacted |
| GEND_GBV_DSD | By PEP service provision (related to sexual violence services provided) | 57 | 57 | Redacted |
| GEND_NORM_DS D | Number of people completing an intervention pertaining to gender norms, that meets minimum criteria | 2,066 | 2,066 | Redacted |
| GEND_NORM_DS D | By Age: 0-9 | 103 | 103 | Redacted |
| GEND_NORM_DS D | By Age: 10-14 | 103 | 103 | Redacted |
| GEND_NORM_DS D | By Age: 15-19 | 248 | 248 | Redacted |
| GEND_NORM_DS D | By Age: 20-24 | 620 | 620 | Redacted |
| GEND_NORM_DS D | By Age: 25+ | 992 | 992 | Redacted |
| GEND_NORM_DS | Sum of Age disaggregates | 2,066 | 2,066 | Redacted |

| | | | | |
|-------------------|---|--------|--------|----------|
| D | | | | |
| GEND_NORM_DS D | By Sex: Male | 1,012 | 1,012 | Redacted |
| GEND_NORM_DS D | By Sex: Female | 1,054 | 1,054 | Redacted |
| GEND_NORM_DS D | Sum of Sex disaggregates | 2,066 | 2,066 | Redacted |
| GEND_NORM_DS D | By type of activity: Individual | 207 | 207 | Redacted |
| GEND_NORM_DS D | By type of activity: Small Group | 413 | 413 | Redacted |
| GEND_NORM_DS D | By type of activity: Community-level | 1,446 | 1,446 | Redacted |
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 7,993 | 7,993 | Redacted |
| OVC_ACC_DSD | Sex: Male | 3,917 | 3,917 | Redacted |
| OVC_ACC_DSD | Sex: Female | 4,076 | 4,076 | Redacted |
| OVC_ACC_DSD | Sum of Sex disaggregates | 7,993 | 7,993 | Redacted |
| OVC_ACC_DSD | Age: <1 | 480 | 480 | Redacted |
| OVC_ACC_DSD | Age: 1-4 | 1,998 | 1,998 | Redacted |
| OVC_ACC_DSD | Age: 5-9 | 2,238 | 2,238 | Redacted |
| OVC_ACC_DSD | Age: 10-14 | 1,918 | 1,918 | Redacted |
| OVC_ACC_DSD | Age: 15-17 | 1,119 | 1,119 | Redacted |
| OVC_ACC_DSD | Age: 18+ | 240 | 240 | Redacted |
| OVC_ACC_DSD | Sum of Age disaggregates | 7,993 | 7,993 | Redacted |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 26,643 | 26,643 | Redacted |
| OVC_SERV_DSD | Sex: Male | 13,055 | 13,055 | Redacted |
| OVC_SERV_DSD | Sex: Female | 13,588 | 13,588 | Redacted |
| OVC_SERV_DSD | Sum of Sex disaggregates | 26,643 | 26,643 | Redacted |
| OVC_SERV_DSD | Age: <1 | 1,599 | 1,599 | Redacted |

| | | | | |
|-------------------|---|--------|--------|----------|
| OVC_SERV_DSD | Age: 1-4 | 6,660 | 6,660 | Redacted |
| OVC_SERV_DSD | Age: 5-9 | 7,460 | 7,460 | Redacted |
| OVC_SERV_DSD | Age: 10-14 | 6,128 | 6,128 | Redacted |
| OVC_SERV_DSD | Age: 15-17 | 3,730 | 3,730 | Redacted |
| OVC_SERV_DSD | Age: 18+ | 1,066 | 1,066 | Redacted |
| OVC_SERV_DSD | Sum of Age disaggregates | 26,643 | 26,643 | Redacted |
| C2.1.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 36,069 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Female | 1,262 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Male | 541 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Female | 23,986 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Male | 10,280 | | Redacted |
| C2.1.D_DSD | Sum of Age/Sex disaggregates | 36,069 | | Redacted |
| C2.1.D_DSD | By Age: <15 | 1,803 | | Redacted |
| C2.1.D_DSD | By Age: 15+ | 34,266 | | Redacted |
| C2.1.D_DSD | Sum of Age disaggregates | 36,069 | | Redacted |
| C2.1.D_DSD | By Sex: Female | 25,248 | | Redacted |
| C2.1.D_DSD | By Sex: Male | 10,821 | | Redacted |
| C2.1.D_DSD | Sum of Sex disaggregates | 36,069 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive patients who were screened for TB in HIV care or treatment setting | 23,706 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 36,069 | | Redacted |
| CARE_CURR_DS D | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 37,873 | 37,873 | Redacted |
| CARE_CURR_DS D | Age/sex: <1 Male | 61 | 61 | Redacted |



| | | | | |
|-------------------|---|--------|--------|----------|
| CARE_CURR_DS D | Age/sex: 1-4 Male | 121 | 121 | Redacted |
| CARE_CURR_DS D | Age/sex: 5-9 Male | 182 | 182 | Redacted |
| CARE_CURR_DS D | Age/sex: 10-14 Male | 242 | 242 | Redacted |
| CARE_CURR_DS D | Age/sex: 15-19 Male | 1,076 | 1,076 | Redacted |
| CARE_CURR_DS D | Age/sex: 20-24 Male | 3,765 | 3,765 | Redacted |
| CARE_CURR_DS D | Age/sex: 25-49 Male | 4,302 | 4,302 | Redacted |
| CARE_CURR_DS D | Age/sex: 50+ Male | 1,613 | 1,613 | Redacted |
| CARE_CURR_DS D | Age/sex: <1 Female | 141 | 141 | Redacted |
| CARE_CURR_DS D | Age/sex: 1-4 Female | 283 | 283 | Redacted |
| CARE_CURR_DS D | Age/sex: 5-9 Female | 424 | 424 | Redacted |
| CARE_CURR_DS D | Age/sex: 10-14 Female | 565 | 565 | Redacted |
| CARE_CURR_DS D | Age/sex: 15-19 Female | 2,510 | 2,510 | Redacted |
| CARE_CURR_DS D | Age/sex: 20-24 Female | 8,784 | 8,784 | Redacted |
| CARE_CURR_DS D | Age/sex: 25-49 Female | 10,039 | 10,039 | Redacted |
| CARE_CURR_DS D | Age/sex: 50+ Female | 3,765 | 3,765 | Redacted |
| CARE_CURR_DS D | Sun of Age/Sex disaggregates | 37,873 | 37,873 | Redacted |
| CARE_CURR_DS D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 606 | 606 | Redacted |

| | | | | |
|-------------------|--|--------|--------|----------|
| CARE_CURR_DS D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 10,756 | 10,756 | Redacted |
| CARE_CURR_DS D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 1,413 | 1,413 | Redacted |
| CARE_CURR_DS D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 25,098 | 25,098 | Redacted |
| CARE_CURR_DS D | Sum of Aggregated Age/Sex disaggregates | 37,873 | 37,873 | Redacted |
| CARE_NEW_DSD | Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load | 3,752 | 3,752 | Redacted |
| CARE_NEW_DSD | Age/sex: <1 Male | 6 | 6 | Redacted |
| CARE_NEW_DSD | Age/sex: 1-4 Male | 12 | 12 | Redacted |
| CARE_NEW_DSD | Age/sex: 5-9 Male | 18 | 18 | Redacted |
| CARE_NEW_DSD | Age/sex: 10-14 Male | 24 | 24 | Redacted |
| CARE_NEW_DSD | Age/sex: 15-19 Male | 107 | 107 | Redacted |
| CARE_NEW_DSD | Age/sex: 20-24 Male | 373 | 373 | Redacted |
| CARE_NEW_DSD | Age/sex: 25-49 Male | 426 | 426 | Redacted |
| CARE_NEW_DSD | Age/sex: 50+ Male | 160 | 160 | Redacted |
| CARE_NEW_DSD | Age/sex: <1 Female | 14 | 14 | Redacted |
| CARE_NEW_DSD | Age/sex: 1-4 Female | 28 | 28 | Redacted |
| CARE_NEW_DSD | Age/sex: 5-9 Female | 42 | 42 | Redacted |
| CARE_NEW_DSD | Age/sex: 10-14 Female | 56 | 56 | Redacted |
| CARE_NEW_DSD | Age/sex: 15-19 Female | 249 | 249 | Redacted |
| CARE_NEW_DSD | Age/sex: 20-24 Female | 870 | 870 | Redacted |
| CARE_NEW_DSD | Age/sex: 25-49 Female | 994 | 994 | Redacted |
| CARE_NEW_DSD | Age/sex: 50+ Female | 373 | 373 | Redacted |
| CARE_NEW_DSD | Sum of Age/sex disaggregates | 3,752 | 3,752 | Redacted |
| CARE_NEW_DSD | Aggregated Age/sex: <15 Male | 60 | 60 | Redacted |
| CARE_NEW_DSD | Aggregated Age/sex: 15+ Male | 1,065 | 1,065 | Redacted |

| | | | | |
|---------------|--|-------|-------|----------|
| CARE_NEW_DSD | Aggregated Age/sex: <15 Female | 141 | 141 | Redacted |
| CARE_NEW_DSD | Aggregated Age/sex: 15+ Female | 2,486 | 2,486 | Redacted |
| CARE_NEW_DSD | Sum of Aggregated Age/sex disaggregates | 3,752 | 3,752 | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 575 | 690 | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period | 676 | 812 | Redacted |
| TB_ART_DSD | Age: 0-4 | 6 | 7 | Redacted |
| TB_ART_DSD | Age: 5-14 | 29 | 35 | Redacted |
| TB_ART_DSD | Age: 15+ | 540 | 648 | Redacted |
| TB_ART_DSD | Male | 282 | 338 | Redacted |
| TB_ART_DSD | Female | 293 | 352 | Redacted |
| TB_ART_DSD | Sum of Sex disaggregates | 575 | 690 | Redacted |
| TB_ART_DSD | Newly tested | 328 | 393 | Redacted |
| TB_ART_DSD | Known HIV-positive | 247 | 297 | Redacted |
| TB_ART_DSD | Sum of Test Status disaggregates | 575 | 690 | Redacted |
| TB_ART_DSD | Aggregated Age: <15 | 35 | 41 | Redacted |
| TB_ART_DSD | Aggregated Age: 15+ | 540 | 649 | Redacted |
| TB_ART_DSD | Sum of Aggregated Age disaggregates | 575 | 690 | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period | 3,001 | 3,001 | Redacted |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 3,410 | 3,298 | Redacted |
| PMTCT_EID_DSD | By infants who received a virologic test within 2 months of birth | 990 | 990 | Redacted |

| | | | | |
|---------------|--|--------|--------|----------|
| PMTCT_EID_DSD | By infants who received their first virologic HIV test between 2 and 12 months of age | 2,011 | 2,011 | Redacted |
| PMTCT_EID_DSD | Sum of Infant Age disaggregates | 3,001 | 3,001 | Redacted |
| PMTCT_EID_DSD | By infants with a positive virologic test result within 12 months of birth | 150 | 150 | Redacted |
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 10,047 | 25,837 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Male | 72 | 72 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Male | 338 | 338 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Male | 615 | 615 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Male | 2,677 | 7,888 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Female | 64 | 64 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Female | 300 | 300 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Female | 545 | 545 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Female | 5,436 | 16,015 | Redacted |
| TX_CURR_DSD | Sum of age/sex disaggregates | 1,934 | 1,934 | Redacted |
| TX_CURR_DSD | Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 19 | 7 | Redacted |
| TX_CURR_DSD | Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 63 | 66 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Male | 72 | 72 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Female | 64 | 64 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male | 1,025 | 1,025 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 2,677 | 7,888 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female | 909 | 909 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Female | 5,436 | 16,015 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 1,934 | 1,934 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex 15+ | 8,113 | 23,903 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex | 10,047 | 25,837 | Redacted |

| | | | | |
|-------------|--|--------|--------|----------|
| | disaggregates | | | |
| TX_CURR_NGI | Number of adults and children receiving antiretroviral therapy (ART) | 10,047 | 25,837 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Male | 72 | 72 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Male | 338 | 338 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Male | 615 | 615 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Male | 2,677 | 7,888 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Female | 64 | 64 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Female | 300 | 300 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Female | 545 | 545 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Female | 5,436 | 16,015 | Redacted |
| TX_CURR_NGI | Sum of Age/Sex disaggregates | 10,047 | 25,837 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Male | 72 | 72 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Female | 64 | 64 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Male | 1,025 | 1,025 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Male | 2,677 | 7,888 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Female | 909 | 909 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Female | 5,436 | 16,015 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex disaggregates | 10,047 | 25,837 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex <15 | 1,934 | 1,934 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex 15+ | 8,113 | 23,903 | Redacted |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 7,763 | 6,398 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Male | 31 | 36 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Male | 44 | 51 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Male | 55 | 63 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Male | 90 | 104 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Male | 342 | 275 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Male | 570 | 459 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Male | 911 | 734 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Male | 456 | 367 | Redacted |

| | | | | |
|------------|---|--------|--------|----------|
| TX_NEW_DSD | By Age/Sex: <1 Female | 29 | 34 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Female | 39 | 45 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Female | 49 | 56 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Female | 78 | 90 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Female | 761 | 613 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Female | 1,268 | 1,021 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Female | 2,028 | 1,634 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Female | 1,014 | 817 | Redacted |
| TX_NEW_DSD | Sum of Age/Sex disaggregates | 7,765 | 6,399 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male | 31 | 36 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male | 219 | 254 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 2,278 | 1,835 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female | 29 | 34 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female | 195 | 225 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 5,071 | 4,084 | Redacted |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 7,763 | 6,398 | Redacted |
| TX_NEW_DSD | Pregnancy status | 406 | 327 | Redacted |
| TX_NEW_DSD | Breastfeeding status | 0 | 0 | Redacted |
| TX_RET_DSD | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 16,584 | 17,412 | Redacted |
| TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 19,510 | 20,485 | Redacted |
| TX_RET_DSD | Age: 0-4 (Numerator: Number of adults | 332 | 348 | Redacted |

| | | | | |
|------------|--|--------|--------|----------|
| | and children who are still alive and on treatment at 12 months after initiating ART) | | | |
| TX_RET_DSD | Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 498 | 522 | Redacted |
| TX_RET_DSD | Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 15,754 | 16,542 | Redacted |
| TX_RET_DSD | Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 390 | 410 | Redacted |
| TX_RET_DSD | Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 585 | 615 | Redacted |
| TX_RET_DSD | Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 18,535 | 19,461 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 829 | 871 | Redacted |

| | | | | |
|-------------|---|--------|--------|----------|
| TX_RET_DSD | Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 15,754 | 16,542 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 976 | 1,024 | Redacted |
| TX_RET_DSD | Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 18,535 | 19,461 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 7,794 | 8,184 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 917 | 963 | Redacted |
| LAB_ACC_DSD | Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such | 37 | 37 | Redacted |



| | | | | |
|---------------|--|--------|--------|----------|
| | accreditation | | | |
| LAB_ACC_DSD | By site support type: Direct Service Delivery (DSD) | 37 | 37 | Redacted |
| LAB_ACC_DSD | Sum of Support Type disaggregates | 37 | 37 | Redacted |
| QI_SITE | Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months | 32 | 32 | Redacted |
| QI_SITE | Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC | 62 | 62 | Redacted |
| TB_SCREEN_DSD | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period | 23,706 | 25,551 | Redacted |
| TB_SCREEN_DSD | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 37,873 | 37,873 | Redacted |
| TB_SCREEN_DSD | Age: <1 | 474 | 511 | Redacted |
| TB_SCREEN_DSD | Age: 1-4 | 237 | 256 | Redacted |
| TB_SCREEN_DSD | Age: 5-9 | 474 | 511 | Redacted |
| TB_SCREEN_DSD | Age: 10-14 | 237 | 256 | Redacted |
| TB_SCREEN_DSD | Age: 15-19 | 2,371 | 2,555 | Redacted |
| TB_SCREEN_DSD | Age: 20-24 | 5,927 | 6,388 | Redacted |
| TB_SCREEN_DSD | Age: 25-49 | 13,038 | 14,053 | Redacted |
| TB_SCREEN_DSD | Age: 50+ | 948 | 1,022 | Redacted |
| TB_SCREEN_DSD | Sum of Age disaggregates | 3,793 | 4,089 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 | 1,422 | 1,533 | Redacted |



| | | | | |
|---------------|--|--------|--------|----------|
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ | 22,284 | 24,018 | Redacted |
| TB_SCREEN_DSD | Sum of Aggregated Age disaggregates | 23,706 | 25,551 | Redacted |
| TB_SCREEN_DSD | Sex: Male | 7,112 | 7,665 | Redacted |
| TB_SCREEN_DSD | Sex: Female | 16,594 | 17,886 | Redacted |
| TB_SCREEN_DSD | Sum of Sex disaggregates | 23,706 | 25,551 | Redacted |

Implementing Mechanism Details

| | |
|--|---|
| Mechanism ID: 16853 | Mechanism Name: Strengthening Human Resources For Health(HRH) for the Provision of HIV/AIDS Services Through In-service Training |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Center for Clinical Care and Clinical Research Ltd | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 400,000 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 400,000 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|--------------------|--------|
| Condom programming | 68,547 |
|--------------------|--------|

Key Issues



(No data provided.)

Budget Code Information

| Mechanism ID: | 16853 | | |
|----------------------------|---|-----------------------|-----------------------|
| Mechanism Name: | Strengthening Human Resources For Health(HRH) for the Provision of HIV/AIDS Services Through In-service Training | | |
| Prime Partner Name: | Center for Clinical Care and Clinical Research Ltd | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 400,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| Mechanism ID: 16852 | Mechanism Name: Development of a Laboratory Network and Society to Implement a Quality Systems |
|---|---|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: African Society for Laboratory Medicine | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 350,000 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 350,000 |

**Sub Partner Name(s)**

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

| Mechanism ID: | 16852 | | |
|----------------------------|--|----------------|----------------|
| Mechanism Name: | Development of a Laboratory Network and Society to Implement a | | |
| Prime Partner Name: | Quality Systems | | |
| | African Society for Laboratory Medicine | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 350,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|--|---|
| Mechanism ID: 16850 | Mechanism Name: Engaging Indigenous Organisation to Sustain and Enhance Comprehensive Clinical Service |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: AIDS Prevention Initiative in Nigeria, LTD | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |

Approved



| | |
|--|---|
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 20,431,131 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 20,431,131 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|---------------------------|---------------------------|
| Gender: GBV | 300,000 |
| Focus Area: | GBV Prevention |
| Sub Area: | Capacity building |
| Focus Area: | Post GBV Care |
| Sub Area: | Monitoring and Evaluation |
| Motor Vehicles: Purchased | 230,833 |
| Condom programming | 542,989 |

Key Issues

TB

Family Planning

Budget Code Information

| | |
|----------------------------|--|
| Mechanism ID: | 16850 |
| Mechanism Name: | Engaging Indigenous Organisation to Sustain and Enhance |
| Prime Partner Name: | Comprehensive Clinical Service |



| AIDS Prevention Initiative in Nigeria, LTD | | | |
|--|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 2,787,363 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 1,418,109 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 688,243 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 167,346 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 2,166,910 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 90,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMBL | 34,502 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMIN | 119,874 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVAB | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 1,244,288 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |



| | | | |
|-----------------------|--------------------|-----------------------|-----------------------|
| Prevention | HVOP | 1,467,827 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 1,783,006 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 7,981,012 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 482,651 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|-------------------|--|-------|-------|-------------------------|
| PMTCT_ARV_DS D | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 5,199 | 5,308 | Redacted |
| PMTCT_ARV_DS D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 5,908 | 5,833 | Redacted |
| PMTCT_ARV_DS D | Life-long ART (including Option B+) | 2,859 | 2,919 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 1,087 | 989 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 1,772 | 1,930 | Redacted |
| PMTCT_ARV_DS D | Maternal triple ARV prophylaxis (provided with the intention to stop at | 2,028 | 2,123 | Redacted |

| | | | | |
|-------------------|--|-------|-------|----------|
| | the end of the breastfeeding period) | | | |
| PMTCT_ARV_DS D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 260 | 265 | Redacted |
| PMTCT_ARV_DS D | Single-dose nevirapine (with or without tail) | 52 | 53 | Redacted |
| PMTCT_ARV_DS D | Sum of Regimen Type disaggregates | 5,199 | 5,360 | Redacted |
| PMTCT_ARV_DS D | Sum of New and Current disaggregates | 2,859 | 2,919 | Redacted |
| PMTCT_ARV_NGI | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 5,199 | 5,308 | Redacted |
| PMTCT_ARV_NGI | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 5,908 | 5,833 | Redacted |
| PMTCT_ARV_NGI | Life-long ART (including Option B+) | 2,859 | 2,919 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 1,087 | 989 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 1,772 | 1,933 | Redacted |
| PMTCT_ARV_NGI | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 2,028 | 2,123 | Redacted |
| PMTCT_ARV_NGI | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 260 | 265 | Redacted |
| PMTCT_ARV_NGI | Single-dose nevirapine (with or without tail) | 52 | | Redacted |
| PMTCT_ARV_NGI | Sum of Regimen disaggregates | 5,199 | 5,307 | Redacted |

| | | | | |
|--------------------|--|---------|---------|----------|
| PMTCT_ARV_NGI | Sum of New and Current disaggregates | 2,859 | 2,922 | Redacted |
| PMTCT_STAT_DS D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 182,244 | 186,539 | Redacted |
| PMTCT_STAT_DS D | Number of new ANC and L&D clients | 200,268 | 204,988 | Redacted |
| PMTCT_STAT_DS D | By: Known positives at entry | 2,363 | 2,333 | Redacted |
| PMTCT_STAT_DS D | By: Number of new positives identified | 3,545 | 3,500 | Redacted |
| PMTCT_STAT_DS D | Sum of Positives Status disaggregates | 5,908 | 5,833 | Redacted |
| PMTCT_STAT_NG I | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 182,244 | 186,539 | Redacted |
| PMTCT_STAT_NG I | Number of new ANC and L&D clients | 200,268 | 204,988 | Redacted |
| PMTCT_STAT_NG I | By: Known positives at entry | 2,363 | 2,333 | Redacted |
| PMTCT_STAT_NG I | By: Number of new positives identified | 3,545 | 3,500 | Redacted |
| PMTCT_STAT_NG I | Sum of Positives Status disaggregates | 5,908 | 5,833 | Redacted |
| BS_COLL | Number of whole blood collections each year by the NBTS network | 26,000 | 26,000 | Redacted |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network laboratory | 23,400 | 23,400 | Redacted |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV | 520 | 520 | Redacted |

| | | | | |
|-------------|---|--------|---------|----------|
| PP_PREV_DSD | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 5,255 | 49,027 | Redacted |
| PP_PREV_DSD | Total number of people in the target population | 12,196 | 178,119 | Redacted |
| PP_PREV_DSD | Age/sex: 10-14 Male | 257 | 2,402 | Redacted |
| PP_PREV_DSD | Age/sex: 15-19 Male | 309 | 2,883 | Redacted |
| PP_PREV_DSD | Age/sex: 20-24 Male | 773 | 7,207 | Redacted |
| PP_PREV_DSD | Age/sex: 25-49 Male | 1,159 | 10,811 | Redacted |
| PP_PREV_DSD | Age/sex: 50+ Male | 77 | 721 | Redacted |
| PP_PREV_DSD | Age/sex: 10-14 Female | 268 | 2,500 | Redacted |
| PP_PREV_DSD | Age/sex: 15-19 Female | 322 | 3,000 | Redacted |
| PP_PREV_DSD | Age/sex: 20-24 Female | 804 | 7,501 | Redacted |
| PP_PREV_DSD | Age/sex: 25-49 Female | 1,206 | 11,252 | Redacted |
| PP_PREV_DSD | Age/sex: 50+ Female | 80 | 750 | Redacted |
| PP_PREV_DSD | Sum of Age/Sex disaggregates | 5,255 | 49,027 | Redacted |
| KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 18,100 | | Redacted |
| KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 16,833 | | Redacted |
| KP_PREV_DSD | By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level | 290 | | Redacted |

| | | | | |
|-------------|--|---------|---------|----------|
| | HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | | | |
| KP_PREV_DSD | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 72 | | Redacted |
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 905 | | Redacted |
| KP_PREV_DSD | By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 91 | | Redacted |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 579,976 | 652,040 | Redacted |
| HTC_TST_DSD | By Test Result: Negative | 564,163 | 634,664 | Redacted |
| HTC_TST_DSD | By Test Result: Positive | 15,813 | 17,376 | Redacted |
| HTC_TST_DSD | Sum of Test Result disaggregates | 579,976 | 652,040 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Male | 2,569 | 2,601 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Male | 1,928 | 2,258 | Redacted |

| | | | | |
|-------------|---|---------|---------|----------|
| HTC_TST_DSD | Age/sex: 5-9 Male | 780 | 914 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Male | 1,744 | 2,043 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Male | 19,346 | 22,659 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Male | 40,023 | 46,903 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Male | 125,803 | 147,348 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Male | 3,901 | 4,569 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Female | 2,674 | 2,707 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Female | 2,019 | 2,365 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Female | 803 | 941 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Female | 1,790 | 2,097 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Female | 38,137 | 42,020 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Female | 104,610 | 113,283 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Female | 229,833 | 254,628 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Female | 4,016 | 4,704 | Redacted |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 579,976 | 652,040 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 7,021 | 7,815 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 189,072 | 221,479 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 7,287 | 8,110 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 376,596 | 414,636 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 14,308 | 15,925 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 565,668 | 636,115 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 579,976 | 652,040 | Redacted |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 579,976 | 652,040 | Redacted |
| HTC_TST_NGI | By Test Result: Negative | 564,163 | 634,664 | Redacted |
| HTC_TST_NGI | By Test Result: Positive | 15,813 | 17,376 | Redacted |
| HTC_TST_NGI | Sum of Test Result disaggregates | 579,976 | 652,040 | Redacted |

| | | | | |
|--------------|--|---------|---------|----------|
| HTC_TST_NGI | Age/sex: <1 Male | 2,569 | 2,601 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Male | 1,928 | 2,258 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Male | 780 | 914 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Male | 1,744 | 2,043 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Male | 19,346 | 22,659 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Male | 40,023 | 46,903 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Male | 125,803 | 147,348 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Male | 3,901 | 4,569 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Female | 2,674 | 2,707 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Female | 2,019 | 2,365 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Female | 803 | 941 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Female | 1,790 | 2,097 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Female | 38,137 | 42,020 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Female | 104,610 | 113,283 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Female | 229,833 | 254,628 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Female | 4,016 | 4,704 | Redacted |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 579,976 | 652,040 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 7,021 | 7,815 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 189,072 | 221,479 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 7,287 | 8,110 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 376,596 | 414,636 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 14,308 | 15,925 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 565,668 | 636,115 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 579,976 | 652,040 | Redacted |
| GEND_GBV_DSD | Number of people receiving post-GBV care | 152 | 152 | Redacted |
| GEND_GBV_DSD | Age: 0-9 | 18 | 18 | Redacted |
| GEND_GBV_DSD | Age: 10-14 | 35 | 35 | Redacted |
| GEND_GBV_DSD | Age: 15-17 | 53 | 53 | Redacted |
| GEND_GBV_DSD | Age: 18-24 | 31 | 31 | Redacted |
| GEND_GBV_DSD | Age: 25+ | 15 | 15 | Redacted |



| | | | | |
|--------------|---|--------|--------|----------|
| GEND_GBV_DSD | Sum of Age disaggregates | 152 | 152 | Redacted |
| GEND_GBV_DSD | Sex: Male | 51 | 51 | Redacted |
| GEND_GBV_DSD | Sex: Female | 101 | 101 | Redacted |
| GEND_GBV_DSD | Sum of Sex disaggregates | 152 | 152 | Redacted |
| GEND_GBV_DSD | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) | 34 | 34 | Redacted |
| GEND_GBV_DSD | By type of service: Sexual Violence (Post-Rape Care) | 118 | 118 | Redacted |
| GEND_GBV_DSD | By PEP service provision (related to sexual violence services provided) | 118 | 118 | Redacted |
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 14,251 | 14,670 | Redacted |
| OVC_ACC_DSD | Sex: Male | 6,983 | 7,188 | Redacted |
| OVC_ACC_DSD | Sex: Female | 7,268 | 7,482 | Redacted |
| OVC_ACC_DSD | Sum of Sex disaggregates | 14,251 | 14,670 | Redacted |
| OVC_ACC_DSD | Age: <1 | 855 | 880 | Redacted |
| OVC_ACC_DSD | Age: 1-4 | 3,563 | 3,668 | Redacted |
| OVC_ACC_DSD | Age: 5-9 | 3,990 | 4,108 | Redacted |
| OVC_ACC_DSD | Age: 10-14 | 3,420 | 3,521 | Redacted |
| OVC_ACC_DSD | Age: 15-17 | 1,995 | 2,053 | Redacted |
| OVC_ACC_DSD | Age: 18+ | 428 | 440 | Redacted |
| OVC_ACC_DSD | Sum of Age disaggregates | 14,251 | 14,670 | Redacted |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 47,506 | 48,900 | Redacted |
| OVC_SERV_DSD | Sex: Male | 23,278 | 23,961 | Redacted |
| OVC_SERV_DSD | Sex: Female | 24,228 | 24,939 | Redacted |
| OVC_SERV_DSD | Sum of Sex disaggregates | 47,506 | 48,900 | Redacted |
| OVC_SERV_DSD | Age: <1 | 2,850 | 2,934 | Redacted |
| OVC_SERV_DSD | Age: 1-4 | 11,877 | 12,225 | Redacted |
| OVC_SERV_DSD | Age: 5-9 | 13,302 | 13,692 | Redacted |

| | | | | |
|--------------|--|--------|--------|----------|
| OVC_SERV_DSD | Age: 10-14 | 11,401 | 11,247 | Redacted |
| OVC_SERV_DSD | Age: 15-17 | 6,651 | 6,846 | Redacted |
| OVC_SERV_DSD | Age: 18+ | 1,425 | 1,956 | Redacted |
| OVC_SERV_DSD | Sum of Age disaggregates | 47,506 | 48,900 | Redacted |
| C2.1.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 77,550 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Female | 2,714 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Male | 1,163 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Female | 51,571 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Male | 22,102 | | Redacted |
| C2.1.D_DSD | Sum of Age/Sex disaggregates | 77,550 | | Redacted |
| C2.1.D_DSD | By Age: <15 | 3,878 | | Redacted |
| C2.1.D_DSD | By Age: 15+ | 73,672 | | Redacted |
| C2.1.D_DSD | Sum of Age disaggregates | 77,550 | | Redacted |
| C2.1.D_DSD | By Sex: Female | 54,285 | | Redacted |
| C2.1.D_DSD | By Sex: Male | 23,265 | | Redacted |
| C2.1.D_DSD | Sum of Sex disaggregates | 77,550 | | Redacted |
| C2.1.D_NGI | Number of HIV-positive individuals receiving a minimum of one clinical service | 77,550 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Female | 2,714 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Male | 1,163 | | Redacted |
| C2.1.D_NGI | By Age/Sex: 15+ Female | 51,571 | | Redacted |
| C2.1.D_NGI | By Age/Sex: 15+ Male | 22,102 | | Redacted |
| C2.1.D_NGI | Sum of Age/Sex disaggregates | 77,550 | | Redacted |
| C2.1.D_NGI | By Age: <15 | 3,878 | | Redacted |
| C2.1.D_NGI | By Age: 15+ | 73,672 | | Redacted |
| C2.1.D_NGI | Sum of Age disaggregates | 77,550 | | Redacted |
| C2.1.D_NGI | By Sex: Female | 54,285 | | Redacted |
| C2.1.D_NGI | By Sex: Male | 23,265 | | Redacted |
| C2.1.D_NGI | Sum of Sex disaggregates | 77,550 | | Redacted |

| | | | | |
|---------------|--|--------|-------|----------|
| C2.4.D_DSD | Number of HIV-positive patients who were screened for TB in HIV care or treatment setting | 69,794 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 77,550 | | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 1,552 | | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period | 1,826 | 1,685 | Redacted |
| TB_ART_DSD | Age: 0-4 | 16 | | Redacted |
| TB_ART_DSD | Age: 5-14 | 78 | | Redacted |
| TB_ART_DSD | Age: 15+ | 1,458 | | Redacted |
| TB_ART_DSD | Male | 760 | | Redacted |
| TB_ART_DSD | Female | 792 | | Redacted |
| TB_ART_DSD | Sum of Sex disaggregates | 1,552 | | Redacted |
| TB_ART_DSD | Newly tested | 885 | | Redacted |
| TB_ART_DSD | Known HIV-positive | 667 | | Redacted |
| TB_ART_DSD | Sum of Test Status disaggregates | 1,552 | | Redacted |
| TB_ART_DSD | Aggregated Age: <15 | 93 | | Redacted |
| TB_ART_DSD | Aggregated Age: 15+ | 1,459 | | Redacted |
| TB_ART_DSD | Sum of Aggregated Age disaggregates | 1,552 | | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period | 5,199 | 5,308 | Redacted |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 5,908 | 6,032 | Redacted |

| | | | | |
|---------------|--|--------|--------|----------|
| PMTCT_EID_DSD | By infants who received a virologic test within 2 months of birth | 1,716 | 1,752 | Redacted |
| PMTCT_EID_DSD | By infants who received their first virologic HIV test between 2 and 12 months of age | 3,483 | 3,556 | Redacted |
| PMTCT_EID_DSD | Sum of Infant Age disaggregates | 5,199 | 5,308 | Redacted |
| PMTCT_EID_DSD | By infants with a positive virologic test result within 12 months of birth | 260 | 265 | Redacted |
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 51,700 | 68,286 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Male | 102 | 135 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Male | 482 | 637 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Male | 876 | 1,158 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Male | 16,152 | 21,333 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Female | 91 | 120 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Female | 427 | 565 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Female | 777 | 1,026 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Female | 32,793 | 43,312 | Redacted |
| TX_CURR_DSD | Sum of age/sex disaggregates | 2,755 | 3,641 | Redacted |
| TX_CURR_DSD | Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 5 | 5 | Redacted |
| TX_CURR_DSD | Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 66 | 66 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Male | 102 | 135 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Female | 91 | 120 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male | 1,461 | 1,929 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 16,152 | 21,333 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female | 1,295 | 1,711 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Female | 32,792 | 43,313 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 2,756 | 3,640 | Redacted |

| | | | | |
|-------------|--|--------|--------|----------|
| TX_CURR_DSD | Sum of Aggregated Age/Sex 15+ | 48,944 | 64,646 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates | 51,700 | 68,286 | Redacted |
| TX_CURR_NGI | Number of adults and children receiving antiretroviral therapy (ART) | 51,700 | 68,286 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Male | 102 | 135 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Male | 482 | 637 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Male | 876 | 1,158 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Male | 16,152 | 21,333 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Female | 91 | 120 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Female | 427 | 565 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Female | 777 | 1,026 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Female | 32,793 | 43,312 | Redacted |
| TX_CURR_NGI | Sum of Age/Sex disaggregates | 51,700 | 68,286 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Male | 102 | 135 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Female | 91 | 120 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Male | 1,461 | 1,929 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Male | 16,152 | 21,333 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Female | 1,295 | 1,711 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Female | 32,792 | 43,313 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex disaggregates | 51,700 | 68,286 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex <15 | 2,756 | 3,640 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex 15+ | 48,944 | 64,646 | Redacted |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 16,689 | 19,019 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Male | 66 | 75 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Male | 94 | 107 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Male | 118 | 134 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Male | 193 | 220 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Male | 735 | 837 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Male | 1,225 | 1,395 | Redacted |

| | | | | |
|------------|---|--------|--------|----------|
| TX_NEW_DSD | By Age/Sex: 25-49 Male | 1,959 | 2,233 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Male | 980 | 1,116 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Female | 63 | 71 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Female | 84 | 95 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Female | 105 | 119 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Female | 167 | 191 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Female | 1,635 | 1,864 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Female | 2,726 | 3,106 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Female | 4,361 | 4,971 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Female | 2,180 | 2,485 | Redacted |
| TX_NEW_DSD | Sum of Age/Sex disaggregates | 16,691 | 19,019 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male | 66 | 75 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male | 472 | 537 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 4,898 | 5,582 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female | 63 | 71 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female | 418 | 477 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 10,902 | 12,424 | Redacted |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 16,690 | 19,020 | Redacted |
| TX_NEW_DSD | Pregnancy status | 872 | 994 | Redacted |
| TX_NEW_DSD | Breastfeeding status | 553 | 630 | Redacted |
| TX_RET_DSD | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 14,437 | 14,186 | Redacted |
| TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, | 16,985 | 16,689 | Redacted |

| | | | | |
|------------|--|--------|--------|----------|
| | those who have stopped ART, and those lost to follow-up | | | |
| TX_RET_DSD | Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 289 | 284 | Redacted |
| TX_RET_DSD | Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 433 | 426 | Redacted |
| TX_RET_DSD | Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 13,715 | 13,476 | Redacted |
| TX_RET_DSD | Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 340 | 334 | Redacted |
| TX_RET_DSD | Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 510 | 501 | Redacted |
| TX_RET_DSD | Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 16,136 | 15,855 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Numerator: | 722 | 709 | Redacted |

| | | | | |
|-------------|---|--------|--------|----------|
| | Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | | | |
| TX_RET_DSD | Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 13,715 | 13,476 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 849 | 834 | Redacted |
| TX_RET_DSD | Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 16,136 | 15,855 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 6,786 | 6,667 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 798 | 784 | Redacted |
| LAB_ACC_DSD | Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or | 7 | 7 | Redacted |

| | | | | |
|-------------|---|----|----|----------|
| | international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation | | | |
| LAB_ACC_DSD | By site support type: Direct Service Delivery (DSD) | 7 | 7 | Redacted |
| LAB_ACC_DSD | Sum of Support Type disaggregates | 7 | 7 | Redacted |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 35 | 35 | Redacted |
| LAB_CAP_DSD | By clinical laboratories | 35 | 35 | Redacted |
| LAB_CAP_DSD | By Point-of-care testing sites | 0 | | Redacted |
| LAB_CAP_DSD | By site support type: Direct Service Delivery (DSD) | 35 | 35 | Redacted |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates | 35 | 35 | Redacted |
| LAB_PT_DSD | HIV serologic/diagnostic testing: Number of laboratories that perform this testing | 1 | 1 | Redacted |
| LAB_PT_DSD | HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program | 60 | 70 | Redacted |
| LAB_PT_DSD | HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 60 | 60 | Redacted |
| LAB_PT_DSD | CD4: Number of laboratories that perform this testing | 94 | 1 | Redacted |
| LAB_PT_DSD | CD4: Number of laboratories that participate in this PT program | 60 | 70 | Redacted |
| LAB_PT_DSD | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 60 | 70 | Redacted |
| LAB_PT_DSD | Early infant diagnostics: Number of | 1 | 1 | Redacted |

| | | | | |
|------------|--|-----|-----|----------|
| | laboratories that perform this testing | | | |
| LAB_PT_DSD | Early infant diagnostics: Number of laboratories that participate in this PT program | 1 | 1 | Redacted |
| LAB_PT_DSD | Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 | 1 | Redacted |
| LAB_PT_DSD | HIV viral load: Number of laboratories that perform this testing | 1 | 1 | Redacted |
| LAB_PT_DSD | HIV viral load: Number of laboratories that participate in this PT program | 1 | 1 | Redacted |
| LAB_PT_DSD | HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 | 1 | Redacted |
| LAB_PT_DSD | TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing | 60 | 70 | Redacted |
| LAB_PT_DSD | TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program | 60 | 70 | Redacted |
| LAB_PT_DSD | TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 60 | 70 | Redacted |
| QI_SITE | Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months | 66 | 86 | Redacted |
| QI_SITE | Total number of PEPFAR-supported sites for any HIV clinical service | 100 | 120 | Redacted |

| | | | | |
|---------------|---|--------|--------|----------|
| | including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC | | | |
| QI_SITE | By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months | 66 | 86 | Redacted |
| QI_SITE | Sum of Numerator Site Support Type disaggregates | 66 | 86 | Redacted |
| QI_SITE | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC | 100 | 120 | Redacted |
| QI_SITE | Sum of Denominator Site Support Type disaggregates | 100 | 120 | Redacted |
| TB_SCREEN_DSD | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period | 69,794 | 75,778 | Redacted |
| TB_SCREEN_DSD | Age: <1 | 1,396 | 1,766 | Redacted |
| TB_SCREEN_DSD | Age: 1-4 | 698 | 1,288 | Redacted |
| TB_SCREEN_DSD | Age: 5-9 | 1,396 | 606 | Redacted |
| TB_SCREEN_DSD | Age: 10-14 | 698 | 379 | Redacted |
| TB_SCREEN_DSD | Age: 15-19 | 6,979 | 7,578 | Redacted |
| TB_SCREEN_DSD | Age: 20-24 | 17,449 | 11,367 | Redacted |
| TB_SCREEN_DSD | Age: 25-49 | 38,386 | 49,255 | Redacted |
| TB_SCREEN_DSD | Age: 50+ | 2,792 | 3,539 | Redacted |
| TB_SCREEN_DSD | Sum of Age disaggregates | 11,167 | 11,617 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 | 4,188 | 4,039 | Redacted |



| | | | | |
|---------------|--|--------|--------|----------|
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ | 65,606 | 71,739 | Redacted |
| TB_SCREEN_DSD | Sum of Aggregated Age disaggregates | 69,794 | 75,778 | Redacted |
| TB_SCREEN_DSD | Sex: Male | 20,938 | 22,733 | Redacted |
| TB_SCREEN_DSD | Sex: Female | 48,856 | 53,045 | Redacted |
| TB_SCREEN_DSD | Sum of Sex disaggregates | 69,794 | 75,778 | Redacted |

Implementing Mechanism Details

| | |
|--|---|
| Mechanism ID: 16849 | Mechanism Name: Strengthening Human Resources For Health(HRH) for the Provision of HIV/AIDS Services Through Pre-service |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Center for Clinical Care and Clinical Research Ltd | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|-------------------------------------|---|
| Total All Funding Sources: 0 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 1 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 0 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



(No data provided.)

Budget Code Information

| Mechanism ID: | 16849 | | |
|----------------------------|---|-----------------------|-----------------------|
| Mechanism Name: | Strengthening Human Resources For Health(HRH) for the Provision of | | |
| Prime Partner Name: | HIV/AIDS Services Through Pre-service | | |
| | Center for Clinical Care and Clinical Research Ltd | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| Mechanism ID: 16848 | Mechanism Name: Engaging Indigenous Organisation to Sustain and Enhance Comprehensive Clinical Service |
|---|---|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Catholic Caritas Foundation of Nigeria (CCFN) | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 14,907,191 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 14,907,191 |



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|-------------------------|---|
| Gender: Gender Equality | 20,296 |
| Focus Area: | Promoting gender-related policies and laws that increase legal protection |
| Sub Area: | Implementation |
| Focus Area: | Equity in HIV prevention, care, treatment and support |
| Sub Area: | Capacity building |
| Gender: GBV | 10,148 |
| Focus Area: | GBV Prevention |
| Focus Area: | Post GBV Care |
| Sub Area: | Monitoring and Evaluation |

Key Issues

TB

Workplace Programs

Family Planning

Budget Code Information

| Mechanism ID: | 16848 | | |
|----------------------------|---|----------------|----------------|
| Mechanism Name: | Engaging Indigenous Organisation to Sustain and Enhance | | |
| Prime Partner Name: | Comprehensive Clinical Service | | |
| | Catholic Caritas Foundation of Nigeria (CCFN) | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 2,560,020 | 0 |



| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|------------------------|-------------|----------------|----------------|
| Care | HKID | 202,967 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 472,796 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 184,946 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 984,461 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 585,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMIN | 26,447 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVAB | 12,312 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 913,352 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 1,046,005 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 7,378,980 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 539,905 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|-------------------|--|-------|-------|-------------------------|
| PMTCT_ARV_DS D | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 3,037 | 3,243 | Redacted |
| PMTCT_ARV_DS D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 3,451 | 3,685 | Redacted |
| PMTCT_ARV_DS D | Life-long ART (including Option B+) | 1,670 | 1,784 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 635 | 678 | Redacted |
| PMTCT_ARV_DS D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 1,035 | 1,106 | Redacted |
| PMTCT_ARV_DS D | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 1,185 | 1,265 | Redacted |
| PMTCT_ARV_DS D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 152 | 162 | Redacted |
| PMTCT_ARV_DS D | Single-dose nevirapine (with or without tail) | 30 | 32 | Redacted |
| PMTCT_ARV_DS D | Sum of Regimen Type disaggregates | 3,037 | 3,243 | Redacted |
| PMTCT_ARV_DS D | Sum of New and Current disaggregates | 1,670 | 1,784 | Redacted |

| | | | | |
|--------------------|--|--------|--------|----------|
| PMTCT_ARV_NGI | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 3,037 | 3,243 | Redacted |
| PMTCT_ARV_NGI | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 3,451 | 3,685 | Redacted |
| PMTCT_ARV_NGI | Life-long ART (including Option B+) | 1,670 | 1,784 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 635 | 678 | Redacted |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 1,035 | 1,106 | Redacted |
| PMTCT_ARV_NGI | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 1,185 | 1,265 | Redacted |
| PMTCT_ARV_NGI | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 152 | 162 | Redacted |
| PMTCT_ARV_NGI | Single-dose nevirapine (with or without tail) | 30 | 32 | Redacted |
| PMTCT_ARV_NGI | Sum of Regimen disaggregates | 3,037 | 3,243 | Redacted |
| PMTCT_ARV_NGI | Sum of New and Current disaggregates | 1,670 | 1,784 | Redacted |
| PMTCT_STAT_DS D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 71,061 | 74,194 | Redacted |
| PMTCT_STAT_DS D | Number of new ANC and L&D clients | 78,089 | 81,532 | Redacted |
| PMTCT_STAT_DS D | By: Known positives at entry | 1,380 | 1,425 | Redacted |
| PMTCT_STAT_DS D | By: Number of new positives identified | 2,071 | 2,138 | Redacted |

| | | | | |
|--------------------|--|--------|--------|----------|
| PMTCT_STAT_DS D | Sum of Positives Status disaggregates | 3,451 | 3,563 | Redacted |
| PMTCT_STAT_NG I | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 71,061 | 74,194 | Redacted |
| PMTCT_STAT_NG I | Number of new ANC and L&D clients | 78,089 | 81,532 | Redacted |
| PMTCT_STAT_NG I | By: Known positives at entry | 1,380 | 1,425 | Redacted |
| PMTCT_STAT_NG I | By: Number of new positives identified | 2,071 | 2,138 | Redacted |
| PMTCT_STAT_NG I | Sum of Positives Status disaggregates | 3,451 | 3,563 | Redacted |
| BS_COLL | Number of whole blood collections each year by the NBTS network | 3,400 | 3,400 | Redacted |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network laboratory | 3,060 | 3,060 | Redacted |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV | 68 | 68 | Redacted |
| PP_PREV_DSD | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 164 | 1,019 | Redacted |
| PP_PREV_DSD | Total number of people in the target population | 381 | 3,702 | Redacted |
| PP_PREV_DSD | Age/sex: 10-14 Male | 8 | 50 | Redacted |
| PP_PREV_DSD | Age/sex: 15-19 Male | 10 | 60 | Redacted |
| PP_PREV_DSD | Age/sex: 20-24 Male | 24 | 150 | Redacted |
| PP_PREV_DSD | Age/sex: 25-49 Male | 36 | 225 | Redacted |

| | | | | |
|-------------|---|---------|---------|----------|
| PP_PREV_DSD | Age/sex: 50+ Male | 2 | 15 | Redacted |
| PP_PREV_DSD | Age/sex: 10-14 Female | 8 | 52 | Redacted |
| PP_PREV_DSD | Age/sex: 15-19 Female | 10 | 62 | Redacted |
| PP_PREV_DSD | Age/sex: 20-24 Female | 25 | 156 | Redacted |
| PP_PREV_DSD | Age/sex: 25-49 Female | 38 | 233 | Redacted |
| PP_PREV_DSD | Age/sex: 50+ Female | 3 | 16 | Redacted |
| PP_PREV_DSD | Sum of Age/Sex disaggregates | 164 | 1,019 | Redacted |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 343,737 | 441,353 | Redacted |
| HTC_TST_DSD | By Test Result: Negative | 333,205 | 428,255 | Redacted |
| HTC_TST_DSD | By Test Result: Positive | 10,532 | 13,098 | Redacted |
| HTC_TST_DSD | Sum of Test Result disaggregates | 343,737 | 441,353 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Male | 1,505 | 1,589 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Male | 1,323 | 1,783 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Male | 535 | 722 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Male | 1,197 | 1,614 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Male | 13,277 | 17,898 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Male | 27,467 | 37,048 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Male | 86,339 | 116,388 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Male | 2,677 | 3,609 | Redacted |
| HTC_TST_DSD | Age/sex: <1 Female | 1,567 | 1,654 | Redacted |
| HTC_TST_DSD | Age/sex: 1-4 Female | 1,386 | 1,868 | Redacted |
| HTC_TST_DSD | Age/sex: 5-9 Female | 551 | 743 | Redacted |
| HTC_TST_DSD | Age/sex: 10-14 Female | 1,229 | 1,656 | Redacted |
| HTC_TST_DSD | Age/sex: 15-19 Female | 20,796 | 25,918 | Redacted |
| HTC_TST_DSD | Age/sex: 20-24 Female | 52,972 | 64,024 | Redacted |
| HTC_TST_DSD | Age/sex: 25-49 Female | 128,160 | 161,124 | Redacted |
| HTC_TST_DSD | Age/sex: 50+ Female | 2,756 | 3,715 | Redacted |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 343,737 | 441,353 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 4,561 | 5,708 | Redacted |

| | | | | |
|-------------|---|---------|---------|----------|
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 129,759 | 174,942 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 4,733 | 5,921 | Redacted |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 204,684 | 254,782 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 9,294 | 11,629 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 334,443 | 429,724 | Redacted |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 343,737 | 441,353 | Redacted |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 343,737 | 441,353 | Redacted |
| HTC_TST_NGI | By Test Result: Negative | 333,205 | 428,254 | Redacted |
| HTC_TST_NGI | By Test Result: Positive | 10,532 | 13,099 | Redacted |
| HTC_TST_NGI | Sum of Test Result disaggregates | 343,737 | 441,353 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Male | 1,505 | 1,589 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Male | 1,323 | 1,783 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Male | 535 | 722 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Male | 1,197 | 1,614 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Male | 13,277 | 17,898 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Male | 27,466 | 37,048 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Male | 86,339 | 116,388 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Male | 2,677 | 3,609 | Redacted |
| HTC_TST_NGI | Age/sex: <1 Female | 1,567 | 1,654 | Redacted |
| HTC_TST_NGI | Age/sex: 1-4 Female | 1,386 | 1,868 | Redacted |
| HTC_TST_NGI | Age/sex: 5-9 Female | 551 | 743 | Redacted |
| HTC_TST_NGI | Age/sex: 10-14 Female | 1,229 | 1,656 | Redacted |
| HTC_TST_NGI | Age/sex: 15-19 Female | 20,796 | 25,918 | Redacted |
| HTC_TST_NGI | Age/sex: 20-24 Female | 52,972 | 64,024 | Redacted |
| HTC_TST_NGI | Age/sex: 25-49 Female | 128,161 | 161,124 | Redacted |
| HTC_TST_NGI | Age/sex: 50+ Female | 2,756 | 3,715 | Redacted |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 343,737 | 441,353 | Redacted |

| | | | | |
|--------------|--|---------|---------|----------|
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 4,561 | 5,708 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 129,759 | 174,942 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 4,733 | 5,921 | Redacted |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 204,684 | 254,782 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 9,294 | 11,629 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 334,443 | 429,724 | Redacted |
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 343,737 | 441,353 | Redacted |
| GEND_GBV_DSD | Number of people receiving post-GBV care | 69 | 69 | Redacted |
| GEND_GBV_DSD | Age: 0-9 | 8 | 8 | Redacted |
| GEND_GBV_DSD | Age: 10-14 | 16 | 16 | Redacted |
| GEND_GBV_DSD | Age: 15-17 | 24 | 24 | Redacted |
| GEND_GBV_DSD | Age: 18-24 | 14 | 14 | Redacted |
| GEND_GBV_DSD | Age: 25+ | 7 | 7 | Redacted |
| GEND_GBV_DSD | Sum of Age disaggregates | 69 | 69 | Redacted |
| GEND_GBV_DSD | Sex: Male | 23 | 23 | Redacted |
| GEND_GBV_DSD | Sex: Female | 46 | 46 | Redacted |
| GEND_GBV_DSD | Sum of Sex disaggregates | 69 | 69 | Redacted |
| GEND_GBV_DSD | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) | 15 | 15 | Redacted |
| GEND_GBV_DSD | By type of service: Sexual Violence (Post-Rape Care) | 54 | 54 | Redacted |
| GEND_GBV_DSD | By PEP service provision (related to sexual violence services provided) | 54 | 54 | Redacted |
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 2,006 | 2,100 | Redacted |
| OVC_ACC_DSD | Sex: Male | 983 | 1,029 | Redacted |
| OVC_ACC_DSD | Sex: Female | 1,023 | 1,071 | Redacted |
| OVC_ACC_DSD | Sum of Sex disaggregates | 2,006 | 2,100 | Redacted |
| OVC_ACC_DSD | Age: <1 | 120 | 126 | Redacted |

| | | | | |
|--------------|---|--------|-------|----------|
| OVC_ACC_DSD | Age: 1-4 | 502 | 526 | Redacted |
| OVC_ACC_DSD | Age: 5-9 | 562 | 588 | Redacted |
| OVC_ACC_DSD | Age: 10-14 | 481 | 485 | Redacted |
| OVC_ACC_DSD | Age: 15-17 | 281 | 295 | Redacted |
| OVC_ACC_DSD | Age: 18+ | 60 | 80 | Redacted |
| OVC_ACC_DSD | Sum of Age disaggregates | 2,006 | 2,100 | Redacted |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 6,688 | 6,999 | Redacted |
| OVC_SERV_DSD | Sex: Male | 3,277 | 3,430 | Redacted |
| OVC_SERV_DSD | Sex: Female | 3,411 | 3,569 | Redacted |
| OVC_SERV_DSD | Sum of Sex disaggregates | 6,688 | 6,999 | Redacted |
| OVC_SERV_DSD | Age: <1 | 205 | 214 | Redacted |
| OVC_SERV_DSD | Age: 1-4 | 853 | 892 | Redacted |
| OVC_SERV_DSD | Age: 5-9 | 955 | 999 | Redacted |
| OVC_SERV_DSD | Age: 10-14 | 785 | 821 | Redacted |
| OVC_SERV_DSD | Age: 15-17 | 478 | 500 | Redacted |
| OVC_SERV_DSD | Age: 18+ | 102 | 107 | Redacted |
| OVC_SERV_DSD | Sum of Age disaggregates | 3,378 | 3,533 | Redacted |
| C2.1.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 55,712 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Female | 1,950 | | Redacted |
| C2.1.D_DSD | By Age/Sex: <15 Male | 836 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Female | 37,048 | | Redacted |
| C2.1.D_DSD | By Age/Sex: 15+ Male | 15,878 | | Redacted |
| C2.1.D_DSD | Sum of Age/Sex disaggregates | 55,712 | | Redacted |
| C2.1.D_DSD | By Age: <15 | 2,786 | | Redacted |
| C2.1.D_DSD | By Age: 15+ | 52,926 | | Redacted |
| C2.1.D_DSD | Sum of Age disaggregates | 55,712 | | Redacted |
| C2.1.D_DSD | By Sex: Female | 38,998 | | Redacted |
| C2.1.D_DSD | By Sex: Male | 16,714 | | Redacted |

| | | | | |
|------------|--|--------|-------|----------|
| C2.1.D_DSD | Sum of Sex disaggregates | 55,712 | | Redacted |
| C2.1.D_NGI | Number of HIV-positive individuals receiving a minimum of one clinical service | 55,712 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Female | 1,950 | | Redacted |
| C2.1.D_NGI | By Age/Sex: <15 Male | 836 | | Redacted |
| C2.1.D_NGI | By Age/Sex: 15+ Female | 37,048 | | Redacted |
| C2.1.D_NGI | By Age/Sex: 15+ Male | 15,878 | | Redacted |
| C2.1.D_NGI | Sum of Age/Sex disaggregates | 55,712 | | Redacted |
| C2.1.D_NGI | By Age: <15 | 2,786 | | Redacted |
| C2.1.D_NGI | By Age: 15+ | 52,926 | | Redacted |
| C2.1.D_NGI | Sum of Age disaggregates | 55,712 | | Redacted |
| C2.1.D_NGI | By Sex: Female | 38,998 | | Redacted |
| C2.1.D_NGI | By Sex: Male | 16,714 | | Redacted |
| C2.1.D_NGI | Sum of Sex disaggregates | 55,712 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive patients who were screened for TB in HIV care or treatment setting | 50,529 | | Redacted |
| C2.4.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 55,712 | | Redacted |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 671 | 1,269 | Redacted |
| TB_ART_DSD | Age: 0-4 | 7 | 13 | Redacted |
| TB_ART_DSD | Age: 5-14 | 34 | 63 | Redacted |
| TB_ART_DSD | Age: 15+ | 630 | 1,193 | Redacted |
| TB_ART_DSD | Male | 329 | 622 | Redacted |
| TB_ART_DSD | Female | 342 | 647 | Redacted |
| TB_ART_DSD | Sum of Sex disaggregates | 671 | 1,269 | Redacted |
| TB_ART_DSD | Newly tested | 382 | 723 | Redacted |

| | | | | |
|---------------|--|--------|--------|----------|
| TB_ART_DSD | Known HIV-positive | 289 | 546 | Redacted |
| TB_ART_DSD | Sum of Test Status disaggregates | 671 | 1,269 | Redacted |
| TB_ART_DSD | Aggregated Age: <15 | 40 | 76 | Redacted |
| TB_ART_DSD | Aggregated Age: 15+ | 631 | 1,193 | Redacted |
| TB_ART_DSD | Sum of Aggregated Age disaggregates | 671 | 1,269 | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period | 3,037 | 3,243 | Redacted |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 3,451 | 3,685 | Redacted |
| PMTCT_EID_DSD | By infants who received a virologic test within 2 months of birth | 1,002 | 1,070 | Redacted |
| PMTCT_EID_DSD | By infants who received their first virologic HIV test between 2 and 12 months of age | 2,035 | 2,173 | Redacted |
| PMTCT_EID_DSD | Sum of Infant Age disaggregates | 3,037 | 3,243 | Redacted |
| PMTCT_EID_DSD | By infants with a positive virologic test result within 12 months of birth | 152 | 162 | Redacted |
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 19,343 | 63,371 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Male | 38 | 125 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Male | 180 | 591 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Male | 328 | 1,074 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Male | 6,043 | 19,798 | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Female | 34 | 111 | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Female | 160 | 524 | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Female | 291 | 953 | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Female | 12,269 | 40,195 | Redacted |
| TX_CURR_DSD | Sum of age/sex disaggregates | 1,031 | 3,378 | Redacted |
| TX_CURR_DSD | Percent children with advanced HIV infection receiving antiretroviral therapy | 5 | 5 | Redacted |



| | | | | |
|-------------|--|--------|--------|----------|
| | (ART) [CURRENT] | | | |
| TX_CURR_DSD | Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 66 | 66 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Male | 38 | 125 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Female | 34 | 111 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male | 546 | 1,790 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 6,043 | 19,798 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female | 485 | 1,588 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Female | 12,269 | 40,195 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 1,031 | 3,378 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex 15+ | 18,312 | 59,993 | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates | 19,343 | 63,371 | Redacted |
| TX_CURR_NGI | Number of adults and children receiving antiretroviral therapy (ART) | 19,343 | 63,371 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Male | 38 | 125 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Male | 180 | 591 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Male | 328 | 1,074 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Male | 6,043 | 19,798 | Redacted |
| TX_CURR_NGI | Age/Sex: <1 Female | 34 | 111 | Redacted |
| TX_CURR_NGI | Age/Sex: 1-4 Female | 160 | 524 | Redacted |
| TX_CURR_NGI | Age/Sex: 5-14 Female | 291 | 953 | Redacted |
| TX_CURR_NGI | Age/Sex: 15+ Female | 12,269 | 40,195 | Redacted |
| TX_CURR_NGI | Sum of Age/Sex disaggregates | 19,343 | 63,371 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Male | 38 | 125 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Female | 34 | 111 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Male | 546 | 1,790 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Male | 6,043 | 19,798 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Female | 485 | 1,588 | Redacted |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Female | 12,269 | 40,195 | Redacted |



| | | | | |
|-------------|--|--------|--------|----------|
| TX_CURR_NGI | Sum of Aggregated Age/Sex disaggregates | 19,343 | 63,371 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex <15 | 1,031 | 3,378 | Redacted |
| TX_CURR_NGI | Sum of Aggregated Age/Sex 15+ | 18,312 | 59,993 | Redacted |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 9,996 | 21,778 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Male | 40 | 86 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Male | 56 | 123 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Male | 71 | 154 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Male | 116 | 252 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Male | 440 | 959 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Male | 733 | 1,598 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Male | 1,173 | 2,557 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Male | 587 | 1,278 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Female | 38 | 82 | Redacted |
| TX_NEW_DSD | By Age/Sex: 1-4 Female | 50 | 109 | Redacted |
| TX_NEW_DSD | By Age/Sex: 5-9 Female | 63 | 136 | Redacted |
| TX_NEW_DSD | By Age/Sex: 10-14 Female | 100 | 218 | Redacted |
| TX_NEW_DSD | By Age/Sex: 15-19 Female | 979 | 2,134 | Redacted |
| TX_NEW_DSD | By Age/Sex: 20-24 Female | 1,632 | 3,556 | Redacted |
| TX_NEW_DSD | By Age/Sex: 25-49 Female | 2,612 | 5,690 | Redacted |
| TX_NEW_DSD | By Age/Sex: 50+ Female | 1,306 | 2,845 | Redacted |
| TX_NEW_DSD | Sum of Age/Sex disaggregates | 9,996 | 21,777 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male | 40 | 86 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male | 282 | 615 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 2,934 | 6,391 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female | 38 | 82 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female | 251 | 546 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ | 6,529 | 14,226 | Redacted |

| | | | | |
|------------|---|-------|--------|----------|
| | Female | | | |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 9,996 | 21,778 | Redacted |
| TX_NEW_DSD | Pregnancy status | 522 | 1,138 | Redacted |
| TX_NEW_DSD | Breastfeeding status | 331 | 722 | Redacted |
| TX_RET_DSD | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 2,702 | 8,497 | Redacted |
| TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 3,179 | 9,996 | Redacted |
| TX_RET_DSD | Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 54 | 170 | Redacted |
| TX_RET_DSD | Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 81 | 255 | Redacted |
| TX_RET_DSD | Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 2,567 | 8,072 | Redacted |
| TX_RET_DSD | Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 64 | 200 | Redacted |
| TX_RET_DSD | Age: 5-14 (Denominator: Total number of adults and children who initiated ART) | 95 | 300 | Redacted |

| | | | | |
|------------|--|-------|-------|----------|
| | in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | | | |
| TX_RET_DSD | Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 3,020 | 9,496 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 135 | 425 | Redacted |
| TX_RET_DSD | Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 2,567 | 8,072 | Redacted |
| TX_RET_DSD | Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 159 | 500 | Redacted |
| TX_RET_DSD | Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 3,020 | 9,496 | Redacted |
| TX_RET_DSD | Pregnancy and breastfeeding status (Numerator: Number of adults and | 1,270 | 399 | Redacted |

| | | | | |
|---------------|---|--------|--------|----------|
| | children who are still alive and on treatment at 12 months after initiating ART) | | | |
| TX_RET_DSD | Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 149 | 470 | Redacted |
| LAB_ACC_DSD | Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation | 3 | 3 | Redacted |
| LAB_ACC_DSD | By site support type: Direct Service Delivery (DSD) | 3 | 3 | Redacted |
| LAB_ACC_DSD | Sum of Support Type disaggregates | 3 | 3 | Redacted |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 31 | 31 | Redacted |
| LAB_CAP_DSD | By clinical laboratories | 31 | 31 | Redacted |
| LAB_CAP_DSD | By Point-of-care testing sites | 0 | | Redacted |
| LAB_CAP_DSD | By site support type: Direct Service Delivery (DSD) | 31 | 31 | Redacted |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates | 31 | 31 | Redacted |
| TB_SCREEN_DSD | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period | 50,529 | 57,607 | Redacted |
| TB_SCREEN_DSD | Age: <1 | 1,011 | 1,152 | Redacted |
| TB_SCREEN_DSD | Age: 1-4 | 505 | 576 | Redacted |



| | | | | |
|---------------|---|--------|--------|----------|
| TB_SCREEN_DSD | Age: 5-9 | 1,011 | 1,152 | Redacted |
| TB_SCREEN_DSD | Age: 10-14 | 505 | 576 | Redacted |
| TB_SCREEN_DSD | Age: 15-19 | 5,053 | 5,761 | Redacted |
| TB_SCREEN_DSD | Age: 20-24 | 12,632 | 14,402 | Redacted |
| TB_SCREEN_DSD | Age: 25-49 | 27,791 | 31,684 | Redacted |
| TB_SCREEN_DSD | Age: 50+ | 2,021 | 2,304 | Redacted |
| TB_SCREEN_DSD | Sum of Age disaggregates | 8,085 | 9,217 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 | 3,032 | 3,456 | Redacted |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ | 47,497 | 54,151 | Redacted |
| TB_SCREEN_DSD | Sum of Aggregated Age disaggregates | 50,529 | 57,607 | Redacted |
| TB_SCREEN_DSD | Sex: Male | 15,159 | 17,282 | Redacted |
| TB_SCREEN_DSD | Sex: Female | 35,370 | 40,325 | Redacted |
| TB_SCREEN_DSD | Sum of Sex disaggregates | 50,529 | 57,607 | Redacted |

Implementing Mechanism Details

| | |
|--|---|
| Mechanism ID: 16846 | Mechanism Name: Strengthening Human Resources For Health(HRH) for the Provision of HIV/AIDS Services Through Pre-service |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Institute of Human Virology, Nigeria | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|-------------------------------------|---|
| Total All Funding Sources: 0 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 1 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 0 |

Approved



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Safe Motherhood

TB

Workplace Programs

End-of-Program Evaluation

Family Planning

Budget Code Information

| Mechanism ID: | 16846 | | |
|----------------------------|--|----------------|----------------|
| Mechanism Name: | Strengthening Human Resources For Health(HRH) for the Provision of | | |
| Prime Partner Name: | HIV/AIDS Services Through Pre-service | | |
| | Institute of Human Virology, Nigeria | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|----------------------------|--|
| Mechanism ID: 16839 | Mechanism Name: Strengthening Human Resources for Health (HRH) for the provision of quality HIV/AIDS services through Pre-service |
|----------------------------|--|



| | |
|--|---|
| | and In- Services Training for Laboratory Personnel |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Institute of Human Virology, Nigeria | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 350,000 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 350,000 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

| | |
|----------------------------|---|
| Mechanism ID: | 16839 |
| Mechanism Name: | Strengthening Human Resources for Health (HRH) for the provision of quality HIV/AIDS services through Pre-service and In- Services Training |
| Prime Partner Name: | for Laboratory Personnel Institute of Human Virology, Nigeria |



| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|------------------------|-------------|----------------|----------------|
| Governance and Systems | HLAB | 350,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|--|---|
| Mechanism ID: 16838 | Mechanism Name: Strengthening Systems for Sustainable Comprehensive HIV/AIDs Prevention, Care and Support and Treatment Programs |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: University of Maryland Baltimore | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| Total All Funding Sources: 425,000 | Total Mechanism Pipeline: Redacted |
|---|---|
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 425,000 |

Sub Partner Name(s)

| | | |
|---|-------------------|--|
| Institute of Human Virology, Nigeria | Solina Health Ltd | |
|---|-------------------|--|

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Key Issues

Safe Motherhood

TB

Workplace Programs

End-of-Program Evaluation

Family Planning

Budget Code Information

| Mechanism ID: | 16838 | | |
|----------------------------|--|----------------|----------------|
| Mechanism Name: | Strengthening Systems for Sustainable Comprehensive HIV/AIDs | | |
| Prime Partner Name: | Prevention, Care and Support and Treatment Programs | | |
| | University of Maryland Baltimore | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 225,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 200,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|----------------------------|---|
| Mechanism ID: 16828 | Mechanism Name: Strengthening Laboratory Services for Sustainable HIV/AIDs Program |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |

Approved



| | |
|--|------------------------------|
| Prime Partner Name: AIDS Prevention Initiative in Nigeria, LTD | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|------------------------------------|------------------------------------|
| Total All Funding Sources: 350,000 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 350,000 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

TB

End-of-Program Evaluation

Budget Code Information

| | | | |
|------------------------|--|----------------|----------------|
| Mechanism ID: | 16828 | | |
| Mechanism Name: | Strengthening Laboratory Services for Sustainable HIV/AIDs Program | | |
| Prime Partner Name: | AIDS Prevention Initiative in Nigeria, LTD | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 350,000 | 0 |



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|---|---|
| Mechanism ID: 16827 | Mechanism Name: Strengthening Human Resources For Health(HRH) for the Provision of HIV/AIDS Services Through Pre-service |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Center for Integrated Health Programs | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 763,046 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 763,046 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

End-of-Program Evaluation



Budget Code Information

| Mechanism ID: | 16827 | | |
|----------------------------|---|-----------------------|-----------------------|
| Mechanism Name: | Strengthening Human Resources For Health(HRH) for the Provision of | | |
| Prime Partner Name: | HIV/AIDS Services Through Pre-service | | |
| | Center for Integrated Health Programs | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 763,046 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|-------------------------|--|-------------|-------------|--------------------------------|
| HRH_PRE | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre | 331 | 331 | Redacted |
| HRH_PRE | By Graduates: Doctors | 33 | 33 | Redacted |
| HRH_PRE | By Graduates: Nurses | 116 | 116 | Redacted |
| HRH_PRE | By Graduates: Midwives | 83 | 83 | Redacted |
| HRH_PRE | By Graduates: Laboratory professionals | 99 | 99 | Redacted |
| HRH_PRE | Sum of Graduates disaggreagtes | 331 | 331 | Redacted |
| HRH_PRE | By new graduates who are licensed and registered: Doctors | 33 | 33 | Redacted |
| HRH_PRE | By new graduates who are licensed and registered: Nurses | 116 | 116 | Redacted |
| HRH_PRE | By new graduates who are licensed | 83 | 83 | Redacted |



| | | | | |
|---------|--|----|----|----------|
| | and registered: Midwives | | | |
| HRH_PRE | By new graduates who are licensed and registered: Laboratorians | 99 | 99 | Redacted |

Implementing Mechanism Details

| | |
|----------------------------|-----------------|
| Mechanism ID: 16797 | TBD: Yes |
| REDACTED | |

Implementing Mechanism Details

| | |
|---|--|
| Mechanism ID: 14768 | Mechanism Name: SUPPLY CHAIN MANAGEMENT SYSTEMS |
| Funding Agency: USAID | Procurement Type: Contract |
| Prime Partner Name: Partnership for Supply Chain Management | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: PR/SR | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 159,768,455 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 159,768,455 |

Sub Partner Name(s)

| | | |
|----------------------------|---------------------|--------------------------------|
| 3I Infotech | Booz Allen Hamilton | Crown Agents |
| i+solutions | John Snow, Inc. | Management Sciences for Health |
| Map International | Northrup Grumman | The Manoff Group |
| UPS Supply Chain Solutions | Voxiva | |

Cross-Cutting Budget Attribution(s)



(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

| Mechanism ID: 14768 | | | |
|--|-------------|----------------|----------------|
| Mechanism Name: SUPPLY CHAIN MANAGEMENT SYSTEMS | | | |
| Prime Partner Name: Partnership for Supply Chain Management | | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 3,368,746 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 667,094 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 1,586,015 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 2,261,905 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 6,489,404 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMBL | 1,107,452 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMIN | 404,134 | 0 |



| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|----------------|-------------|----------------|----------------|
| Prevention | HVCT | 15,820,818 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 6,559,064 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXD | 99,660,534 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 20,731,472 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 1,111,817 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|---------------------|----------|
| Mechanism ID: 14666 | TBD: Yes |
| REDACTED | |

Implementing Mechanism Details

| | |
|---|---|
| Mechanism ID: 14664 | Mechanism Name: Integrated MSM Prevention Program |
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Heartland Alliance for Human Needs and Human Rights | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |



| | |
|---|---|
| Total All Funding Sources: 1,716,440 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 1,716,440 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|-----------------------------|---|
| Key Populations: MSM and TG | 400,000 |
| Focus Area: | Training of health workers and community outreach workers |
| Focus Area: | Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance |
| Focus Area: | Collection and use of strategic information |
| Focus Area: | Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners |
| Focus Area: | Monitoring and evaluation of MSM/TG programs |
| Gender: Gender Equality | 40,000 |
| Focus Area: | Changing harmful gender norms and promoting positive gender norms |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Sub Area: | Operation Research |
| Condom programming | 250,000 |



Key Issues

(No data provided.)

Budget Code Information

| Mechanism ID: | 14664 | | |
|----------------------------|---|----------------|----------------|
| Mechanism Name: | Integrated MSM Prevention Program | | |
| Prime Partner Name: | Heartland Alliance for Human Needs and Human Rights | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 216,440 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 1,500,000 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 |
|------------------|---|--------|------|
| KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 37,333 | |
| KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 34,720 | |
| KP_PREV_DSD | By key population type: Males who inject drugs (Male PWID) (Numerator: Number of | 597 | |



| | | | |
|-------------|--|--------|--------|
| | key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | | |
| KP_PREV_DSD | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 149 | |
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 1,867 | |
| KP_PREV_DSD | By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 187 | |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 87,837 | 54,110 |
| HTC_TST_DSD | By Test Result: Negative | 85,355 | 52,581 |
| HTC_TST_DSD | By Test Result: Positive | 2,482 | 1,529 |
| HTC_TST_DSD | Sum of Test Result disaggregates | 87,837 | 54,110 |
| HTC_TST_DSD | Age/sex: <1 Male | 342 | 211 |
| HTC_TST_DSD | Age/sex: 1-4 Male | 311 | 191 |
| HTC_TST_DSD | Age/sex: 5-9 Male | 126 | 77 |
| HTC_TST_DSD | Age/sex: 10-14 Male | 281 | 173 |
| HTC_TST_DSD | Age/sex: 15-19 Male | 3,118 | 1,921 |



| | | | |
|-------------|---|--------|--------|
| HTC_TST_DSD | Age/sex: 20-24 Male | 6,449 | 3,973 |
| HTC_TST_DSD | Age/sex: 25-49 Male | 20,277 | 12,491 |
| HTC_TST_DSD | Age/sex: 50+ Male | 629 | 387 |
| HTC_TST_DSD | Age/sex: <1 Female | 356 | 219 |
| HTC_TST_DSD | Age/sex: 1-4 Female | 325 | 200 |
| HTC_TST_DSD | Age/sex: 5-9 Female | 129 | 80 |
| HTC_TST_DSD | Age/sex: 10-14 Female | 289 | 178 |
| HTC_TST_DSD | Age/sex: 15-19 Female | 5,598 | 3,448 |
| HTC_TST_DSD | Age/sex: 20-24 Female | 14,937 | 9,201 |
| HTC_TST_DSD | Age/sex: 25-49 Female | 34,024 | 20,959 |
| HTC_TST_DSD | Age/sex: 50+ Female | 646 | 401 |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 87,837 | 54,110 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 1,060 | 653 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 30,473 | 18,772 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 1,099 | 677 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 55,205 | 34,008 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 2,159 | 1,330 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 85,678 | 52,780 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 87,837 | 54,110 |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 87,837 | 54,110 |
| HTC_TST_NGI | By Test Result: Negative | 85,355 | 52,581 |
| HTC_TST_NGI | By Test Result: Positive | 2,482 | 1,529 |
| HTC_TST_NGI | Sum of Test Result disaggregates | 87,837 | 54,110 |
| HTC_TST_NGI | Age/sex: <1 Male | 342 | 211 |
| HTC_TST_NGI | Age/sex: 1-4 Male | 311 | 191 |
| HTC_TST_NGI | Age/sex: 5-9 Male | 126 | 77 |
| HTC_TST_NGI | Age/sex: 10-14 Male | 281 | 173 |



| | | | |
|-------------|---|--------|--------|
| HTC_TST_NGI | Age/sex: 15-19 Male | 3,118 | 1,921 |
| HTC_TST_NGI | Age/sex: 20-24 Male | 6,449 | 3,973 |
| HTC_TST_NGI | Age/sex: 25-49 Male | 20,277 | 12,491 |
| HTC_TST_NGI | Age/sex: 50+ Male | 629 | 387 |
| HTC_TST_NGI | Age/sex: <1 Female | 356 | 219 |
| HTC_TST_NGI | Age/sex: 1-4 Female | 325 | 200 |
| HTC_TST_NGI | Age/sex: 5-9 Female | 129 | 80 |
| HTC_TST_NGI | Age/sex: 10-14 Female | 289 | 178 |
| HTC_TST_NGI | Age/sex: 15-19 Female | 5,598 | 3,448 |
| HTC_TST_NGI | Age/sex: 20-24 Female | 14,937 | 9,201 |
| HTC_TST_NGI | Age/sex: 25-49 Female | 34,024 | 20,959 |
| HTC_TST_NGI | Age/sex: 50+ Female | 646 | 401 |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 87,837 | 54,110 |
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 1,060 | 653 |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 30,473 | 18,772 |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 1,099 | 677 |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 55,205 | 34,008 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 2,159 | 1,330 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 85,678 | 52,780 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 87,837 | 54,110 |

Implementing Mechanism Details

| | |
|--|--|
| Mechanism ID: 14505 | Mechanism Name: STRENGTHENING INTERGRATED DELIVERY OF HIV/AIDS SERVICES(SIDHAS) |
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: FHI 360 | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: PR/SR | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 63,955,545 | Total Mechanism Pipeline: Redacted |



| Applied Pipeline Amount: 0 | |
|------------------------------------|-----------------------|
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 63,955,545 |

Sub Partner Name(s)

| | | |
|---|---|--|
| Abia State University Teaching Hospital | Achieving Health Nigeria Initiative | Association for Reproductive and Family Health |
| Axios Foundation Inc. | Deloitte Consulting Limited | ECWA Clinic and Maternity |
| Federal Medical Center Gusau | Federal Medical Center Owerri, Imo State | Federal Medical Center Owo |
| Federal Medical Center Yenagoa | Federal Medical Center, B/Kebbi | Federal Medical Center, Jalingo |
| Federal Medical Center, Yola | German Leprosy and TB Relief Association (GLRA) | Holy Family Catholic Hospital Ikom |
| Immaculate Heart Hospital and Maternity Nkpor | Iyi Enu Hospital | Mambilla Baptist Hospital, Gembu |
| Oko Community Hospital | Population Council | Redeemed Action Committee on AIDS, Lagos |
| Regina Caeli Maternity Hospital Awka | Regina Mundi Catholic Hospital, Mushin | Santa maria Catholic Hospital Uzairrue |
| St Mary's Hospital | University of Nigeria, Nsukka | |

Cross-Cutting Budget Attribution(s)

| | |
|----------------------------|---|
| Human Resources for Health | 2,000,000 |
| Renovation | 2,636,000 |
| Gender: Gender Equality | 25,000 |
| Focus Area: | Changing harmful gender norms and promoting positive gender norms |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Focus Area: | Promoting gender-related policies and laws that |



| | |
|--|--|
| | increase legal protection |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Focus Area: | Equity in HIV prevention, care, treatment and support |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Gender: GBV | 15,000 |
| Focus Area: | GBV Prevention |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Focus Area: | Post GBV Care |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Key Populations: FSW | 10,000 |
| Focus Area: | Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention |
| Focus Area: | Training of health workers and community outreach workers |
| Focus Area: | Collection and use of strategic information on SWs and clients |
| Focus Area: | Monitoring and evaluation of SW programs |
| Food and Nutrition: Policy, Tools, and Service | 10,000 |



| | |
|------------------------|---------|
| Delivery | |
| Condom programming | 10,000 |
| Motor Vehicles: Leased | 425,455 |

Key Issues

Malaria (PMI)
 Child Survival Activities
 Mobile Population
 Safe Motherhood
 TB
 Family Planning

Budget Code Information

| Mechanism ID: | 14505 | | |
|----------------------------|--|----------------|----------------|
| Mechanism Name: | STRENGTHENING INTERGRATED DELIVERY OF HIV/AIDS | | |
| Prime Partner Name: | SERVICES(SIDHAS) | | |
| | FHI 360 | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 9,017,769 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 2,212,294 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 2,391,735 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 475,416 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |



| | | | |
|------------------------|--------------------|-----------------------|-----------------------|
| Governance and Systems | HLAB | 6,465,148 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 1,401,113 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMBL | 58,432 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMIN | 188,760 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 5,088,517 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 150,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 8,910,499 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 26,165,142 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 1,430,720 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 |
|------------------|--|--------|--------|
| PMTCT_ARV_DSD | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of | 18,502 | 24,764 |



| | | | |
|---------------|--|--------|--------|
| | mother-to-child-transmission (MTCT) during pregnancy and delivery | | |
| PMTCT_ARV_DSD | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 21,025 | 27,213 |
| PMTCT_ARV_DSD | Life-long ART (including Option B+) | 10,176 | 13,620 |
| PMTCT_ARV_DSD | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 3,868 | 4,615 |
| PMTCT_ARV_DSD | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 6,308 | 9,005 |
| PMTCT_ARV_DSD | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) | 7,216 | 9,906 |
| PMTCT_ARV_DSD | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 925 | 1,238 |
| PMTCT_ARV_DSD | Single-dose nevirapine (with or without tail) | 185 | 0 |
| PMTCT_ARV_DSD | Sum of Regimen Type disaggregates | 18,502 | 24,764 |
| PMTCT_ARV_DSD | Sum of New and Current disaggregates | 10,176 | 13,620 |
| PMTCT_ARV_NGI | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 18,502 | 24,764 |
| PMTCT_ARV_NGI | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) | 21,025 | 27,213 |
| PMTCT_ARV_NGI | Life-long ART (including Option B+) | 10,176 | 13,620 |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy | 3,868 | 4,615 |
| PMTCT_ARV_NGI | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy | 6,308 | 9,005 |
| PMTCT_ARV_NGI | Maternal triple ARV prophylaxis (provided with | 7,216 | 9,906 |

| | | | |
|----------------|---|---------|-----------|
| | the intention to stop at the end of the breastfeeding period) | | |
| PMTCT_ARV_NGI | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) | 925 | 1,238 |
| PMTCT_ARV_NGI | Single-dose nevirapine (with or without tail) | 185 | 0 |
| PMTCT_ARV_NGI | Sum of Regimen disaggregates | 18,502 | 24,764 |
| PMTCT_ARV_NGI | Sum of New and Current disaggregates | 10,176 | 13,620 |
| PMTCT_STAT_DSD | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 770,628 | 947,660 |
| PMTCT_STAT_DSD | Number of new ANC and L&D clients | 846,844 | 1,041,385 |
| PMTCT_STAT_DSD | By: Known positives at entry | 8,410 | 10,885 |
| PMTCT_STAT_DSD | By: Number of new positives identified | 12,615 | 16,328 |
| PMTCT_STAT_DSD | Sum of Positives Status disaggregates | 21,025 | 27,213 |
| PMTCT_STAT_NGI | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 770,628 | 947,660 |
| PMTCT_STAT_NGI | Number of new ANC and L&D clients | 846,844 | 1,041,385 |
| PMTCT_STAT_NGI | By: Known positives at entry | 8,410 | 10,885 |
| PMTCT_STAT_NGI | By: Number of new positives identified | 12,615 | 16,328 |
| PMTCT_STAT_NGI | Sum of Positives Status disaggregates | 21,025 | 27,213 |
| KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 2,000 | 7,143 |
| KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 1,860 | 6,643 |
| KP_PREV_DSD | By key population type: Males who inject | 32 | 114 |



| | | | |
|-------------|--|-----------|-----------|
| | drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | | |
| KP_PREV_DSD | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 8 | 29 |
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 100 | 357 |
| KP_PREV_DSD | By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 10 | 36 |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 1,593,881 | 1,966,538 |
| HTC_TST_DSD | By Test Result: Negative | 1,548,844 | 1,910,971 |
| HTC_TST_DSD | By Test Result: Positive | 45,037 | 55,567 |
| HTC_TST_DSD | Sum of Test Result disaggregates | 1,593,881 | 1,966,538 |
| HTC_TST_DSD | Age/sex: <1 Male | 6,205 | 7,656 |
| HTC_TST_DSD | Age/sex: 1-4 Male | 5,639 | 6,957 |
| HTC_TST_DSD | Age/sex: 5-9 Male | 2,282 | 2,815 |
| HTC_TST_DSD | Age/sex: 10-14 Male | 5,101 | 6,293 |

| | | | |
|-------------|---|-----------|-----------|
| HTC_TST_DSD | Age/sex: 15-19 Male | 56,581 | 69,811 |
| HTC_TST_DSD | Age/sex: 20-24 Male | 117,024 | 144,385 |
| HTC_TST_DSD | Age/sex: 25-49 Male | 367,943 | 453,970 |
| HTC_TST_DSD | Age/sex: 50+ Male | 11,408 | 14,075 |
| HTC_TST_DSD | Age/sex: <1 Female | 6,459 | 7,969 |
| HTC_TST_DSD | Age/sex: 1-4 Female | 5,906 | 7,287 |
| HTC_TST_DSD | Age/sex: 5-9 Female | 2,349 | 2,899 |
| HTC_TST_DSD | Age/sex: 10-14 Female | 5,237 | 6,461 |
| HTC_TST_DSD | Age/sex: 15-19 Female | 101,573 | 125,322 |
| HTC_TST_DSD | Age/sex: 20-24 Female | 271,039 | 334,410 |
| HTC_TST_DSD | Age/sex: 25-49 Female | 617,387 | 761,735 |
| HTC_TST_DSD | Age/sex: 50+ Female | 11,748 | 14,493 |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 1,593,881 | 1,966,538 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 19,226 | 23,721 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 552,957 | 682,241 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 19,951 | 24,616 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 1,001,747 | 1,235,960 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 39,177 | 48,337 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 1,554,704 | 1,918,201 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 1,593,881 | 1,966,538 |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 1,626,409 | 2,006,671 |
| HTC_TST_NGI | By Test Result: Negative | 1,580,453 | 1,949,971 |
| HTC_TST_NGI | By Test Result: Positive | 45,956 | 56,700 |
| HTC_TST_NGI | Sum of Test Result disaggregates | 1,626,409 | 2,006,671 |
| HTC_TST_NGI | Age/sex: <1 Male | 6,332 | 7,812 |
| HTC_TST_NGI | Age/sex: 1-4 Male | 5,754 | 7,099 |
| HTC_TST_NGI | Age/sex: 5-9 Male | 2,328 | 2,872 |



| | | | |
|-------------|---|-----------|-----------|
| HTC_TST_NGI | Age/sex: 10-14 Male | 5,205 | 6,422 |
| HTC_TST_NGI | Age/sex: 15-19 Male | 57,736 | 71,235 |
| HTC_TST_NGI | Age/sex: 20-24 Male | 119,413 | 147,332 |
| HTC_TST_NGI | Age/sex: 25-49 Male | 375,452 | 463,234 |
| HTC_TST_NGI | Age/sex: 50+ Male | 11,641 | 14,362 |
| HTC_TST_NGI | Age/sex: <1 Female | 6,590 | 8,131 |
| HTC_TST_NGI | Age/sex: 1-4 Female | 6,027 | 7,436 |
| HTC_TST_NGI | Age/sex: 5-9 Female | 2,397 | 2,958 |
| HTC_TST_NGI | Age/sex: 10-14 Female | 5,344 | 6,593 |
| HTC_TST_NGI | Age/sex: 15-19 Female | 103,646 | 127,879 |
| HTC_TST_NGI | Age/sex: 20-24 Female | 276,571 | 341,234 |
| HTC_TST_NGI | Age/sex: 25-49 Female | 629,987 | 777,282 |
| HTC_TST_NGI | Age/sex: 50+ Female | 11,986 | 14,790 |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 1,626,409 | 2,006,671 |
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 19,619 | 24,206 |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 564,242 | 696,164 |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 20,358 | 25,118 |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 1,022,190 | 1,261,183 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 39,977 | 49,324 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 1,586,432 | 1,957,347 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 1,626,409 | 2,006,671 |
| HTC_TST_TA | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 32,528 | 40,133 |
| HTC_TST_TA | By Test Result: Negative | 31,553 | 38,930 |
| HTC_TST_TA | By Test Result: Positive | 975 | 1,203 |
| HTC_TST_TA | Sum of Test Result disaggregates | 32,528 | 40,133 |
| HTC_TST_TA | Age/sex: <1 Male | 112 | 138 |
| HTC_TST_TA | Age/sex: 1-4 Male | 159 | 196 |
| HTC_TST_TA | Age/sex: 5-9 Male | 64 | 79 |
| HTC_TST_TA | Age/sex: 10-14 Male | 144 | 177 |
| HTC_TST_TA | Age/sex: 15-19 Male | 1,594 | 1,966 |

| | | | |
|--------------|--|--------|--------|
| HTC_TST_TA | Age/sex: 20-24 Male | 3,187 | 3,932 |
| HTC_TST_TA | Age/sex: 25-49 Male | 10,363 | 12,785 |
| HTC_TST_TA | Age/sex: 50+ Male | 321 | 397 |
| HTC_TST_TA | Age/sex: <1 Female | 115 | 142 |
| HTC_TST_TA | Age/sex: 1-4 Female | 166 | 205 |
| HTC_TST_TA | Age/sex: 5-9 Female | 66 | 82 |
| HTC_TST_TA | Age/sex: 10-14 Female | 147 | 182 |
| HTC_TST_TA | Age/sex: 15-19 Female | 1,660 | 2,048 |
| HTC_TST_TA | Age/sex: 20-24 Female | 3,318 | 4,093 |
| HTC_TST_TA | Age/sex: 25-49 Female | 10,782 | 13,303 |
| HTC_TST_TA | Age/sex: 50+ Female | 330 | 408 |
| HTC_TST_TA | Sum of Age/Sex disaggregates | 32,528 | 40,133 |
| HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 478 | 590 |
| HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 15,465 | 19,080 |
| HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 495 | 611 |
| HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 16,090 | 19,852 |
| HTC_TST_TA | Sum of Aggregated Age/Sex <15 | 973 | 1,201 |
| HTC_TST_TA | Sum of Aggregated Age/Sex 15+ | 31,555 | 38,932 |
| HTC_TST_TA | Sum of Aggregated Age/Sex disaggregates | 32,528 | 40,133 |
| GEND_GBV_DSD | Number of people receiving post-GBV care | 588 | 588 |
| GEND_GBV_DSD | Age: 0-9 | 68 | 68 |
| GEND_GBV_DSD | Age: 10-14 | 138 | 138 |
| GEND_GBV_DSD | Age: 15-17 | 204 | 204 |
| GEND_GBV_DSD | Age: 18-24 | 120 | 120 |
| GEND_GBV_DSD | Age: 25+ | 58 | 58 |
| GEND_GBV_DSD | Sum of Age disaggregates | 588 | 588 |
| GEND_GBV_DSD | Sex: Male | 196 | 196 |
| GEND_GBV_DSD | Sex: Female | 392 | 392 |



| | | | |
|--------------|---|--------|--------|
| GEND_GBV_DSD | Sum of Sex disaggregates | 588 | 588 |
| GEND_GBV_DSD | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) | 132 | 132 |
| GEND_GBV_DSD | By type of service: Sexual Violence (Post-Rape Care) | 456 | 456 |
| GEND_GBV_DSD | By PEP service provision (related to sexual violence services provided) | 456 | 456 |
| OVC_ACC_DSD | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 22,886 | 25,174 |
| OVC_ACC_DSD | Sex: Male | 11,214 | 12,335 |
| OVC_ACC_DSD | Sex: Female | 11,672 | 12,839 |
| OVC_ACC_DSD | Sum of Sex disaggregates | 22,886 | 25,174 |
| OVC_ACC_DSD | Age: <1 | 1,373 | 1,510 |
| OVC_ACC_DSD | Age: 1-4 | 5,722 | 6,294 |
| OVC_ACC_DSD | Age: 5-9 | 6,408 | 7,049 |
| OVC_ACC_DSD | Age: 10-14 | 5,264 | 5,790 |
| OVC_ACC_DSD | Age: 15-17 | 3,204 | 3,524 |
| OVC_ACC_DSD | Age: 18+ | 915 | 1,007 |
| OVC_ACC_DSD | Sum of Age disaggregates | 22,886 | 25,174 |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 76,286 | 83,915 |
| OVC_SERV_DSD | Sex: Male | 37,380 | 41,118 |
| OVC_SERV_DSD | Sex: Female | 38,906 | 42,797 |
| OVC_SERV_DSD | Sum of Sex disaggregates | 76,286 | 83,915 |
| OVC_SERV_DSD | Age: <1 | 4,577 | 5,035 |
| OVC_SERV_DSD | Age: 1-4 | 19,072 | 20,979 |
| OVC_SERV_DSD | Age: 5-9 | 21,360 | 23,496 |
| OVC_SERV_DSD | Age: 10-14 | 17,546 | 19,300 |
| OVC_SERV_DSD | Age: 15-17 | 10,680 | 11,748 |
| OVC_SERV_DSD | Age: 18+ | 3,051 | 3,357 |
| OVC_SERV_DSD | Sum of Age disaggregates | 76,286 | 83,915 |

| | | | |
|-------------|---|---------|--|
| C2.1.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 295,625 | |
| C2.1.D_DSD | By Age/Sex: <15 Female | 10,347 | |
| C2.1.D_DSD | By Age/Sex: <15 Male | 4,434 | |
| C2.1.D_DSD | By Age/Sex: 15+ Female | 196,590 | |
| C2.1.D_DSD | By Age/Sex: 15+ Male | 84,254 | |
| C2.1.D_DSD | Sum of Age/Sex disaggregates | 295,625 | |
| C2.1.D_DSD | By Age: <15 | 14,781 | |
| C2.1.D_DSD | By Age: 15+ | 280,844 | |
| C2.1.D_DSD | Sum of Age disaggregates | 295,625 | |
| C2.1.D_DSD | By Sex: Female | 206,937 | |
| C2.1.D_DSD | By Sex: Male | 88,688 | |
| C2.1.D_DSD | Sum of Sex disaggregates | 295,625 | |
| C2.1.D_NGI | Number of HIV-positive individuals receiving a minimum of one clinical service | 295,625 | |
| C2.1.D_NGI | By Age/Sex: <15 Female | 10,347 | |
| C2.1.D_NGI | By Age/Sex: <15 Male | 4,434 | |
| C2.1.D_NGI | By Age/Sex: 15+ Female | 196,590 | |
| C2.1.D_NGI | By Age/Sex: 15+ Male | 84,254 | |
| C2.1.D_NGI | Sum of Age/Sex disaggregates | 295,625 | |
| C2.1.D_NGI | By Age: <15 | 14,781 | |
| C2.1.D_NGI | By Age: 15+ | 280,844 | |
| C2.1.D_NGI | Sum of Age disaggregates | 295,625 | |
| C2.1.D_NGI | By Sex: Female | 206,937 | |
| C2.1.D_NGI | By Sex: Male | 88,688 | |
| C2.1.D_NGI | Sum of Sex disaggregates | 295,625 | |
| C2.4.D_DSD | Number of HIV-positive patients who were screened for TB in HIV care or treatment setting | 266,066 | |
| C2.4.D_DSD | Number of HIV-positive individuals receiving a minimum of one clinical service | 295,625 | |
| FN_THER_DSD | Number of clinically malnourished PLHIV who received therapeutic and/or supplementary | 11,825 | |

| | | | |
|---------------|--|--------|--------|
| | food during the reporting period. | | |
| FN_THER_DSD | Number of PLHIV who were nutritionally assessed and found to be clinically undernourished. | 11,825 | |
| FN_THER_DSD | Age: <1 | 591 | |
| FN_THER_DSD | Age: 1-4 | 1,419 | |
| FN_THER_DSD | Age: 5-14 | 1,538 | |
| FN_THER_DSD | Age: 15-17 | 1,182 | |
| FN_THER_DSD | Age: 18+ | 7,095 | |
| FN_THER_DSD | Sum of Age disaggregates | 11,825 | |
| FN_THER_DSD | Aggregated Age: <18 | 4,730 | |
| FN_THER_DSD | Aggregated Age: 18+ | 7,095 | |
| FN_THER_DSD | Sum of Aggregated Age disaggregates | 11,825 | |
| TB_ART_DSD | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 8,835 | 9,635 |
| TB_ART_DSD | Age: 0-4 | 0 | 0 |
| TB_ART_DSD | Age: 5-14 | 530 | 578 |
| TB_ART_DSD | Age: 15+ | 8,305 | 9,057 |
| TB_ART_DSD | Male | 4,329 | 4,721 |
| TB_ART_DSD | Female | 4,506 | 4,914 |
| TB_ART_DSD | Sum of Sex disaggregates | 8,835 | 9,635 |
| TB_ART_DSD | Newly tested | 6,803 | 7,419 |
| TB_ART_DSD | Known HIV-positive | 2,032 | 2,216 |
| TB_ART_DSD | Sum of Test Status disaggregates | 8,835 | 9,635 |
| TB_ART_DSD | Aggregated Age: <15 | 530 | 578 |
| TB_ART_DSD | Aggregated Age: 15+ | 8,305 | 9,057 |
| TB_ART_DSD | Sum of Aggregated Age disaggregates | 8,835 | 9,635 |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period | 17,103 | 23,365 |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women | 23,724 | 29,520 |

| | | | |
|---------------|--|---------|---------|
| | identified during the reporting period (include known HIV-positive women at entry into PMTCT) | | |
| PMTCT_EID_DSD | By infants who received a virologic test within 2 months of birth | 5,644 | 7,711 |
| PMTCT_EID_DSD | By infants who received their first virologic HIV test between 2 and 12 months of age | 11,459 | 15,654 |
| PMTCT_EID_DSD | Sum of Infant Age disaggregates | 17,103 | 23,365 |
| PMTCT_EID_DSD | By infants with a positive virologic test result within 12 months of birth | 1,168 | 1,168 |
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 197,084 | 219,534 |
| TX_CURR_DSD | Age/Sex: <1 Male | 328 | 370 |
| TX_CURR_DSD | Age/Sex: 1-4 Male | 1,548 | 1,744 |
| TX_CURR_DSD | Age/Sex: 5-14 Male | 2,814 | 3,171 |
| TX_CURR_DSD | Age/Sex: 15+ Male | 62,118 | 69,155 |
| TX_CURR_DSD | Age/Sex: <1 Female | 291 | 328 |
| TX_CURR_DSD | Age/Sex: 1-4 Female | 1,372 | 1,547 |
| TX_CURR_DSD | Age/Sex: 5-14 Female | 2,495 | 2,812 |
| TX_CURR_DSD | Age/Sex: 15+ Female | 126,118 | 140,407 |
| TX_CURR_DSD | Sum of age/sex disaggregates | 8,848 | 9,972 |
| TX_CURR_DSD | Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 4 | 5 |
| TX_CURR_DSD | Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] | 66 | 66 |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Male | 328 | 370 |
| TX_CURR_DSD | Aggregated Age/Sex: <1 Female | 291 | 328 |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male | 4,689 | 5,285 |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 62,118 | 69,155 |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female | 4,159 | 4,687 |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Female | 126,118 | 140,407 |

| | | | |
|-------------|--|---------|---------|
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 8,848 | 9,972 |
| TX_CURR_DSD | Sum of Aggregated Age/Sex 15+ | 188,236 | 209,562 |
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates | 197,084 | 219,534 |
| TX_CURR_NGI | Number of adults and children receiving antiretroviral therapy (ART) | 197,084 | 219,534 |
| TX_CURR_NGI | Age/Sex: <1 Male | 328 | 370 |
| TX_CURR_NGI | Age/Sex: 1-4 Male | 1,548 | 1,744 |
| TX_CURR_NGI | Age/Sex: 5-14 Male | 2,814 | 3,171 |
| TX_CURR_NGI | Age/Sex: 15+ Male | 62,118 | 69,155 |
| TX_CURR_NGI | Age/Sex: <1 Female | 291 | 328 |
| TX_CURR_NGI | Age/Sex: 1-4 Female | 1,372 | 1,547 |
| TX_CURR_NGI | Age/Sex: 5-14 Female | 2,495 | 2,812 |
| TX_CURR_NGI | Age/Sex: 15+ Female | 126,118 | 140,407 |
| TX_CURR_NGI | Sum of Age/Sex disaggregates | 197,084 | 219,534 |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Male | 328 | 370 |
| TX_CURR_NGI | Aggregated Age/Sex: <1 Female | 291 | 328 |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Male | 4,689 | 5,285 |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Male | 62,118 | 69,155 |
| TX_CURR_NGI | Aggregated Age/Sex: <15 Female | 4,159 | 4,687 |
| TX_CURR_NGI | Aggregated Age/Sex: 15+ Female | 126,118 | 140,407 |
| TX_CURR_NGI | Sum of Aggregated Age/Sex disaggregates | 197,084 | 219,534 |
| TX_CURR_NGI | Sum of Aggregated Age/Sex <15 | 8,848 | 9,972 |
| TX_CURR_NGI | Sum of Aggregated Age/Sex 15+ | 188,236 | 209,562 |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 63,620 | 66,358 |
| TX_NEW_DSD | By Age/Sex: <1 Male | 445 | 464 |
| TX_NEW_DSD | By Age/Sex: 1-4 Male | 324 | 338 |
| TX_NEW_DSD | By Age/Sex: 5-9 Male | 153 | 159 |
| TX_NEW_DSD | By Age/Sex: 10-14 Male | 95 | 100 |
| TX_NEW_DSD | By Age/Sex: 15-19 Male | 1,909 | 1,991 |
| TX_NEW_DSD | By Age/Sex: 20-24 Male | 2,863 | 2,986 |
| TX_NEW_DSD | By Age/Sex: 25-49 Male | 12,406 | 12,940 |

| | | | |
|------------|---|--------|--------|
| TX_NEW_DSD | By Age/Sex: 50+ Male | 891 | 930 |
| TX_NEW_DSD | By Age/Sex: <1 Female | 1,038 | 1,082 |
| TX_NEW_DSD | By Age/Sex: 1-4 Female | 757 | 790 |
| TX_NEW_DSD | By Age/Sex: 5-9 Female | 356 | 372 |
| TX_NEW_DSD | By Age/Sex: 10-14 Female | 223 | 232 |
| TX_NEW_DSD | By Age/Sex: 15-19 Female | 4,453 | 4,645 |
| TX_NEW_DSD | By Age/Sex: 20-24 Female | 6,680 | 6,968 |
| TX_NEW_DSD | By Age/Sex: 25-49 Female | 28,947 | 30,193 |
| TX_NEW_DSD | By Age/Sex: 50+ Female | 2,080 | 2,168 |
| TX_NEW_DSD | Sum of Age/Sex disaggregates | 63,620 | 66,358 |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male | 445 | 464 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male | 1,017 | 1,061 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 18,069 | 18,846 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female | 1,038 | 1,082 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female | 2,374 | 2,476 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 42,160 | 43,975 |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 63,620 | 66,358 |
| TX_NEW_DSD | Pregnancy status | 4,886 | 4,397 |
| TX_NEW_DSD | Breastfeeding status | 2,108 | 2,199 |
| TX_RET_DSD | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 29,431 | 54,077 |
| TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 34,625 | 63,620 |
| TX_RET_DSD | Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 589 | 1,082 |
| TX_RET_DSD | Age: 5-14 (Numerator: Number of adults and | 1,177 | 2,163 |

| | | | |
|------------|--|--------|--------|
| | children who are still alive and on treatment at 12 months after initiating ART) | | |
| TX_RET_DSD | Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 27,665 | 50,832 |
| TX_RET_DSD | Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 693 | 1,272 |
| TX_RET_DSD | Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 1,385 | 2,545 |
| TX_RET_DSD | Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 32,548 | 59,803 |
| TX_RET_DSD | Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 1,766 | 3,245 |
| TX_RET_DSD | Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 27,665 | 50,832 |
| TX_RET_DSD | Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 2,078 | 3,817 |



| | | | |
|-------------|---|--------|--------|
| TX_RET_DSD | Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 32,548 | 59,803 |
| TX_RET_DSD | Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 0 | 2,542 |
| TX_RET_DSD | Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 0 | 4,216 |
| LAB_ACC_DSD | Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation | 8 | 8 |
| LAB_ACC_DSD | By site support type: Direct Service Delivery (DSD) | 8 | 8 |
| LAB_ACC_DSD | Sum of Support Type disaggregates | 8 | 8 |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 126 | 126 |
| LAB_CAP_DSD | By clinical laboratories | 126 | 126 |
| LAB_CAP_DSD | By site support type: Direct Service Delivery (DSD) | 126 | 126 |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates | 126 | 126 |
| LAB_PT_DSD | Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that | 1 | 1 |

| | | | |
|---------------|--|---------|---------|
| | participate and successfully pass in an analyte-specific proficiency testing (PT) program | | |
| LAB_PT_DSD | HIV serologic/diagnostic testing: Number of laboratories that perform this testing | 126 | 126 |
| LAB_PT_DSD | HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program | 105 | 105 |
| LAB_PT_DSD | HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 96 | 96 |
| LAB_PT_DSD | CD4: Number of laboratories that perform this testing | 126 | 126 |
| LAB_PT_DSD | CD4: Number of laboratories that participate in this PT program | 105 | 105 |
| LAB_PT_DSD | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 96 | 96 |
| LAB_PT_DSD | Early infant diagnostics: Number of laboratories that perform this testing | 8 | 8 |
| LAB_PT_DSD | Early infant diagnostics: Number of laboratories that participate in this PT program | 7 | 7 |
| LAB_PT_DSD | Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 6 | 6 |
| TB_SCREEN_DSD | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period | 266,066 | 296,371 |
| TB_SCREEN_DSD | Age: <1 | 6,199 | 6,905 |
| TB_SCREEN_DSD | Age: 1-4 | 4,523 | 5,038 |
| TB_SCREEN_DSD | Age: 5-9 | 2,129 | 2,371 |
| TB_SCREEN_DSD | Age: 10-14 | 1,330 | 1,482 |
| TB_SCREEN_DSD | Age: 15-19 | 26,607 | 29,637 |
| TB_SCREEN_DSD | Age: 20-24 | 39,910 | 44,456 |
| TB_SCREEN_DSD | Age: 25-49 | 172,943 | 192,641 |



| | | | |
|---------------|--|---------|---------|
| TB_SCREEN_DSD | Age: 50+ | 12,425 | 13,841 |
| TB_SCREEN_DSD | Sum of Age disaggregates | 40,788 | 45,433 |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 | 14,181 | 15,797 |
| TB_SCREEN_DSD | Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ | 251,885 | 280,574 |
| TB_SCREEN_DSD | Sum of Aggregated Age disaggregates | 266,066 | 296,371 |
| TB_SCREEN_DSD | Sex: Male | 79,820 | 88,911 |
| TB_SCREEN_DSD | Sex: Female | 186,246 | 207,460 |
| TB_SCREEN_DSD | Sum of Sex disaggregates | 266,066 | 296,371 |

Implementing Mechanism Details

| | |
|---|---|
| Mechanism ID: 14446 | Mechanism Name: Nigeria Monitoring and Evaluation Management Services (NMEMS II) |
| Funding Agency: USAID | Procurement Type: Contract |
| Prime Partner Name: The Mitchell Group | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 400,000 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 95,000 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 400,000 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

End-of-Program Evaluation

Budget Code Information

| Mechanism ID: | 14446 | | |
|----------------------------|--|----------------|----------------|
| Mechanism Name: | Nigeria Monitoring and Evaluation Management Services (NMEMS II) | | |
| Prime Partner Name: | The Mitchell Group | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 400,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|----------------------------|-----------------|
| Mechanism ID: 14302 | TBD: Yes |
| REDACTED | |

Implementing Mechanism Details

| | |
|---|--|
| Mechanism ID: 14298 | Mechanism Name: Enhancing Nigerian Capacity for AIDS Prevention |
| Funding Agency: USAID | Procurement Type: Contract |
| Prime Partner Name: Deloitte Consulting Limited | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |



| | |
|---|---|
| Total All Funding Sources: 948,237 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 948,237 |

Sub Partner Name(s)

| | | |
|---|--|---|
| Catholic Action Committee on AIDS | Christian Reform Church of Nigeria AIDS Action Committee, Wukari, Taraba State | ECUMENICAL CENTER, BENUE |
| Education As A Vaccine Against AIDS (EVA) | FHI 360 | Global Agenda for Total Emancipation, Abuja |
| JIREH FOUNDATION, BENUE | New Generation | Ohonyeta Care Group, Otukpo |
| OSA Foundation, Makurdi | | |

Cross-Cutting Budget Attribution(s)

| | |
|----------------------------|---|
| Human Resources for Health | 20,000 |
| Gender: Gender Equality | 10,000 |
| Focus Area: | Changing harmful gender norms and promoting positive gender norms |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |

Key Issues

Mobile Population



Budget Code Information

| Mechanism ID: 14298 | | | |
|--|-------------|----------------|----------------|
| Mechanism Name: Enhancing Nigerian Capacity for AIDS Prevention | | | |
| Prime Partner Name: Deloitte Consulting Limited | | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVAB | 360,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 338,237 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 250,000 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 |
|------------------|--|--------|---------|
| SITE_SUPP | By program area/support type: HTC Direct Service Delivery (DSD) | 20 | 20 |
| SITE_SUPP | By program area/support type: HTC Technical Assistance-only (TA) | 20 | 20 |
| SITE_SUPP | By program area/support type: General Population Prevention Direct Service Delivery (DSD) | 32 | 32 |
| SITE_SUPP | By program area/support type: General Population Prevention Technical Assistance-only (TA) | 32 | 32 |
| PP_PREV_DSD | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 17,143 | 153,153 |
| PP_PREV_DSD | Total number of people in the target | 39,786 | 556,420 |



| | population | | |
|-------------|--|--------|---------|
| PP_PREV_DSD | Age/sex: 10-14 Male | 840 | 7,505 |
| PP_PREV_DSD | Age/sex: 15-19 Male | 1,008 | 9,005 |
| PP_PREV_DSD | Age/sex: 20-24 Male | 2,520 | 22,514 |
| PP_PREV_DSD | Age/sex: 25-49 Male | 3,780 | 33,771 |
| PP_PREV_DSD | Age/sex: 50+ Male | 252 | 2,251 |
| PP_PREV_DSD | Age/sex: 10-14 Female | 875 | 7,811 |
| PP_PREV_DSD | Age/sex: 15-19 Female | 1,049 | 9,373 |
| PP_PREV_DSD | Age/sex: 20-24 Female | 2,623 | 23,432 |
| PP_PREV_DSD | Age/sex: 25-49 Female | 3,935 | 35,149 |
| PP_PREV_DSD | Age/sex: 50+ Female | 261 | 2,342 |
| PP_PREV_DSD | Sum of Age/Sex disaggregates | 17,143 | 153,153 |
| KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 3,333 | |
| KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 3,100 | |
| KP_PREV_DSD | By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 53 | |
| KP_PREV_DSD | By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the | 13 | |



| | | | |
|-------------|--|---------|--------|
| | minimum standards required) | | |
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 167 | |
| KP_PREV_DSD | By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 17 | |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 154,991 | 84,559 |
| HTC_TST_DSD | By Test Result: Negative | 150,611 | 82,169 |
| HTC_TST_DSD | By Test Result: Positive | 4,380 | 2,390 |
| HTC_TST_DSD | Sum of Test Result disaggregates | 154,991 | 84,559 |
| HTC_TST_DSD | Age/sex: <1 Male | 603 | 329 |
| HTC_TST_DSD | Age/sex: 1-4 Male | 548 | 300 |
| HTC_TST_DSD | Age/sex: 5-9 Male | 221 | 121 |
| HTC_TST_DSD | Age/sex: 10-14 Male | 496 | 270 |
| HTC_TST_DSD | Age/sex: 15-19 Male | 5,502 | 3,002 |
| HTC_TST_DSD | Age/sex: 20-24 Male | 11,379 | 6,208 |
| HTC_TST_DSD | Age/sex: 25-49 Male | 35,779 | 19,520 |
| HTC_TST_DSD | Age/sex: 50+ Male | 1,109 | 605 |
| HTC_TST_DSD | Age/sex: <1 Female | 628 | 343 |
| HTC_TST_DSD | Age/sex: 1-4 Female | 574 | 313 |
| HTC_TST_DSD | Age/sex: 5-9 Female | 228 | 125 |
| HTC_TST_DSD | Age/sex: 10-14 Female | 510 | 278 |
| HTC_TST_DSD | Age/sex: 15-19 Female | 9,877 | 5,389 |



| | | | |
|-------------|---|---------|--------|
| HTC_TST_DSD | Age/sex: 20-24 Female | 26,357 | 14,379 |
| HTC_TST_DSD | Age/sex: 25-49 Female | 60,035 | 32,754 |
| HTC_TST_DSD | Age/sex: 50+ Female | 1,145 | 623 |
| HTC_TST_DSD | Sum of Age/Sex disaggregates | 154,991 | 84,559 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 1,870 | 1,020 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 53,770 | 29,335 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 1,940 | 1,059 |
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 97,411 | 53,145 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 3,810 | 2,079 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 151,181 | 82,480 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 154,991 | 84,559 |
| HTC_TST_NGI | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 154,991 | 84,559 |
| HTC_TST_NGI | By Test Result: Negative | 150,611 | 82,169 |
| HTC_TST_NGI | By Test Result: Positive | 4,380 | 2,390 |
| HTC_TST_NGI | Sum of Test Result disaggregates | 154,991 | 84,559 |
| HTC_TST_NGI | Age/sex: <1 Male | 603 | 329 |
| HTC_TST_NGI | Age/sex: 1-4 Male | 548 | 300 |
| HTC_TST_NGI | Age/sex: 5-9 Male | 221 | 121 |
| HTC_TST_NGI | Age/sex: 10-14 Male | 496 | 270 |
| HTC_TST_NGI | Age/sex: 15-19 Male | 5,502 | 3,002 |
| HTC_TST_NGI | Age/sex: 20-24 Male | 11,379 | 6,208 |
| HTC_TST_NGI | Age/sex: 25-49 Male | 35,779 | 19,520 |
| HTC_TST_NGI | Age/sex: 50+ Male | 1,109 | 605 |
| HTC_TST_NGI | Age/sex: <1 Female | 628 | 343 |
| HTC_TST_NGI | Age/sex: 1-4 Female | 574 | 313 |
| HTC_TST_NGI | Age/sex: 5-9 Female | 228 | 125 |
| HTC_TST_NGI | Age/sex: 10-14 Female | 510 | 278 |



| | | | |
|-------------|---|---------|--------|
| HTC_TST_NGI | Age/sex: 15-19 Female | 9,877 | 5,389 |
| HTC_TST_NGI | Age/sex: 20-24 Female | 26,357 | 14,379 |
| HTC_TST_NGI | Age/sex: 25-49 Female | 60,035 | 32,754 |
| HTC_TST_NGI | Age/sex: 50+ Female | 1,145 | 623 |
| HTC_TST_NGI | Sum of Age/Sex disaggregates | 154,991 | 84,559 |
| HTC_TST_NGI | Aggregated Age/sex: <15 Male | 1,870 | 1,020 |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Male | 53,770 | 29,335 |
| HTC_TST_NGI | Aggregated Age/sex: <15 Female | 1,940 | 1,059 |
| HTC_TST_NGI | Aggregated Age/sex: 15+ Female | 97,411 | 53,145 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex <15 | 3,810 | 2,079 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex 15+ | 151,181 | 82,480 |
| HTC_TST_NGI | Sum of Aggregated Age/Sex disaggregates | 154,991 | 84,559 |

Implementing Mechanism Details

| | |
|---|--|
| Mechanism ID: 14169 | Mechanism Name: Health Finance and Governance Project |
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Abt Associates | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 700,000 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 500,000 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 700,000 |

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

| | |
|----------------------------|---------|
| Human Resources for Health | 250,000 |
|----------------------------|---------|

Key Issues

(No data provided.)

Budget Code Information

| Mechanism ID: | 14169 | | |
|----------------------------|---------------------------------------|----------------|----------------|
| Mechanism Name: | Health Finance and Governance Project | | |
| Prime Partner Name: | Abt Associates | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 700,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|---|---|
| Mechanism ID: 14162 | Mechanism Name: African Center for Laboratory Equipments Maintenance |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: CDC Foundation | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 0 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 1 | |

Approved



| FY 2013 Burn Rate: Redacted | |
|-----------------------------|----------------|
| Funding Source | Funding Amount |
| GHP-State | 0 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

TB

Workplace Programs

Budget Code Information

| Mechanism ID: 14162 | | | |
|---|-------------|----------------|----------------|
| Mechanism Name: African Center for Laboratory Equipments Maintenance | | | |
| Prime Partner Name: CDC Foundation | | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|----------------------------|---|
| Mechanism ID: 14064 | Mechanism Name: Capacity Plus |
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |



| | |
|--|------------------------------|
| Prime Partner Name: IntraHealth International, Inc | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| Total All Funding Sources: 400,000 | Total Mechanism Pipeline: Redacted |
|---|---|
| Applied Pipeline Amount: 200,000 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 400,000 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|-------------------------|---|
| Gender: GBV | 20,000 |
| Focus Area: | GBV Prevention |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Gender: Gender Equality | 30,000 |
| Focus Area: | Changing harmful gender norms and promoting positive gender norms |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Focus Area: | Promoting gender-related policies and laws that |



| | |
|-------------|--|
| | increase legal protection |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Focus Area: | Increase gender-equitable access to income and productive resources, including education |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |

Key Issues

Child Survival Activities

End-of-Program Evaluation

Budget Code Information

| Mechanism ID: | 14064 | | |
|----------------------------|--------------------------------|----------------|----------------|
| Mechanism Name: | Capacity Plus | | |
| Prime Partner Name: | IntraHealth International, Inc | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 400,000 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 |
|------------------|--|------|------|
| HRH_PRE | Number of new HCW who graduated from a | 541 | |



| | | | |
|---------|---|-----|--|
| | pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre | | |
| HRH_PRE | By Graduates: Midwives | 110 | |
| HRH_PRE | By Graduates: Other | 431 | |
| HRH_PRE | Sum of Graduates disaggregates | 541 | |

Implementing Mechanism Details

| | |
|--|---|
| Mechanism ID: 14055 | Mechanism Name: PLAN-Health |
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Management Sciences for Health | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: TA | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 1,213,000 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 600,000 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 1,213,000 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

| | |
|-------------------------|---|
| Gender: Gender Equality | 50,000 |
| Focus Area: | Changing harmful gender norms and promoting positive gender norms |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |



| | |
|----------------------------|---|
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Focus Area: | Promoting gender-related policies and laws that increase legal protection |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Human Resources for Health | 56,077 |

Key Issues

(No data provided.)

Budget Code Information

| Mechanism ID: | 14055 | | |
|----------------------------|--------------------------------|----------------|----------------|
| Mechanism Name: | PLAN-Health | | |
| Prime Partner Name: | Management Sciences for Health | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 1,213,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|--|---|
| Mechanism ID: 14054 | Mechanism Name: MEASURE Evaluation III |
| Funding Agency: USAID | Procurement Type: Umbrella Agreement |
| Prime Partner Name: University of North Carolina | |



| | |
|---|------------------------------|
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |

| | |
|---|---|
| Total All Funding Sources: 3,480,100 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 659,000 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 3,480,100 |

Sub Partner Name(s)

| | | |
|---------------|-----------------|--|
| Futures Group | John Snow, Inc. | |
|---------------|-----------------|--|

Cross-Cutting Budget Attribution(s)

| | |
|----------------------------|--------|
| Human Resources for Health | 60,000 |
|----------------------------|--------|

Key Issues

(No data provided.)

Budget Code Information

| | | | |
|----------------------------|------------------------------|-----------------------|-----------------------|
| Mechanism ID: | 14054 | | |
| Mechanism Name: | MEASURE Evaluation III | | |
| Prime Partner Name: | University of North Carolina | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 1,700,100 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |

Approved



| | | | |
|------------------------|------|-----------|---|
| Governance and Systems | HVSI | 1,780,000 | 0 |
|------------------------|------|-----------|---|

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|---|--|
| Mechanism ID: 13753 | Mechanism Name: Program for HIV/AIDS Integration and Decentralisation |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: National Primary Health Care Development Agency | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: Yes | Managing Agency: HHS/CDC |
| Total All Funding Sources: 0 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 1 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 0 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Malaria (PMI)

Approved



Child Survival Activities

Safe Motherhood

TB

Family Planning

Budget Code Information

| Mechanism ID: | 13753 | | |
|----------------------------|---|----------------|----------------|
| Mechanism Name: | Program for HIV/AIDS Integration and Decentralisation | | |
| Prime Partner Name: | National Primary Health Care Development Agency | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|---|--|
| Mechanism ID: 13713 | Mechanism Name: Medical Laboratories Science Council of Nigeria |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Medical Laboratories Science Council of Nigeria | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: Yes | Managing Agency: HHS/CDC |

| Total All Funding Sources: 608,002 | Total Mechanism Pipeline: Redacted |
|---|---|
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |



| | |
|-----------|---------|
| GHP-State | 608,002 |
|-----------|---------|

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

| Mechanism ID: | 13713 | | |
|----------------------------|---|----------------|----------------|
| Mechanism Name: | Medical Laboratories Science Council of Nigeria | | |
| Prime Partner Name: | Medical Laboratories Science Council of Nigeria | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 608,002 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|------------------|--|------|------|-------------------------|
| LAB_ACC_DSD | Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable | 1 | 1 | Redacted |



| | | | | |
|-------------|---|---|---|----------|
| | level towards attainment of such accreditation | | | |
| LAB_ACC_DSD | By site support type: Direct Service Delivery (DSD) | 1 | 1 | Redacted |
| LAB_ACC_DSD | Sum of Support Type disaggregates | 1 | 1 | Redacted |

Implementing Mechanism Details

| | |
|---|--|
| Mechanism ID: 13667 | Mechanism Name: Center for Integrated Health Program (CIHP) |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Center for Integrated Health Programs | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: TA | |
| G2G: No | Managing Agency: |

| | |
|-------------------------------------|---|
| Total All Funding Sources: 0 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 1 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 0 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Malaria (PMI)

Child Survival Activities

Safe Motherhood

Custom

Approved



TB

Family Planning

Budget Code Information

| Mechanism ID: 13667 | | | |
|---|-------------|----------------|----------------|
| Mechanism Name: Center for Intergrated Health Program (CIHP) | | | |
| Prime Partner Name: Center for Integrated Health Programs | | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HKID | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |



| | | | |
|-----------------------|--------------------|-----------------------|-----------------------|
| Prevention | HMBL | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMIN | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVAB | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXD | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 0 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|--------------------|---|---------|------|-------------------------|
| PMTCT_STAT_DS D | Number of pregnant women with known HIV status (includes women who were | 212,816 | | Redacted |



| | | | | |
|--------------------|--|---------|--|----------|
| | tested for HIV and received their results) | | | |
| PMTCT_STAT_DS D | Number of new ANC and L&D clients | 233,864 | | Redacted |
| PMTCT_STAT_DS D | By: Known positives at entry | 5,480 | | Redacted |
| PMTCT_STAT_DS D | By: Number of new positives identified | 8,221 | | Redacted |
| PMTCT_STAT_DS D | Sum of Positives Status disaggregates | 13,701 | | Redacted |

Implementing Mechanism Details

| | |
|---|--|
| Mechanism ID: 13564 | Mechanism Name: Federal Ministry of Health, Nigeria |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Federal Ministry of Health, Nigeria | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: Yes | Managing Agency: HHS/CDC |

| | |
|-------------------------------------|---|
| Total All Funding Sources: 0 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 1 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 0 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

Malaria (PMI)
 Child Survival Activities
 Safe Motherhood
 TB
 Family Planning

Budget Code Information

| Mechanism ID: 13564 Mechanism Name: Federal Ministry of Health, Nigeria Prime Partner Name: Federal Ministry of Health, Nigeria | | | |
|--|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|--|---|
| Mechanism ID: 13190 | Mechanism Name: Institute of Human Virology, Nigeria - Community-in-Action |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Institute of Human Virology, Nigeria | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |

Approved



| | |
|---|---|
| Global Fund / Multilateral Engagement: TA | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 0 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 1 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 0 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Malaria (PMI)
Child Survival Activities
Safe Motherhood
TB
Family Planning

Budget Code Information

| | | | |
|----------------------------|--|-----------------------|-----------------------|
| Mechanism ID: | 13190 | | |
| Mechanism Name: | Institute of Human Virology, Nigeria - Community-in-Action | | |
| Prime Partner Name: | Institute of Human Virology, Nigeria | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 0 | 0 |



| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|------------------------|-------------|----------------|----------------|
| Governance and Systems | OHSS | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | MTCT | 0 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|--------------------|--|---------|------|-------------------------|
| PMTCT_STAT_DS D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 401,176 | | Redacted |
| PMTCT_STAT_DS D | Number of new ANC and L&D clients | 440,853 | | Redacted |
| PMTCT_STAT_DS D | By: Known positives at entry | 5,087 | | Redacted |
| PMTCT_STAT_DS D | By: Number of new positives identified | 7,630 | | Redacted |
| PMTCT_STAT_DS D | Sum of Positives Status disaggregates | 12,717 | | Redacted |

Implementing Mechanism Details

| | |
|--|--|
| Mechanism ID: 12831 | Mechanism Name: African Field Epidemiology Network |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: African Field Epidemiology Network | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |

Approved



| | |
|---|------------------------------------|
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 2,435,734 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 2,435,734 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Malaria (PMI)

Child Survival Activities

Safe Motherhood

TB

Budget Code Information

| | | | |
|------------------------|------------------------------------|----------------|----------------|
| Mechanism ID: | 12831 | | |
| Mechanism Name: | African Field Epidemiology Network | | |
| Prime Partner Name: | African Field Epidemiology Network | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 270,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |



| Governance and Systems | OHSS | 2,165,734 | 0 |
|------------------------|------|-----------|---|

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|------------------|--|------|------|-------------------------|
| HRH_PRE | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre | 210 | 210 | Redacted |
| HRH_PRE | By Graduates: Doctors | 40 | 40 | Redacted |
| HRH_PRE | By Graduates: Nurses | 70 | 70 | Redacted |
| HRH_PRE | By Graduates: Midwives | 55 | 55 | Redacted |
| HRH_PRE | By Graduates: Laboratory professionals | 35 | 35 | Redacted |
| HRH_PRE | By Graduates: Other | 10 | 10 | Redacted |
| HRH_PRE | Sum of Graduates disaggregates | 210 | 210 | Redacted |

Implementing Mechanism Details

| | |
|---|---|
| Mechanism ID: 10263 | Mechanism Name: Global Laboratory Capacity Strengthening Program |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: American Society for Microbiology | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 400,000 | Total Mechanism Pipeline: Redacted |



| Applied Pipeline Amount: 0 | |
|------------------------------------|-----------------------|
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 400,000 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

TB

Budget Code Information

| Mechanism ID: | 10263 | | |
|----------------------------|--|-----------------------|-----------------------|
| Mechanism Name: | Global Laboratory Capacity Strengthening Program | | |
| Prime Partner Name: | American Society for Microbiology | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HVTB | 300,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 100,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

| | |
|--|---|
| Mechanism ID: 10019 | Mechanism Name: Safe Blood for Africa Foundation |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Safe Blood for Africa Foundation | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: Yes | Managing Agency: HHS/CDC |
| Total All Funding Sources: 443,281 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 443,281 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Child Survival Activities

Military Population

Mobile Population

Workplace Programs

Budget Code Information

| | |
|----------------------|--------------|
| Mechanism ID: | 10019 |
|----------------------|--------------|



| | | | |
|----------------------------|---|-----------------------|-----------------------|
| Mechanism Name: | Safe Blood for Africa Foundation | | |
| Prime Partner Name: | Safe Blood for Africa Foundation | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMBL | 443,281 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| | |
|---|---|
| Mechanism ID: 10015 | Mechanism Name: NATIONAL BLOOD TRANSFUSION SERVICE |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: National Blood Transfusion Service of Nigeria | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: Yes | Managing Agency: HHS/CDC |
| Total All Funding Sources: 1,431,980 | Total Mechanism Pipeline: Redacted |
| Applied Pipeline Amount: 1,000,000 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 1,431,980 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

Malaria (PMI)

Family Planning

Budget Code Information

| Mechanism ID: | 10015 | | |
|----------------------------|---|----------------|----------------|
| Mechanism Name: | NATIONAL BLOOD TRANSFUSION SERVICE | | |
| Prime Partner Name: | National Blood Transfusion Service of Nigeria | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HMBL | 1,431,980 | 0 |

Implementing Mechanism Indicator Information

| Indicator Number | Label | 2014 | 2015 | Planning Budget Targets |
|------------------|--|--------|--------|-------------------------|
| BS_COLL | Number of whole blood collections each year by the NBTS network | 70,000 | 70,000 | Redacted |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network laboratory | 63,000 | 63,000 | Redacted |
| BS_COLL | By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV | 1,400 | 1,400 | Redacted |

Implementing Mechanism Details

| | |
|----------------------------|---|
| Mechanism ID: 10004 | Mechanism Name: Association of Public Health Laboratories (APHL) |
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |

Approved



| | |
|---|------------------------------|
| Prime Partner Name: Association of Public Health Laboratories | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| Global Fund / Multilateral Engagement: No | |
| G2G: No | Managing Agency: |
| Total All Funding Sources: 250,000 | |
| Total Mechanism Pipeline: Redacted | |
| Applied Pipeline Amount: 0 | |
| FY 2013 Burn Rate: Redacted | |
| Funding Source | Funding Amount |
| GHP-State | 250,000 |

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

TB

Budget Code Information

| | | | |
|------------------------|--|----------------|----------------|
| Mechanism ID: | 10004 | | |
| Mechanism Name: | Association of Public Health Laboratories (APHL) | | |
| Prime Partner Name: | Association of Public Health Laboratories | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 250,000 | 0 |

Approved



Implementing Mechanism Indicator Information

(No data provided.)



Agency Information - Costs of Doing Business U.S. Agency for International Development

| Agency Cost of Doing Business | GAP | GHP-State | GHP-USAID | Planned Amount As Of Last Q1 | Cost of Doing Business Category Total | Applied Pipeline |
|--|----------|-------------------|-----------|------------------------------|---------------------------------------|------------------|
| Computers/IT Services | | 696,126 | | Redacted | 696,126 | 0 |
| ICASS | | 1,761,838 | | Redacted | 1,761,838 | 0 |
| Management Meetings/Professional Development | | 845,371 | | Redacted | 845,371 | 0 |
| Non-ICASS Administrative Costs | | 1,495,764 | | Redacted | 1,495,764 | 0 |
| Staff Program Travel | | 1,369,208 | | Redacted | 1,369,208 | 0 |
| USG Staff Salaries and Benefits | | 4,334,748 | | Redacted | 4,334,748 | 2,000,000 |
| Total | 0 | 10,503,055 | 0 | 0 | 10,503,055 | 2,000,000 |

U.S. Agency for International Development Other Costs Details

| Category | Item | Funding Source | Description | Planned Amount As Of Last Q1 | Amount | Applied Pipeline |
|-----------------------|------|----------------|-------------|------------------------------|-----------|------------------|
| Computers/IT Services | | GHP-State | | Redacted | 696,126 | 0 |
| ICASS | | GHP-State | | Redacted | 1,761,838 | 0 |
| Management | | GHP-State | | Redacted | 845,371 | 0 |



| | | | | | | |
|-----------------------------------|--|-----------|--|----------|-----------|---|
| Meetings/Professional Development | | | | | | |
| Non-ICASS Administrative Costs | | GHP-State | | Redacted | 1,495,764 | 0 |

U.S. Department of Defense

| Agency Cost of Doing Business | GAP | GHP-State | GHP-USAID | Planned Amount As Of Last Q1 | Cost of Doing Business Category Total | Applied Pipeline |
|--|----------|------------------|-----------|------------------------------|---------------------------------------|------------------|
| Capital Security Cost Sharing | | 400,000 | | Redacted | 400,000 | 0 |
| Computers/IT Services | | 300,000 | | Redacted | 300,000 | 0 |
| ICASS | | 1,400,000 | | Redacted | 1,400,000 | 0 |
| Indirect Costs | | 750,000 | | Redacted | 750,000 | 0 |
| Management Meetings/Professional Development | | 150,000 | | Redacted | 150,000 | 0 |
| Non-ICASS Administrative Costs | | 300,000 | | Redacted | 300,000 | 0 |
| Staff Program Travel | | 300,000 | | Redacted | 300,000 | 0 |
| USG Staff Salaries and Benefits | | 1,400,000 | | Redacted | 1,400,000 | 0 |
| Total | 0 | 5,000,000 | 0 | 0 | 5,000,000 | 0 |

U.S. Department of Defense Other Costs Details



| Category | Item | Funding Source | Description | Planned Amount As Of Last Q1 | Amount | Applied Pipeline |
|--|------|----------------|-------------|------------------------------|-----------|------------------|
| Capital Security Cost Sharing | | GHP-State | | Redacted | 400,000 | 0 |
| Computers/IT Services | | GHP-State | | Redacted | 300,000 | 0 |
| ICASS | | GHP-State | | Redacted | 1,400,000 | 0 |
| Indirect Costs | | GHP-State | | Redacted | 750,000 | 0 |
| Management Meetings/Professional Development | | GHP-State | | Redacted | 150,000 | 0 |
| Non-ICASS Administrative Costs | | GHP-State | | Redacted | 300,000 | 0 |

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

| Agency Cost of Doing Business | GAP | GHP-State | GHP-USAID | Planned Amount As Of Last Q1 | Cost of Doing Business Category Total | Applied Pipeline |
|-------------------------------|-----|-----------|-----------|------------------------------|---------------------------------------|------------------|
| Capital Security Cost Sharing | | 1,047,518 | | Redacted | 1,047,518 | 0 |
| Computers/IT Services | | 659,290 | | Redacted | 659,290 | 0 |
| ICASS | | 3,031,962 | | Redacted | 3,031,962 | 0 |
| Institutional Contractors | | | | Redacted | 0 | 0 |
| Management Meetings/Profes | | 0 | | Redacted | 0 | 0 |



| | | | | | | |
|---------------------------------------|------------------|-------------------|----------|----------|-------------------|----------|
| sional Development | | | | | | |
| Non-ICASS Administrative Costs | | 4,707,032 | | Redacted | 4,707,032 | 0 |
| Non-ICASS Motor Vehicles | | 415,000 | | Redacted | 415,000 | 0 |
| Staff Program Travel | | 1,283,041 | | Redacted | 1,283,041 | 0 |
| USG Staff Salaries and Benefits | 1,962,500 | 1,893,658 | | Redacted | 3,856,158 | 0 |
| Total | 1,962,500 | 13,037,501 | 0 | 0 | 15,000,001 | 0 |

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention Other Costs Details

| Category | Item | Funding Source | Description | Planned Amount As Of Last Q1 | Amount | Applied Pipeline |
|--|-------------------------------|----------------|---|------------------------------|-----------|------------------|
| Capital Security Cost Sharing | Capital Security Cost Sharing | GHP-State | Capital Security Cost Share with Department of State | Redacted | 1,047,518 | 0 |
| Computers/IT Services | IT Services | GHP-State | ITSO CDC HQ costs and communication and network maintenance costs | Redacted | 659,290 | 0 |
| ICASS | ICASS | GHP-State | ICASS | Redacted | 3,031,962 | 0 |
| Management Meetings/Professional Development | | GHP-State | | Redacted | 0 | 0 |

| | | | | | | |
|--------------------------------------|--------------------------------------|-----------|--|----------|-----------|---|
| Non-ICASS Administrative Costs | Non-ICASS administrative costs | GHP-State | Include non-USG building Office and residential leases (\$637,531), permanent change of station and office equipment shipping (\$180,000), office Utilities and supplies (\$224,000), relocation to Embassy New Office Annex (\$300,000), contracts for procurements and maintenance of office equipments, office, vehicle, etc, (\$3,365,500). | Redacted | 4,707,032 | 0 |
| Non-ICASS Motor Vehicles | Five Light Armored Vehicles | GHP-State | Fund is requested in COP14 to purchase five Light Armored Vehicles (LAV) needed | Redacted | 415,000 | 0 |



| | | | | | | |
|--|--|--|---|--|--|--|
| | | | to facilitate full implementation of the Site Monitoring Strategy (SMS) in managing CDC cooperative agreements. | | | |
|--|--|--|---|--|--|--|

U.S. Department of State

| Agency Cost of Doing Business | GAP | GHP-State | GHP-USAID | Planned Amount As Of Last Q1 | Cost of Doing Business Category Total | Applied Pipeline |
|--|----------|----------------|-----------|------------------------------|---------------------------------------|------------------|
| ICASS | | 126,250 | | Redacted | 126,250 | 0 |
| Management Meetings/Professional Development | | 0 | | Redacted | 0 | 0 |
| Non-ICASS Administrative Costs | | 0 | | Redacted | 0 | 0 |
| Staff Program Travel | | 0 | | Redacted | 0 | 0 |
| USG Staff Salaries and Benefits | | 185,000 | | Redacted | 185,000 | 200,000 |
| Total | 0 | 311,250 | 0 | 0 | 311,250 | 200,000 |

U.S. Department of State Other Costs Details

| Category | Item | Funding Source | Description | Planned Amount As | Amount | Applied Pipeline |
|----------|------|----------------|-------------|-------------------|--------|------------------|
|----------|------|----------------|-------------|-------------------|--------|------------------|

Approved



| | | | | Of Last Q1 | | |
|--|-----------------------------|-----------|--|------------|---------|---|
| ICASS | | GHP-State | | Redacted | 126,250 | 0 |
| Management Meetings/Professional Development | | GHP-State | | Redacted | 0 | 0 |
| Non-ICASS Administrative Costs | Printing and phone expenses | GHP-State | | Redacted | 0 | 0 |